[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fD87qVQ8j3oBKJXH47bQMMsr4vikUAwTIIPmGGkiLpHI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Yonsei University",[4],1382,false,201,39,4837871,130,773,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Coronary Artery Disease",52,{"name":18,"count":19},"Atrial Fibrillation",31,{"name":21,"count":22},"Gastric Cancer",30,{"name":24,"count":25},"General Anesthesia",20,{"name":27,"count":28},"Stroke",15,{"name":30,"count":28},"Breast Cancer",{"name":32,"count":33},"Colorectal Cancer",13,{"name":35,"count":36},"Prostate Cancer",12,[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT07198191","SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study","2022-06-30","SGLT2 inhibitors",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04250116","Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents","2025-04","NOAC monotherapy",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05455918","Paclitaxel\u002FIfosfamide\u002FCisplatin Chemotherapy for High Risk Pediatric Germ Cell Tumor","2025-06","TIP treatment",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06897176","Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study","2025-06-14","Cerebrolyisin",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05914285","Assessment of Salbutamol Effect on Arterial Oxygenation in COPD Patients During One-lung Ventilation","2025-06-20","5ml of inhaled normal saline",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT03059069","The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients","2025-06-30","Chonline Alphoscerate",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05908916","Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma","2025-07","AtezoBev with combined radiotherapy",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06784557","Effect of Ezetimibe on Gut Microbiota","2025-07-01","Atorvastatin 40mg",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT03947229","A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial","2025-08-16","Clopidogrel mono-therapy",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT05508737","Pembrolizumab and Trifluridine\u002FTipiracil With Previously Treated Advanced Gastric Cancer","2025-11-02","Pembrolizumab",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,133,171,265,329,350,379,406,424,442,463,485,503,529,547,572,590,617,644,668,696,714,732,755,773,799,817,840,866,884,945,985,1024,1052,1087,1105,1130,1148,1175,1193,1247,1303,1354,1404,1482,1524,1567,1589,1614,1639,1662,1688,1706,1724,1742,1760,1778,1804,1827,1853,1871,1896,1922,1940,1964,1991,2009,2027,2053,2071,2089,2107,2135,2153,2171,2189,2213,2231,2256,2281,2306,2329,2352,2373,2397,2415,2439,2457,2477,2499,2524,2560,2598,2633,2667,2694,2712,2739,2757,2782,2800,2827,2845,2869,2893,2923,2941,2959,2977,3002,3020,3038,3062,3080,3108,3126,3152,3170,3188,3206,3230,3254,3272,3297,3315,3333,3351,3380,3398,3416,3434,3476,3502,3536,3558,3593,3615,3641,3669,3694,3712,3738,3756,3780,3805,3823,3848,3871,3895,3919,3944,3970,3988,4015,4033,4051,4076,4094,4119,4137,4160,4184,4208,4232,4256,4281,4306,4324,4349,4367,4390,4408,4434,4459,4485,4503,4521,4546,4570,4594,4618,4642,4660,4686,4710,4734,4758,4785,4803,4821,4839,4865,4883,4906,4931,4949,4972,4999,5022,5040,5062,5088,5106,5131,5149,5172,5201,5227,5245,5270,5295,5313,5339,5357,5381,5405,5430,5454,5472,5497,5515,5540,5558,5582,5600,5624,5642,5668,5686,5704,5726,5750,5777,5795,5813,5835,5859,5877,5901,5927,5945,5967,5991,6016,6034,6055,6091,6114,6138,6156,6179,6197,6219,6244,6262,6287,6305,6323,6348,6366,6391,6416,6434,6459,6487,6505,6531,6549,6575,6596,6618,6644,6662,6688,6706,6724,6749,6767,6791,6813,6835,6858,6876,6894,6918,6936,6957,6981,7005,7032,7050,7068,7092,7110,7135,7153,7184,7221,7255,7281,7307,7325,7343,7366,7394,7412,7433,7451,7469,7487,7512,7530,7557,7575,7593,7617,7635,7661,7686,7704,7728,7746,7770,7824,7864,7897,7927,7958,7980,8002,8029,8063,8090,8108,8134,8152,8176,8202,8220,8242,8267,8292,8316,8340,8363,8381,8404,8428,8452,8474,8492,8510,8534,8557,8575,8600,8623,8641,8667,8690,8708,8726,8747,8772,8794,8819,8837,8861,8883,8908,8931,8949,8973,8998,9023,9041,9059,9083,9101,9126,9150,9168,9194,9216,9239,9262,9286,9307,9330,9353,9378,9402,9425,9443,9466,9488,9510,9533,9560,9584,9602,9626,9644,9668,9686,9704,9726,9749,9767,9790,9808,9833,9855,9880,9903,9925,9948,9970,9992,10015,10038,10061,10079,10101,10125,10147,10170,10193,10215,10236,10259,10277,10295,10313,10342,10360,10378,10396,10414,10432,10459,10477,10495,10513,10531,10549,10567,10585,10608,10633,10651,10675,10698,10721,10743,10764,10789,11040,11231,11388,11483,11556,11609,11663,11721,11775,11809,11850,11887,11935,11965,12017,12067,12100,12140,12188,12224,12258,12294,12320,12355,12389,12415,12444,12476,12509,12535,12572,12594,12624,12656,12678,12700,12725,12758,12788,12814,12850,12872,12905,12927,12951,12979,13014,13049,13077,13105,13132,13154,13176,13202,13229,13255,13273,13291,13315,13333,13351,13369,13387,13410,13428,13450,13468,13492,13514,13532,13555,13573,13596,13618,13643,13661,13685,13703,13721,13739,13766,13784,13802,13825,13847,13865,13883,13904,13922,13948,13966,13988,14016,14034,14059,14077,14095,14113,14138,14156,14179,14197,14215,14239,14257,14282,14300,14318,14343,14361,14379,14401,14423,14447,14465,14492,14510,14528,14550,14573,14591,14615,14633,14657,14681,14699,14723,14741,14764,14787,14805,14830,14848,14866,14884,14905,14927,14945,14968,14986,15008,15031,15053,15071,15089,15115,15133,15158,15176,15199,15217,15241,15259,15284,15310,15328,15352,15370,15392,15415,15433,15456,15474,15500,15522,15540,15562,15588,15611,15637,15655,15676,15699,15722,15740,15758,15776,15797,15819,15837,15864,15882,15904,15928,15946,15969,15987,16010,16028,16054,16072,16090,16108,16131,16155,16173,16195,16219,16237,16255,16277,16303,16321,16343,16365,16389,16407,16429,16454,16472,16495,16513,16538,16561,16586,16604,16627,16650,16673,16691,16713,16735,16753,16775,16793,16811,16833,16858,16876,16898,16922,16946,16964,16988,17013,17031,17049,17067,17089,17112,17130,17152,17177,17195,17213,17231,17254,17277,17295,17317,17335,17357,17375,17393,17411,17435,17453,17475,17493,17517,17535,17553,17579,17597,17615,17633,17655,17673,17698,17716,17734,17756,17774,17792,17817,17835,17857,17875,17893,17911,17929,17952,17970,17991,18009,18027,18045,18066,18090,18108,18131,18149,18173,18191,18209,18227,18252,18270,18295,18313,18331,18355,18378],{"intervention":97,"totalTrials":98,"cells":99},"Anticoagulation group",2,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":131},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[],{"trials":108,"activeCount":102},[],{"trials":110,"activeCount":98,"soonestReadout":116},[111,123],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":122},"NCT04437654","The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)","RECRUITING",[93],"2026-07","2028-10","2020-07-28",1800,[121],"Atrial Fibrillation Patients With Intermediate Stroke Risk",[97],{"nctId":124,"briefTitle":125,"status":114,"phases":126,"primaryCompletion":116,"completion":117,"start":118,"enrollment":127,"conditions":128,"interventions":130},"NCT04432220","AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)",[93],840,[129],"Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation",[97],{"trials":132,"activeCount":102},[],{"intervention":134,"totalTrials":98,"cells":135},"Enavogliflozin",{"EARLY_PHASE1":136,"PHASE1":138,"PHASE2":140,"PHASE3":142,"PHASE4":144,"NA":169},{"trials":137,"activeCount":102},[],{"trials":139,"activeCount":102},[],{"trials":141,"activeCount":102},[],{"trials":143,"activeCount":102},[],{"trials":145,"activeCount":98,"soonestReadout":164},[146,160],{"nctId":147,"briefTitle":148,"status":114,"phases":149,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":158},"NCT06642623","A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients",[93],"2029-09-30","2030-12-31","2024-01-22",2862,[155,156,157],"Diabetes Mellitus, Type 2","Cardiovascular Diseases","Kidney Diseases",[134,159],"Dapagliflozin or Empagliflozin",{"nctId":161,"briefTitle":162,"status":114,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":168},"NCT06528262","Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation",[93],"2027-05-31","2025-04-03",390,[18],[134],{"trials":170,"activeCount":102},[],{"intervention":172,"totalTrials":173,"cells":174},"Midazolam",6,{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":214},{"trials":176,"activeCount":102},[],{"trials":178,"activeCount":102},[],{"trials":180,"activeCount":102},[],{"trials":182,"activeCount":102},[],{"trials":184,"activeCount":213,"soonestReadout":190},[185,201],{"nctId":186,"briefTitle":187,"status":188,"phases":189,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":199},"NCT07265128","Remimazolam vs Midazolam to Reduce Delirium in Adults ≥65 Undergoing CPB Valve Surgery","NOT_YET_RECRUITING",[93],"2027-09","2025-12",300,[194,195,196,197,198],"Delirium","Critical Illness","Aged","Cardiopulmonary Bypass","Benzodiazepines",[172,200],"Remimazolam",{"nctId":202,"briefTitle":203,"status":204,"phases":205,"primaryCompletion":206,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":211},"NCT01527903","A Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation in the Intensive Care Unit","COMPLETED",[93],"2010-06","2009-09",77,[210],"Sedation",[212,172],"Propofol",1,{"trials":215,"activeCount":213,"soonestReadout":220},[216,227,240,252],{"nctId":217,"briefTitle":218,"status":188,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":225},"NCT07386054","The Effectiveness of Binaural Beats on Midazolam Requirement During Cesarean Section With Spinal Anesthesia",[94],"2027-01-31","2026-02-01",100,[224],"Pregnancy, Cesarean Section, Spinal Anesthesia",[226,172],"binaural beats",{"nctId":228,"briefTitle":229,"status":204,"phases":230,"primaryCompletion":231,"completion":232,"start":231,"enrollment":233,"conditions":234,"interventions":238},"NCT05736341","Comparison of Remimazolam and Midazolam for Preventing Intraoperative Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia",[94],"2023-05-17","2024-01-06",80,[235,236,237],"Pregnancy","Cesarean Section","Spinal Anesthesia",[239,172],"Remimazolam besylate",{"nctId":241,"briefTitle":242,"status":243,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT01617707","Safe and Effective Sedation in Chronic Alcoholic Patients Underwent Diagnostic Endoscopic Procedures: Study Comparing Midazolam and Propofol With Midazolam","TERMINATED",[94],"2015-01-30","2012-05-09",11,[249],"Chronic Alcoholism",[251,172],"Midazolam plus propofol",{"nctId":253,"briefTitle":254,"status":204,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT02929095","The Effect of Remifentanil-dexmedetomidine Compared With Remifentanil-midazolam on Patient's Satisfaction",[94],"2018-04-02","2016-10-01",70,[260],"Peripheral Arterial Occlusive Disease",[262,263,264],"dexmedetomidine","midazolam","remifentanil",{"intervention":266,"totalTrials":267,"cells":268},"Clopidogrel",4,{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":277,"NA":327},{"trials":270,"activeCount":102},[],{"trials":272,"activeCount":102},[],{"trials":274,"activeCount":102},[],{"trials":276,"activeCount":102},[],{"trials":278,"activeCount":213,"soonestReadout":296},[279,292,305,316],{"nctId":280,"briefTitle":281,"status":243,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":290},"NCT02037412","Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome",[93],"2016-09-30","2014-01",148,[287,288,289],"Acute Coronary Syndrome","Acute Myocardial Infarction","Unstable Angina (Intermediate Coronary Syndrome)",[291,266],"Ticagrelor",{"nctId":293,"briefTitle":294,"status":188,"phases":295,"primaryCompletion":296,"completion":297,"start":191,"enrollment":298,"conditions":299,"interventions":303},"NCT07237308","BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis",[93],"2029-07","2029-10",586,[27,300,18,301,302],"Ischemic","Intracrnaial Arterioscelrosis","Arteriosclerosis",[304,266],"Apixaban",{"nctId":306,"briefTitle":307,"status":308,"phases":309,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":315},"NCT05166538","Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass","UNKNOWN",[93],"2023-12","2022-02-01",204,[314],"Multi Vessel Coronary Artery Disease",[291,266],{"nctId":317,"briefTitle":318,"status":204,"phases":319,"primaryCompletion":320,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":324},"NCT01192724","Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation",[93],"2012-12","2010-03",630,[15],[325,326,266],"Cilostazol","Aspirin",{"trials":328,"activeCount":102},[],{"intervention":67,"totalTrials":213,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":348},{"trials":332,"activeCount":102},[],{"trials":334,"activeCount":102},[],{"trials":336,"activeCount":102},[],{"trials":338,"activeCount":102},[],{"trials":340,"activeCount":213,"soonestReadout":66},[341],{"nctId":64,"briefTitle":65,"status":114,"phases":342,"primaryCompletion":66,"completion":66,"start":343,"enrollment":344,"conditions":345,"interventions":347},[93],"2016-06-01",60,[346],"Type2 Diabetes With Depressive Mood",[67],{"trials":349,"activeCount":102},[],{"intervention":351,"totalTrials":213,"cells":352},"Ferric derisomaltose",{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":359,"PHASE4":361,"NA":377},{"trials":354,"activeCount":102},[],{"trials":356,"activeCount":102},[],{"trials":358,"activeCount":102},[],{"trials":360,"activeCount":102},[],{"trials":362,"activeCount":213,"soonestReadout":367},[363],{"nctId":364,"briefTitle":365,"status":188,"phases":366,"primaryCompletion":367,"completion":368,"start":191,"enrollment":369,"conditions":370,"interventions":376},"NCT07238972","Postoperative Intravenous Ferric Derisomaltose for Prevention of Long-term Anemia After Cardiac Surgery",[93],"2030-08","2030-10",180,[371,372,373,374,375],"Anemia","Iron Deficiencies","Iron Deficiency Anemia","Cardiac Surgery","Heart Valve Diseases",[351],{"trials":378,"activeCount":102},[],{"intervention":380,"totalTrials":213,"cells":381},"Intensive targeting group",{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":390,"NA":404},{"trials":383,"activeCount":102},[],{"trials":385,"activeCount":102},[],{"trials":387,"activeCount":102},[],{"trials":389,"activeCount":102},[],{"trials":391,"activeCount":213,"soonestReadout":397},[392],{"nctId":393,"briefTitle":394,"status":395,"phases":396,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":400,"interventions":402},"NCT05361421","Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD Trial","ACTIVE_NOT_RECRUITING",[93],"2027-10-15","2022-07-19",1200,[401],"Cardiovascular Disease",[380,403],"Conventional therapy group",{"trials":405,"activeCount":102},[],{"intervention":403,"totalTrials":213,"cells":407},{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":414,"PHASE4":416,"NA":422},{"trials":409,"activeCount":102},[],{"trials":411,"activeCount":102},[],{"trials":413,"activeCount":102},[],{"trials":415,"activeCount":102},[],{"trials":417,"activeCount":213,"soonestReadout":397},[418],{"nctId":393,"briefTitle":394,"status":395,"phases":419,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":420,"interventions":421},[93],[401],[380,403],{"trials":423,"activeCount":102},[],{"intervention":159,"totalTrials":213,"cells":425},{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":440},{"trials":427,"activeCount":102},[],{"trials":429,"activeCount":102},[],{"trials":431,"activeCount":102},[],{"trials":433,"activeCount":102},[],{"trials":435,"activeCount":213,"soonestReadout":150},[436],{"nctId":147,"briefTitle":148,"status":114,"phases":437,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":438,"interventions":439},[93],[155,156,157],[134,159],{"trials":441,"activeCount":102},[],{"intervention":57,"totalTrials":213,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":452,"NA":461},{"trials":445,"activeCount":102},[],{"trials":447,"activeCount":102},[],{"trials":449,"activeCount":102},[],{"trials":451,"activeCount":102},[],{"trials":453,"activeCount":213,"soonestReadout":56},[454],{"nctId":54,"briefTitle":55,"status":114,"phases":455,"primaryCompletion":56,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":460},[93],"2027-12-31","2025-03-12",40,[27],[57],{"trials":462,"activeCount":102},[],{"intervention":47,"totalTrials":213,"cells":464},{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":473,"NA":483},{"trials":466,"activeCount":102},[],{"trials":468,"activeCount":102},[],{"trials":470,"activeCount":102},[],{"trials":472,"activeCount":102},[],{"trials":474,"activeCount":213,"soonestReadout":46},[475],{"nctId":44,"briefTitle":45,"status":395,"phases":476,"primaryCompletion":46,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":481},[93],"2026-04","2020-04-28",960,[18],[47,482],"Dual antithrombotic therapy with NOAC and clopidogrel",{"trials":484,"activeCount":102},[],{"intervention":482,"totalTrials":213,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":495,"NA":501},{"trials":488,"activeCount":102},[],{"trials":490,"activeCount":102},[],{"trials":492,"activeCount":102},[],{"trials":494,"activeCount":102},[],{"trials":496,"activeCount":213,"soonestReadout":46},[497],{"nctId":44,"briefTitle":45,"status":395,"phases":498,"primaryCompletion":46,"completion":477,"start":478,"enrollment":479,"conditions":499,"interventions":500},[93],[18],[47,482],{"trials":502,"activeCount":102},[],{"intervention":504,"totalTrials":213,"cells":505},"enavogliflozin 0.3mg",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":512,"PHASE4":514,"NA":527},{"trials":507,"activeCount":102},[],{"trials":509,"activeCount":102},[],{"trials":511,"activeCount":102},[],{"trials":513,"activeCount":102},[],{"trials":515,"activeCount":213,"soonestReadout":520},[516],{"nctId":517,"briefTitle":518,"status":114,"phases":519,"primaryCompletion":520,"completion":520,"start":521,"enrollment":522,"conditions":523,"interventions":525},"NCT06580717","ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy",[93],"2026-11-30","2024-10-15",200,[524],"Nonobstructive Hypertrophic Cardiomyopathy",[504,526],"enavogliflozin Placebo",{"trials":528,"activeCount":102},[],{"intervention":526,"totalTrials":213,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":545},{"trials":532,"activeCount":102},[],{"trials":534,"activeCount":102},[],{"trials":536,"activeCount":102},[],{"trials":538,"activeCount":102},[],{"trials":540,"activeCount":213,"soonestReadout":520},[541],{"nctId":517,"briefTitle":518,"status":114,"phases":542,"primaryCompletion":520,"completion":520,"start":521,"enrollment":522,"conditions":543,"interventions":544},[93],[524],[504,526],{"trials":546,"activeCount":102},[],{"intervention":548,"totalTrials":213,"cells":549},"Zastaprazan",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":558,"NA":570},{"trials":551,"activeCount":102},[],{"trials":553,"activeCount":102},[],{"trials":555,"activeCount":102},[],{"trials":557,"activeCount":102},[],{"trials":559,"activeCount":213,"soonestReadout":564},[560],{"nctId":561,"briefTitle":562,"status":114,"phases":563,"primaryCompletion":564,"completion":564,"start":565,"enrollment":222,"conditions":566,"interventions":568},"NCT07471867","Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention",[93],"2028-07-12","2026-04-02",[567],"Chronic Coronary Syndrome",[548,569],"Rabeprazole",{"trials":571,"activeCount":102},[],{"intervention":569,"totalTrials":213,"cells":573},{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":582,"NA":588},{"trials":575,"activeCount":102},[],{"trials":577,"activeCount":102},[],{"trials":579,"activeCount":102},[],{"trials":581,"activeCount":102},[],{"trials":583,"activeCount":213,"soonestReadout":564},[584],{"nctId":561,"briefTitle":562,"status":114,"phases":585,"primaryCompletion":564,"completion":564,"start":565,"enrollment":222,"conditions":586,"interventions":587},[93],[567],[548,569],{"trials":589,"activeCount":102},[],{"intervention":591,"totalTrials":213,"cells":592},"Monofer",{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":601,"NA":615},{"trials":594,"activeCount":102},[],{"trials":596,"activeCount":102},[],{"trials":598,"activeCount":102},[],{"trials":600,"activeCount":102},[],{"trials":602,"activeCount":213,"soonestReadout":607},[603],{"nctId":604,"briefTitle":605,"status":188,"phases":606,"primaryCompletion":607,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":613},"NCT05719376","The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes",[93],"2026-05","2026-06","2023-02",302,[612],"Kidney Failure, Chronic",[591,614],"control group",{"trials":616,"activeCount":102},[],{"intervention":618,"totalTrials":213,"cells":619},"Botulinum toxin A",{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":628,"NA":642},{"trials":621,"activeCount":102},[],{"trials":623,"activeCount":102},[],{"trials":625,"activeCount":102},[],{"trials":627,"activeCount":102},[],{"trials":629,"activeCount":213,"soonestReadout":634},[630],{"nctId":631,"briefTitle":632,"status":114,"phases":633,"primaryCompletion":634,"completion":634,"start":635,"enrollment":28,"conditions":636,"interventions":641},"NCT06878482","Effect of Blood Flow by Botulinum Toxin Injection for Severe Peripheral Artery Occlusive Disease",[93],"2026-03-31","2023-04-17",[637,638,639,640],"Chronic Ulcer of Lower Extremity","Wound","Botulinum Toxins, Type A","Blood Circulation",[618],{"trials":643,"activeCount":102},[],{"intervention":645,"totalTrials":213,"cells":646},"a high dose of statin\u002Fezetimib",{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":653,"PHASE4":655,"NA":666},{"trials":648,"activeCount":102},[],{"trials":650,"activeCount":102},[],{"trials":652,"activeCount":102},[],{"trials":654,"activeCount":102},[],{"trials":656,"activeCount":213,"soonestReadout":661},[657],{"nctId":658,"briefTitle":659,"status":395,"phases":660,"primaryCompletion":661,"completion":661,"start":662,"enrollment":522,"conditions":663,"interventions":665},"NCT05910476","Comparative Study of Rosuvastatin\u002FEzetimib 20\u002F10 mg and Atovastatin\u002FEzetimib 40\u002F10 mg (TOLERANT Trial)",[93],"2026-09-22","2023-05-03",[15,664],"Dyslipidemias",[645],{"trials":667,"activeCount":102},[],{"intervention":669,"totalTrials":213,"cells":670},"Sitagliptin 100 mg",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":679,"NA":694},{"trials":672,"activeCount":102},[],{"trials":674,"activeCount":102},[],{"trials":676,"activeCount":102},[],{"trials":678,"activeCount":102},[],{"trials":680,"activeCount":213,"soonestReadout":685},[681],{"nctId":682,"briefTitle":683,"status":188,"phases":684,"primaryCompletion":685,"completion":686,"start":687,"enrollment":222,"conditions":688,"interventions":691},"NCT07108985","Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors",[93],"2029-09-01","2030-08-31","2025-09",[155,689,690],"Hyperglycemia","Insulin Resistance",[669,692,692,693],"Sitagliptin 100 mg + Dapagliflozin 10 mg","Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg",{"trials":695,"activeCount":102},[],{"intervention":692,"totalTrials":213,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":712},{"trials":699,"activeCount":102},[],{"trials":701,"activeCount":102},[],{"trials":703,"activeCount":102},[],{"trials":705,"activeCount":102},[],{"trials":707,"activeCount":213,"soonestReadout":685},[708],{"nctId":682,"briefTitle":683,"status":188,"phases":709,"primaryCompletion":685,"completion":686,"start":687,"enrollment":222,"conditions":710,"interventions":711},[93],[155,689,690],[669,692,692,693],{"trials":713,"activeCount":102},[],{"intervention":693,"totalTrials":213,"cells":715},{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":722,"PHASE4":724,"NA":730},{"trials":717,"activeCount":102},[],{"trials":719,"activeCount":102},[],{"trials":721,"activeCount":102},[],{"trials":723,"activeCount":102},[],{"trials":725,"activeCount":213,"soonestReadout":685},[726],{"nctId":682,"briefTitle":683,"status":188,"phases":727,"primaryCompletion":685,"completion":686,"start":687,"enrollment":222,"conditions":728,"interventions":729},[93],[155,689,690],[669,692,692,693],{"trials":731,"activeCount":102},[],{"intervention":82,"totalTrials":213,"cells":733},{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":740,"PHASE4":742,"NA":753},{"trials":735,"activeCount":102},[],{"trials":737,"activeCount":102},[],{"trials":739,"activeCount":102},[],{"trials":741,"activeCount":102},[],{"trials":743,"activeCount":213,"soonestReadout":81},[744],{"nctId":79,"briefTitle":80,"status":395,"phases":745,"primaryCompletion":81,"completion":746,"start":747,"enrollment":748,"conditions":749,"interventions":751},[93],"2026-08-16","2019-08-14",3200,[15,750],"DES",[82,752],"Dual-antiplatelet therapy",{"trials":754,"activeCount":102},[],{"intervention":752,"totalTrials":213,"cells":756},{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":763,"PHASE4":765,"NA":771},{"trials":758,"activeCount":102},[],{"trials":760,"activeCount":102},[],{"trials":762,"activeCount":102},[],{"trials":764,"activeCount":102},[],{"trials":766,"activeCount":213,"soonestReadout":81},[767],{"nctId":79,"briefTitle":80,"status":395,"phases":768,"primaryCompletion":81,"completion":746,"start":747,"enrollment":748,"conditions":769,"interventions":770},[93],[15,750],[82,752],{"trials":772,"activeCount":102},[],{"intervention":774,"totalTrials":213,"cells":775},"Low intensity statin",{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":780,"PHASE3":782,"PHASE4":784,"NA":797},{"trials":777,"activeCount":102},[],{"trials":779,"activeCount":102},[],{"trials":781,"activeCount":102},[],{"trials":783,"activeCount":102},[],{"trials":785,"activeCount":213,"soonestReadout":790},[786],{"nctId":787,"briefTitle":788,"status":114,"phases":789,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":793,"interventions":795},"NCT03770312","Low- and Moderate-intensity Statin and Clinical Outcome of Primary Prevention in Individuals Aged >70 Years: the SCOPE-70 RCT Study",[93],"2026-01-16","2020-03-05",724,[794],"Healthy Elderly Individuals With High LDL-cholesterol or Risk of Cardiovascular Disease",[774,796],"Moderate intensity statin",{"trials":798,"activeCount":102},[],{"intervention":796,"totalTrials":213,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":809,"NA":815},{"trials":802,"activeCount":102},[],{"trials":804,"activeCount":102},[],{"trials":806,"activeCount":102},[],{"trials":808,"activeCount":102},[],{"trials":810,"activeCount":213,"soonestReadout":790},[811],{"nctId":787,"briefTitle":788,"status":114,"phases":812,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":813,"interventions":814},[93],[794],[774,796],{"trials":816,"activeCount":102},[],{"intervention":818,"totalTrials":213,"cells":819},"Atorvastatin 20mg+Ezetimibe 10mg",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":828,"NA":838},{"trials":821,"activeCount":102},[],{"trials":823,"activeCount":102},[],{"trials":825,"activeCount":102},[],{"trials":827,"activeCount":102},[],{"trials":829,"activeCount":213,"soonestReadout":76},[830],{"nctId":74,"briefTitle":75,"status":114,"phases":831,"primaryCompletion":76,"completion":832,"start":833,"enrollment":834,"conditions":835,"interventions":837},[93],"2025-10-01","2024-02-28",110,[836],"Atherosclerotic Cardiovascular Disease With Dyslipidemia",[77,818],{"trials":839,"activeCount":102},[],{"intervention":841,"totalTrials":213,"cells":842},"Vemlidy",{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":851,"NA":864},{"trials":844,"activeCount":102},[],{"trials":846,"activeCount":102},[],{"trials":848,"activeCount":102},[],{"trials":850,"activeCount":102},[],{"trials":852,"activeCount":213,"soonestReadout":857},[853],{"nctId":854,"briefTitle":855,"status":188,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":222,"conditions":860,"interventions":862},"NCT06221657","Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral Treatment",[93],"2026-12-01","2026-12-31","2024-02-01",[861],"Patients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication",[841,863],"Virreal",{"trials":865,"activeCount":102},[],{"intervention":863,"totalTrials":213,"cells":867},{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":874,"PHASE4":876,"NA":882},{"trials":869,"activeCount":102},[],{"trials":871,"activeCount":102},[],{"trials":873,"activeCount":102},[],{"trials":875,"activeCount":102},[],{"trials":877,"activeCount":213,"soonestReadout":857},[878],{"nctId":854,"briefTitle":855,"status":188,"phases":879,"primaryCompletion":857,"completion":858,"start":859,"enrollment":222,"conditions":880,"interventions":881},[93],[861],[841,863],{"trials":883,"activeCount":102},[],{"intervention":614,"totalTrials":885,"cells":886},5,{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":893,"PHASE4":905,"NA":911},{"trials":888,"activeCount":102},[],{"trials":890,"activeCount":102},[],{"trials":892,"activeCount":102},[],{"trials":894,"activeCount":102},[895],{"nctId":896,"briefTitle":897,"status":204,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":233,"conditions":901,"interventions":902},"NCT01392105","Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction",[91,92],"2010-05","2007-03",[288],[903,904],"Mesenchymal stem cell","Control group",{"trials":906,"activeCount":213,"soonestReadout":607},[907],{"nctId":604,"briefTitle":605,"status":188,"phases":908,"primaryCompletion":607,"completion":608,"start":609,"enrollment":610,"conditions":909,"interventions":910},[93],[612],[591,614],{"trials":912,"activeCount":102},[913,923,935],{"nctId":914,"briefTitle":915,"status":204,"phases":916,"primaryCompletion":917,"completion":917,"start":918,"enrollment":16,"conditions":919,"interventions":921},"NCT02902380","The Effect of Dexmedetomidine on Neuroendocrine Stress Hormone Release and Heart Rate Variability in Patients Undergoing Major Spinal Surgery",[94],"2017-07-01","2016-09-27",[920],"Spinal Stenosis",[922,614],"dexmedetomidine group",{"nctId":924,"briefTitle":925,"status":204,"phases":926,"primaryCompletion":927,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":932},"NCT03871387","The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change",[94],"2020-02-24","2019-03-04",88,[931],"Thyroid Neoplasms",[933,934],"Deep Group","Control Group",{"nctId":936,"briefTitle":937,"status":204,"phases":938,"primaryCompletion":939,"completion":939,"start":940,"enrollment":222,"conditions":941,"interventions":943},"NCT02896413","The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection",[94],"2018-10-24","2016-06-02",[942],"Uterine Cancer",[944,904],"Dexmedetomidine group",{"intervention":77,"totalTrials":946,"cells":947},3,{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":954,"PHASE4":956,"NA":973},{"trials":949,"activeCount":102},[],{"trials":951,"activeCount":102},[],{"trials":953,"activeCount":102},[],{"trials":955,"activeCount":102},[],{"trials":957,"activeCount":213,"soonestReadout":76},[958,969],{"nctId":959,"briefTitle":960,"status":204,"phases":961,"primaryCompletion":962,"completion":963,"start":964,"enrollment":344,"conditions":965,"interventions":967},"NCT01856374","Serial EValuation of multiplE Coronary Artery Diseases by an Optical Coherence Tomography; Assessment of the Changes of de Novo Lesions and Comparisons of Neointimal Coverage Between Xience Prime® Versus Cypher SelectTM Stents; SEVEN-Xience Study",[93],"2014-03","2014-10","2011-08",[966],"Multi-vessel Diseases, Angina",[968,77],"Pravastatin 20mg",{"nctId":74,"briefTitle":75,"status":114,"phases":970,"primaryCompletion":76,"completion":832,"start":833,"enrollment":834,"conditions":971,"interventions":972},[93],[836],[77,818],{"trials":974,"activeCount":102},[975],{"nctId":976,"briefTitle":977,"status":204,"phases":978,"primaryCompletion":979,"completion":980,"start":981,"enrollment":22,"conditions":982,"interventions":983},"NCT02155530","COmparison and Modification in Neointimal Pattern Assessed by Optical Coherence Tomography With High Versus Moderate Efficacy Statin Treatment After Drug Eluting Stent Implantation: COMPASS Trial",[94],"2016-05","2016-06","2014-06",[15],[77,984],"pravastatin 20 mg",{"intervention":986,"totalTrials":946,"cells":987},"remimazolam",{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":994,"PHASE4":996,"NA":1002},{"trials":989,"activeCount":102},[],{"trials":991,"activeCount":102},[],{"trials":993,"activeCount":102},[],{"trials":995,"activeCount":102},[],{"trials":997,"activeCount":213,"soonestReadout":190},[998],{"nctId":186,"briefTitle":187,"status":188,"phases":999,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":1000,"interventions":1001},[93],[194,195,196,197,198],[172,200],{"trials":1003,"activeCount":102},[1004,1014],{"nctId":1005,"briefTitle":1006,"status":204,"phases":1007,"primaryCompletion":1008,"completion":1008,"start":1009,"enrollment":1010,"conditions":1011,"interventions":1013},"NCT06093971","Remimazolam Versus Propofol for General Anesthesia Induction in Patients on Renin-angiotensin System Blockers Undergoing Robot-assisted Laparoscopic Prostatectomy",[94],"2024-10-22","2023-11-17",112,[1012],"Prostate Tumor",[986,212],{"nctId":1015,"briefTitle":1016,"status":204,"phases":1017,"primaryCompletion":1018,"completion":1018,"start":1019,"enrollment":222,"conditions":1020,"interventions":1022},"NCT05164146","The Comparison of Hypotension Incidence Between Remimazolam and Propofol in Hypertensive Patients Undergoing Neurosurgery",[94],"2022-08-10","2022-02-23",[1021],"Patients Undergoing Neurosurgery",[1023,986],"propofol",{"intervention":304,"totalTrials":98,"cells":1025},{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1032,"PHASE4":1034,"NA":1040},{"trials":1027,"activeCount":102},[],{"trials":1029,"activeCount":102},[],{"trials":1031,"activeCount":102},[],{"trials":1033,"activeCount":102},[],{"trials":1035,"activeCount":213,"soonestReadout":296},[1036],{"nctId":293,"briefTitle":294,"status":188,"phases":1037,"primaryCompletion":296,"completion":297,"start":191,"enrollment":298,"conditions":1038,"interventions":1039},[93],[27,300,18,301,302],[304,266],{"trials":1041,"activeCount":102},[1042],{"nctId":1043,"briefTitle":1044,"status":308,"phases":1045,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":522,"conditions":1048,"interventions":1050},"NCT02633774","Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation",[94],"2020-11","2015-11",[1049],"Persistent Atrial Fibrillation",[1051,304],"Propafenone",{"intervention":1053,"totalTrials":98,"cells":1054},"phenylephrine",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1061,"PHASE4":1083,"NA":1085},{"trials":1056,"activeCount":102},[],{"trials":1058,"activeCount":102},[],{"trials":1060,"activeCount":102},[],{"trials":1062,"activeCount":213,"soonestReadout":190},[1063,1074],{"nctId":1064,"briefTitle":1065,"status":243,"phases":1066,"primaryCompletion":1067,"completion":1068,"start":1069,"enrollment":946,"conditions":1070,"interventions":1072},"NCT04839224","Comparing Between CO2 and Phenylephrine Treatment in Patients With Progressive Lacunar Infarction (CARBOGEN Study)",[92],"2022-10-18","2024-09-12","2021-04-05",[1071],"Acute Ischemic Stroke",[1073,1053],"carbogen",{"nctId":1075,"briefTitle":1076,"status":188,"phases":1077,"primaryCompletion":190,"completion":1078,"start":1079,"enrollment":458,"conditions":1080,"interventions":1081},"NCT06770426","CompARing Between CO2 Phenylephrine and Phenylephrine Only Treatment in Patients With proGrEssing Cerebral infarctioN",[92],"2027-12","2025-02",[1071],[1082,1053],"carbogen with or without phenyleprhine",{"trials":1084,"activeCount":102},[],{"trials":1086,"activeCount":102},[],{"intervention":1082,"totalTrials":213,"cells":1088},{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1095,"PHASE4":1101,"NA":1103},{"trials":1090,"activeCount":102},[],{"trials":1092,"activeCount":102},[],{"trials":1094,"activeCount":102},[],{"trials":1096,"activeCount":213,"soonestReadout":190},[1097],{"nctId":1075,"briefTitle":1076,"status":188,"phases":1098,"primaryCompletion":190,"completion":1078,"start":1079,"enrollment":458,"conditions":1099,"interventions":1100},[92],[1071],[1082,1053],{"trials":1102,"activeCount":102},[],{"trials":1104,"activeCount":102},[],{"intervention":1106,"totalTrials":213,"cells":1107},"BP lowering drugs",{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1112,"PHASE3":1114,"PHASE4":1126,"NA":1128},{"trials":1109,"activeCount":102},[],{"trials":1111,"activeCount":102},[],{"trials":1113,"activeCount":102},[],{"trials":1115,"activeCount":213,"soonestReadout":1120},[1116],{"nctId":1117,"briefTitle":1118,"status":114,"phases":1119,"primaryCompletion":1120,"completion":1120,"start":1121,"enrollment":1122,"conditions":1123,"interventions":1124},"NCT06677970","Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)",[92],"2029-12-03","2024-10-01",176,[1071],[1106,1125],"BP raising drug",{"trials":1127,"activeCount":102},[],{"trials":1129,"activeCount":102},[],{"intervention":1125,"totalTrials":213,"cells":1131},{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1138,"PHASE4":1144,"NA":1146},{"trials":1133,"activeCount":102},[],{"trials":1135,"activeCount":102},[],{"trials":1137,"activeCount":102},[],{"trials":1139,"activeCount":213,"soonestReadout":1120},[1140],{"nctId":1117,"briefTitle":1118,"status":114,"phases":1141,"primaryCompletion":1120,"completion":1120,"start":1121,"enrollment":1122,"conditions":1142,"interventions":1143},[92],[1071],[1106,1125],{"trials":1145,"activeCount":102},[],{"trials":1147,"activeCount":102},[],{"intervention":1149,"totalTrials":213,"cells":1150},"celecoxib monotherapy",{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1157,"PHASE4":1171,"NA":1173},{"trials":1152,"activeCount":102},[],{"trials":1154,"activeCount":102},[],{"trials":1156,"activeCount":102},[],{"trials":1158,"activeCount":213,"soonestReadout":1163},[1159],{"nctId":1160,"briefTitle":1161,"status":114,"phases":1162,"primaryCompletion":1163,"completion":1164,"start":1165,"enrollment":1166,"conditions":1167,"interventions":1169},"NCT06545526","Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis",[92],"2026-06-24","2026-06-30","2024-08-13",28,[1168],"Familial Adenomatous Polyposis",[1149,1170],"celecoxib and metformin combination",{"trials":1172,"activeCount":102},[],{"trials":1174,"activeCount":102},[],{"intervention":1170,"totalTrials":213,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1183,"PHASE4":1189,"NA":1191},{"trials":1178,"activeCount":102},[],{"trials":1180,"activeCount":102},[],{"trials":1182,"activeCount":102},[],{"trials":1184,"activeCount":213,"soonestReadout":1163},[1185],{"nctId":1160,"briefTitle":1161,"status":114,"phases":1186,"primaryCompletion":1163,"completion":1164,"start":1165,"enrollment":1166,"conditions":1187,"interventions":1188},[92],[1168],[1149,1170],{"trials":1190,"activeCount":102},[],{"trials":1192,"activeCount":102},[],{"intervention":1194,"totalTrials":267,"cells":1195},"Nivolumab",{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1200,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1197,"activeCount":102},[],{"trials":1199,"activeCount":102},[],{"trials":1201,"activeCount":98,"soonestReadout":477},[1202,1212,1222],{"nctId":1203,"briefTitle":1204,"status":114,"phases":1205,"primaryCompletion":1206,"completion":1206,"start":1207,"enrollment":22,"conditions":1208,"interventions":1211},"NCT05795244","Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)",[91],"2029-12","2023-10-31",[1209,1210],"Endometrial Neoplasms","Endometrial Cancer",[1194],{"nctId":1213,"briefTitle":1214,"status":308,"phases":1215,"primaryCompletion":1216,"completion":310,"start":1217,"enrollment":1166,"conditions":1218,"interventions":1220},"NCT05224999","Nivolumab for Recurrent\u002FMetastatic Carcinosarcoma",[91],"2023-01","2019-11-13",[1219],"Recurrent\u002FMetastatic Carcinosarcoma",[1221],"nivolumab",{"nctId":1223,"briefTitle":1224,"status":114,"phases":1225,"primaryCompletion":477,"completion":607,"start":1226,"enrollment":1227,"conditions":1228,"interventions":1230},"NCT04910347","Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma",[91],"2022-02-07",57,[1229],"Locally Advanced Nasopharyngeal Carcinoma",[1194],{"trials":1232,"activeCount":102},[],{"trials":1234,"activeCount":102},[],{"trials":1236,"activeCount":213,"soonestReadout":1241},[1237],{"nctId":1238,"briefTitle":1239,"status":395,"phases":1240,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1243,"conditions":1244,"interventions":1246},"NCT04603248","A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and\u002For Metastatic Head and Neck Squamous Cell Carcinoma",[94],"2026-09","2020-08-30",50,[1245],"Head and Neck Squamous Cell Carcinoma (HNSCC)",[1194],{"intervention":87,"totalTrials":267,"cells":1248},{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1253,"PHASE3":1297,"PHASE4":1299,"NA":1301},{"trials":1250,"activeCount":102},[],{"trials":1252,"activeCount":102},[],{"trials":1254,"activeCount":98,"soonestReadout":86},[1255,1263,1273,1284],{"nctId":84,"briefTitle":85,"status":395,"phases":1256,"primaryCompletion":86,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1262},[90,91],"2025-12-01","2022-12-01",75,[1261],"Gastric and Gastroesophageal Junction Adenocarcinoma",[87],{"nctId":1264,"briefTitle":1265,"status":308,"phases":1266,"primaryCompletion":1267,"completion":1268,"start":1269,"enrollment":22,"conditions":1270,"interventions":1272},"NCT03492918","Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)",[91],"2023-04","2023-05","2022-04",[1271],"Metastatic Breast Cancer",[87],{"nctId":1274,"briefTitle":1275,"status":114,"phases":1276,"primaryCompletion":1078,"completion":1078,"start":1068,"enrollment":1277,"conditions":1278,"interventions":1282},"NCT06502743","First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer",[91],92,[1210,1279,1280,1281,1209],"Recurrent Endometrial Carcinoma","Endometrial Carcinoma","Gynecologycal Cancer",[1283,87],"Nesuparib",{"nctId":1285,"briefTitle":1286,"status":308,"phases":1287,"primaryCompletion":1288,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1293},"NCT02901301","Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer",[90,91],"2020-10-31","2021-10","2017-02-06",41,[21],[87,1294,1295,1296],"Trastuzumab","Capecitabine","Cisplatin",{"trials":1298,"activeCount":102},[],{"trials":1300,"activeCount":102},[],{"trials":1302,"activeCount":102},[],{"intervention":1304,"totalTrials":946,"cells":1305},"Everolimus",{"EARLY_PHASE1":1306,"PHASE1":1308,"PHASE2":1310,"PHASE3":1348,"PHASE4":1350,"NA":1352},{"trials":1307,"activeCount":102},[],{"trials":1309,"activeCount":102},[],{"trials":1311,"activeCount":98,"soonestReadout":1341},[1312,1329,1337],{"nctId":1313,"briefTitle":1314,"status":188,"phases":1315,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1328},"NCT07477548","A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies",[91],"2030-10-31","2030-11-30","2026-04-01",67,[1321,1322,1323,1324,1325,1326,1327],"Vascular Malformations","Arteriovenous Malformations","Venous Malformation","Lymphangioma","Nevus, Port-Wine","Hemangioendothelioma","Hemangioma",[1304],{"nctId":1330,"briefTitle":1331,"status":204,"phases":1332,"primaryCompletion":963,"completion":963,"start":321,"enrollment":458,"conditions":1333,"interventions":1335},"NCT01164176","Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer",[91],[1334],"Head and Neck Cancer",[1336],"everolimus",{"nctId":1338,"briefTitle":1339,"status":188,"phases":1340,"primaryCompletion":1341,"completion":1341,"start":1342,"enrollment":1343,"conditions":1344,"interventions":1346},"NCT07619950","EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma",[91],"2028-11-30","2026-07-01",94,[1345],"Neoplasms of Bone and Articular Cartilage With Unspecified Anatomical Site",[1347,1304],"Everolimus and Lenvatinib",{"trials":1349,"activeCount":102},[],{"trials":1351,"activeCount":102},[],{"trials":1353,"activeCount":102},[],{"intervention":1355,"totalTrials":946,"cells":1356},"durvalumab",{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1398,"PHASE4":1400,"NA":1402},{"trials":1358,"activeCount":102},[],{"trials":1360,"activeCount":102},[],{"trials":1362,"activeCount":98,"soonestReadout":1391},[1363,1378,1387],{"nctId":1364,"briefTitle":1365,"status":308,"phases":1366,"primaryCompletion":1367,"completion":1367,"start":1368,"enrollment":1369,"conditions":1370,"interventions":1375},"NCT03737968","Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab\u002FTremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.",[91],"2023-10","2019-01-02",48,[1371,1372,1373,1374],"Stage II-IVB Operable HNSCC Oral Cavity","Hypopharynx","Oropharynx","Larynx",[1376,1377],"Durvalumab","durvalumab + tremelimumab",{"nctId":1379,"briefTitle":1380,"status":114,"phases":1381,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":9,"conditions":1384,"interventions":1386},"NCT03694236","Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC",[90,91],"2027-05","2019-02-12",[1385],"Potentially Resectable Stage II\u002FIIIa NSCLC",[1355],{"nctId":1388,"briefTitle":1389,"status":395,"phases":1390,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":1394,"conditions":1395,"interventions":1397},"NCT05206812","Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)",[91],"2027-01","2028-07","2022-09-01",25,[1396],"Non Small Cell Lung Cancer",[1355],{"trials":1399,"activeCount":102},[],{"trials":1401,"activeCount":102},[],{"trials":1403,"activeCount":102},[],{"intervention":1405,"totalTrials":885,"cells":1406},"Bevacizumab",{"EARLY_PHASE1":1407,"PHASE1":1409,"PHASE2":1411,"PHASE3":1447,"PHASE4":1449,"NA":1451},{"trials":1408,"activeCount":102},[],{"trials":1410,"activeCount":102},[],{"trials":1412,"activeCount":98,"soonestReadout":1417},[1413,1428],{"nctId":1414,"briefTitle":1415,"status":114,"phases":1416,"primaryCompletion":1417,"completion":151,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1425},"NCT07340164","Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy",[91],"2026-12-30","2026-02-26",116,[1421,1422,1423,1424],"Ovarian Cancer","Ovarian Carcinoma, Recurrent","Ovarian Cancer Metastatic Recurrent","Ovarian Cancer (OvCa)",[1426,1405,1427],"Trastzumab Deruxtecan","Platinum Based Chemotherapy",{"nctId":1429,"briefTitle":1430,"status":114,"phases":1431,"primaryCompletion":1432,"completion":1433,"start":152,"enrollment":1434,"conditions":1435,"interventions":1441},"NCT06023862","A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7\u002F ENGOT-ov80 Study)",[91],"2027-08-31","2029-12-31",198,[1436,1209,1437,1438,1439,1440],"Ovarian Neoplasms","Uterine Cervical Neoplasms","Vulvar Cancer","Vagina Neoplasm","Clear Cell Carcinoma",[1442,1405,1443,1444,1445,1446],"Dostarlimab","Doxorubicin","Gemcitabine","Paclitaxel","Pegylated liposomal doxorubicin",{"trials":1448,"activeCount":102},[],{"trials":1450,"activeCount":102},[],{"trials":1452,"activeCount":102},[1453,1463,1472],{"nctId":1454,"briefTitle":1455,"status":204,"phases":1456,"primaryCompletion":1457,"completion":1457,"start":1458,"enrollment":1243,"conditions":1459,"interventions":1460},"NCT03367182","Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer",[],"2018-01-31","2017-09-01",[1421],[1461,1462,1446,1405],"Weekly paclitaxel","Topotecan",{"nctId":1464,"briefTitle":1465,"status":204,"phases":1466,"completion":900,"start":1467,"enrollment":25,"conditions":1468,"interventions":1470},"NCT00423059","Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy",[94],"2006-12",[1469],"Diabetic Retinopathy",[1471],"bevacizumab",{"nctId":1473,"briefTitle":1474,"status":1475,"phases":1476,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":102,"conditions":1479,"interventions":1481},"NCT00515684","Corneal Thinning During Topical Bevacizumab Therapy","WITHDRAWN",[94],"2008-12","2007-05",[1480],"Corneal Neovascularization",[1471],{"intervention":1445,"totalTrials":946,"cells":1483},{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1518,"PHASE4":1520,"NA":1522},{"trials":1485,"activeCount":102},[],{"trials":1487,"activeCount":102},[],{"trials":1489,"activeCount":213,"soonestReadout":1432},[1490,1494,1507],{"nctId":1429,"briefTitle":1430,"status":114,"phases":1491,"primaryCompletion":1432,"completion":1433,"start":152,"enrollment":1434,"conditions":1492,"interventions":1493},[91],[1436,1209,1437,1438,1439,1440],[1442,1405,1443,1444,1445,1446],{"nctId":1495,"briefTitle":1496,"status":204,"phases":1497,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":1502,"interventions":1504},"NCT02501603","Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer",[91],"2021-12-31","2022-12-20","2016-07",72,[21,1503],"Gastroesophageal Junction Cancer",[1505,1506],"afatinib","paclitaxel",{"nctId":1508,"briefTitle":1509,"status":204,"phases":1510,"primaryCompletion":1511,"completion":1511,"start":1512,"enrollment":1513,"conditions":1514,"interventions":1516},"NCT02615730","PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma",[90,91],"2021-03-31","2016-02",42,[1515],"Advanced Gastric Adenocarcinoma",[1517,1445],"GSK2636771",{"trials":1519,"activeCount":102},[],{"trials":1521,"activeCount":102},[],{"trials":1523,"activeCount":102},[],{"intervention":1525,"totalTrials":946,"cells":1526},"Lazertinib",{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1561,"PHASE4":1563,"NA":1565},{"trials":1528,"activeCount":102},[],{"trials":1530,"activeCount":102},[],{"trials":1532,"activeCount":213,"soonestReadout":608},[1533,1543,1552],{"nctId":1534,"briefTitle":1535,"status":114,"phases":1536,"primaryCompletion":608,"completion":1537,"start":1226,"enrollment":1538,"conditions":1539,"interventions":1541},"NCT06268210","Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer",[91],"2028-06",160,[1540],"Non-small Cell Lung Cancer",[1542,1525],"Lazertinib+Pemetrexed+Carboplatin",{"nctId":1544,"briefTitle":1545,"status":308,"phases":1546,"primaryCompletion":1547,"completion":191,"start":1548,"enrollment":1549,"conditions":1550,"interventions":1551},"NCT06020989","Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy",[91],"2024-09","2023-09",129,[1396],[1542,1525,1525],{"nctId":1553,"briefTitle":1554,"status":308,"phases":1555,"primaryCompletion":1556,"completion":1556,"start":1269,"enrollment":1557,"conditions":1558,"interventions":1560},"NCT05277701","Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations",[91],"2024-12",36,[1559],"NSCLC",[1525],{"trials":1562,"activeCount":102},[],{"trials":1564,"activeCount":102},[],{"trials":1566,"activeCount":102},[],{"intervention":1542,"totalTrials":98,"cells":1568},{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1573,"PHASE3":1583,"PHASE4":1585,"NA":1587},{"trials":1570,"activeCount":102},[],{"trials":1572,"activeCount":102},[],{"trials":1574,"activeCount":213,"soonestReadout":608},[1575,1579],{"nctId":1534,"briefTitle":1535,"status":114,"phases":1576,"primaryCompletion":608,"completion":1537,"start":1226,"enrollment":1538,"conditions":1577,"interventions":1578},[91],[1540],[1542,1525],{"nctId":1544,"briefTitle":1545,"status":308,"phases":1580,"primaryCompletion":1547,"completion":191,"start":1548,"enrollment":1549,"conditions":1581,"interventions":1582},[91],[1396],[1542,1525,1525],{"trials":1584,"activeCount":102},[],{"trials":1586,"activeCount":102},[],{"trials":1588,"activeCount":102},[],{"intervention":1590,"totalTrials":213,"cells":1591},"Certirobell®",{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1608,"PHASE4":1610,"NA":1612},{"trials":1593,"activeCount":102},[],{"trials":1595,"activeCount":102},[],{"trials":1597,"activeCount":213,"soonestReadout":1602},[1598],{"nctId":1599,"briefTitle":1600,"status":188,"phases":1601,"primaryCompletion":1602,"completion":1603,"start":76,"enrollment":344,"conditions":1604,"interventions":1607},"NCT06972758","Adjuvant Everolimus in High-Risk Hepatocellular Carcinoma After Curative Resection (SEVERANCE Trial)",[91],"2030-07-01","2030-07-30",[1605,1606],"Carcinom","Hepatocellular",[1590],{"trials":1609,"activeCount":102},[],{"trials":1611,"activeCount":102},[],{"trials":1613,"activeCount":102},[],{"intervention":1615,"totalTrials":213,"cells":1616},"nivolumab-GX-188E-GX-I7",{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1621,"PHASE3":1633,"PHASE4":1635,"NA":1637},{"trials":1618,"activeCount":102},[],{"trials":1620,"activeCount":102},[],{"trials":1622,"activeCount":213,"soonestReadout":1627},[1623],{"nctId":1624,"briefTitle":1625,"status":114,"phases":1626,"primaryCompletion":1627,"completion":1627,"start":1628,"enrollment":1629,"conditions":1630,"interventions":1632},"NCT05280457","HPV 16-positive and\u002For HPV 18-positive Recurrent and\u002For For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy",[91],"2026-03","2022-04-15",21,[1631],"Head and Neck Squamous Cell Carcinoma",[1615],{"trials":1634,"activeCount":102},[],{"trials":1636,"activeCount":102},[],{"trials":1638,"activeCount":102},[],{"intervention":1640,"totalTrials":213,"cells":1641},"pembrolizumab, pazopanib",{"EARLY_PHASE1":1642,"PHASE1":1644,"PHASE2":1646,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1643,"activeCount":102},[],{"trials":1645,"activeCount":102},[],{"trials":1647,"activeCount":213,"soonestReadout":858},[1648],{"nctId":1649,"briefTitle":1650,"status":114,"phases":1651,"primaryCompletion":858,"completion":858,"start":1652,"enrollment":1419,"conditions":1653,"interventions":1655},"NCT05679921","Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma",[91],"2024-03-01",[1654],"Soft Tissue Sarcoma",[1640],{"trials":1657,"activeCount":102},[],{"trials":1659,"activeCount":102},[],{"trials":1661,"activeCount":102},[],{"intervention":1663,"totalTrials":213,"cells":1664},"Trastuzumab+Nivolumab+Gemcitabine+Cisplatin",{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1669,"PHASE3":1682,"PHASE4":1684,"NA":1686},{"trials":1666,"activeCount":102},[],{"trials":1668,"activeCount":102},[],{"trials":1670,"activeCount":213,"soonestReadout":1675},[1671],{"nctId":1672,"briefTitle":1673,"status":114,"phases":1674,"primaryCompletion":1675,"completion":1676,"start":1677,"enrollment":1678,"conditions":1679,"interventions":1681},"NCT05749900","First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib\u002FII Trial (HERBOT)",[90,91],"2026-02-28","2027-02-28","2023-05-12",44,[1680],"HER2 Positive Advanced\u002FMetastatic\u002FNonresectable Biliary Tract Cancer",[1663],{"trials":1683,"activeCount":102},[],{"trials":1685,"activeCount":102},[],{"trials":1687,"activeCount":102},[],{"intervention":1426,"totalTrials":213,"cells":1689},{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1700,"PHASE4":1702,"NA":1704},{"trials":1691,"activeCount":102},[],{"trials":1693,"activeCount":102},[],{"trials":1695,"activeCount":213,"soonestReadout":1417},[1696],{"nctId":1414,"briefTitle":1415,"status":114,"phases":1697,"primaryCompletion":1417,"completion":151,"start":1418,"enrollment":1419,"conditions":1698,"interventions":1699},[91],[1421,1422,1423,1424],[1426,1405,1427],{"trials":1701,"activeCount":102},[],{"trials":1703,"activeCount":102},[],{"trials":1705,"activeCount":102},[],{"intervention":1427,"totalTrials":213,"cells":1707},{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1712,"PHASE3":1718,"PHASE4":1720,"NA":1722},{"trials":1709,"activeCount":102},[],{"trials":1711,"activeCount":102},[],{"trials":1713,"activeCount":213,"soonestReadout":1417},[1714],{"nctId":1414,"briefTitle":1415,"status":114,"phases":1715,"primaryCompletion":1417,"completion":151,"start":1418,"enrollment":1419,"conditions":1716,"interventions":1717},[91],[1421,1422,1423,1424],[1426,1405,1427],{"trials":1719,"activeCount":102},[],{"trials":1721,"activeCount":102},[],{"trials":1723,"activeCount":102},[],{"intervention":1442,"totalTrials":213,"cells":1725},{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1730,"PHASE3":1736,"PHASE4":1738,"NA":1740},{"trials":1727,"activeCount":102},[],{"trials":1729,"activeCount":102},[],{"trials":1731,"activeCount":213,"soonestReadout":1432},[1732],{"nctId":1429,"briefTitle":1430,"status":114,"phases":1733,"primaryCompletion":1432,"completion":1433,"start":152,"enrollment":1434,"conditions":1734,"interventions":1735},[91],[1436,1209,1437,1438,1439,1440],[1442,1405,1443,1444,1445,1446],{"trials":1737,"activeCount":102},[],{"trials":1739,"activeCount":102},[],{"trials":1741,"activeCount":102},[],{"intervention":1443,"totalTrials":213,"cells":1743},{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1748,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1745,"activeCount":102},[],{"trials":1747,"activeCount":102},[],{"trials":1749,"activeCount":213,"soonestReadout":1432},[1750],{"nctId":1429,"briefTitle":1430,"status":114,"phases":1751,"primaryCompletion":1432,"completion":1433,"start":152,"enrollment":1434,"conditions":1752,"interventions":1753},[91],[1436,1209,1437,1438,1439,1440],[1442,1405,1443,1444,1445,1446],{"trials":1755,"activeCount":102},[],{"trials":1757,"activeCount":102},[],{"trials":1759,"activeCount":102},[],{"intervention":1444,"totalTrials":213,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1772,"PHASE4":1774,"NA":1776},{"trials":1763,"activeCount":102},[],{"trials":1765,"activeCount":102},[],{"trials":1767,"activeCount":213,"soonestReadout":1432},[1768],{"nctId":1429,"briefTitle":1430,"status":114,"phases":1769,"primaryCompletion":1432,"completion":1433,"start":152,"enrollment":1434,"conditions":1770,"interventions":1771},[91],[1436,1209,1437,1438,1439,1440],[1442,1405,1443,1444,1445,1446],{"trials":1773,"activeCount":102},[],{"trials":1775,"activeCount":102},[],{"trials":1777,"activeCount":102},[],{"intervention":1779,"totalTrials":213,"cells":1780},"olaparib+pembrolizumab+paclitaxel",{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1798,"PHASE4":1800,"NA":1802},{"trials":1782,"activeCount":102},[],{"trials":1784,"activeCount":102},[],{"trials":1786,"activeCount":213,"soonestReadout":1791},[1787],{"nctId":1788,"briefTitle":1789,"status":114,"phases":1790,"primaryCompletion":1791,"completion":1792,"start":1793,"enrollment":1794,"conditions":1795,"interventions":1797},"NCT04592211","Pembrolizumab, Olaparib, Recurrent\u002FAdvanced Gastric and Gastro-esophageal Junction(GEJ) Cancer",[90,91],"2025-12-31","2026-05-31","2021-10-01",71,[1796],"Gastric Cancer Stage IV",[1779],{"trials":1799,"activeCount":102},[],{"trials":1801,"activeCount":102},[],{"trials":1803,"activeCount":102},[],{"intervention":1805,"totalTrials":213,"cells":1806},"ABN401",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1811,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1808,"activeCount":102},[],{"trials":1810,"activeCount":102},[],{"trials":1812,"activeCount":213,"soonestReadout":1791},[1813],{"nctId":1814,"briefTitle":1815,"status":114,"phases":1816,"primaryCompletion":1791,"completion":1791,"start":1817,"enrollment":25,"conditions":1818,"interventions":1820},"NCT05882292","c-MET Inhibitor in Advanced Solid Tumors With c-MET Gene Aberration",[91],"2023-11-10",[1819],"Neoplasms",[1805],{"trials":1822,"activeCount":102},[],{"trials":1824,"activeCount":102},[],{"trials":1826,"activeCount":102},[],{"intervention":1828,"totalTrials":213,"cells":1829},"Experimental treatment arm",{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1847,"PHASE4":1849,"NA":1851},{"trials":1831,"activeCount":102},[],{"trials":1833,"activeCount":102},[],{"trials":1835,"activeCount":213,"soonestReadout":1840},[1836],{"nctId":1837,"briefTitle":1838,"status":114,"phases":1839,"primaryCompletion":1840,"completion":1840,"start":1841,"enrollment":1842,"conditions":1843,"interventions":1845},"NCT06837792","Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer",[91],"2026-10-01","2023-10-01",141,[1844],"Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)",[1828,1846],"Control treatment arm",{"trials":1848,"activeCount":102},[],{"trials":1850,"activeCount":102},[],{"trials":1852,"activeCount":102},[],{"intervention":1846,"totalTrials":213,"cells":1854},{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1856,"activeCount":102},[],{"trials":1858,"activeCount":102},[],{"trials":1860,"activeCount":213,"soonestReadout":1840},[1861],{"nctId":1837,"briefTitle":1838,"status":114,"phases":1862,"primaryCompletion":1840,"completion":1840,"start":1841,"enrollment":1842,"conditions":1863,"interventions":1864},[91],[1844],[1828,1846],{"trials":1866,"activeCount":102},[],{"trials":1868,"activeCount":102},[],{"trials":1870,"activeCount":102},[],{"intervention":1872,"totalTrials":213,"cells":1873},"T-Dxd(Trastuzmab deruxtecan), Ramucirumab",{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1878,"PHASE3":1890,"PHASE4":1892,"NA":1894},{"trials":1875,"activeCount":102},[],{"trials":1877,"activeCount":102},[],{"trials":1879,"activeCount":213,"soonestReadout":1257},[1880],{"nctId":1881,"briefTitle":1882,"status":114,"phases":1883,"primaryCompletion":1257,"completion":1884,"start":1885,"enrollment":1886,"conditions":1887,"interventions":1889},"NCT05894824","T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",[90,91],"2026-01-01","2024-02-05",58,[21,1888],"Gastroesophageal Junction (GEJ) Cancer",[1872],{"trials":1891,"activeCount":102},[],{"trials":1893,"activeCount":102},[],{"trials":1895,"activeCount":102},[],{"intervention":1897,"totalTrials":213,"cells":1898},"SLC-3010 + Axitinib",{"EARLY_PHASE1":1899,"PHASE1":1901,"PHASE2":1903,"PHASE3":1916,"PHASE4":1918,"NA":1920},{"trials":1900,"activeCount":102},[],{"trials":1902,"activeCount":102},[],{"trials":1904,"activeCount":213,"soonestReadout":297},[1905],{"nctId":1906,"briefTitle":1907,"status":114,"phases":1908,"primaryCompletion":297,"completion":297,"start":1627,"enrollment":1909,"conditions":1910,"interventions":1914},"NCT07469683","An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma",[91],78,[1911,1819,1912,1913],"Clear Cell Renal Cell Carcinoma","Malignant Neoplasms","Malignant Neoplasm of Kidney, Except Renal Pelvis",[1897,1915],"Axitinib",{"trials":1917,"activeCount":102},[],{"trials":1919,"activeCount":102},[],{"trials":1921,"activeCount":102},[],{"intervention":1915,"totalTrials":213,"cells":1923},{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1934,"PHASE4":1936,"NA":1938},{"trials":1925,"activeCount":102},[],{"trials":1927,"activeCount":102},[],{"trials":1929,"activeCount":213,"soonestReadout":297},[1930],{"nctId":1906,"briefTitle":1907,"status":114,"phases":1931,"primaryCompletion":297,"completion":297,"start":1627,"enrollment":1909,"conditions":1932,"interventions":1933},[91],[1911,1819,1912,1913],[1897,1915],{"trials":1935,"activeCount":102},[],{"trials":1937,"activeCount":102},[],{"trials":1939,"activeCount":102},[],{"intervention":1941,"totalTrials":213,"cells":1942},"Amivantamab + FOLFIRI",{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1947,"PHASE3":1958,"PHASE4":1960,"NA":1962},{"trials":1944,"activeCount":102},[],{"trials":1946,"activeCount":102},[],{"trials":1948,"activeCount":213,"soonestReadout":1382},[1949],{"nctId":1950,"briefTitle":1951,"status":188,"phases":1952,"primaryCompletion":1382,"completion":1078,"start":1953,"enrollment":1954,"conditions":1955,"interventions":1957},"NCT06855849","An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS\u002FBRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.",[91],"2025-05",85,[1956],"RAS\u002FBRAF Wild-type Advanced Colorectal Cancer Patients",[1941],{"trials":1959,"activeCount":102},[],{"trials":1961,"activeCount":102},[],{"trials":1963,"activeCount":102},[],{"intervention":1965,"totalTrials":213,"cells":1966},"GX-188E, GX-I7, Pembrolizumab",{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1971,"PHASE3":1985,"PHASE4":1987,"NA":1989},{"trials":1968,"activeCount":102},[],{"trials":1970,"activeCount":102},[],{"trials":1972,"activeCount":213,"soonestReadout":1977},[1973],{"nctId":1974,"briefTitle":1975,"status":395,"phases":1976,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":1980,"conditions":1981,"interventions":1982},"NCT05286060","Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and\u002For 18 Positive Head and Neck Cancer",[91],"2026-10","2026-12","2022-03-01",56,[1631],[1965,1983,1965,1984],"GX-188E, Pembrolizumab","GX-188E, GX-I7",{"trials":1986,"activeCount":102},[],{"trials":1988,"activeCount":102},[],{"trials":1990,"activeCount":102},[],{"intervention":1983,"totalTrials":213,"cells":1992},{"EARLY_PHASE1":1993,"PHASE1":1995,"PHASE2":1997,"PHASE3":2003,"PHASE4":2005,"NA":2007},{"trials":1994,"activeCount":102},[],{"trials":1996,"activeCount":102},[],{"trials":1998,"activeCount":213,"soonestReadout":1977},[1999],{"nctId":1974,"briefTitle":1975,"status":395,"phases":2000,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":1980,"conditions":2001,"interventions":2002},[91],[1631],[1965,1983,1965,1984],{"trials":2004,"activeCount":102},[],{"trials":2006,"activeCount":102},[],{"trials":2008,"activeCount":102},[],{"intervention":1984,"totalTrials":213,"cells":2010},{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2021,"PHASE4":2023,"NA":2025},{"trials":2012,"activeCount":102},[],{"trials":2014,"activeCount":102},[],{"trials":2016,"activeCount":213,"soonestReadout":1977},[2017],{"nctId":1974,"briefTitle":1975,"status":395,"phases":2018,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":1980,"conditions":2019,"interventions":2020},[91],[1631],[1965,1983,1965,1984],{"trials":2022,"activeCount":102},[],{"trials":2024,"activeCount":102},[],{"trials":2026,"activeCount":102},[],{"intervention":2028,"totalTrials":213,"cells":2029},"Consolidation #4",{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2034,"PHASE3":2047,"PHASE4":2049,"NA":2051},{"trials":2031,"activeCount":102},[],{"trials":2033,"activeCount":102},[],{"trials":2035,"activeCount":213,"soonestReadout":2040},[2036],{"nctId":2037,"briefTitle":2038,"status":114,"phases":2039,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":458,"conditions":2043,"interventions":2045},"NCT06516679","Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia",[91],"2032-08-31","2032-12-31","2024-12-11",[2044],"Leukemia, Lymphoid",[2028,2028,2046],"Allogeneic hematopoietic stem cell transplantation after Consolidation #4",{"trials":2048,"activeCount":102},[],{"trials":2050,"activeCount":102},[],{"trials":2052,"activeCount":102},[],{"intervention":2046,"totalTrials":213,"cells":2054},{"EARLY_PHASE1":2055,"PHASE1":2057,"PHASE2":2059,"PHASE3":2065,"PHASE4":2067,"NA":2069},{"trials":2056,"activeCount":102},[],{"trials":2058,"activeCount":102},[],{"trials":2060,"activeCount":213,"soonestReadout":2040},[2061],{"nctId":2037,"briefTitle":2038,"status":114,"phases":2062,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":458,"conditions":2063,"interventions":2064},[91],[2044],[2028,2028,2046],{"trials":2066,"activeCount":102},[],{"trials":2068,"activeCount":102},[],{"trials":2070,"activeCount":102},[],{"intervention":1347,"totalTrials":213,"cells":2072},{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":2074,"activeCount":102},[],{"trials":2076,"activeCount":102},[],{"trials":2078,"activeCount":213,"soonestReadout":1341},[2079],{"nctId":1338,"briefTitle":1339,"status":188,"phases":2080,"primaryCompletion":1341,"completion":1341,"start":1342,"enrollment":1343,"conditions":2081,"interventions":2082},[91],[1345],[1347,1304],{"trials":2084,"activeCount":102},[],{"trials":2086,"activeCount":102},[],{"trials":2088,"activeCount":102},[],{"intervention":1283,"totalTrials":213,"cells":2090},{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2095,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2092,"activeCount":102},[],{"trials":2094,"activeCount":102},[],{"trials":2096,"activeCount":213,"soonestReadout":1078},[2097],{"nctId":1274,"briefTitle":1275,"status":114,"phases":2098,"primaryCompletion":1078,"completion":1078,"start":1068,"enrollment":1277,"conditions":2099,"interventions":2100},[91],[1210,1279,1280,1281,1209],[1283,87],{"trials":2102,"activeCount":102},[],{"trials":2104,"activeCount":102},[],{"trials":2106,"activeCount":102},[],{"intervention":2108,"totalTrials":213,"cells":2109},"Durvalumab or Pembrolizumab",{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2114,"PHASE3":2129,"PHASE4":2131,"NA":2133},{"trials":2111,"activeCount":102},[],{"trials":2113,"activeCount":102},[],{"trials":2115,"activeCount":213,"soonestReadout":2120},[2116],{"nctId":2117,"briefTitle":2118,"status":188,"phases":2119,"primaryCompletion":2120,"completion":2120,"start":191,"enrollment":1538,"conditions":2121,"interventions":2125},"NCT07269158","A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer",[90,91],"2029-09",[2122,2123,2124],"Biliary Tract Neoplasms","Advanced Cancer","Immunotherapy",[2108,2126,2127,2128],"Durvalumab or Pembrolizumab + Levnatinib","Durvalumab or Pembrolizumab + Venadaparib","Durvalumab or Pembrolizumab + SCL-3010",{"trials":2130,"activeCount":102},[],{"trials":2132,"activeCount":102},[],{"trials":2134,"activeCount":102},[],{"intervention":2126,"totalTrials":213,"cells":2136},{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2141,"PHASE3":2147,"PHASE4":2149,"NA":2151},{"trials":2138,"activeCount":102},[],{"trials":2140,"activeCount":102},[],{"trials":2142,"activeCount":213,"soonestReadout":2120},[2143],{"nctId":2117,"briefTitle":2118,"status":188,"phases":2144,"primaryCompletion":2120,"completion":2120,"start":191,"enrollment":1538,"conditions":2145,"interventions":2146},[90,91],[2122,2123,2124],[2108,2126,2127,2128],{"trials":2148,"activeCount":102},[],{"trials":2150,"activeCount":102},[],{"trials":2152,"activeCount":102},[],{"intervention":2127,"totalTrials":213,"cells":2154},{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2159,"PHASE3":2165,"PHASE4":2167,"NA":2169},{"trials":2156,"activeCount":102},[],{"trials":2158,"activeCount":102},[],{"trials":2160,"activeCount":213,"soonestReadout":2120},[2161],{"nctId":2117,"briefTitle":2118,"status":188,"phases":2162,"primaryCompletion":2120,"completion":2120,"start":191,"enrollment":1538,"conditions":2163,"interventions":2164},[90,91],[2122,2123,2124],[2108,2126,2127,2128],{"trials":2166,"activeCount":102},[],{"trials":2168,"activeCount":102},[],{"trials":2170,"activeCount":102},[],{"intervention":2128,"totalTrials":213,"cells":2172},{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2177,"PHASE3":2183,"PHASE4":2185,"NA":2187},{"trials":2174,"activeCount":102},[],{"trials":2176,"activeCount":102},[],{"trials":2178,"activeCount":213,"soonestReadout":2120},[2179],{"nctId":2117,"briefTitle":2118,"status":188,"phases":2180,"primaryCompletion":2120,"completion":2120,"start":191,"enrollment":1538,"conditions":2181,"interventions":2182},[90,91],[2122,2123,2124],[2108,2126,2127,2128],{"trials":2184,"activeCount":102},[],{"trials":2186,"activeCount":102},[],{"trials":2188,"activeCount":102},[],{"intervention":2190,"totalTrials":213,"cells":2191},"AR1005",{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2196,"PHASE3":2207,"PHASE4":2209,"NA":2211},{"trials":2193,"activeCount":102},[],{"trials":2195,"activeCount":102},[],{"trials":2197,"activeCount":213,"soonestReadout":191},[2198],{"nctId":2199,"briefTitle":2200,"status":114,"phases":2201,"primaryCompletion":191,"completion":191,"start":2202,"enrollment":344,"conditions":2203,"interventions":2205},"NCT06537076","Safety and Efficacy of AR1005 in Patients with Lewy Body Disease",[91],"2024-01-01",[2204],"Lewy Body Dementia",[2190,2206],"Rivastigmine 3 mg",{"trials":2208,"activeCount":102},[],{"trials":2210,"activeCount":102},[],{"trials":2212,"activeCount":102},[],{"intervention":2206,"totalTrials":213,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2216,"activeCount":102},[],{"trials":2218,"activeCount":102},[],{"trials":2220,"activeCount":213,"soonestReadout":191},[2221],{"nctId":2199,"briefTitle":2200,"status":114,"phases":2222,"primaryCompletion":191,"completion":191,"start":2202,"enrollment":344,"conditions":2223,"interventions":2224},[91],[2204],[2190,2206],{"trials":2226,"activeCount":102},[],{"trials":2228,"activeCount":102},[],{"trials":2230,"activeCount":102},[],{"intervention":2232,"totalTrials":213,"cells":2233},"pemetrexed+cisplatin",{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2238,"PHASE3":2250,"PHASE4":2252,"NA":2254},{"trials":2235,"activeCount":102},[],{"trials":2237,"activeCount":102},[],{"trials":2239,"activeCount":213,"soonestReadout":2244},[2240],{"nctId":2241,"briefTitle":2242,"status":114,"phases":2243,"primaryCompletion":2244,"completion":2244,"start":2245,"enrollment":2246,"conditions":2247,"interventions":2249},"NCT04605770","Pemetrexed, Cisplatin With Soft Tissue Sarcoma",[91],"2027-11-01","2020-12-22",164,[2248],"Sarcoma,Soft Tissue",[2232],{"trials":2251,"activeCount":102},[],{"trials":2253,"activeCount":102},[],{"trials":2255,"activeCount":102},[],{"intervention":2257,"totalTrials":213,"cells":2258},"Olaparib-Pembrolizumab-Bevacizumab",{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2260,"activeCount":102},[],{"trials":2262,"activeCount":102},[],{"trials":2264,"activeCount":213,"soonestReadout":607},[2265],{"nctId":2266,"briefTitle":2267,"status":2268,"phases":2269,"primaryCompletion":607,"completion":2270,"start":2271,"enrollment":1678,"conditions":2272,"interventions":2274},"NCT04361370","Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer","ENROLLING_BY_INVITATION",[91],"2026-08","2020-10-28",[2273],"Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer",[2257],{"trials":2276,"activeCount":102},[],{"trials":2278,"activeCount":102},[],{"trials":2280,"activeCount":102},[],{"intervention":2282,"totalTrials":213,"cells":2283},"STUP-001",{"EARLY_PHASE1":2284,"PHASE1":2286,"PHASE2":2288,"PHASE3":2300,"PHASE4":2302,"NA":2304},{"trials":2285,"activeCount":102},[],{"trials":2287,"activeCount":102},[],{"trials":2289,"activeCount":213,"soonestReadout":858},[2290],{"nctId":2291,"briefTitle":2292,"status":114,"phases":2293,"primaryCompletion":858,"completion":456,"start":2294,"enrollment":2295,"conditions":2296,"interventions":2299},"NCT06922890","First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A\u002FB Chronic Spinal Cord Injury",[90,91],"2025-07-30",9,[2297,2298],"Spinal Cord Injury","Chronic Spinal Cord Injury",[2282],{"trials":2301,"activeCount":102},[],{"trials":2303,"activeCount":102},[],{"trials":2305,"activeCount":102},[],{"intervention":2307,"totalTrials":213,"cells":2308},"Lazertinib\u002FPemetrexed\u002FCarboplatin",{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2313,"PHASE3":2323,"PHASE4":2325,"NA":2327},{"trials":2310,"activeCount":102},[],{"trials":2312,"activeCount":102},[],{"trials":2314,"activeCount":213,"soonestReadout":2270},[2315],{"nctId":2316,"briefTitle":2317,"status":395,"phases":2318,"primaryCompletion":2270,"completion":2270,"start":2319,"enrollment":2320,"conditions":2321,"interventions":2322},"NCT05786430","Lazertinib+Pemetrexed\u002FCarboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib",[91],"2023-04-07",87,[1540],[2307],{"trials":2324,"activeCount":102},[],{"trials":2326,"activeCount":102},[],{"trials":2328,"activeCount":102},[],{"intervention":2330,"totalTrials":213,"cells":2331},"Trastuzumab deruxtecan",{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2336,"PHASE3":2346,"PHASE4":2348,"NA":2350},{"trials":2333,"activeCount":102},[],{"trials":2335,"activeCount":102},[],{"trials":2337,"activeCount":213,"soonestReadout":1978},[2338],{"nctId":2339,"briefTitle":2340,"status":2268,"phases":2341,"primaryCompletion":1978,"completion":1978,"start":2342,"enrollment":2343,"conditions":2344,"interventions":2345},"NCT06250777","Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases",[91],"2024-07-11",27,[1396],[2330],{"trials":2347,"activeCount":102},[],{"trials":2349,"activeCount":102},[],{"trials":2351,"activeCount":102},[],{"intervention":72,"totalTrials":213,"cells":2353},{"EARLY_PHASE1":2354,"PHASE1":2356,"PHASE2":2358,"PHASE3":2367,"PHASE4":2369,"NA":2371},{"trials":2355,"activeCount":102},[],{"trials":2357,"activeCount":102},[],{"trials":2359,"activeCount":213,"soonestReadout":71},[2360],{"nctId":69,"briefTitle":70,"status":188,"phases":2361,"primaryCompletion":71,"completion":116,"start":2362,"enrollment":2363,"conditions":2364,"interventions":2366},[91],"2023-07",51,[2365],"Hepatocellular Carcinoma",[72],{"trials":2368,"activeCount":102},[],{"trials":2370,"activeCount":102},[],{"trials":2372,"activeCount":102},[],{"intervention":2374,"totalTrials":213,"cells":2375},"Bev + Gem + Doc",{"EARLY_PHASE1":2376,"PHASE1":2378,"PHASE2":2380,"PHASE3":2391,"PHASE4":2393,"NA":2395},{"trials":2377,"activeCount":102},[],{"trials":2379,"activeCount":102},[],{"trials":2381,"activeCount":213,"soonestReadout":1341},[2382],{"nctId":2383,"briefTitle":2384,"status":188,"phases":2385,"primaryCompletion":1341,"completion":1341,"start":2386,"enrollment":1277,"conditions":2387,"interventions":2389},"NCT07547592","Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma",[91],"2026-06-01",[2388],"Neoplasms of Connective and Soft Tissue With an Unspecified Anatomical Site",[2374,2390],"Gem + Doc",{"trials":2392,"activeCount":102},[],{"trials":2394,"activeCount":102},[],{"trials":2396,"activeCount":102},[],{"intervention":2390,"totalTrials":213,"cells":2398},{"EARLY_PHASE1":2399,"PHASE1":2401,"PHASE2":2403,"PHASE3":2409,"PHASE4":2411,"NA":2413},{"trials":2400,"activeCount":102},[],{"trials":2402,"activeCount":102},[],{"trials":2404,"activeCount":213,"soonestReadout":1341},[2405],{"nctId":2383,"briefTitle":2384,"status":188,"phases":2406,"primaryCompletion":1341,"completion":1341,"start":2386,"enrollment":1277,"conditions":2407,"interventions":2408},[91],[2388],[2374,2390],{"trials":2410,"activeCount":102},[],{"trials":2412,"activeCount":102},[],{"trials":2414,"activeCount":102},[],{"intervention":2416,"totalTrials":213,"cells":2417},"Amivantamab SC + Lazertinib PO",{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2422,"PHASE3":2433,"PHASE4":2435,"NA":2437},{"trials":2419,"activeCount":102},[],{"trials":2421,"activeCount":102},[],{"trials":2423,"activeCount":213,"soonestReadout":2428},[2424],{"nctId":2425,"briefTitle":2426,"status":188,"phases":2427,"primaryCompletion":2428,"completion":2428,"start":2429,"enrollment":233,"conditions":2430,"interventions":2431},"NCT07507188","Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic\u002FRecurrent Non-Small Cell Lung Cancer (INSTAR Study)",[91],"2031-01-31","2026-04-06",[1396],[2416,2432],"Amivantamab SC + Chemotherapy",{"trials":2434,"activeCount":102},[],{"trials":2436,"activeCount":102},[],{"trials":2438,"activeCount":102},[],{"intervention":2432,"totalTrials":213,"cells":2440},{"EARLY_PHASE1":2441,"PHASE1":2443,"PHASE2":2445,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2442,"activeCount":102},[],{"trials":2444,"activeCount":102},[],{"trials":2446,"activeCount":213,"soonestReadout":2428},[2447],{"nctId":2425,"briefTitle":2426,"status":188,"phases":2448,"primaryCompletion":2428,"completion":2428,"start":2429,"enrollment":233,"conditions":2449,"interventions":2450},[91],[1396],[2416,2432],{"trials":2452,"activeCount":102},[],{"trials":2454,"activeCount":102},[],{"trials":2456,"activeCount":102},[],{"intervention":52,"totalTrials":213,"cells":2458},{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2471,"PHASE4":2473,"NA":2475},{"trials":2460,"activeCount":102},[],{"trials":2462,"activeCount":102},[],{"trials":2464,"activeCount":213,"soonestReadout":51},[2465],{"nctId":49,"briefTitle":50,"status":114,"phases":2466,"primaryCompletion":51,"completion":1537,"start":2467,"enrollment":1513,"conditions":2468,"interventions":2470},[91],"2020-07-26",[2469],"Pediatric Germ Cell Tumor",[52],{"trials":2472,"activeCount":102},[],{"trials":2474,"activeCount":102},[],{"trials":2476,"activeCount":102},[],{"intervention":1446,"totalTrials":98,"cells":2478},{"EARLY_PHASE1":2479,"PHASE1":2481,"PHASE2":2483,"PHASE3":2489,"PHASE4":2491,"NA":2493},{"trials":2480,"activeCount":102},[],{"trials":2482,"activeCount":102},[],{"trials":2484,"activeCount":213,"soonestReadout":1432},[2485],{"nctId":1429,"briefTitle":1430,"status":114,"phases":2486,"primaryCompletion":1432,"completion":1433,"start":152,"enrollment":1434,"conditions":2487,"interventions":2488},[91],[1436,1209,1437,1438,1439,1440],[1442,1405,1443,1444,1445,1446],{"trials":2490,"activeCount":102},[],{"trials":2492,"activeCount":102},[],{"trials":2494,"activeCount":102},[2495],{"nctId":1454,"briefTitle":1455,"status":204,"phases":2496,"primaryCompletion":1457,"completion":1457,"start":1458,"enrollment":1243,"conditions":2497,"interventions":2498},[],[1421],[1461,1462,1446,1405],{"intervention":2500,"totalTrials":213,"cells":2501},"AB-201 Dose escalation",{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2516,"PHASE3":2518,"PHASE4":2520,"NA":2522},{"trials":2503,"activeCount":102},[],{"trials":2505,"activeCount":213,"soonestReadout":116},[2506],{"nctId":2507,"briefTitle":2508,"status":188,"phases":2509,"primaryCompletion":116,"completion":2510,"start":2511,"enrollment":2512,"conditions":2513,"interventions":2515},"NCT07333820","Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201",[90],"2028-03","2026-02",18,[2514],"Malignant Neoplasm of Stomach, Unspecified",[2500],{"trials":2517,"activeCount":102},[],{"trials":2519,"activeCount":102},[],{"trials":2521,"activeCount":102},[],{"trials":2523,"activeCount":102},[],{"intervention":2525,"totalTrials":98,"cells":2526},"Clopidogrel monotherapy",{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2533,"PHASE4":2535,"NA":2537},{"trials":2528,"activeCount":102},[],{"trials":2530,"activeCount":102},[],{"trials":2532,"activeCount":102},[],{"trials":2534,"activeCount":102},[],{"trials":2536,"activeCount":102},[],{"trials":2538,"activeCount":98,"soonestReadout":1382},[2539,2549],{"nctId":2540,"briefTitle":2541,"status":114,"phases":2542,"primaryCompletion":1382,"completion":2543,"start":2544,"enrollment":2545,"conditions":2546,"interventions":2547},"NCT05936606","Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients",[94],"2029-05","2023-08-16",3434,[15],[2525,2548],"Tailored anti-platelet therapy",{"nctId":2550,"briefTitle":2551,"status":114,"phases":2552,"primaryCompletion":2553,"completion":2553,"start":2554,"enrollment":2555,"conditions":2556,"interventions":2558},"NCT05320926","Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial",[94],"2028-07-10","2022-07-26",3744,[2557],"Ischemic Heart Disease",[2525,2559],"Aspirin monotherapy",{"intervention":2561,"totalTrials":98,"cells":2562},"high-intensity statin monotherapy",{"EARLY_PHASE1":2563,"PHASE1":2565,"PHASE2":2567,"PHASE3":2569,"PHASE4":2571,"NA":2573},{"trials":2564,"activeCount":102},[],{"trials":2566,"activeCount":102},[],{"trials":2568,"activeCount":102},[],{"trials":2570,"activeCount":102},[],{"trials":2572,"activeCount":102},[],{"trials":2574,"activeCount":98,"soonestReadout":1078},[2575,2584],{"nctId":2576,"briefTitle":2577,"status":114,"phases":2578,"primaryCompletion":1078,"completion":1078,"start":2319,"enrollment":2579,"conditions":2580,"interventions":2582},"NCT05782777","Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial",[94],4310,[2581],"Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation",[2583,2561],"ezetimibe\u002Fhigh-intensity statin combination therapy",{"nctId":2585,"briefTitle":2586,"status":188,"phases":2587,"primaryCompletion":2588,"completion":2588,"start":2386,"enrollment":2589,"conditions":2590,"interventions":2595},"NCT07524101","Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD",[94],"2031-01-22",1952,[2591,2592,2593,2594,156],"Renal Insufficiency","Atherosclerosis","Dyslipidemia","Hypercholesterolemia",[2596,2597],"Moderate-intensity statin and ezetimibe combination therapy","High-intensity statin monotherapy",{"intervention":2599,"totalTrials":98,"cells":2600},"Pegfilgrastim",{"EARLY_PHASE1":2601,"PHASE1":2603,"PHASE2":2605,"PHASE3":2618,"PHASE4":2620,"NA":2622},{"trials":2602,"activeCount":102},[],{"trials":2604,"activeCount":102},[],{"trials":2606,"activeCount":102},[2607],{"nctId":2608,"briefTitle":2609,"status":204,"phases":2610,"primaryCompletion":2611,"completion":2612,"start":2613,"enrollment":2614,"conditions":2615,"interventions":2616},"NCT03575520","Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients",[91],"2017-02-15","2017-03-15","2016-06-07",63,[30],[2599,2617],"Doxorubicin\u002FCyclophosphamide(AC) treatment",{"trials":2619,"activeCount":102},[],{"trials":2621,"activeCount":102},[],{"trials":2623,"activeCount":213,"soonestReadout":2628},[2624],{"nctId":2625,"briefTitle":2626,"status":114,"phases":2627,"primaryCompletion":2628,"completion":2628,"start":2629,"enrollment":458,"conditions":2630,"interventions":2632},"NCT07525869","An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy",[94],"2026-10-27","2025-10-28",[2631],"Triple-Negative Breast Cancer",[2599],{"intervention":62,"totalTrials":98,"cells":2634},{"EARLY_PHASE1":2635,"PHASE1":2637,"PHASE2":2639,"PHASE3":2641,"PHASE4":2643,"NA":2645},{"trials":2636,"activeCount":102},[],{"trials":2638,"activeCount":102},[],{"trials":2640,"activeCount":102},[],{"trials":2642,"activeCount":102},[],{"trials":2644,"activeCount":102},[],{"trials":2646,"activeCount":213,"soonestReadout":61},[2647,2657],{"nctId":2648,"briefTitle":2649,"status":308,"phases":2650,"primaryCompletion":2651,"completion":2651,"start":2652,"enrollment":344,"conditions":2653,"interventions":2655},"NCT04927039","Effects of Iloprost on Oxygenation During One-lung Ventilation in Supine-positioned Patients",[94],"2023-06","2021-06-24",[2654],"Mediastinal Mass",[62,2656],"20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline",{"nctId":59,"briefTitle":60,"status":395,"phases":2658,"primaryCompletion":61,"completion":2659,"start":2660,"enrollment":2661,"conditions":2662,"interventions":2665},[94],"2025-07-21","2023-04-25",90,[2663,2664],"One-lung Ventilation","Chronic Obstructive Pulmonary Disease",[62,2666],"2.5mg (2.5ml) of inhaled salbutamol and 2.5ml of inhaled normal saline",{"intervention":2668,"totalTrials":213,"cells":2669},"Beta-blocker treatment group",{"EARLY_PHASE1":2670,"PHASE1":2672,"PHASE2":2674,"PHASE3":2676,"PHASE4":2678,"NA":2680},{"trials":2671,"activeCount":102},[],{"trials":2673,"activeCount":102},[],{"trials":2675,"activeCount":102},[],{"trials":2677,"activeCount":102},[],{"trials":2679,"activeCount":102},[],{"trials":2681,"activeCount":213,"soonestReadout":1341},[2682],{"nctId":2683,"briefTitle":2684,"status":188,"phases":2685,"primaryCompletion":1341,"completion":2686,"start":687,"enrollment":2687,"conditions":2688,"interventions":2692},"NCT07123506","Beta-blockers for Prevention of Supraventricular Arrhythmia Following PFO Closure",[94],"2029-05-03",350,[18,2689,2690,2691],"Atrial Flutter","Tachycardia, Supraventricular","Heart Septal Defects, Atrial",[2668,2693],"Non-treatment group",{"intervention":2693,"totalTrials":213,"cells":2695},{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2702,"PHASE4":2704,"NA":2706},{"trials":2697,"activeCount":102},[],{"trials":2699,"activeCount":102},[],{"trials":2701,"activeCount":102},[],{"trials":2703,"activeCount":102},[],{"trials":2705,"activeCount":102},[],{"trials":2707,"activeCount":213,"soonestReadout":1341},[2708],{"nctId":2683,"briefTitle":2684,"status":188,"phases":2709,"primaryCompletion":1341,"completion":2686,"start":687,"enrollment":2687,"conditions":2710,"interventions":2711},[94],[18,2689,2690,2691],[2668,2693],{"intervention":2713,"totalTrials":213,"cells":2714},"Aspirin single antiplatelet therapy",{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2719,"PHASE3":2721,"PHASE4":2723,"NA":2725},{"trials":2716,"activeCount":102},[],{"trials":2718,"activeCount":102},[],{"trials":2720,"activeCount":102},[],{"trials":2722,"activeCount":102},[],{"trials":2724,"activeCount":102},[],{"trials":2726,"activeCount":213,"soonestReadout":2731},[2727],{"nctId":2728,"briefTitle":2729,"status":114,"phases":2730,"primaryCompletion":2731,"completion":2732,"start":2733,"enrollment":2734,"conditions":2735,"interventions":2737},"NCT05493657","Aspirin vs Clopidogrel After TAVR",[94],"2026-07-21","2027-07-21","2023-02-02",254,[2736],"Severe Aortic Stenosis",[2713,2738],"Clopidogrel single antiplatelet therapy",{"intervention":2738,"totalTrials":213,"cells":2740},{"EARLY_PHASE1":2741,"PHASE1":2743,"PHASE2":2745,"PHASE3":2747,"PHASE4":2749,"NA":2751},{"trials":2742,"activeCount":102},[],{"trials":2744,"activeCount":102},[],{"trials":2746,"activeCount":102},[],{"trials":2748,"activeCount":102},[],{"trials":2750,"activeCount":102},[],{"trials":2752,"activeCount":213,"soonestReadout":2731},[2753],{"nctId":2728,"briefTitle":2729,"status":114,"phases":2754,"primaryCompletion":2731,"completion":2732,"start":2733,"enrollment":2734,"conditions":2755,"interventions":2756},[94],[2736],[2713,2738],{"intervention":2758,"totalTrials":213,"cells":2759},"Ticagrelor-based dual-antiplatelet therapy",{"EARLY_PHASE1":2760,"PHASE1":2762,"PHASE2":2764,"PHASE3":2766,"PHASE4":2768,"NA":2770},{"trials":2761,"activeCount":102},[],{"trials":2763,"activeCount":102},[],{"trials":2765,"activeCount":102},[],{"trials":2767,"activeCount":102},[],{"trials":2769,"activeCount":102},[],{"trials":2771,"activeCount":213,"soonestReadout":608},[2772],{"nctId":2773,"briefTitle":2774,"status":188,"phases":2775,"primaryCompletion":608,"completion":608,"start":2776,"enrollment":2777,"conditions":2778,"interventions":2780},"NCT04989257","24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial",[94],"2021-08",3488,[2779],"High Ischemic Risk",[2758,2781],"Clopidogrel-based dual-antiplatelet therapy",{"intervention":2781,"totalTrials":213,"cells":2783},{"EARLY_PHASE1":2784,"PHASE1":2786,"PHASE2":2788,"PHASE3":2790,"PHASE4":2792,"NA":2794},{"trials":2785,"activeCount":102},[],{"trials":2787,"activeCount":102},[],{"trials":2789,"activeCount":102},[],{"trials":2791,"activeCount":102},[],{"trials":2793,"activeCount":102},[],{"trials":2795,"activeCount":213,"soonestReadout":608},[2796],{"nctId":2773,"briefTitle":2774,"status":188,"phases":2797,"primaryCompletion":608,"completion":608,"start":2776,"enrollment":2777,"conditions":2798,"interventions":2799},[94],[2779],[2758,2781],{"intervention":2801,"totalTrials":213,"cells":2802},"dual anti-platelet therapy at least 6 months",{"EARLY_PHASE1":2803,"PHASE1":2805,"PHASE2":2807,"PHASE3":2809,"PHASE4":2811,"NA":2813},{"trials":2804,"activeCount":102},[],{"trials":2806,"activeCount":102},[],{"trials":2808,"activeCount":102},[],{"trials":2810,"activeCount":102},[],{"trials":2812,"activeCount":102},[],{"trials":2814,"activeCount":213,"soonestReadout":2819},[2815],{"nctId":2816,"briefTitle":2817,"status":114,"phases":2818,"primaryCompletion":2819,"completion":2820,"start":2821,"enrollment":2822,"conditions":2823,"interventions":2825},"NCT04708587","Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)",[94],"2027-03-13","2028-03-13","2021-03-23",900,[2824],"Chronic Kidney Diseases",[2801,2826],"dual anti-platelet therapy 3months or less",{"intervention":2826,"totalTrials":213,"cells":2828},{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2833,"PHASE3":2835,"PHASE4":2837,"NA":2839},{"trials":2830,"activeCount":102},[],{"trials":2832,"activeCount":102},[],{"trials":2834,"activeCount":102},[],{"trials":2836,"activeCount":102},[],{"trials":2838,"activeCount":102},[],{"trials":2840,"activeCount":213,"soonestReadout":2819},[2841],{"nctId":2816,"briefTitle":2817,"status":114,"phases":2842,"primaryCompletion":2819,"completion":2820,"start":2821,"enrollment":2822,"conditions":2843,"interventions":2844},[94],[2824],[2801,2826],{"intervention":2846,"totalTrials":213,"cells":2847},"Lecanemab",{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2852,"PHASE3":2854,"PHASE4":2856,"NA":2858},{"trials":2849,"activeCount":102},[],{"trials":2851,"activeCount":102},[],{"trials":2853,"activeCount":102},[],{"trials":2855,"activeCount":102},[],{"trials":2857,"activeCount":102},[],{"trials":2859,"activeCount":213,"soonestReadout":2864},[2860],{"nctId":2861,"briefTitle":2862,"status":188,"phases":2863,"primaryCompletion":2864,"completion":2865,"start":607,"enrollment":344,"conditions":2866,"interventions":2868},"NCT07544953","Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology",[94],"2030-06","2030-11",[2867],"Parkinson Disease",[2846],{"intervention":2870,"totalTrials":213,"cells":2871},"Ifosfamide\u002Fmesna",{"EARLY_PHASE1":2872,"PHASE1":2874,"PHASE2":2876,"PHASE3":2878,"PHASE4":2880,"NA":2882},{"trials":2873,"activeCount":102},[],{"trials":2875,"activeCount":102},[],{"trials":2877,"activeCount":102},[],{"trials":2879,"activeCount":102},[],{"trials":2881,"activeCount":102},[],{"trials":2883,"activeCount":213,"soonestReadout":2888},[2884],{"nctId":2885,"briefTitle":2886,"status":114,"phases":2887,"primaryCompletion":2888,"completion":2888,"start":2889,"enrollment":344,"conditions":2890,"interventions":2892},"NCT06236789","Observation Study to Evaluate the Efficacy and Safety of Ifosfamide\u002FMesna in Patients With Metastatic Castration-resistant Prostate Cancer",[],"2026-11","2016-11",[2891],"Prostatic Neoplasm",[2870],{"intervention":2894,"totalTrials":213,"cells":2895},"Surgeon-Performed Adductor Canal Block",{"EARLY_PHASE1":2896,"PHASE1":2898,"PHASE2":2900,"PHASE3":2902,"PHASE4":2904,"NA":2906},{"trials":2897,"activeCount":102},[],{"trials":2899,"activeCount":102},[],{"trials":2901,"activeCount":102},[],{"trials":2903,"activeCount":102},[],{"trials":2905,"activeCount":102},[],{"trials":2907,"activeCount":213,"soonestReadout":2912},[2908],{"nctId":2909,"briefTitle":2910,"status":188,"phases":2911,"primaryCompletion":2912,"completion":2913,"start":2914,"enrollment":1369,"conditions":2915,"interventions":2921},"NCT07506629","Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty",[94],"2029-01-01","2029-03-01","2026-05-01",[2916,2917,2918,2919,2920],"Knee Osteoarthritis","Total Knee Arthroplasty","Postoperative Pain","Peripheral Nerve Block","Adductor Canal Block",[2894,2922],"Ultrasound-Guided Adductor Canal Block",{"intervention":2922,"totalTrials":213,"cells":2924},{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2931,"PHASE4":2933,"NA":2935},{"trials":2926,"activeCount":102},[],{"trials":2928,"activeCount":102},[],{"trials":2930,"activeCount":102},[],{"trials":2932,"activeCount":102},[],{"trials":2934,"activeCount":102},[],{"trials":2936,"activeCount":213,"soonestReadout":2912},[2937],{"nctId":2909,"briefTitle":2910,"status":188,"phases":2938,"primaryCompletion":2912,"completion":2913,"start":2914,"enrollment":1369,"conditions":2939,"interventions":2940},[94],[2916,2917,2918,2919,2920],[2894,2922],{"intervention":226,"totalTrials":213,"cells":2942},{"EARLY_PHASE1":2943,"PHASE1":2945,"PHASE2":2947,"PHASE3":2949,"PHASE4":2951,"NA":2953},{"trials":2944,"activeCount":102},[],{"trials":2946,"activeCount":102},[],{"trials":2948,"activeCount":102},[],{"trials":2950,"activeCount":102},[],{"trials":2952,"activeCount":102},[],{"trials":2954,"activeCount":213,"soonestReadout":220},[2955],{"nctId":217,"briefTitle":218,"status":188,"phases":2956,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":2957,"interventions":2958},[94],[224],[226,172],{"intervention":2548,"totalTrials":213,"cells":2960},{"EARLY_PHASE1":2961,"PHASE1":2963,"PHASE2":2965,"PHASE3":2967,"PHASE4":2969,"NA":2971},{"trials":2962,"activeCount":102},[],{"trials":2964,"activeCount":102},[],{"trials":2966,"activeCount":102},[],{"trials":2968,"activeCount":102},[],{"trials":2970,"activeCount":102},[],{"trials":2972,"activeCount":213,"soonestReadout":1382},[2973],{"nctId":2540,"briefTitle":2541,"status":114,"phases":2974,"primaryCompletion":1382,"completion":2543,"start":2544,"enrollment":2545,"conditions":2975,"interventions":2976},[94],[15],[2525,2548],{"intervention":2978,"totalTrials":213,"cells":2979},"Maxigesic",{"EARLY_PHASE1":2980,"PHASE1":2982,"PHASE2":2984,"PHASE3":2986,"PHASE4":2988,"NA":2990},{"trials":2981,"activeCount":102},[],{"trials":2983,"activeCount":102},[],{"trials":2985,"activeCount":102},[],{"trials":2987,"activeCount":102},[],{"trials":2989,"activeCount":102},[],{"trials":2991,"activeCount":213,"soonestReadout":2996},[2992],{"nctId":2993,"briefTitle":2994,"status":114,"phases":2995,"primaryCompletion":2996,"completion":2996,"start":2997,"enrollment":2998,"conditions":2999,"interventions":3000},"NCT06174363","Analgesic Efficacy of Maxigesic in Breast Cancer Surgery",[94],"2025-12-26","2023-12-28",84,[30],[2978,3001],"0.9% saline solution",{"intervention":3001,"totalTrials":213,"cells":3003},{"EARLY_PHASE1":3004,"PHASE1":3006,"PHASE2":3008,"PHASE3":3010,"PHASE4":3012,"NA":3014},{"trials":3005,"activeCount":102},[],{"trials":3007,"activeCount":102},[],{"trials":3009,"activeCount":102},[],{"trials":3011,"activeCount":102},[],{"trials":3013,"activeCount":102},[],{"trials":3015,"activeCount":213,"soonestReadout":2996},[3016],{"nctId":2993,"briefTitle":2994,"status":114,"phases":3017,"primaryCompletion":2996,"completion":2996,"start":2997,"enrollment":2998,"conditions":3018,"interventions":3019},[94],[30],[2978,3001],{"intervention":2583,"totalTrials":213,"cells":3021},{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3026,"PHASE3":3028,"PHASE4":3030,"NA":3032},{"trials":3023,"activeCount":102},[],{"trials":3025,"activeCount":102},[],{"trials":3027,"activeCount":102},[],{"trials":3029,"activeCount":102},[],{"trials":3031,"activeCount":102},[],{"trials":3033,"activeCount":213,"soonestReadout":1078},[3034],{"nctId":2576,"briefTitle":2577,"status":114,"phases":3035,"primaryCompletion":1078,"completion":1078,"start":2319,"enrollment":2579,"conditions":3036,"interventions":3037},[94],[2581],[2583,2561],{"intervention":42,"totalTrials":213,"cells":3039},{"EARLY_PHASE1":3040,"PHASE1":3042,"PHASE2":3044,"PHASE3":3046,"PHASE4":3048,"NA":3050},{"trials":3041,"activeCount":102},[],{"trials":3043,"activeCount":102},[],{"trials":3045,"activeCount":102},[],{"trials":3047,"activeCount":102},[],{"trials":3049,"activeCount":102},[],{"trials":3051,"activeCount":213,"soonestReadout":41},[3052],{"nctId":39,"briefTitle":40,"status":395,"phases":3053,"primaryCompletion":41,"completion":3054,"start":3055,"enrollment":3056,"conditions":3057,"interventions":3060},[],"2026-08-30","2014-09-01",200000,[3058,3059],"Acute Myocardial Infarction (AMI)","Type 2 Diabetes Mellitus (T2DM)",[42,3061],"DPP4 inhibitors",{"intervention":3061,"totalTrials":213,"cells":3063},{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3068,"PHASE3":3070,"PHASE4":3072,"NA":3074},{"trials":3065,"activeCount":102},[],{"trials":3067,"activeCount":102},[],{"trials":3069,"activeCount":102},[],{"trials":3071,"activeCount":102},[],{"trials":3073,"activeCount":102},[],{"trials":3075,"activeCount":213,"soonestReadout":41},[3076],{"nctId":39,"briefTitle":40,"status":395,"phases":3077,"primaryCompletion":41,"completion":3054,"start":3055,"enrollment":3056,"conditions":3078,"interventions":3079},[],[3058,3059],[42,3061],{"intervention":3081,"totalTrials":213,"cells":3082},"Combination therapy of high-intensity dose rosuvastatin and ezetimibe",{"EARLY_PHASE1":3083,"PHASE1":3085,"PHASE2":3087,"PHASE3":3089,"PHASE4":3091,"NA":3093},{"trials":3084,"activeCount":102},[],{"trials":3086,"activeCount":102},[],{"trials":3088,"activeCount":102},[],{"trials":3090,"activeCount":102},[],{"trials":3092,"activeCount":102},[],{"trials":3094,"activeCount":213,"soonestReadout":3099},[3095],{"nctId":3096,"briefTitle":3097,"status":114,"phases":3098,"primaryCompletion":3099,"completion":3100,"start":3101,"enrollment":3102,"conditions":3103,"interventions":3106},"NCT06231966","Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin\u002FEzetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)",[94],"2026-05-06","2029-05-06","2024-04-22",2462,[3104,3105],"Peripheral Artery Disease","Polyvascular Disease",[3081,3107],"Rosuvastatin monotherapy for treat-to-target",{"intervention":3107,"totalTrials":213,"cells":3109},{"EARLY_PHASE1":3110,"PHASE1":3112,"PHASE2":3114,"PHASE3":3116,"PHASE4":3118,"NA":3120},{"trials":3111,"activeCount":102},[],{"trials":3113,"activeCount":102},[],{"trials":3115,"activeCount":102},[],{"trials":3117,"activeCount":102},[],{"trials":3119,"activeCount":102},[],{"trials":3121,"activeCount":213,"soonestReadout":3099},[3122],{"nctId":3096,"briefTitle":3097,"status":114,"phases":3123,"primaryCompletion":3099,"completion":3100,"start":3101,"enrollment":3102,"conditions":3124,"interventions":3125},[94],[3104,3105],[3081,3107],{"intervention":3127,"totalTrials":213,"cells":3128},"Discontinuation strategy + Combination lipid-lowering therapy",{"EARLY_PHASE1":3129,"PHASE1":3131,"PHASE2":3133,"PHASE3":3135,"PHASE4":3137,"NA":3139},{"trials":3130,"activeCount":102},[],{"trials":3132,"activeCount":102},[],{"trials":3134,"activeCount":102},[],{"trials":3136,"activeCount":102},[],{"trials":3138,"activeCount":102},[],{"trials":3140,"activeCount":213,"soonestReadout":3145},[3141],{"nctId":3142,"briefTitle":3143,"status":188,"phases":3144,"primaryCompletion":3145,"completion":3145,"start":2511,"enrollment":3146,"conditions":3147,"interventions":3148},"NCT07432516","Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial",[94],"2033-06",4400,[15],[3127,3149,3150,3151],"Switching strategy + Combination lipid-lowering therapy","Discontinuation strategy + High-intensity statin therapy","Switching strategy + High-intensity statin therapy",{"intervention":3149,"totalTrials":213,"cells":3153},{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3160,"PHASE4":3162,"NA":3164},{"trials":3155,"activeCount":102},[],{"trials":3157,"activeCount":102},[],{"trials":3159,"activeCount":102},[],{"trials":3161,"activeCount":102},[],{"trials":3163,"activeCount":102},[],{"trials":3165,"activeCount":213,"soonestReadout":3145},[3166],{"nctId":3142,"briefTitle":3143,"status":188,"phases":3167,"primaryCompletion":3145,"completion":3145,"start":2511,"enrollment":3146,"conditions":3168,"interventions":3169},[94],[15],[3127,3149,3150,3151],{"intervention":3150,"totalTrials":213,"cells":3171},{"EARLY_PHASE1":3172,"PHASE1":3174,"PHASE2":3176,"PHASE3":3178,"PHASE4":3180,"NA":3182},{"trials":3173,"activeCount":102},[],{"trials":3175,"activeCount":102},[],{"trials":3177,"activeCount":102},[],{"trials":3179,"activeCount":102},[],{"trials":3181,"activeCount":102},[],{"trials":3183,"activeCount":213,"soonestReadout":3145},[3184],{"nctId":3142,"briefTitle":3143,"status":188,"phases":3185,"primaryCompletion":3145,"completion":3145,"start":2511,"enrollment":3146,"conditions":3186,"interventions":3187},[94],[15],[3127,3149,3150,3151],{"intervention":3151,"totalTrials":213,"cells":3189},{"EARLY_PHASE1":3190,"PHASE1":3192,"PHASE2":3194,"PHASE3":3196,"PHASE4":3198,"NA":3200},{"trials":3191,"activeCount":102},[],{"trials":3193,"activeCount":102},[],{"trials":3195,"activeCount":102},[],{"trials":3197,"activeCount":102},[],{"trials":3199,"activeCount":102},[],{"trials":3201,"activeCount":213,"soonestReadout":3145},[3202],{"nctId":3142,"briefTitle":3143,"status":188,"phases":3203,"primaryCompletion":3145,"completion":3145,"start":2511,"enrollment":3146,"conditions":3204,"interventions":3205},[94],[15],[3127,3149,3150,3151],{"intervention":3207,"totalTrials":213,"cells":3208},"Discontinuation of antiviral treatment in chronic hepatitis B cohort patients",{"EARLY_PHASE1":3209,"PHASE1":3211,"PHASE2":3213,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3210,"activeCount":102},[],{"trials":3212,"activeCount":102},[],{"trials":3214,"activeCount":102},[],{"trials":3216,"activeCount":102},[],{"trials":3218,"activeCount":102},[],{"trials":3220,"activeCount":213,"soonestReadout":2270},[3221],{"nctId":3222,"briefTitle":3223,"status":114,"phases":3224,"primaryCompletion":2270,"completion":2270,"start":3225,"enrollment":3226,"conditions":3227,"interventions":3229},"NCT04139850","The Establishment of Korean Hepatitis B Patients Cohort",[],"2015-09-25",2000,[3228],"Chronic Hepatitis B",[3207],{"intervention":3231,"totalTrials":213,"cells":3232},"midazolam with fentanyl",{"EARLY_PHASE1":3233,"PHASE1":3235,"PHASE2":3237,"PHASE3":3239,"PHASE4":3241,"NA":3243},{"trials":3234,"activeCount":102},[],{"trials":3236,"activeCount":102},[],{"trials":3238,"activeCount":102},[],{"trials":3240,"activeCount":102},[],{"trials":3242,"activeCount":102},[],{"trials":3244,"activeCount":213,"soonestReadout":1537},[3245],{"nctId":3246,"briefTitle":3247,"status":188,"phases":3248,"primaryCompletion":1537,"completion":1537,"start":3249,"enrollment":3250,"conditions":3251,"interventions":3253},"NCT03401593","Long Term Evaluation and Management of Atrial Fibrillation in Pacemaker Patients",[94],"2019-10",135,[3252],"Permanent Pacemaker Implantation",[3231],{"intervention":2596,"totalTrials":213,"cells":3255},{"EARLY_PHASE1":3256,"PHASE1":3258,"PHASE2":3260,"PHASE3":3262,"PHASE4":3264,"NA":3266},{"trials":3257,"activeCount":102},[],{"trials":3259,"activeCount":102},[],{"trials":3261,"activeCount":102},[],{"trials":3263,"activeCount":102},[],{"trials":3265,"activeCount":102},[],{"trials":3267,"activeCount":213,"soonestReadout":2588},[3268],{"nctId":2585,"briefTitle":2586,"status":188,"phases":3269,"primaryCompletion":2588,"completion":2588,"start":2386,"enrollment":2589,"conditions":3270,"interventions":3271},[94],[2591,2592,2593,2594,156],[2596,2597],{"intervention":3273,"totalTrials":213,"cells":3274},"Anticoagulation Monotherapy",{"EARLY_PHASE1":3275,"PHASE1":3277,"PHASE2":3279,"PHASE3":3281,"PHASE4":3283,"NA":3285},{"trials":3276,"activeCount":102},[],{"trials":3278,"activeCount":102},[],{"trials":3280,"activeCount":102},[],{"trials":3282,"activeCount":102},[],{"trials":3284,"activeCount":102},[],{"trials":3286,"activeCount":213,"soonestReadout":3291},[3287],{"nctId":3288,"briefTitle":3289,"status":188,"phases":3290,"primaryCompletion":3291,"completion":3291,"start":3292,"enrollment":3293,"conditions":3294,"interventions":3295},"NCT06866665","Antithrombotic Strategy for AF Patients With High Risk CAD",[94],"2030-12","2025-03",1400,[18,15],[3273,3296],"Combination therapy",{"intervention":3296,"totalTrials":213,"cells":3298},{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3303,"PHASE3":3305,"PHASE4":3307,"NA":3309},{"trials":3300,"activeCount":102},[],{"trials":3302,"activeCount":102},[],{"trials":3304,"activeCount":102},[],{"trials":3306,"activeCount":102},[],{"trials":3308,"activeCount":102},[],{"trials":3310,"activeCount":213,"soonestReadout":3291},[3311],{"nctId":3288,"briefTitle":3289,"status":188,"phases":3312,"primaryCompletion":3291,"completion":3291,"start":3292,"enrollment":3293,"conditions":3313,"interventions":3314},[94],[18,15],[3273,3296],{"intervention":2559,"totalTrials":213,"cells":3316},{"EARLY_PHASE1":3317,"PHASE1":3319,"PHASE2":3321,"PHASE3":3323,"PHASE4":3325,"NA":3327},{"trials":3318,"activeCount":102},[],{"trials":3320,"activeCount":102},[],{"trials":3322,"activeCount":102},[],{"trials":3324,"activeCount":102},[],{"trials":3326,"activeCount":102},[],{"trials":3328,"activeCount":213,"soonestReadout":2553},[3329],{"nctId":2550,"briefTitle":2551,"status":114,"phases":3330,"primaryCompletion":2553,"completion":2553,"start":2554,"enrollment":2555,"conditions":3331,"interventions":3332},[94],[2557],[2525,2559],{"intervention":2666,"totalTrials":213,"cells":3334},{"EARLY_PHASE1":3335,"PHASE1":3337,"PHASE2":3339,"PHASE3":3341,"PHASE4":3343,"NA":3345},{"trials":3336,"activeCount":102},[],{"trials":3338,"activeCount":102},[],{"trials":3340,"activeCount":102},[],{"trials":3342,"activeCount":102},[],{"trials":3344,"activeCount":102},[],{"trials":3346,"activeCount":213,"soonestReadout":61},[3347],{"nctId":59,"briefTitle":60,"status":395,"phases":3348,"primaryCompletion":61,"completion":2659,"start":2660,"enrollment":2661,"conditions":3349,"interventions":3350},[94],[2663,2664],[62,2666],{"intervention":3352,"totalTrials":213,"cells":3353},"Intensive control of SBP and intensive control of LDL-C",{"EARLY_PHASE1":3354,"PHASE1":3356,"PHASE2":3358,"PHASE3":3360,"PHASE4":3362,"NA":3364},{"trials":3355,"activeCount":102},[],{"trials":3357,"activeCount":102},[],{"trials":3359,"activeCount":102},[],{"trials":3361,"activeCount":102},[],{"trials":3363,"activeCount":102},[],{"trials":3365,"activeCount":213,"soonestReadout":3370},[3366],{"nctId":3367,"briefTitle":3368,"status":114,"phases":3369,"primaryCompletion":3370,"completion":3371,"start":3372,"enrollment":3373,"conditions":3374,"interventions":3376},"NCT06322056","Exploring Approaches With Lower Targets of Blood Pressure and Lipid for Improving Renal Outcome in Advanced Chronic Kidney Disease",[94],"2029-05-31","2029-08-31","2024-05-13",642,[2824,3375,664],"Hypertension",[3352,3377,3378,3379],"Intensive control of SBP and standard control of LDL-C","Standard control of SBP and intensive control of LDL-C","Standard control of SBP and standard control of LDL-C",{"intervention":3377,"totalTrials":213,"cells":3381},{"EARLY_PHASE1":3382,"PHASE1":3384,"PHASE2":3386,"PHASE3":3388,"PHASE4":3390,"NA":3392},{"trials":3383,"activeCount":102},[],{"trials":3385,"activeCount":102},[],{"trials":3387,"activeCount":102},[],{"trials":3389,"activeCount":102},[],{"trials":3391,"activeCount":102},[],{"trials":3393,"activeCount":213,"soonestReadout":3370},[3394],{"nctId":3367,"briefTitle":3368,"status":114,"phases":3395,"primaryCompletion":3370,"completion":3371,"start":3372,"enrollment":3373,"conditions":3396,"interventions":3397},[94],[2824,3375,664],[3352,3377,3378,3379],{"intervention":3378,"totalTrials":213,"cells":3399},{"EARLY_PHASE1":3400,"PHASE1":3402,"PHASE2":3404,"PHASE3":3406,"PHASE4":3408,"NA":3410},{"trials":3401,"activeCount":102},[],{"trials":3403,"activeCount":102},[],{"trials":3405,"activeCount":102},[],{"trials":3407,"activeCount":102},[],{"trials":3409,"activeCount":102},[],{"trials":3411,"activeCount":213,"soonestReadout":3370},[3412],{"nctId":3367,"briefTitle":3368,"status":114,"phases":3413,"primaryCompletion":3370,"completion":3371,"start":3372,"enrollment":3373,"conditions":3414,"interventions":3415},[94],[2824,3375,664],[3352,3377,3378,3379],{"intervention":3379,"totalTrials":213,"cells":3417},{"EARLY_PHASE1":3418,"PHASE1":3420,"PHASE2":3422,"PHASE3":3424,"PHASE4":3426,"NA":3428},{"trials":3419,"activeCount":102},[],{"trials":3421,"activeCount":102},[],{"trials":3423,"activeCount":102},[],{"trials":3425,"activeCount":102},[],{"trials":3427,"activeCount":102},[],{"trials":3429,"activeCount":213,"soonestReadout":3370},[3430],{"nctId":3367,"briefTitle":3368,"status":114,"phases":3431,"primaryCompletion":3370,"completion":3371,"start":3372,"enrollment":3373,"conditions":3432,"interventions":3433},[94],[2824,3375,664],[3352,3377,3378,3379],{"intervention":3435,"totalTrials":946,"cells":3436},"Entecavir",{"EARLY_PHASE1":3437,"PHASE1":3439,"PHASE2":3441,"PHASE3":3443,"PHASE4":3445,"NA":3474},{"trials":3438,"activeCount":102},[],{"trials":3440,"activeCount":102},[],{"trials":3442,"activeCount":102},[],{"trials":3444,"activeCount":102},[],{"trials":3446,"activeCount":102},[3447,3458,3464],{"nctId":3448,"briefTitle":3449,"status":204,"phases":3450,"primaryCompletion":3451,"completion":3452,"start":3453,"enrollment":1501,"conditions":3454,"interventions":3456},"NCT00625560","Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA",[93],"2009-11","2010-11","2008-02",[3455],"Hepatitis B, Chronic",[3435,3457],"Lamivudine",{"nctId":3459,"briefTitle":3460,"status":204,"phases":3461,"primaryCompletion":3452,"completion":3452,"start":3453,"enrollment":1501,"conditions":3462,"interventions":3463},"NCT00625339","Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA",[93],[3455],[3435,3457],{"nctId":3465,"briefTitle":3466,"status":308,"phases":3467,"primaryCompletion":3468,"completion":3469,"start":3470,"enrollment":3471,"conditions":3472,"interventions":3473},"NCT00823550","Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients",[93],"2014-07","2015-07","2009-01",462,[3455],[3435,3457],{"trials":3475,"activeCount":102},[],{"intervention":3457,"totalTrials":946,"cells":3477},{"EARLY_PHASE1":3478,"PHASE1":3480,"PHASE2":3482,"PHASE3":3484,"PHASE4":3486,"NA":3500},{"trials":3479,"activeCount":102},[],{"trials":3481,"activeCount":102},[],{"trials":3483,"activeCount":102},[],{"trials":3485,"activeCount":102},[],{"trials":3487,"activeCount":102},[3488,3492,3496],{"nctId":3448,"briefTitle":3449,"status":204,"phases":3489,"primaryCompletion":3451,"completion":3452,"start":3453,"enrollment":1501,"conditions":3490,"interventions":3491},[93],[3455],[3435,3457],{"nctId":3459,"briefTitle":3460,"status":204,"phases":3493,"primaryCompletion":3452,"completion":3452,"start":3453,"enrollment":1501,"conditions":3494,"interventions":3495},[93],[3455],[3435,3457],{"nctId":3465,"briefTitle":3466,"status":308,"phases":3497,"primaryCompletion":3468,"completion":3469,"start":3470,"enrollment":3471,"conditions":3498,"interventions":3499},[93],[3455],[3435,3457],{"trials":3501,"activeCount":102},[],{"intervention":3503,"totalTrials":98,"cells":3504},"Desflurane balanced anesthesia",{"EARLY_PHASE1":3505,"PHASE1":3507,"PHASE2":3509,"PHASE3":3511,"PHASE4":3513,"NA":3534},{"trials":3506,"activeCount":102},[],{"trials":3508,"activeCount":102},[],{"trials":3510,"activeCount":102},[],{"trials":3512,"activeCount":102},[],{"trials":3514,"activeCount":102},[3515,3525],{"nctId":3516,"briefTitle":3517,"status":204,"phases":3518,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":173,"conditions":3521,"interventions":3523},"NCT01870011","A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Renal Protection During Deceased Brain Dead Donor Kidney Transplantation - A Prospective, Randomized Trial",[93],"2014-11","2013-12",[3522],"End Stage Renal Disease",[3503,3524],"Propofol total intravenous anesthesia",{"nctId":3526,"briefTitle":3527,"status":204,"phases":3528,"primaryCompletion":3529,"completion":3529,"start":981,"enrollment":3530,"conditions":3531,"interventions":3533},"NCT02504138","A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Hepatic Protection During Living-donor Liver Transplantation",[93],"2017-05",136,[3532],"End Stage Liver Disease",[3503,3524],{"trials":3535,"activeCount":102},[],{"intervention":3524,"totalTrials":98,"cells":3537},{"EARLY_PHASE1":3538,"PHASE1":3540,"PHASE2":3542,"PHASE3":3544,"PHASE4":3546,"NA":3556},{"trials":3539,"activeCount":102},[],{"trials":3541,"activeCount":102},[],{"trials":3543,"activeCount":102},[],{"trials":3545,"activeCount":102},[],{"trials":3547,"activeCount":102},[3548,3552],{"nctId":3516,"briefTitle":3517,"status":204,"phases":3549,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":173,"conditions":3550,"interventions":3551},[93],[3522],[3503,3524],{"nctId":3526,"briefTitle":3527,"status":204,"phases":3553,"primaryCompletion":3529,"completion":3529,"start":981,"enrollment":3530,"conditions":3554,"interventions":3555},[93],[3532],[3503,3524],{"trials":3557,"activeCount":102},[],{"intervention":3559,"totalTrials":98,"cells":3560},"Lipid modification",{"EARLY_PHASE1":3561,"PHASE1":3563,"PHASE2":3565,"PHASE3":3567,"PHASE4":3569,"NA":3591},{"trials":3562,"activeCount":102},[],{"trials":3564,"activeCount":102},[],{"trials":3566,"activeCount":102},[],{"trials":3568,"activeCount":102},[],{"trials":3570,"activeCount":102},[3571,3580],{"nctId":3572,"briefTitle":3573,"status":204,"phases":3574,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":369,"conditions":3577,"interventions":3579},"NCT01414803","Tolerability and Efficacy of Rosuvastatin - Fenofibrate Combine Therapy in Korean Patients With Combined Hyperlipidemia",[93],"2011-04","2009-03",[3578],"Hyperlipidemia",[3559,3559],{"nctId":3581,"briefTitle":3582,"status":204,"phases":3583,"primaryCompletion":3584,"completion":3584,"start":3585,"enrollment":3586,"conditions":3587,"interventions":3589},"NCT01122355","Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol",[93],"2010-01","2009-02",240,[3588],"Hypertriglyceridemia With Low HDL-cholesterol",[3590],"lipid modification",{"trials":3592,"activeCount":102},[],{"intervention":291,"totalTrials":98,"cells":3594},{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3599,"PHASE3":3601,"PHASE4":3603,"NA":3613},{"trials":3596,"activeCount":102},[],{"trials":3598,"activeCount":102},[],{"trials":3600,"activeCount":102},[],{"trials":3602,"activeCount":102},[],{"trials":3604,"activeCount":102},[3605,3609],{"nctId":280,"briefTitle":281,"status":243,"phases":3606,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":3607,"interventions":3608},[93],[287,288,289],[291,266],{"nctId":306,"briefTitle":307,"status":308,"phases":3610,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":3611,"interventions":3612},[93],[314],[291,266],{"trials":3614,"activeCount":102},[],{"intervention":968,"totalTrials":98,"cells":3616},{"EARLY_PHASE1":3617,"PHASE1":3619,"PHASE2":3621,"PHASE3":3623,"PHASE4":3625,"NA":3639},{"trials":3618,"activeCount":102},[],{"trials":3620,"activeCount":102},[],{"trials":3622,"activeCount":102},[],{"trials":3624,"activeCount":102},[],{"trials":3626,"activeCount":102},[3627,3635],{"nctId":3628,"briefTitle":3629,"status":204,"phases":3630,"primaryCompletion":3631,"completion":284,"start":3451,"enrollment":1538,"conditions":3632,"interventions":3633},"NCT01857843","Early Effects of Intensive Lipid Lowering Treatment With Ezetimibe\u002F Simvastatin (Vytorin®) Assessed by Virtual Histology-Intravascular Ultrasound (VH-IVUS) and Optical Coherence Tomography (OCT) on Plaque Characteristics in Patients With Acute Coronary Syndrome",[93],"2013-11",[287],[3634,968],"Ezetimibe 10mg & Simvastatin 40mg",{"nctId":959,"briefTitle":960,"status":204,"phases":3636,"primaryCompletion":962,"completion":963,"start":964,"enrollment":344,"conditions":3637,"interventions":3638},[93],[966],[968,77],{"trials":3640,"activeCount":102},[],{"intervention":326,"totalTrials":98,"cells":3642},{"EARLY_PHASE1":3643,"PHASE1":3645,"PHASE2":3647,"PHASE3":3649,"PHASE4":3651,"NA":3667},{"trials":3644,"activeCount":102},[],{"trials":3646,"activeCount":102},[],{"trials":3648,"activeCount":102},[],{"trials":3650,"activeCount":102},[],{"trials":3652,"activeCount":102},[3653,3663],{"nctId":3654,"briefTitle":3655,"status":204,"phases":3656,"primaryCompletion":3657,"completion":3658,"start":3575,"enrollment":1277,"conditions":3659,"interventions":3661},"NCT01612273","The Effect of Triflusal on Peripheral Microcirculation Dysfunction",[93],"2013-01","2013-06",[3660],"Vasospastic Syndrome",[3662,326],"Triflusal",{"nctId":317,"briefTitle":318,"status":204,"phases":3664,"primaryCompletion":320,"completion":320,"start":321,"enrollment":322,"conditions":3665,"interventions":3666},[93],[15],[325,326,266],{"trials":3668,"activeCount":102},[],{"intervention":3670,"totalTrials":213,"cells":3671},"Beta-blocker-Atenolol 50mg, PO(peroral), Once daily",{"EARLY_PHASE1":3672,"PHASE1":3674,"PHASE2":3676,"PHASE3":3678,"PHASE4":3680,"NA":3692},{"trials":3673,"activeCount":102},[],{"trials":3675,"activeCount":102},[],{"trials":3677,"activeCount":102},[],{"trials":3679,"activeCount":102},[],{"trials":3681,"activeCount":102},[3682],{"nctId":3683,"briefTitle":3684,"status":204,"phases":3685,"primaryCompletion":3686,"completion":3686,"start":284,"enrollment":3687,"conditions":3688,"interventions":3690},"NCT01904981","Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm and Hypertension (BASE Trial)",[93],"2017-04-18",19,[3689],"Small Abdominal Aortic Aneurysm",[3670,3691],"Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily",{"trials":3693,"activeCount":102},[],{"intervention":3691,"totalTrials":213,"cells":3695},{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3700,"PHASE3":3702,"PHASE4":3704,"NA":3710},{"trials":3697,"activeCount":102},[],{"trials":3699,"activeCount":102},[],{"trials":3701,"activeCount":102},[],{"trials":3703,"activeCount":102},[],{"trials":3705,"activeCount":102},[3706],{"nctId":3683,"briefTitle":3684,"status":204,"phases":3707,"primaryCompletion":3686,"completion":3686,"start":284,"enrollment":3687,"conditions":3708,"interventions":3709},[93],[3689],[3670,3691],{"trials":3711,"activeCount":102},[],{"intervention":3713,"totalTrials":213,"cells":3714},"A) TEST",{"EARLY_PHASE1":3715,"PHASE1":3717,"PHASE2":3719,"PHASE3":3721,"PHASE4":3723,"NA":3736},{"trials":3716,"activeCount":102},[],{"trials":3718,"activeCount":102},[],{"trials":3720,"activeCount":102},[],{"trials":3722,"activeCount":102},[],{"trials":3724,"activeCount":102},[3725],{"nctId":3726,"briefTitle":3727,"status":204,"phases":3728,"primaryCompletion":3729,"completion":3729,"start":3730,"enrollment":3731,"conditions":3732,"interventions":3734},"NCT01680952","Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients",[93],"2016-01","2012-09",158,[3733],"Kidney Transplant Patients",[3713,3735],"B) CONTROL",{"trials":3737,"activeCount":102},[],{"intervention":3735,"totalTrials":213,"cells":3739},{"EARLY_PHASE1":3740,"PHASE1":3742,"PHASE2":3744,"PHASE3":3746,"PHASE4":3748,"NA":3754},{"trials":3741,"activeCount":102},[],{"trials":3743,"activeCount":102},[],{"trials":3745,"activeCount":102},[],{"trials":3747,"activeCount":102},[],{"trials":3749,"activeCount":102},[3750],{"nctId":3726,"briefTitle":3727,"status":204,"phases":3751,"primaryCompletion":3729,"completion":3729,"start":3730,"enrollment":3731,"conditions":3752,"interventions":3753},[93],[3733],[3713,3735],{"trials":3755,"activeCount":102},[],{"intervention":3757,"totalTrials":213,"cells":3758},"GIK solution",{"EARLY_PHASE1":3759,"PHASE1":3761,"PHASE2":3763,"PHASE3":3765,"PHASE4":3767,"NA":3778},{"trials":3760,"activeCount":102},[],{"trials":3762,"activeCount":102},[],{"trials":3764,"activeCount":102},[],{"trials":3766,"activeCount":102},[],{"trials":3768,"activeCount":102},[3769],{"nctId":3770,"briefTitle":3771,"status":204,"phases":3772,"primaryCompletion":3773,"completion":3773,"start":3774,"enrollment":3775,"conditions":3776,"interventions":3777},"NCT01384656","Effect of Glucose-insulin-potassium Solution on Myocardial Protection During Off-pump Coronary Bypass Surgery in Patients With Acute Coronary Syndrome",[93],"2012-02","2011-02",66,[287],[3757],{"trials":3779,"activeCount":102},[],{"intervention":3781,"totalTrials":213,"cells":3782},"Levetiracetam",{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3787,"PHASE3":3789,"PHASE4":3791,"NA":3803},{"trials":3784,"activeCount":102},[],{"trials":3786,"activeCount":102},[],{"trials":3788,"activeCount":102},[],{"trials":3790,"activeCount":102},[],{"trials":3792,"activeCount":102},[3793],{"nctId":3794,"briefTitle":3795,"status":204,"phases":3796,"primaryCompletion":3520,"completion":3797,"start":3798,"enrollment":1259,"conditions":3799,"interventions":3801},"NCT02208492","The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study",[93],"2014-02","2011-09",[3800],"Focal Epilepsy",[3781,3802],"Carabamazepine",{"trials":3804,"activeCount":102},[],{"intervention":3802,"totalTrials":213,"cells":3806},{"EARLY_PHASE1":3807,"PHASE1":3809,"PHASE2":3811,"PHASE3":3813,"PHASE4":3815,"NA":3821},{"trials":3808,"activeCount":102},[],{"trials":3810,"activeCount":102},[],{"trials":3812,"activeCount":102},[],{"trials":3814,"activeCount":102},[],{"trials":3816,"activeCount":102},[3817],{"nctId":3794,"briefTitle":3795,"status":204,"phases":3818,"primaryCompletion":3520,"completion":3797,"start":3798,"enrollment":1259,"conditions":3819,"interventions":3820},[93],[3800],[3781,3802],{"trials":3822,"activeCount":102},[],{"intervention":3824,"totalTrials":213,"cells":3825},"adenosine infusion treatment",{"EARLY_PHASE1":3826,"PHASE1":3828,"PHASE2":3830,"PHASE3":3832,"PHASE4":3834,"NA":3846},{"trials":3827,"activeCount":102},[],{"trials":3829,"activeCount":102},[],{"trials":3831,"activeCount":102},[],{"trials":3833,"activeCount":102},[],{"trials":3835,"activeCount":102},[3836],{"nctId":3837,"briefTitle":3838,"status":243,"phases":3839,"primaryCompletion":3840,"completion":3840,"start":3841,"enrollment":3842,"conditions":3843,"interventions":3845},"NCT01918111","Effects of REnal Denervation for Resistant Hypertension on Exercise Diastolic Function and Regression of Atherosclerosis and the Evaluation of NEW Methods Predicting A successfuL Renal Sympathetic Denervation (RENEWAL-EXERCISE, -REGRESS, and -PREDICT Trial From RENEWAL RDN Registry)",[93],"2016-05-27","2013-08",16,[3844],"Resistant Hypertension",[3824],{"trials":3847,"activeCount":102},[],{"intervention":3849,"totalTrials":213,"cells":3850},"Entecavir + Tenofovir",{"EARLY_PHASE1":3851,"PHASE1":3853,"PHASE2":3855,"PHASE3":3857,"PHASE4":3859,"NA":3869},{"trials":3852,"activeCount":102},[],{"trials":3854,"activeCount":102},[],{"trials":3856,"activeCount":102},[],{"trials":3858,"activeCount":102},[],{"trials":3860,"activeCount":102},[3861],{"nctId":3862,"briefTitle":3863,"status":308,"phases":3864,"primaryCompletion":3865,"completion":3865,"start":3866,"enrollment":2661,"conditions":3867,"interventions":3868},"NCT01594905","Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection",[93],"2014-04","2012-08",[3228],[3849],{"trials":3870,"activeCount":102},[],{"intervention":3872,"totalTrials":213,"cells":3873},"subconjunctival triamcinolone",{"EARLY_PHASE1":3874,"PHASE1":3876,"PHASE2":3878,"PHASE3":3880,"PHASE4":3882,"NA":3893},{"trials":3875,"activeCount":102},[],{"trials":3877,"activeCount":102},[],{"trials":3879,"activeCount":102},[],{"trials":3881,"activeCount":102},[],{"trials":3883,"activeCount":102},[3884],{"nctId":3885,"briefTitle":3886,"status":204,"phases":3887,"primaryCompletion":3888,"completion":3888,"start":3889,"enrollment":1243,"conditions":3890,"interventions":3892},"NCT01599273","Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections",[93],"2014-08","2012-05",[3891],"Thyroid-associated Ophthalmopathy",[3872],{"trials":3894,"activeCount":102},[],{"intervention":3896,"totalTrials":213,"cells":3897},"Prostaglandin I2",{"EARLY_PHASE1":3898,"PHASE1":3900,"PHASE2":3902,"PHASE3":3904,"PHASE4":3906,"NA":3917},{"trials":3899,"activeCount":102},[],{"trials":3901,"activeCount":102},[],{"trials":3903,"activeCount":102},[],{"trials":3905,"activeCount":102},[],{"trials":3907,"activeCount":102},[3908],{"nctId":3909,"briefTitle":3910,"status":204,"phases":3911,"primaryCompletion":3912,"completion":3912,"start":3584,"enrollment":834,"conditions":3913,"interventions":3916},"NCT01061060","The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients",[93],"2010-10",[3914,3915],"Type 2 Diabetes Mellitus","Peripheral Microvascular Symptoms",[3896],{"trials":3918,"activeCount":102},[],{"intervention":3920,"totalTrials":213,"cells":3921},"fentanyl citrate",{"EARLY_PHASE1":3922,"PHASE1":3924,"PHASE2":3926,"PHASE3":3928,"PHASE4":3930,"NA":3942},{"trials":3923,"activeCount":102},[],{"trials":3925,"activeCount":102},[],{"trials":3927,"activeCount":102},[],{"trials":3929,"activeCount":102},[],{"trials":3931,"activeCount":102},[3932],{"nctId":3933,"briefTitle":3934,"status":204,"phases":3935,"primaryCompletion":3936,"completion":3936,"start":3937,"enrollment":1513,"conditions":3938,"interventions":3940},"NCT01308320","Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia",[93],"2010-07","2010-02",[3939],"Thyroid Neoplasm",[3920,3941],"saline",{"trials":3943,"activeCount":102},[],{"intervention":3945,"totalTrials":213,"cells":3946},"TZD group",{"EARLY_PHASE1":3947,"PHASE1":3949,"PHASE2":3951,"PHASE3":3953,"PHASE4":3955,"NA":3968},{"trials":3948,"activeCount":102},[],{"trials":3950,"activeCount":102},[],{"trials":3952,"activeCount":102},[],{"trials":3954,"activeCount":102},[],{"trials":3956,"activeCount":102},[3957],{"nctId":3958,"briefTitle":3959,"status":204,"phases":3960,"primaryCompletion":3961,"completion":3962,"start":3963,"enrollment":3964,"conditions":3965,"interventions":3966},"NCT04013581","Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen",[93],"2020-05-13","2020-05-28","2019-08-05",121,[3914],[3945,3967],"SGLT-2 group",{"trials":3969,"activeCount":102},[],{"intervention":3967,"totalTrials":213,"cells":3971},{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3976,"PHASE3":3978,"PHASE4":3980,"NA":3986},{"trials":3973,"activeCount":102},[],{"trials":3975,"activeCount":102},[],{"trials":3977,"activeCount":102},[],{"trials":3979,"activeCount":102},[],{"trials":3981,"activeCount":102},[3982],{"nctId":3958,"briefTitle":3959,"status":204,"phases":3983,"primaryCompletion":3961,"completion":3962,"start":3963,"enrollment":3964,"conditions":3984,"interventions":3985},[93],[3914],[3945,3967],{"trials":3987,"activeCount":102},[],{"intervention":3989,"totalTrials":213,"cells":3990},"ramosetron 0.3",{"EARLY_PHASE1":3991,"PHASE1":3993,"PHASE2":3995,"PHASE3":3997,"PHASE4":3999,"NA":4013},{"trials":3992,"activeCount":102},[],{"trials":3994,"activeCount":102},[],{"trials":3996,"activeCount":102},[],{"trials":3998,"activeCount":102},[],{"trials":4000,"activeCount":102},[4001],{"nctId":4002,"briefTitle":4003,"status":204,"phases":4004,"primaryCompletion":4005,"completion":4005,"start":4006,"enrollment":4007,"conditions":4008,"interventions":4010},"NCT02478645","Dose-ranging Study of Ramosetron for the Prevention of Nausea and Vomiting After Gynecologic Laparoscopic Surgery",[93],"2016-02-06","2015-06-19",177,[4009],"Postoperative Nausea and Vomiting",[3989,4011,4012],"ramosetron 0.45","ramosetron 0.6",{"trials":4014,"activeCount":102},[],{"intervention":4011,"totalTrials":213,"cells":4016},{"EARLY_PHASE1":4017,"PHASE1":4019,"PHASE2":4021,"PHASE3":4023,"PHASE4":4025,"NA":4031},{"trials":4018,"activeCount":102},[],{"trials":4020,"activeCount":102},[],{"trials":4022,"activeCount":102},[],{"trials":4024,"activeCount":102},[],{"trials":4026,"activeCount":102},[4027],{"nctId":4002,"briefTitle":4003,"status":204,"phases":4028,"primaryCompletion":4005,"completion":4005,"start":4006,"enrollment":4007,"conditions":4029,"interventions":4030},[93],[4009],[3989,4011,4012],{"trials":4032,"activeCount":102},[],{"intervention":4012,"totalTrials":213,"cells":4034},{"EARLY_PHASE1":4035,"PHASE1":4037,"PHASE2":4039,"PHASE3":4041,"PHASE4":4043,"NA":4049},{"trials":4036,"activeCount":102},[],{"trials":4038,"activeCount":102},[],{"trials":4040,"activeCount":102},[],{"trials":4042,"activeCount":102},[],{"trials":4044,"activeCount":102},[4045],{"nctId":4002,"briefTitle":4003,"status":204,"phases":4046,"primaryCompletion":4005,"completion":4005,"start":4006,"enrollment":4007,"conditions":4047,"interventions":4048},[93],[4009],[3989,4011,4012],{"trials":4050,"activeCount":102},[],{"intervention":4052,"totalTrials":213,"cells":4053},"fixed high potent statin therapy",{"EARLY_PHASE1":4054,"PHASE1":4056,"PHASE2":4058,"PHASE3":4060,"PHASE4":4062,"NA":4074},{"trials":4055,"activeCount":102},[],{"trials":4057,"activeCount":102},[],{"trials":4059,"activeCount":102},[],{"trials":4061,"activeCount":102},[],{"trials":4063,"activeCount":102},[4064],{"nctId":4065,"briefTitle":4066,"status":308,"phases":4067,"primaryCompletion":4068,"completion":4068,"start":4069,"enrollment":3146,"conditions":4070,"interventions":4072},"NCT02579499","Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease",[93],"2022-11","2016-09-09",[4071],"Coronary Artery Diseasse",[4052,4073],"targeted LDL-C goal statin",{"trials":4075,"activeCount":102},[],{"intervention":4073,"totalTrials":213,"cells":4077},{"EARLY_PHASE1":4078,"PHASE1":4080,"PHASE2":4082,"PHASE3":4084,"PHASE4":4086,"NA":4092},{"trials":4079,"activeCount":102},[],{"trials":4081,"activeCount":102},[],{"trials":4083,"activeCount":102},[],{"trials":4085,"activeCount":102},[],{"trials":4087,"activeCount":102},[4088],{"nctId":4065,"briefTitle":4066,"status":308,"phases":4089,"primaryCompletion":4068,"completion":4068,"start":4069,"enrollment":3146,"conditions":4090,"interventions":4091},[93],[4071],[4052,4073],{"trials":4093,"activeCount":102},[],{"intervention":4095,"totalTrials":213,"cells":4096},"Ipragliflozin",{"EARLY_PHASE1":4097,"PHASE1":4099,"PHASE2":4101,"PHASE3":4103,"PHASE4":4105,"NA":4117},{"trials":4098,"activeCount":102},[],{"trials":4100,"activeCount":102},[],{"trials":4102,"activeCount":102},[],{"trials":4104,"activeCount":102},[],{"trials":4106,"activeCount":102},[4107],{"nctId":4108,"briefTitle":4109,"status":204,"phases":4110,"primaryCompletion":4111,"completion":4111,"start":4112,"enrollment":1678,"conditions":4113,"interventions":4115},"NCT02875821","Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone",[93],"2017-06-07","2016-04-26",[4114],"Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)",[4095,4116],"metformin with pioglitazone",{"trials":4118,"activeCount":102},[],{"intervention":4116,"totalTrials":213,"cells":4120},{"EARLY_PHASE1":4121,"PHASE1":4123,"PHASE2":4125,"PHASE3":4127,"PHASE4":4129,"NA":4135},{"trials":4122,"activeCount":102},[],{"trials":4124,"activeCount":102},[],{"trials":4126,"activeCount":102},[],{"trials":4128,"activeCount":102},[],{"trials":4130,"activeCount":102},[4131],{"nctId":4108,"briefTitle":4109,"status":204,"phases":4132,"primaryCompletion":4111,"completion":4111,"start":4112,"enrollment":1678,"conditions":4133,"interventions":4134},[93],[4114],[4095,4116],{"trials":4136,"activeCount":102},[],{"intervention":4138,"totalTrials":213,"cells":4139},"Dapagliflozin 10mg",{"EARLY_PHASE1":4140,"PHASE1":4142,"PHASE2":4144,"PHASE3":4146,"PHASE4":4148,"NA":4158},{"trials":4141,"activeCount":102},[],{"trials":4143,"activeCount":102},[],{"trials":4145,"activeCount":102},[],{"trials":4147,"activeCount":102},[],{"trials":4149,"activeCount":102},[4150],{"nctId":4151,"briefTitle":4152,"status":204,"phases":4153,"primaryCompletion":4154,"completion":4154,"start":4155,"enrollment":344,"conditions":4156,"interventions":4157},"NCT02751398","Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients",[93],"2020-06-15","2016-08-18",[3914],[4138],{"trials":4159,"activeCount":102},[],{"intervention":4161,"totalTrials":213,"cells":4162},"Oral administration of Lobeglitazone",{"EARLY_PHASE1":4163,"PHASE1":4165,"PHASE2":4167,"PHASE3":4169,"PHASE4":4171,"NA":4182},{"trials":4164,"activeCount":102},[],{"trials":4166,"activeCount":102},[],{"trials":4168,"activeCount":102},[],{"trials":4170,"activeCount":102},[],{"trials":4172,"activeCount":102},[4173],{"nctId":4174,"briefTitle":4175,"status":204,"phases":4176,"primaryCompletion":1047,"completion":1047,"start":3519,"enrollment":4177,"conditions":4178,"interventions":4181},"NCT02285205","A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD",[93],38,[4179,4180],"Type 2 Diabetes","Non-alcoholic Fatty Liver Disease",[4161],{"trials":4183,"activeCount":102},[],{"intervention":4185,"totalTrials":213,"cells":4186},"pretreatment with intravenous nicorandil vs. placebo before coronary angiography",{"EARLY_PHASE1":4187,"PHASE1":4189,"PHASE2":4191,"PHASE3":4193,"PHASE4":4195,"NA":4206},{"trials":4188,"activeCount":102},[],{"trials":4190,"activeCount":102},[],{"trials":4192,"activeCount":102},[],{"trials":4194,"activeCount":102},[],{"trials":4196,"activeCount":102},[4197],{"nctId":4198,"briefTitle":4199,"status":204,"phases":4200,"primaryCompletion":4201,"completion":4201,"start":321,"enrollment":4202,"conditions":4203,"interventions":4205},"NCT01103336","Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study)",[93],"2011-06",173,[4204],"Chronic Renal Failure",[4185],{"trials":4207,"activeCount":102},[],{"intervention":4209,"totalTrials":213,"cells":4210},"Neoadjuvant Chemotherapy with Docetaxel",{"EARLY_PHASE1":4211,"PHASE1":4213,"PHASE2":4215,"PHASE3":4217,"PHASE4":4219,"NA":4230},{"trials":4212,"activeCount":102},[],{"trials":4214,"activeCount":102},[],{"trials":4216,"activeCount":102},[],{"trials":4218,"activeCount":102},[],{"trials":4220,"activeCount":102},[4221],{"nctId":4222,"briefTitle":4223,"status":204,"phases":4224,"primaryCompletion":4225,"completion":4225,"start":3575,"enrollment":4226,"conditions":4227,"interventions":4229},"NCT01660542","An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer",[93],"2015-06",96,[4228],"Locally Advanced Breast Cancer",[4209],{"trials":4231,"activeCount":102},[],{"intervention":4233,"totalTrials":213,"cells":4234},"Anticoagulation with nafamostat mesilate",{"EARLY_PHASE1":4235,"PHASE1":4237,"PHASE2":4239,"PHASE3":4241,"PHASE4":4243,"NA":4254},{"trials":4236,"activeCount":102},[],{"trials":4238,"activeCount":102},[],{"trials":4240,"activeCount":102},[],{"trials":4242,"activeCount":102},[],{"trials":4244,"activeCount":102},[4245],{"nctId":4246,"briefTitle":4247,"status":204,"phases":4248,"primaryCompletion":4249,"completion":4249,"start":4250,"enrollment":3775,"conditions":4251,"interventions":4253},"NCT01761994","The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy",[93],"2010-08","2007-09",[4252],"Acute Kidney Injury",[4233],{"trials":4255,"activeCount":102},[],{"intervention":4257,"totalTrials":213,"cells":4258},"Albis®",{"EARLY_PHASE1":4259,"PHASE1":4261,"PHASE2":4263,"PHASE3":4265,"PHASE4":4267,"NA":4279},{"trials":4260,"activeCount":102},[],{"trials":4262,"activeCount":102},[],{"trials":4264,"activeCount":102},[],{"trials":4266,"activeCount":102},[],{"trials":4268,"activeCount":102},[4269],{"nctId":4270,"briefTitle":4271,"status":1475,"phases":4272,"primaryCompletion":4273,"completion":4274,"start":4275,"enrollment":102,"conditions":4276,"interventions":4278},"NCT02570529","Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy",[93],"2017-10","2018-02","2015-10",[4277],"Pancreatic Ductal Adenocarcinoma",[4257],{"trials":4280,"activeCount":102},[],{"intervention":4282,"totalTrials":213,"cells":4283},"Olostar Tab",{"EARLY_PHASE1":4284,"PHASE1":4286,"PHASE2":4288,"PHASE3":4290,"PHASE4":4292,"NA":4304},{"trials":4285,"activeCount":102},[],{"trials":4287,"activeCount":102},[],{"trials":4289,"activeCount":102},[],{"trials":4291,"activeCount":102},[],{"trials":4293,"activeCount":102},[4294],{"nctId":4295,"briefTitle":4296,"status":204,"phases":4297,"primaryCompletion":4298,"completion":4298,"start":4299,"enrollment":4300,"conditions":4301,"interventions":4302},"NCT04061824","Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia",[93],"2018-12-20","2016-05-24",150,[3375,664],[4282,4303],"Two separated drugs",{"trials":4305,"activeCount":102},[],{"intervention":4303,"totalTrials":213,"cells":4307},{"EARLY_PHASE1":4308,"PHASE1":4310,"PHASE2":4312,"PHASE3":4314,"PHASE4":4316,"NA":4322},{"trials":4309,"activeCount":102},[],{"trials":4311,"activeCount":102},[],{"trials":4313,"activeCount":102},[],{"trials":4315,"activeCount":102},[],{"trials":4317,"activeCount":102},[4318],{"nctId":4295,"briefTitle":4296,"status":204,"phases":4319,"primaryCompletion":4298,"completion":4298,"start":4299,"enrollment":4300,"conditions":4320,"interventions":4321},[93],[3375,664],[4282,4303],{"trials":4323,"activeCount":102},[],{"intervention":4325,"totalTrials":213,"cells":4326},"gluconon tab 15mg",{"EARLY_PHASE1":4327,"PHASE1":4329,"PHASE2":4331,"PHASE3":4333,"PHASE4":4335,"NA":4347},{"trials":4328,"activeCount":102},[],{"trials":4330,"activeCount":102},[],{"trials":4332,"activeCount":102},[],{"trials":4334,"activeCount":102},[],{"trials":4336,"activeCount":102},[4337],{"nctId":4338,"briefTitle":4339,"status":308,"phases":4340,"primaryCompletion":4341,"completion":4341,"start":4342,"enrollment":458,"conditions":4343,"interventions":4345},"NCT04584242","Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes",[93],"2022-05","2020-09-03",[4344],"Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes",[4325,4346],"suganon tab 5mg",{"trials":4348,"activeCount":102},[],{"intervention":4346,"totalTrials":213,"cells":4350},{"EARLY_PHASE1":4351,"PHASE1":4353,"PHASE2":4355,"PHASE3":4357,"PHASE4":4359,"NA":4365},{"trials":4352,"activeCount":102},[],{"trials":4354,"activeCount":102},[],{"trials":4356,"activeCount":102},[],{"trials":4358,"activeCount":102},[],{"trials":4360,"activeCount":102},[4361],{"nctId":4338,"briefTitle":4339,"status":308,"phases":4362,"primaryCompletion":4341,"completion":4341,"start":4342,"enrollment":458,"conditions":4363,"interventions":4364},[93],[4344],[4325,4346],{"trials":4366,"activeCount":102},[],{"intervention":4368,"totalTrials":213,"cells":4369},"amlodipine\u002Fvalsartan",{"EARLY_PHASE1":4370,"PHASE1":4372,"PHASE2":4374,"PHASE3":4376,"PHASE4":4378,"NA":4388},{"trials":4371,"activeCount":102},[],{"trials":4373,"activeCount":102},[],{"trials":4375,"activeCount":102},[],{"trials":4377,"activeCount":102},[],{"trials":4379,"activeCount":102},[4380],{"nctId":4381,"briefTitle":4382,"status":204,"phases":4383,"primaryCompletion":3519,"completion":3519,"start":4384,"enrollment":3842,"conditions":4385,"interventions":4386},"NCT01819220","Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine\u002FValsartan vs Hydrochlorothiazide\u002FTelmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome",[93],"2009-04",[3375],[4368,4387],"hydrochlorothiazide\u002Ftelmisartan",{"trials":4389,"activeCount":102},[],{"intervention":4387,"totalTrials":213,"cells":4391},{"EARLY_PHASE1":4392,"PHASE1":4394,"PHASE2":4396,"PHASE3":4398,"PHASE4":4400,"NA":4406},{"trials":4393,"activeCount":102},[],{"trials":4395,"activeCount":102},[],{"trials":4397,"activeCount":102},[],{"trials":4399,"activeCount":102},[],{"trials":4401,"activeCount":102},[4402],{"nctId":4381,"briefTitle":4382,"status":204,"phases":4403,"primaryCompletion":3519,"completion":3519,"start":4384,"enrollment":3842,"conditions":4404,"interventions":4405},[93],[3375],[4368,4387],{"trials":4407,"activeCount":102},[],{"intervention":4409,"totalTrials":213,"cells":4410},"Rosuvastatin\u002Fezetimibe combination",{"EARLY_PHASE1":4411,"PHASE1":4413,"PHASE2":4415,"PHASE3":4417,"PHASE4":4419,"NA":4432},{"trials":4412,"activeCount":102},[],{"trials":4414,"activeCount":102},[],{"trials":4416,"activeCount":102},[],{"trials":4418,"activeCount":102},[],{"trials":4420,"activeCount":102},[4421],{"nctId":4422,"briefTitle":4423,"status":204,"phases":4424,"primaryCompletion":4425,"completion":4425,"start":4426,"enrollment":4427,"conditions":4428,"interventions":4430},"NCT03434613","Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin \u002F Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease",[93],"2019-09-11","2018-05-14",64,[4429,664],"Nonalcoholic Fatty Liver Disease",[4431,4409],"Rosuvastatin",{"trials":4433,"activeCount":102},[],{"intervention":4435,"totalTrials":213,"cells":4436},"Peginterferon alfa-2a",{"EARLY_PHASE1":4437,"PHASE1":4439,"PHASE2":4441,"PHASE3":4443,"PHASE4":4445,"NA":4457},{"trials":4438,"activeCount":102},[],{"trials":4440,"activeCount":102},[],{"trials":4442,"activeCount":102},[],{"trials":4444,"activeCount":102},[],{"trials":4446,"activeCount":102},[4447],{"nctId":4448,"briefTitle":4449,"status":308,"phases":4450,"primaryCompletion":4451,"completion":4452,"start":4453,"enrollment":4454,"conditions":4455,"interventions":4456},"NCT02822547","Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults",[93],"2016-09","2016-12","2015-03",253,[3228],[4435],{"trials":4458,"activeCount":102},[],{"intervention":4460,"totalTrials":213,"cells":4461},"Rivaroxaban",{"EARLY_PHASE1":4462,"PHASE1":4464,"PHASE2":4466,"PHASE3":4468,"PHASE4":4470,"NA":4483},{"trials":4463,"activeCount":102},[],{"trials":4465,"activeCount":102},[],{"trials":4467,"activeCount":102},[],{"trials":4469,"activeCount":102},[],{"trials":4471,"activeCount":102},[4472],{"nctId":4473,"briefTitle":4474,"status":308,"phases":4475,"primaryCompletion":4476,"completion":4477,"start":4478,"enrollment":4300,"conditions":4479,"interventions":4481},"NCT03490994","Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)",[93],"2019-09","2020-01","2018-04-10",[4480],"Acute Heart Failure",[4460,4482],"Warfarin + LMWH",{"trials":4484,"activeCount":102},[],{"intervention":4482,"totalTrials":213,"cells":4486},{"EARLY_PHASE1":4487,"PHASE1":4489,"PHASE2":4491,"PHASE3":4493,"PHASE4":4495,"NA":4501},{"trials":4488,"activeCount":102},[],{"trials":4490,"activeCount":102},[],{"trials":4492,"activeCount":102},[],{"trials":4494,"activeCount":102},[],{"trials":4496,"activeCount":102},[4497],{"nctId":4473,"briefTitle":4474,"status":308,"phases":4498,"primaryCompletion":4476,"completion":4477,"start":4478,"enrollment":4300,"conditions":4499,"interventions":4500},[93],[4480],[4460,4482],{"trials":4502,"activeCount":102},[],{"intervention":3634,"totalTrials":213,"cells":4504},{"EARLY_PHASE1":4505,"PHASE1":4507,"PHASE2":4509,"PHASE3":4511,"PHASE4":4513,"NA":4519},{"trials":4506,"activeCount":102},[],{"trials":4508,"activeCount":102},[],{"trials":4510,"activeCount":102},[],{"trials":4512,"activeCount":102},[],{"trials":4514,"activeCount":102},[4515],{"nctId":3628,"briefTitle":3629,"status":204,"phases":4516,"primaryCompletion":3631,"completion":284,"start":3451,"enrollment":1538,"conditions":4517,"interventions":4518},[93],[287],[3634,968],{"trials":4520,"activeCount":102},[],{"intervention":4522,"totalTrials":213,"cells":4523},"Clotinab",{"EARLY_PHASE1":4524,"PHASE1":4526,"PHASE2":4528,"PHASE3":4530,"PHASE4":4532,"NA":4544},{"trials":4525,"activeCount":102},[],{"trials":4527,"activeCount":102},[],{"trials":4529,"activeCount":102},[],{"trials":4531,"activeCount":102},[],{"trials":4533,"activeCount":102},[4534],{"nctId":4535,"briefTitle":4536,"status":204,"phases":4537,"primaryCompletion":4538,"completion":4538,"start":4539,"enrollment":4540,"conditions":4541,"interventions":4543},"NCT00841438","Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction",[93],"2009-12","2007-07",786,[4542],"Myocardial Infarction",[4522,4522],{"trials":4545,"activeCount":102},[],{"intervention":4547,"totalTrials":213,"cells":4548},"contrast enhanced ultrasound",{"EARLY_PHASE1":4549,"PHASE1":4551,"PHASE2":4553,"PHASE3":4555,"PHASE4":4557,"NA":4568},{"trials":4550,"activeCount":102},[],{"trials":4552,"activeCount":102},[],{"trials":4554,"activeCount":102},[],{"trials":4556,"activeCount":102},[],{"trials":4558,"activeCount":102},[4559],{"nctId":4560,"briefTitle":4561,"status":308,"phases":4562,"primaryCompletion":4563,"completion":4563,"start":4564,"enrollment":25,"conditions":4565,"interventions":4567},"NCT04660136","Usefulness of Contrast-enhanced Ultrasound (CEUS) in Crohn's Disease Pediatric Patients",[93],"2023-03","2020-12-01",[4566],"Crohn's Disease in Pediatric Patient",[4547],{"trials":4569,"activeCount":102},[],{"intervention":4571,"totalTrials":213,"cells":4572},"teneligliptin",{"EARLY_PHASE1":4573,"PHASE1":4575,"PHASE2":4577,"PHASE3":4579,"PHASE4":4581,"NA":4592},{"trials":4574,"activeCount":102},[],{"trials":4576,"activeCount":102},[],{"trials":4578,"activeCount":102},[],{"trials":4580,"activeCount":102},[],{"trials":4582,"activeCount":102},[4583],{"nctId":4584,"briefTitle":4585,"status":204,"phases":4586,"primaryCompletion":4587,"completion":4588,"start":4589,"enrollment":222,"conditions":4590,"interventions":4591},"NCT04446026","A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen",[93],"2020-12-07","2021-05-17","2020-07-08",[3914],[4571],{"trials":4593,"activeCount":102},[],{"intervention":4595,"totalTrials":213,"cells":4596},"Gynoflor E",{"EARLY_PHASE1":4597,"PHASE1":4599,"PHASE2":4601,"PHASE3":4603,"PHASE4":4605,"NA":4616},{"trials":4598,"activeCount":102},[],{"trials":4600,"activeCount":102},[],{"trials":4602,"activeCount":102},[],{"trials":4604,"activeCount":102},[],{"trials":4606,"activeCount":102},[4607],{"nctId":4608,"briefTitle":4609,"status":308,"phases":4610,"primaryCompletion":899,"completion":3936,"start":4611,"enrollment":4612,"conditions":4613,"interventions":4615},"NCT00900653","Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women",[93],"2009-05",142,[4614],"Urinary Tract Infections",[4595],{"trials":4617,"activeCount":102},[],{"intervention":4619,"totalTrials":213,"cells":4620},"Ticagrelor monotherapy",{"EARLY_PHASE1":4621,"PHASE1":4623,"PHASE2":4625,"PHASE3":4627,"PHASE4":4629,"NA":4640},{"trials":4622,"activeCount":102},[],{"trials":4624,"activeCount":102},[],{"trials":4626,"activeCount":102},[],{"trials":4628,"activeCount":102},[],{"trials":4630,"activeCount":102},[4631],{"nctId":4632,"briefTitle":4633,"status":308,"phases":4634,"primaryCompletion":1268,"completion":1268,"start":4635,"enrollment":4636,"conditions":4637,"interventions":4638},"NCT02494895","Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)",[93],"2015-08-01",3056,[287],[4619,4639],"Ticagrelor with Aspirin DAPT",{"trials":4641,"activeCount":102},[],{"intervention":4639,"totalTrials":213,"cells":4643},{"EARLY_PHASE1":4644,"PHASE1":4646,"PHASE2":4648,"PHASE3":4650,"PHASE4":4652,"NA":4658},{"trials":4645,"activeCount":102},[],{"trials":4647,"activeCount":102},[],{"trials":4649,"activeCount":102},[],{"trials":4651,"activeCount":102},[],{"trials":4653,"activeCount":102},[4654],{"nctId":4632,"briefTitle":4633,"status":308,"phases":4655,"primaryCompletion":1268,"completion":1268,"start":4635,"enrollment":4636,"conditions":4656,"interventions":4657},[93],[287],[4619,4639],{"trials":4659,"activeCount":102},[],{"intervention":4661,"totalTrials":213,"cells":4662},"Rosuvastatin 20mg",{"EARLY_PHASE1":4663,"PHASE1":4665,"PHASE2":4667,"PHASE3":4669,"PHASE4":4671,"NA":4684},{"trials":4664,"activeCount":102},[],{"trials":4666,"activeCount":102},[],{"trials":4668,"activeCount":102},[],{"trials":4670,"activeCount":102},[],{"trials":4672,"activeCount":102},[4673],{"nctId":4674,"briefTitle":4675,"status":204,"phases":4676,"primaryCompletion":4677,"completion":4678,"start":4679,"enrollment":222,"conditions":4680,"interventions":4682},"NCT03988101","Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event",[93],"2024-03-29","2025-05-30","2019-09-19",[4681,664],"Venous Thromboembolism",[4661,4683],"Control",{"trials":4685,"activeCount":102},[],{"intervention":4687,"totalTrials":213,"cells":4688},"Propofol anesthesia",{"EARLY_PHASE1":4689,"PHASE1":4691,"PHASE2":4693,"PHASE3":4695,"PHASE4":4697,"NA":4708},{"trials":4690,"activeCount":102},[],{"trials":4692,"activeCount":102},[],{"trials":4694,"activeCount":102},[],{"trials":4696,"activeCount":102},[],{"trials":4698,"activeCount":102},[4699],{"nctId":4700,"briefTitle":4701,"status":204,"phases":4702,"primaryCompletion":3575,"completion":4201,"start":4703,"enrollment":4704,"conditions":4705,"interventions":4707},"NCT01402622","The Effect of Total Intravenous Anesthesia With Propofol on Postoperative Nausea and Vomiting in Patients Undergoing Robot-assisted Laparoscopic Radical Prostatectomy",[93],"2010-12",93,[4706],"Robotic Radical Prostatectomy",[4687],{"trials":4709,"activeCount":102},[],{"intervention":4711,"totalTrials":213,"cells":4712},"Immunosuppressive treatment",{"EARLY_PHASE1":4713,"PHASE1":4715,"PHASE2":4717,"PHASE3":4719,"PHASE4":4721,"NA":4732},{"trials":4714,"activeCount":102},[],{"trials":4716,"activeCount":102},[],{"trials":4718,"activeCount":102},[],{"trials":4720,"activeCount":102},[],{"trials":4722,"activeCount":102},[4723],{"nctId":4724,"briefTitle":4725,"status":308,"phases":4726,"primaryCompletion":1268,"completion":1268,"start":4727,"enrollment":4728,"conditions":4729,"interventions":4731},"NCT03468972","Effect of Immunosuppression in IgA Nephropathy",[93],"2019-03",174,[4730],"Biopsy-proven IgA Nephropathy",[4711],{"trials":4733,"activeCount":102},[],{"intervention":4735,"totalTrials":213,"cells":4736},"Propofol and dexmedetomidine",{"EARLY_PHASE1":4737,"PHASE1":4739,"PHASE2":4741,"PHASE3":4743,"PHASE4":4745,"NA":4756},{"trials":4738,"activeCount":102},[],{"trials":4740,"activeCount":102},[],{"trials":4742,"activeCount":102},[],{"trials":4744,"activeCount":102},[],{"trials":4746,"activeCount":102},[4747],{"nctId":4748,"briefTitle":4749,"status":204,"phases":4750,"primaryCompletion":3797,"completion":3797,"start":4751,"enrollment":3775,"conditions":4752,"interventions":4754},"NCT01569048","Randomized Controlled Trial to Evaluate of Dexmedetomidine for the Effect on Operative Visibility in Patients Undergoing Endoscopic Sinus Surgery",[93],"2012-03",[4753],"Chronic Sinusitis",[4735,4755],"propofol and remifentanil",{"trials":4757,"activeCount":102},[],{"intervention":4759,"totalTrials":213,"cells":4760},"pravastatin 20mg\u002Fday after DES implantation",{"EARLY_PHASE1":4761,"PHASE1":4763,"PHASE2":4765,"PHASE3":4767,"PHASE4":4769,"NA":4783},{"trials":4762,"activeCount":102},[],{"trials":4764,"activeCount":102},[],{"trials":4766,"activeCount":102},[],{"trials":4768,"activeCount":102},[],{"trials":4770,"activeCount":102},[4771],{"nctId":4772,"briefTitle":4773,"status":204,"phases":4774,"primaryCompletion":4775,"completion":4225,"start":3936,"enrollment":4776,"conditions":4777,"interventions":4779},"NCT01502904","Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents",[93],"2015-05",120,[4778],"Stable Angina or Acute Coronary Syndrome Considered for Percutaneous Coronary Intervention With Dyslipidemia or Hypertension",[4759,4780,4781,4782],"pitavastatin 2mg\u002Fday after DES implantation","Non-ARB \u002Fday after DES implantation","Eposartan 600mg\u002Fday after DES implantation",{"trials":4784,"activeCount":102},[],{"intervention":4780,"totalTrials":213,"cells":4786},{"EARLY_PHASE1":4787,"PHASE1":4789,"PHASE2":4791,"PHASE3":4793,"PHASE4":4795,"NA":4801},{"trials":4788,"activeCount":102},[],{"trials":4790,"activeCount":102},[],{"trials":4792,"activeCount":102},[],{"trials":4794,"activeCount":102},[],{"trials":4796,"activeCount":102},[4797],{"nctId":4772,"briefTitle":4773,"status":204,"phases":4798,"primaryCompletion":4775,"completion":4225,"start":3936,"enrollment":4776,"conditions":4799,"interventions":4800},[93],[4778],[4759,4780,4781,4782],{"trials":4802,"activeCount":102},[],{"intervention":4781,"totalTrials":213,"cells":4804},{"EARLY_PHASE1":4805,"PHASE1":4807,"PHASE2":4809,"PHASE3":4811,"PHASE4":4813,"NA":4819},{"trials":4806,"activeCount":102},[],{"trials":4808,"activeCount":102},[],{"trials":4810,"activeCount":102},[],{"trials":4812,"activeCount":102},[],{"trials":4814,"activeCount":102},[4815],{"nctId":4772,"briefTitle":4773,"status":204,"phases":4816,"primaryCompletion":4775,"completion":4225,"start":3936,"enrollment":4776,"conditions":4817,"interventions":4818},[93],[4778],[4759,4780,4781,4782],{"trials":4820,"activeCount":102},[],{"intervention":4782,"totalTrials":213,"cells":4822},{"EARLY_PHASE1":4823,"PHASE1":4825,"PHASE2":4827,"PHASE3":4829,"PHASE4":4831,"NA":4837},{"trials":4824,"activeCount":102},[],{"trials":4826,"activeCount":102},[],{"trials":4828,"activeCount":102},[],{"trials":4830,"activeCount":102},[],{"trials":4832,"activeCount":102},[4833],{"nctId":4772,"briefTitle":4773,"status":204,"phases":4834,"primaryCompletion":4775,"completion":4225,"start":3936,"enrollment":4776,"conditions":4835,"interventions":4836},[93],[4778],[4759,4780,4781,4782],{"trials":4838,"activeCount":102},[],{"intervention":4840,"totalTrials":213,"cells":4841},"iron isomaltoside (Monofer) intravenous",{"EARLY_PHASE1":4842,"PHASE1":4844,"PHASE2":4846,"PHASE3":4848,"PHASE4":4850,"NA":4863},{"trials":4843,"activeCount":102},[],{"trials":4845,"activeCount":102},[],{"trials":4847,"activeCount":102},[],{"trials":4849,"activeCount":102},[],{"trials":4851,"activeCount":102},[4852],{"nctId":4853,"briefTitle":4854,"status":308,"phases":4855,"primaryCompletion":4856,"completion":4856,"start":4857,"enrollment":4858,"conditions":4859,"interventions":4861},"NCT03229954","Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial",[93],"2019-04","2017-08-28",358,[4860],"Post Gastrectomy Anemia",[4840,4862],"Ferrous sulfate(Feroba-YOU) per",{"trials":4864,"activeCount":102},[],{"intervention":4862,"totalTrials":213,"cells":4866},{"EARLY_PHASE1":4867,"PHASE1":4869,"PHASE2":4871,"PHASE3":4873,"PHASE4":4875,"NA":4881},{"trials":4868,"activeCount":102},[],{"trials":4870,"activeCount":102},[],{"trials":4872,"activeCount":102},[],{"trials":4874,"activeCount":102},[],{"trials":4876,"activeCount":102},[4877],{"nctId":4853,"briefTitle":4854,"status":308,"phases":4878,"primaryCompletion":4856,"completion":4856,"start":4857,"enrollment":4858,"conditions":4879,"interventions":4880},[93],[4860],[4840,4862],{"trials":4882,"activeCount":102},[],{"intervention":4884,"totalTrials":213,"cells":4885},"recombinant human erythropoietin",{"EARLY_PHASE1":4886,"PHASE1":4888,"PHASE2":4890,"PHASE3":4892,"PHASE4":4894,"NA":4904},{"trials":4887,"activeCount":102},[],{"trials":4889,"activeCount":102},[],{"trials":4891,"activeCount":102},[],{"trials":4893,"activeCount":102},[],{"trials":4895,"activeCount":102},[4896],{"nctId":4897,"briefTitle":4898,"status":204,"phases":4899,"primaryCompletion":3657,"completion":3657,"start":4900,"enrollment":3775,"conditions":4901,"interventions":4903},"NCT01369732","Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest",[93],"2011-05",[4902],"Dissection of Thoracic Aorta",[4884,3941],{"trials":4905,"activeCount":102},[],{"intervention":4907,"totalTrials":213,"cells":4908},"Spironolactone",{"EARLY_PHASE1":4909,"PHASE1":4911,"PHASE2":4913,"PHASE3":4915,"PHASE4":4917,"NA":4929},{"trials":4910,"activeCount":102},[],{"trials":4912,"activeCount":102},[],{"trials":4914,"activeCount":102},[],{"trials":4916,"activeCount":102},[],{"trials":4918,"activeCount":102},[4919],{"nctId":4920,"briefTitle":4921,"status":204,"phases":4922,"primaryCompletion":4923,"completion":4923,"start":4924,"enrollment":4925,"conditions":4926,"interventions":4927},"NCT04331691","Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension",[93],"2024-05-23","2020-11-16",118,[3844],[4907,4928],"Amiloride",{"trials":4930,"activeCount":102},[],{"intervention":4928,"totalTrials":213,"cells":4932},{"EARLY_PHASE1":4933,"PHASE1":4935,"PHASE2":4937,"PHASE3":4939,"PHASE4":4941,"NA":4947},{"trials":4934,"activeCount":102},[],{"trials":4936,"activeCount":102},[],{"trials":4938,"activeCount":102},[],{"trials":4940,"activeCount":102},[],{"trials":4942,"activeCount":102},[4943],{"nctId":4920,"briefTitle":4921,"status":204,"phases":4944,"primaryCompletion":4923,"completion":4923,"start":4924,"enrollment":4925,"conditions":4945,"interventions":4946},[93],[3844],[4907,4928],{"trials":4948,"activeCount":102},[],{"intervention":4950,"totalTrials":213,"cells":4951},"dexmedetomidine with remifentanil",{"EARLY_PHASE1":4952,"PHASE1":4954,"PHASE2":4956,"PHASE3":4958,"PHASE4":4960,"NA":4970},{"trials":4953,"activeCount":102},[],{"trials":4955,"activeCount":102},[],{"trials":4957,"activeCount":102},[],{"trials":4959,"activeCount":102},[],{"trials":4961,"activeCount":102},[4962],{"nctId":4963,"briefTitle":4964,"status":204,"phases":4965,"primaryCompletion":3730,"completion":3730,"start":4900,"enrollment":4966,"conditions":4967,"interventions":4969},"NCT01365923","Comparison of Dexmedetomidin and Remifentanil for the Effect on Airway Reflex and Hemodynamic Response During Emergence in Patients Undergoing Craniotomy",[93],74,[4968],"Open Craniotomy",[264,4950],{"trials":4971,"activeCount":102},[],{"intervention":4973,"totalTrials":213,"cells":4974},"Erythropoietin",{"EARLY_PHASE1":4975,"PHASE1":4977,"PHASE2":4979,"PHASE3":4981,"PHASE4":4983,"NA":4997},{"trials":4976,"activeCount":102},[],{"trials":4978,"activeCount":102},[],{"trials":4980,"activeCount":102},[],{"trials":4982,"activeCount":102},[],{"trials":4984,"activeCount":102},[4985],{"nctId":4986,"briefTitle":4987,"status":204,"phases":4988,"primaryCompletion":4989,"completion":4990,"start":4991,"enrollment":4992,"conditions":4993,"interventions":4995},"NCT06178835","EPO for Postop Delirium in Elderly Patients",[93],"2019-07-28","2019-08-28","2017-09-12",76,[4994],"Postoperative Delirium",[4973,4996],"normal saline",{"trials":4998,"activeCount":102},[],{"intervention":5000,"totalTrials":213,"cells":5001},"Dixon up-and-down method",{"EARLY_PHASE1":5002,"PHASE1":5004,"PHASE2":5006,"PHASE3":5008,"PHASE4":5010,"NA":5020},{"trials":5003,"activeCount":102},[],{"trials":5005,"activeCount":102},[],{"trials":5007,"activeCount":102},[],{"trials":5009,"activeCount":102},[],{"trials":5011,"activeCount":102},[5012],{"nctId":5013,"briefTitle":5014,"status":204,"phases":5015,"completion":899,"start":321,"enrollment":5016,"conditions":5017,"interventions":5019},"NCT01291849","The Effect-site Concentration of Remifentanil for Preventing Cough During Emergence From Balanced Anesthesia for Nasal Surgery",[93],24,[5018],"Cough",[5000],{"trials":5021,"activeCount":102},[],{"intervention":3662,"totalTrials":213,"cells":5023},{"EARLY_PHASE1":5024,"PHASE1":5026,"PHASE2":5028,"PHASE3":5030,"PHASE4":5032,"NA":5038},{"trials":5025,"activeCount":102},[],{"trials":5027,"activeCount":102},[],{"trials":5029,"activeCount":102},[],{"trials":5031,"activeCount":102},[],{"trials":5033,"activeCount":102},[5034],{"nctId":3654,"briefTitle":3655,"status":204,"phases":5035,"primaryCompletion":3657,"completion":3658,"start":3575,"enrollment":1277,"conditions":5036,"interventions":5037},[93],[3660],[3662,326],{"trials":5039,"activeCount":102},[],{"intervention":5041,"totalTrials":213,"cells":5042},"ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.",{"EARLY_PHASE1":5043,"PHASE1":5045,"PHASE2":5047,"PHASE3":5049,"PHASE4":5051,"NA":5060},{"trials":5044,"activeCount":102},[],{"trials":5046,"activeCount":102},[],{"trials":5048,"activeCount":102},[],{"trials":5050,"activeCount":102},[],{"trials":5052,"activeCount":102},[5053],{"nctId":5054,"briefTitle":5055,"status":308,"phases":5056,"primaryCompletion":3797,"start":4249,"enrollment":5057,"conditions":5058,"interventions":5059},"NCT01508663","The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease",[93],1600,[15],[5041],{"trials":5061,"activeCount":102},[],{"intervention":5063,"totalTrials":213,"cells":5064},"Zoledronic acid, once",{"EARLY_PHASE1":5065,"PHASE1":5067,"PHASE2":5069,"PHASE3":5071,"PHASE4":5073,"NA":5086},{"trials":5066,"activeCount":102},[],{"trials":5068,"activeCount":102},[],{"trials":5070,"activeCount":102},[],{"trials":5072,"activeCount":102},[],{"trials":5074,"activeCount":102},[5075],{"nctId":5076,"briefTitle":5077,"status":204,"phases":5078,"primaryCompletion":5079,"completion":5079,"start":5080,"enrollment":5081,"conditions":5082,"interventions":5084},"NCT05361408","A Clinical Trial to Evaluate Efficacy of Once or Twice ZOledronic Acid After Different Duration of denOsumMab Administration in Postmenopausal Women With Osteoporosis (ZOOM Study)",[93],"2024-02-13","2022-02-11",114,[5083],"Osteoporosis",[5063,5085],"Zoledronic acid, twice",{"trials":5087,"activeCount":102},[],{"intervention":5085,"totalTrials":213,"cells":5089},{"EARLY_PHASE1":5090,"PHASE1":5092,"PHASE2":5094,"PHASE3":5096,"PHASE4":5098,"NA":5104},{"trials":5091,"activeCount":102},[],{"trials":5093,"activeCount":102},[],{"trials":5095,"activeCount":102},[],{"trials":5097,"activeCount":102},[],{"trials":5099,"activeCount":102},[5100],{"nctId":5076,"briefTitle":5077,"status":204,"phases":5101,"primaryCompletion":5079,"completion":5079,"start":5080,"enrollment":5081,"conditions":5102,"interventions":5103},[93],[5083],[5063,5085],{"trials":5105,"activeCount":102},[],{"intervention":5107,"totalTrials":213,"cells":5108},"Dexmedetomidine + Remifentanil-low dose",{"EARLY_PHASE1":5109,"PHASE1":5111,"PHASE2":5113,"PHASE3":5115,"PHASE4":5117,"NA":5129},{"trials":5110,"activeCount":102},[],{"trials":5112,"activeCount":102},[],{"trials":5114,"activeCount":102},[],{"trials":5116,"activeCount":102},[],{"trials":5118,"activeCount":102},[5119],{"nctId":5120,"briefTitle":5121,"status":204,"phases":5122,"primaryCompletion":3469,"completion":5123,"start":3797,"enrollment":5124,"conditions":5125,"interventions":5127},"NCT02208505","Antitussive Effect of Single-dose Dexmedetomidine With Low-dose Remifentanil Infusion",[93],"2015-12",168,[5126],"Thyroidectomy",[5107,5128],"Remifentanil-high dose",{"trials":5130,"activeCount":102},[],{"intervention":5128,"totalTrials":213,"cells":5132},{"EARLY_PHASE1":5133,"PHASE1":5135,"PHASE2":5137,"PHASE3":5139,"PHASE4":5141,"NA":5147},{"trials":5134,"activeCount":102},[],{"trials":5136,"activeCount":102},[],{"trials":5138,"activeCount":102},[],{"trials":5140,"activeCount":102},[],{"trials":5142,"activeCount":102},[5143],{"nctId":5120,"briefTitle":5121,"status":204,"phases":5144,"primaryCompletion":3469,"completion":5123,"start":3797,"enrollment":5124,"conditions":5145,"interventions":5146},[93],[5126],[5107,5128],{"trials":5148,"activeCount":102},[],{"intervention":5150,"totalTrials":213,"cells":5151},"Aprepitant",{"EARLY_PHASE1":5152,"PHASE1":5154,"PHASE2":5156,"PHASE3":5158,"PHASE4":5160,"NA":5170},{"trials":5153,"activeCount":102},[],{"trials":5155,"activeCount":102},[],{"trials":5157,"activeCount":102},[],{"trials":5159,"activeCount":102},[],{"trials":5161,"activeCount":102},[5162],{"nctId":5163,"briefTitle":5164,"status":204,"phases":5165,"primaryCompletion":3658,"completion":3658,"start":5166,"enrollment":5167,"conditions":5168,"interventions":5169},"NCT01897337","The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting",[93],"2012-06",125,[4009],[5150],{"trials":5171,"activeCount":102},[],{"intervention":5173,"totalTrials":213,"cells":5174},"plain ropivacaine",{"EARLY_PHASE1":5175,"PHASE1":5177,"PHASE2":5179,"PHASE3":5181,"PHASE4":5183,"NA":5199},{"trials":5176,"activeCount":102},[],{"trials":5178,"activeCount":102},[],{"trials":5180,"activeCount":102},[],{"trials":5182,"activeCount":102},[],{"trials":5184,"activeCount":102},[5185],{"nctId":5186,"briefTitle":5187,"status":204,"phases":5188,"primaryCompletion":5189,"completion":5189,"start":5190,"enrollment":458,"conditions":5191,"interventions":5196},"NCT02848157","Effects of Dexmedetomidine as Adjunct to Pudendal Block for Pediatric Penile Surgery",[93],"2017-03-24","2016-06-17",[5192,5193,5194,5195],"Elective Penile Surgeries","Hypospadias","Urethral Fistula or Stricture After Hypospadias Repair","Penile Curvature",[5197,5173,5198],"Dexmedetomidine","Ropivacaine",{"trials":5200,"activeCount":102},[],{"intervention":5202,"totalTrials":213,"cells":5203},"Plasma solution-A",{"EARLY_PHASE1":5204,"PHASE1":5206,"PHASE2":5208,"PHASE3":5210,"PHASE4":5212,"NA":5225},{"trials":5205,"activeCount":102},[],{"trials":5207,"activeCount":102},[],{"trials":5209,"activeCount":102},[],{"trials":5211,"activeCount":102},[],{"trials":5213,"activeCount":102},[5214],{"nctId":5215,"briefTitle":5216,"status":204,"phases":5217,"primaryCompletion":5218,"completion":5218,"start":5219,"enrollment":5220,"conditions":5221,"interventions":5223},"NCT03699462","The Effect of Balanced Crystalloid Versus 5% Albumin on Endothelial Glycocalyx Degradation in Patients Undergoing Off-pump Coronary Artery Bypass Surgery",[93],"2020-10-17","2018-11-13",106,[5222],"Coronary Artery Occlusive Disease(CAOD)",[5202,5224],"5% Albumin",{"trials":5226,"activeCount":102},[],{"intervention":5224,"totalTrials":213,"cells":5228},{"EARLY_PHASE1":5229,"PHASE1":5231,"PHASE2":5233,"PHASE3":5235,"PHASE4":5237,"NA":5243},{"trials":5230,"activeCount":102},[],{"trials":5232,"activeCount":102},[],{"trials":5234,"activeCount":102},[],{"trials":5236,"activeCount":102},[],{"trials":5238,"activeCount":102},[5239],{"nctId":5215,"briefTitle":5216,"status":204,"phases":5240,"primaryCompletion":5218,"completion":5218,"start":5219,"enrollment":5220,"conditions":5241,"interventions":5242},[93],[5222],[5202,5224],{"trials":5244,"activeCount":102},[],{"intervention":5246,"totalTrials":213,"cells":5247},"Nesinaact 25\u002F15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks",{"EARLY_PHASE1":5248,"PHASE1":5250,"PHASE2":5252,"PHASE3":5254,"PHASE4":5256,"NA":5268},{"trials":5249,"activeCount":102},[],{"trials":5251,"activeCount":102},[],{"trials":5253,"activeCount":102},[],{"trials":5255,"activeCount":102},[],{"trials":5257,"activeCount":102},[5258],{"nctId":5259,"briefTitle":5260,"status":308,"phases":5261,"primaryCompletion":5262,"completion":5262,"start":5263,"enrollment":344,"conditions":5264,"interventions":5267},"NCT03950505","To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes",[93],"2020-12","2020-05-29",[5265,5266],"Non-alcoholic Steatohepatitis","Type2 Diabetes",[5246],{"trials":5269,"activeCount":102},[],{"intervention":5271,"totalTrials":213,"cells":5272},"Lansoprazole",{"EARLY_PHASE1":5273,"PHASE1":5275,"PHASE2":5277,"PHASE3":5279,"PHASE4":5281,"NA":5293},{"trials":5274,"activeCount":102},[],{"trials":5276,"activeCount":102},[],{"trials":5278,"activeCount":102},[],{"trials":5280,"activeCount":102},[],{"trials":5282,"activeCount":102},[5283],{"nctId":5284,"briefTitle":5285,"status":204,"phases":5286,"primaryCompletion":5287,"completion":5287,"start":5288,"enrollment":1513,"conditions":5289,"interventions":5291},"NCT05946135","Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids",[93],"2025-09-08","2023-11-07",[5290],"Patients on Treatment With Systemic Steroids",[5271,5292],"Fexuprazan Hydrochloride",{"trials":5294,"activeCount":102},[],{"intervention":5292,"totalTrials":213,"cells":5296},{"EARLY_PHASE1":5297,"PHASE1":5299,"PHASE2":5301,"PHASE3":5303,"PHASE4":5305,"NA":5311},{"trials":5298,"activeCount":102},[],{"trials":5300,"activeCount":102},[],{"trials":5302,"activeCount":102},[],{"trials":5304,"activeCount":102},[],{"trials":5306,"activeCount":102},[5307],{"nctId":5284,"briefTitle":5285,"status":204,"phases":5308,"primaryCompletion":5287,"completion":5287,"start":5288,"enrollment":1513,"conditions":5309,"interventions":5310},[93],[5290],[5271,5292],{"trials":5312,"activeCount":102},[],{"intervention":5314,"totalTrials":213,"cells":5315},"Prasugrel group",{"EARLY_PHASE1":5316,"PHASE1":5318,"PHASE2":5320,"PHASE3":5322,"PHASE4":5324,"NA":5337},{"trials":5317,"activeCount":102},[],{"trials":5319,"activeCount":102},[],{"trials":5321,"activeCount":102},[],{"trials":5323,"activeCount":102},[],{"trials":5325,"activeCount":102},[5326],{"nctId":5327,"briefTitle":5328,"status":308,"phases":5329,"primaryCompletion":71,"completion":5330,"start":5331,"enrollment":5332,"conditions":5333,"interventions":5335},"NCT05359224","Low Dose Prasugrel vs Clopidogrel for Stenting or Flow Diverter for Unruptured Aneurysm",[93],"2025-08","2022-06-13",406,[5334],"Intracranial Aneurysm",[5314,5336],"Clopidogrel group",{"trials":5338,"activeCount":102},[],{"intervention":5336,"totalTrials":213,"cells":5340},{"EARLY_PHASE1":5341,"PHASE1":5343,"PHASE2":5345,"PHASE3":5347,"PHASE4":5349,"NA":5355},{"trials":5342,"activeCount":102},[],{"trials":5344,"activeCount":102},[],{"trials":5346,"activeCount":102},[],{"trials":5348,"activeCount":102},[],{"trials":5350,"activeCount":102},[5351],{"nctId":5327,"briefTitle":5328,"status":308,"phases":5352,"primaryCompletion":71,"completion":5330,"start":5331,"enrollment":5332,"conditions":5353,"interventions":5354},[93],[5334],[5314,5336],{"trials":5356,"activeCount":102},[],{"intervention":5358,"totalTrials":213,"cells":5359},"Carvedilol SR",{"EARLY_PHASE1":5360,"PHASE1":5362,"PHASE2":5364,"PHASE3":5366,"PHASE4":5368,"NA":5379},{"trials":5361,"activeCount":102},[],{"trials":5363,"activeCount":102},[],{"trials":5365,"activeCount":102},[],{"trials":5367,"activeCount":102},[],{"trials":5369,"activeCount":102},[5370],{"nctId":5371,"briefTitle":5372,"status":308,"phases":5373,"primaryCompletion":5262,"completion":5374,"start":5375,"enrollment":192,"conditions":5376,"interventions":5378},"NCT03948685","Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction",[93],"2021-01","2019-05",[5377],"Heart Failure With Preserved Ejection Fraction",[5358],{"trials":5380,"activeCount":102},[],{"intervention":5382,"totalTrials":213,"cells":5383},"Botulinum toxin type A",{"EARLY_PHASE1":5384,"PHASE1":5386,"PHASE2":5388,"PHASE3":5390,"PHASE4":5392,"NA":5403},{"trials":5385,"activeCount":102},[],{"trials":5387,"activeCount":102},[],{"trials":5389,"activeCount":102},[],{"trials":5391,"activeCount":102},[],{"trials":5393,"activeCount":102},[5394],{"nctId":5395,"briefTitle":5396,"status":308,"phases":5397,"primaryCompletion":964,"completion":5398,"start":5399,"enrollment":5016,"conditions":5400,"interventions":5402},"NCT01336439","Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism",[93],"2011-12","2011-03",[5401],"Sleep Bruxism",[5382],{"trials":5404,"activeCount":102},[],{"intervention":5406,"totalTrials":213,"cells":5407},"Vitis Vinifera seed extract medication plus therapeutic lifestyle change",{"EARLY_PHASE1":5408,"PHASE1":5410,"PHASE2":5412,"PHASE3":5414,"PHASE4":5416,"NA":5428},{"trials":5409,"activeCount":102},[],{"trials":5411,"activeCount":102},[],{"trials":5413,"activeCount":102},[],{"trials":5415,"activeCount":102},[],{"trials":5417,"activeCount":102},[5418],{"nctId":5419,"briefTitle":5420,"status":204,"phases":5421,"primaryCompletion":5422,"completion":5423,"start":5424,"enrollment":522,"conditions":5425,"interventions":5427},"NCT05851183","Effect of Vitis Vinifera Seed Extract on Venous Reflux Time in Varicose Vein",[93],"2024-09-30","2025-01-30","2023-07-20",[5426],"Varicose Veins of Lower Limb",[5406],{"trials":5429,"activeCount":102},[],{"intervention":5431,"totalTrials":213,"cells":5432},"Dabigatrain plus aspirin",{"EARLY_PHASE1":5433,"PHASE1":5435,"PHASE2":5437,"PHASE3":5439,"PHASE4":5441,"NA":5452},{"trials":5434,"activeCount":102},[],{"trials":5436,"activeCount":102},[],{"trials":5438,"activeCount":102},[],{"trials":5440,"activeCount":102},[],{"trials":5442,"activeCount":102},[5443],{"nctId":5444,"briefTitle":5445,"status":243,"phases":5446,"primaryCompletion":5447,"completion":5447,"start":5448,"enrollment":2295,"conditions":5449,"interventions":5450},"NCT02606552","Safety and Efficacy of Left Atrial Appendage Closure Versus Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Due to Complex Coronary Artery Disease",[93],"2017-06-23","2016-07-20",[18,15],[5431,5451],"Dabigatrain plus clopidogrel",{"trials":5453,"activeCount":102},[],{"intervention":5451,"totalTrials":213,"cells":5455},{"EARLY_PHASE1":5456,"PHASE1":5458,"PHASE2":5460,"PHASE3":5462,"PHASE4":5464,"NA":5470},{"trials":5457,"activeCount":102},[],{"trials":5459,"activeCount":102},[],{"trials":5461,"activeCount":102},[],{"trials":5463,"activeCount":102},[],{"trials":5465,"activeCount":102},[5466],{"nctId":5444,"briefTitle":5445,"status":243,"phases":5467,"primaryCompletion":5447,"completion":5447,"start":5448,"enrollment":2295,"conditions":5468,"interventions":5469},[93],[18,15],[5431,5451],{"trials":5471,"activeCount":102},[],{"intervention":5473,"totalTrials":213,"cells":5474},"Rosuvastatin 20",{"EARLY_PHASE1":5475,"PHASE1":5477,"PHASE2":5479,"PHASE3":5481,"PHASE4":5483,"NA":5495},{"trials":5476,"activeCount":102},[],{"trials":5478,"activeCount":102},[],{"trials":5480,"activeCount":102},[],{"trials":5482,"activeCount":102},[],{"trials":5484,"activeCount":102},[5485],{"nctId":5486,"briefTitle":5487,"status":308,"phases":5488,"primaryCompletion":2651,"completion":310,"start":5489,"enrollment":522,"conditions":5490,"interventions":5493},"NCT04433533","Compare the Efficacy and Safety of Rosuvastatin\u002FEzetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia",[93],"2021-01-06",[5491,5492],"Left Ventricular Diastolic Dysfunction","Hyperlipidemias",[5473,5494],"Rosuvamibe 10\u002F10",{"trials":5496,"activeCount":102},[],{"intervention":5494,"totalTrials":213,"cells":5498},{"EARLY_PHASE1":5499,"PHASE1":5501,"PHASE2":5503,"PHASE3":5505,"PHASE4":5507,"NA":5513},{"trials":5500,"activeCount":102},[],{"trials":5502,"activeCount":102},[],{"trials":5504,"activeCount":102},[],{"trials":5506,"activeCount":102},[],{"trials":5508,"activeCount":102},[5509],{"nctId":5486,"briefTitle":5487,"status":308,"phases":5510,"primaryCompletion":2651,"completion":310,"start":5489,"enrollment":522,"conditions":5511,"interventions":5512},[93],[5491,5492],[5473,5494],{"trials":5514,"activeCount":102},[],{"intervention":5516,"totalTrials":213,"cells":5517},"Ferinject",{"EARLY_PHASE1":5518,"PHASE1":5520,"PHASE2":5522,"PHASE3":5524,"PHASE4":5526,"NA":5538},{"trials":5519,"activeCount":102},[],{"trials":5521,"activeCount":102},[],{"trials":5523,"activeCount":102},[],{"trials":5525,"activeCount":102},[],{"trials":5527,"activeCount":102},[5528],{"nctId":5529,"briefTitle":5530,"status":308,"phases":5531,"primaryCompletion":5532,"completion":5533,"start":5534,"enrollment":222,"conditions":5535,"interventions":5536},"NCT04898569","Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response and Transfusion in Patients With Iron Deficiency Anemia After Off-Pump Coronary Artery Bypass Grafting",[93],"2022-10-01","2022-12-31","2019-02-10",[15],[5516,5537],"Normal Saline Flush",{"trials":5539,"activeCount":102},[],{"intervention":5537,"totalTrials":213,"cells":5541},{"EARLY_PHASE1":5542,"PHASE1":5544,"PHASE2":5546,"PHASE3":5548,"PHASE4":5550,"NA":5556},{"trials":5543,"activeCount":102},[],{"trials":5545,"activeCount":102},[],{"trials":5547,"activeCount":102},[],{"trials":5549,"activeCount":102},[],{"trials":5551,"activeCount":102},[5552],{"nctId":5529,"briefTitle":5530,"status":308,"phases":5553,"primaryCompletion":5532,"completion":5533,"start":5534,"enrollment":222,"conditions":5554,"interventions":5555},[93],[15],[5516,5537],{"trials":5557,"activeCount":102},[],{"intervention":5559,"totalTrials":213,"cells":5560},"the dexmedetomidine group",{"EARLY_PHASE1":5561,"PHASE1":5563,"PHASE2":5565,"PHASE3":5567,"PHASE4":5569,"NA":5580},{"trials":5562,"activeCount":102},[],{"trials":5564,"activeCount":102},[],{"trials":5566,"activeCount":102},[],{"trials":5568,"activeCount":102},[],{"trials":5570,"activeCount":102},[5571],{"nctId":5572,"briefTitle":5573,"status":204,"phases":5574,"primaryCompletion":5575,"completion":5575,"start":981,"enrollment":1277,"conditions":5576,"interventions":5578},"NCT02164448","The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy",[93],"2015-01",[5577],"Gastric Cancer Patients Undergoing Laparoscopic Gastrectomy",[5559,5579],"the control group",{"trials":5581,"activeCount":102},[],{"intervention":5579,"totalTrials":213,"cells":5583},{"EARLY_PHASE1":5584,"PHASE1":5586,"PHASE2":5588,"PHASE3":5590,"PHASE4":5592,"NA":5598},{"trials":5585,"activeCount":102},[],{"trials":5587,"activeCount":102},[],{"trials":5589,"activeCount":102},[],{"trials":5591,"activeCount":102},[],{"trials":5593,"activeCount":102},[5594],{"nctId":5572,"briefTitle":5573,"status":204,"phases":5595,"primaryCompletion":5575,"completion":5575,"start":981,"enrollment":1277,"conditions":5596,"interventions":5597},[93],[5577],[5559,5579],{"trials":5599,"activeCount":102},[],{"intervention":5601,"totalTrials":213,"cells":5602},"genotyping and selection of renin-angiotensin system blocker",{"EARLY_PHASE1":5603,"PHASE1":5605,"PHASE2":5607,"PHASE3":5609,"PHASE4":5611,"NA":5622},{"trials":5604,"activeCount":102},[],{"trials":5606,"activeCount":102},[],{"trials":5608,"activeCount":102},[],{"trials":5610,"activeCount":102},[],{"trials":5612,"activeCount":102},[5613],{"nctId":5614,"briefTitle":5615,"status":204,"phases":5616,"primaryCompletion":5617,"completion":5617,"start":5618,"enrollment":208,"conditions":5619,"interventions":5620},"NCT05535595","Precision Treatment With Angiotensin Converting Enzyme Inhibitor",[93],"2021-08-02","2019-11-06",[3375],[5601,5621],"Perindopril",{"trials":5623,"activeCount":102},[],{"intervention":5621,"totalTrials":213,"cells":5625},{"EARLY_PHASE1":5626,"PHASE1":5628,"PHASE2":5630,"PHASE3":5632,"PHASE4":5634,"NA":5640},{"trials":5627,"activeCount":102},[],{"trials":5629,"activeCount":102},[],{"trials":5631,"activeCount":102},[],{"trials":5633,"activeCount":102},[],{"trials":5635,"activeCount":102},[5636],{"nctId":5614,"briefTitle":5615,"status":204,"phases":5637,"primaryCompletion":5617,"completion":5617,"start":5618,"enrollment":208,"conditions":5638,"interventions":5639},[93],[3375],[5601,5621],{"trials":5641,"activeCount":102},[],{"intervention":5643,"totalTrials":213,"cells":5644},"Evolocumab 140 MG\u002FML",{"EARLY_PHASE1":5645,"PHASE1":5647,"PHASE2":5649,"PHASE3":5651,"PHASE4":5653,"NA":5666},{"trials":5646,"activeCount":102},[],{"trials":5648,"activeCount":102},[],{"trials":5650,"activeCount":102},[],{"trials":5652,"activeCount":102},[],{"trials":5654,"activeCount":102},[5655],{"nctId":5656,"briefTitle":5657,"status":204,"phases":5658,"primaryCompletion":5659,"completion":5659,"start":1258,"enrollment":5660,"conditions":5661,"interventions":5663},"NCT05661552","Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI",[93],"2025-02-05",108,[5662],"Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia",[5643,5664,5665],"Rosuvastatin 5mg","Ezetimibe 10mg",{"trials":5667,"activeCount":102},[],{"intervention":5664,"totalTrials":213,"cells":5669},{"EARLY_PHASE1":5670,"PHASE1":5672,"PHASE2":5674,"PHASE3":5676,"PHASE4":5678,"NA":5684},{"trials":5671,"activeCount":102},[],{"trials":5673,"activeCount":102},[],{"trials":5675,"activeCount":102},[],{"trials":5677,"activeCount":102},[],{"trials":5679,"activeCount":102},[5680],{"nctId":5656,"briefTitle":5657,"status":204,"phases":5681,"primaryCompletion":5659,"completion":5659,"start":1258,"enrollment":5660,"conditions":5682,"interventions":5683},[93],[5662],[5643,5664,5665],{"trials":5685,"activeCount":102},[],{"intervention":5665,"totalTrials":213,"cells":5687},{"EARLY_PHASE1":5688,"PHASE1":5690,"PHASE2":5692,"PHASE3":5694,"PHASE4":5696,"NA":5702},{"trials":5689,"activeCount":102},[],{"trials":5691,"activeCount":102},[],{"trials":5693,"activeCount":102},[],{"trials":5695,"activeCount":102},[],{"trials":5697,"activeCount":102},[5698],{"nctId":5656,"briefTitle":5657,"status":204,"phases":5699,"primaryCompletion":5659,"completion":5659,"start":1258,"enrollment":5660,"conditions":5700,"interventions":5701},[93],[5662],[5643,5664,5665],{"trials":5703,"activeCount":102},[],{"intervention":5705,"totalTrials":213,"cells":5706},"Meloxicam",{"EARLY_PHASE1":5707,"PHASE1":5709,"PHASE2":5711,"PHASE3":5713,"PHASE4":5715,"NA":5724},{"trials":5708,"activeCount":102},[],{"trials":5710,"activeCount":102},[],{"trials":5712,"activeCount":102},[],{"trials":5714,"activeCount":102},[],{"trials":5716,"activeCount":102},[5717],{"nctId":5718,"briefTitle":5719,"status":204,"phases":5720,"primaryCompletion":4201,"completion":5398,"start":207,"enrollment":1243,"conditions":5721,"interventions":5723},"NCT02298218","Clinical Study About the Role of COX-2 Inhibitor in Liver Cirrhosis With Biliary Atresia",[93],[5722],"Biliary Atresia, Kasai Portoenterostomy Status",[5705],{"trials":5725,"activeCount":102},[],{"intervention":5727,"totalTrials":213,"cells":5728},"Pravastatin",{"EARLY_PHASE1":5729,"PHASE1":5731,"PHASE2":5733,"PHASE3":5735,"PHASE4":5737,"NA":5748},{"trials":5730,"activeCount":102},[],{"trials":5732,"activeCount":102},[],{"trials":5734,"activeCount":102},[],{"trials":5736,"activeCount":102},[],{"trials":5738,"activeCount":102},[5739],{"nctId":5740,"briefTitle":5741,"status":308,"phases":5742,"primaryCompletion":5743,"completion":5743,"start":3936,"enrollment":3226,"conditions":5744,"interventions":5746},"NCT01557075","Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation",[93],"2015-08",[5745],"Drug-eluting Stent (DES)",[5747,5727],"Atorvastatin",{"trials":5749,"activeCount":102},[],{"intervention":5751,"totalTrials":213,"cells":5752},"Letibotulinum toxin A",{"EARLY_PHASE1":5753,"PHASE1":5755,"PHASE2":5757,"PHASE3":5759,"PHASE4":5761,"NA":5775},{"trials":5754,"activeCount":102},[],{"trials":5756,"activeCount":102},[],{"trials":5758,"activeCount":102},[],{"trials":5760,"activeCount":102},[],{"trials":5762,"activeCount":102},[5763],{"nctId":5764,"briefTitle":5765,"status":204,"phases":5766,"primaryCompletion":5767,"completion":5768,"start":5769,"enrollment":25,"conditions":5770,"interventions":5772},"NCT07072806","A Study Comparing the Safety, Efficacy, and Diffusion of Letibotulinum Toxin A Versus Other Botulinum Toxin Products in Adults With Moderate-to-Severe Forehead Wrinkles",[93],"2022-08-26","2022-09-07","2022-06-14",[5771],"Forehead Rhytides",[5751,5773,5774],"Prabotulinum toxin A","Onabotulinum toxin A",{"trials":5776,"activeCount":102},[],{"intervention":5773,"totalTrials":213,"cells":5778},{"EARLY_PHASE1":5779,"PHASE1":5781,"PHASE2":5783,"PHASE3":5785,"PHASE4":5787,"NA":5793},{"trials":5780,"activeCount":102},[],{"trials":5782,"activeCount":102},[],{"trials":5784,"activeCount":102},[],{"trials":5786,"activeCount":102},[],{"trials":5788,"activeCount":102},[5789],{"nctId":5764,"briefTitle":5765,"status":204,"phases":5790,"primaryCompletion":5767,"completion":5768,"start":5769,"enrollment":25,"conditions":5791,"interventions":5792},[93],[5771],[5751,5773,5774],{"trials":5794,"activeCount":102},[],{"intervention":5774,"totalTrials":213,"cells":5796},{"EARLY_PHASE1":5797,"PHASE1":5799,"PHASE2":5801,"PHASE3":5803,"PHASE4":5805,"NA":5811},{"trials":5798,"activeCount":102},[],{"trials":5800,"activeCount":102},[],{"trials":5802,"activeCount":102},[],{"trials":5804,"activeCount":102},[],{"trials":5806,"activeCount":102},[5807],{"nctId":5764,"briefTitle":5765,"status":204,"phases":5808,"primaryCompletion":5767,"completion":5768,"start":5769,"enrollment":25,"conditions":5809,"interventions":5810},[93],[5771],[5751,5773,5774],{"trials":5812,"activeCount":102},[],{"intervention":5814,"totalTrials":213,"cells":5815},"ulinastatin, saline solution",{"EARLY_PHASE1":5816,"PHASE1":5818,"PHASE2":5820,"PHASE3":5822,"PHASE4":5824,"NA":5833},{"trials":5817,"activeCount":102},[],{"trials":5819,"activeCount":102},[],{"trials":5821,"activeCount":102},[],{"trials":5823,"activeCount":102},[],{"trials":5825,"activeCount":102},[5826],{"nctId":5827,"briefTitle":5828,"status":204,"phases":5829,"primaryCompletion":4900,"completion":4900,"start":3584,"enrollment":233,"conditions":5830,"interventions":5832},"NCT01084044","Effects of Ulinastatin on Coagulation in High Risk Patients Undergoing Off Pump Coronary Artery Bypass Graft Surgery",[93],[5831],"Coronary Artery Occlusive Disease",[5814],{"trials":5834,"activeCount":102},[],{"intervention":5836,"totalTrials":213,"cells":5837},"ascorbic acid 10g\u002F20ml",{"EARLY_PHASE1":5838,"PHASE1":5840,"PHASE2":5842,"PHASE3":5844,"PHASE4":5846,"NA":5857},{"trials":5839,"activeCount":102},[],{"trials":5841,"activeCount":102},[],{"trials":5843,"activeCount":102},[],{"trials":5845,"activeCount":102},[],{"trials":5847,"activeCount":102},[5848],{"nctId":5849,"briefTitle":5850,"status":308,"phases":5851,"primaryCompletion":5852,"completion":5852,"start":3841,"enrollment":344,"conditions":5853,"interventions":5855},"NCT01926132","High-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage in Chronic Fatigue Patients: Randomized-controlled Study",[93],"2013-10",[5854],"Chronic Fatigue",[5836,5856],"Normal Saline 150ml",{"trials":5858,"activeCount":102},[],{"intervention":5856,"totalTrials":213,"cells":5860},{"EARLY_PHASE1":5861,"PHASE1":5863,"PHASE2":5865,"PHASE3":5867,"PHASE4":5869,"NA":5875},{"trials":5862,"activeCount":102},[],{"trials":5864,"activeCount":102},[],{"trials":5866,"activeCount":102},[],{"trials":5868,"activeCount":102},[],{"trials":5870,"activeCount":102},[5871],{"nctId":5849,"briefTitle":5850,"status":308,"phases":5872,"primaryCompletion":5852,"completion":5852,"start":3841,"enrollment":344,"conditions":5873,"interventions":5874},[93],[5854],[5836,5856],{"trials":5876,"activeCount":102},[],{"intervention":5878,"totalTrials":213,"cells":5879},"Early intensive rosuvastatin therapy",{"EARLY_PHASE1":5880,"PHASE1":5882,"PHASE2":5884,"PHASE3":5886,"PHASE4":5888,"NA":5899},{"trials":5881,"activeCount":102},[],{"trials":5883,"activeCount":102},[],{"trials":5885,"activeCount":102},[],{"trials":5887,"activeCount":102},[],{"trials":5889,"activeCount":102},[5890],{"nctId":5891,"briefTitle":5892,"status":204,"phases":5893,"primaryCompletion":5894,"completion":5894,"start":5895,"enrollment":5167,"conditions":5896,"interventions":5898},"NCT01153334","Efficacy of Early Intensive ROsuvastatin Therapy in Patients With ST-segment Elevation Myocardial Infarction Undergoing PrimARY Percutaneous Coronary Intervention (the ROSEMARY Trial)",[93],"2013-06-27","2010-08-02",[5897],"ST-segment Elevation AMI",[5878],{"trials":5900,"activeCount":102},[],{"intervention":5902,"totalTrials":213,"cells":5903},"CRESTOR, reference formulation of rosuvastatin",{"EARLY_PHASE1":5904,"PHASE1":5906,"PHASE2":5908,"PHASE3":5910,"PHASE4":5912,"NA":5925},{"trials":5905,"activeCount":102},[],{"trials":5907,"activeCount":102},[],{"trials":5909,"activeCount":102},[],{"trials":5911,"activeCount":102},[],{"trials":5913,"activeCount":102},[5914],{"nctId":5915,"briefTitle":5916,"status":204,"phases":5917,"primaryCompletion":5918,"completion":5919,"start":5920,"enrollment":5921,"conditions":5922,"interventions":5923},"NCT03949374","Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients",[93],"2018-04-16","2018-06-01","2015-10-23",126,[2594,664],[5902,5924],"ROVASRO, generic formulation of rosuvastatin",{"trials":5926,"activeCount":102},[],{"intervention":5924,"totalTrials":213,"cells":5928},{"EARLY_PHASE1":5929,"PHASE1":5931,"PHASE2":5933,"PHASE3":5935,"PHASE4":5937,"NA":5943},{"trials":5930,"activeCount":102},[],{"trials":5932,"activeCount":102},[],{"trials":5934,"activeCount":102},[],{"trials":5936,"activeCount":102},[],{"trials":5938,"activeCount":102},[5939],{"nctId":5915,"briefTitle":5916,"status":204,"phases":5940,"primaryCompletion":5918,"completion":5919,"start":5920,"enrollment":5921,"conditions":5941,"interventions":5942},[93],[2594,664],[5902,5924],{"trials":5944,"activeCount":102},[],{"intervention":5946,"totalTrials":213,"cells":5947},"Cilostazol, Probucol \u002F placebo of probucol",{"EARLY_PHASE1":5948,"PHASE1":5950,"PHASE2":5952,"PHASE3":5954,"PHASE4":5956,"NA":5965},{"trials":5949,"activeCount":102},[],{"trials":5951,"activeCount":102},[],{"trials":5953,"activeCount":102},[],{"trials":5955,"activeCount":102},[],{"trials":5957,"activeCount":102},[5958],{"nctId":5959,"briefTitle":5960,"status":204,"phases":5961,"primaryCompletion":4201,"completion":4201,"start":3451,"enrollment":4925,"conditions":5962,"interventions":5964},"NCT01031667","Synergistic Effect of Combination Therapy With Cilostazol and Probucol on Plaque Stabilization and Lesion Regression: Serial Intravascular Ultrasound and Virtual Histology Study(SECURE Study)",[93],[5963],"Therapy",[5946],{"trials":5966,"activeCount":102},[],{"intervention":5968,"totalTrials":213,"cells":5969},"Vitamin C",{"EARLY_PHASE1":5970,"PHASE1":5972,"PHASE2":5974,"PHASE3":5976,"PHASE4":5978,"NA":5989},{"trials":5971,"activeCount":102},[],{"trials":5973,"activeCount":102},[],{"trials":5975,"activeCount":102},[],{"trials":5977,"activeCount":102},[],{"trials":5979,"activeCount":102},[5980],{"nctId":5981,"briefTitle":5982,"status":308,"phases":5983,"primaryCompletion":5984,"completion":5984,"start":5985,"enrollment":5986,"conditions":5987,"interventions":5988},"NCT04210453","The Impact of Vitamin C on Postoperative Acute Kidney Injury in Risk Patients Undergoing Valvular Heart Surgery",[93],"2022-12","2020-03-24",264,[4252],[5968,4683],{"trials":5990,"activeCount":102},[],{"intervention":5992,"totalTrials":213,"cells":5993},"Olmesartan",{"EARLY_PHASE1":5994,"PHASE1":5996,"PHASE2":5998,"PHASE3":6000,"PHASE4":6002,"NA":6014},{"trials":5995,"activeCount":102},[],{"trials":5997,"activeCount":102},[],{"trials":5999,"activeCount":102},[],{"trials":6001,"activeCount":102},[],{"trials":6003,"activeCount":102},[6004],{"nctId":6005,"briefTitle":6006,"status":243,"phases":6007,"primaryCompletion":6008,"completion":6008,"start":6009,"enrollment":213,"conditions":6010,"interventions":6012},"NCT02373462","Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)",[93],"2015-11-17","2015-08-25",[6011],"Peripheral Artery Disease With Intermittent Claudication",[5992,6013],"other anti-hypertensive drug",{"trials":6015,"activeCount":102},[],{"intervention":6013,"totalTrials":213,"cells":6017},{"EARLY_PHASE1":6018,"PHASE1":6020,"PHASE2":6022,"PHASE3":6024,"PHASE4":6026,"NA":6032},{"trials":6019,"activeCount":102},[],{"trials":6021,"activeCount":102},[],{"trials":6023,"activeCount":102},[],{"trials":6025,"activeCount":102},[],{"trials":6027,"activeCount":102},[6028],{"nctId":6005,"briefTitle":6006,"status":243,"phases":6029,"primaryCompletion":6008,"completion":6008,"start":6009,"enrollment":213,"conditions":6030,"interventions":6031},[93],[6011],[5992,6013],{"trials":6033,"activeCount":102},[],{"intervention":6035,"totalTrials":213,"cells":6036},"Gp 2b 3a inhibitor",{"EARLY_PHASE1":6037,"PHASE1":6039,"PHASE2":6041,"PHASE3":6043,"PHASE4":6045,"NA":6053},{"trials":6038,"activeCount":102},[],{"trials":6040,"activeCount":102},[],{"trials":6042,"activeCount":102},[],{"trials":6044,"activeCount":102},[],{"trials":6046,"activeCount":102},[6047],{"nctId":6048,"briefTitle":6049,"status":204,"phases":6050,"primaryCompletion":3773,"completion":3773,"start":4703,"enrollment":458,"conditions":6051,"interventions":6052},"NCT01404507","Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMI",[93],[288],[6035],{"trials":6054,"activeCount":102},[],{"intervention":6056,"totalTrials":213,"cells":6057},"Combination of pioglitazone and empagliflozin",{"EARLY_PHASE1":6058,"PHASE1":6060,"PHASE2":6062,"PHASE3":6064,"PHASE4":6066,"NA":6089},{"trials":6059,"activeCount":102},[],{"trials":6061,"activeCount":102},[],{"trials":6063,"activeCount":102},[],{"trials":6065,"activeCount":102},[],{"trials":6067,"activeCount":102},[6068],{"nctId":6069,"briefTitle":6070,"status":204,"phases":6071,"primaryCompletion":6072,"completion":6072,"start":6073,"enrollment":2363,"conditions":6074,"interventions":6088},"NCT03646292","Antidiabetic Drugs for Steatotic Liver Disease",[93],"2022-06-16","2018-12-06",[6075,4179,6076,6077,6078,6079,6080,6081,6082,6083,6084,6085,6086,6087],"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Digestive System Disease","Liver Diseases","Fatty Liver","Metabolic Dysfunction-Associated Steatotic Liver Disease","Non-Alcoholic Fatty Liver Disease","Hypoglycemic Agents","Physiological Effects of Drugs","Sodium-Glucose Cotransporter 2 Inhibitors","Pioglitazone","Molecular Mechanisms of Pharmacological Action","Empagliflozin","Thiazolidinediones",[6084,6086,6056],{"trials":6090,"activeCount":102},[],{"intervention":6092,"totalTrials":213,"cells":6093},"Cerebrolysin",{"EARLY_PHASE1":6094,"PHASE1":6096,"PHASE2":6098,"PHASE3":6100,"PHASE4":6102,"NA":6112},{"trials":6095,"activeCount":102},[],{"trials":6097,"activeCount":102},[],{"trials":6099,"activeCount":102},[],{"trials":6101,"activeCount":102},[],{"trials":6103,"activeCount":102},[6104],{"nctId":6105,"briefTitle":6106,"status":308,"phases":6107,"primaryCompletion":6108,"completion":6108,"start":6109,"enrollment":22,"conditions":6110,"interventions":6111},"NCT04913831","Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study",[93],"2024-03","2021-06",[27],[6092],{"trials":6113,"activeCount":102},[],{"intervention":6115,"totalTrials":213,"cells":6116},"Atorvastatin 20mg loading",{"EARLY_PHASE1":6117,"PHASE1":6119,"PHASE2":6121,"PHASE3":6123,"PHASE4":6125,"NA":6136},{"trials":6118,"activeCount":102},[],{"trials":6120,"activeCount":102},[],{"trials":6122,"activeCount":102},[],{"trials":6124,"activeCount":102},[],{"trials":6126,"activeCount":102},[6127],{"nctId":6128,"briefTitle":6129,"status":243,"phases":6130,"primaryCompletion":3657,"completion":3657,"start":6131,"enrollment":213,"conditions":6132,"interventions":6134},"NCT01394848","Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy",[93],"2011-10",[6133],"Stable Angina",[6115,6135],"Atorvastatin 80mg loading",{"trials":6137,"activeCount":102},[],{"intervention":6135,"totalTrials":213,"cells":6139},{"EARLY_PHASE1":6140,"PHASE1":6142,"PHASE2":6144,"PHASE3":6146,"PHASE4":6148,"NA":6154},{"trials":6141,"activeCount":102},[],{"trials":6143,"activeCount":102},[],{"trials":6145,"activeCount":102},[],{"trials":6147,"activeCount":102},[],{"trials":6149,"activeCount":102},[6150],{"nctId":6128,"briefTitle":6129,"status":243,"phases":6151,"primaryCompletion":3657,"completion":3657,"start":6131,"enrollment":213,"conditions":6152,"interventions":6153},[93],[6133],[6115,6135],{"trials":6155,"activeCount":102},[],{"intervention":6157,"totalTrials":213,"cells":6158},"Administration of anesthesia: Propofol",{"EARLY_PHASE1":6159,"PHASE1":6161,"PHASE2":6163,"PHASE3":6165,"PHASE4":6167,"NA":6177},{"trials":6160,"activeCount":102},[],{"trials":6162,"activeCount":102},[],{"trials":6164,"activeCount":102},[],{"trials":6166,"activeCount":102},[],{"trials":6168,"activeCount":102},[6169],{"nctId":6170,"briefTitle":6171,"status":204,"phases":6172,"primaryCompletion":1500,"completion":1500,"start":3631,"enrollment":344,"conditions":6173,"interventions":6175},"NCT02009280","A Comparison of Propofol Based Total Intravenous Anesthesia and Sevoflurane Based Balanced Anesthesia on Renal Protection During Lung Transplantation Under Extracorporeal Membrane Oxygenation - A Prospective, Randomized Trial",[93],[6174],"Patients Undergoing Lung Transplantation Under Extracorporeal Membrane Oxygenation",[6157,6176],"Administration of anesthesia: Sevoflurane",{"trials":6178,"activeCount":102},[],{"intervention":6176,"totalTrials":213,"cells":6180},{"EARLY_PHASE1":6181,"PHASE1":6183,"PHASE2":6185,"PHASE3":6187,"PHASE4":6189,"NA":6195},{"trials":6182,"activeCount":102},[],{"trials":6184,"activeCount":102},[],{"trials":6186,"activeCount":102},[],{"trials":6188,"activeCount":102},[],{"trials":6190,"activeCount":102},[6191],{"nctId":6170,"briefTitle":6171,"status":204,"phases":6192,"primaryCompletion":1500,"completion":1500,"start":3631,"enrollment":344,"conditions":6193,"interventions":6194},[93],[6174],[6157,6176],{"trials":6196,"activeCount":102},[],{"intervention":6198,"totalTrials":213,"cells":6199},"N-acetylcysteine, saline",{"EARLY_PHASE1":6200,"PHASE1":6202,"PHASE2":6204,"PHASE3":6206,"PHASE4":6208,"NA":6217},{"trials":6201,"activeCount":102},[],{"trials":6203,"activeCount":102},[],{"trials":6205,"activeCount":102},[],{"trials":6207,"activeCount":102},[],{"trials":6209,"activeCount":102},[6210],{"nctId":6211,"briefTitle":6212,"status":204,"phases":6213,"enrollment":1369,"conditions":6214,"interventions":6216},"NCT01021163","Effects of N-acetylcysteine on Pulmonary Function in High-risk Patients Undergoing Off-pump Coronary Bypass Surgery",[93],[6215],"Coronary Artery Occlusion",[6198],{"trials":6218,"activeCount":102},[],{"intervention":6220,"totalTrials":213,"cells":6221},"alfacalcidol",{"EARLY_PHASE1":6222,"PHASE1":6224,"PHASE2":6226,"PHASE3":6228,"PHASE4":6230,"NA":6242},{"trials":6223,"activeCount":102},[],{"trials":6225,"activeCount":102},[],{"trials":6227,"activeCount":102},[],{"trials":6229,"activeCount":102},[],{"trials":6231,"activeCount":102},[6232],{"nctId":6233,"briefTitle":6234,"status":308,"phases":6235,"primaryCompletion":6236,"completion":6236,"start":5079,"enrollment":6237,"conditions":6238,"interventions":6240},"NCT06272227","Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients",[93],"2025-09-01",340,[6239],"Sarcopenia",[6220,6241],"Denosumab",{"trials":6243,"activeCount":102},[],{"intervention":6241,"totalTrials":213,"cells":6245},{"EARLY_PHASE1":6246,"PHASE1":6248,"PHASE2":6250,"PHASE3":6252,"PHASE4":6254,"NA":6260},{"trials":6247,"activeCount":102},[],{"trials":6249,"activeCount":102},[],{"trials":6251,"activeCount":102},[],{"trials":6253,"activeCount":102},[],{"trials":6255,"activeCount":102},[6256],{"nctId":6233,"briefTitle":6234,"status":308,"phases":6257,"primaryCompletion":6236,"completion":6236,"start":5079,"enrollment":6237,"conditions":6258,"interventions":6259},[93],[6239],[6220,6241],{"trials":6261,"activeCount":102},[],{"intervention":6263,"totalTrials":213,"cells":6264},"Triple antiplatelet therapy",{"EARLY_PHASE1":6265,"PHASE1":6267,"PHASE2":6269,"PHASE3":6271,"PHASE4":6273,"NA":6285},{"trials":6266,"activeCount":102},[],{"trials":6268,"activeCount":102},[],{"trials":6270,"activeCount":102},[],{"trials":6272,"activeCount":102},[],{"trials":6274,"activeCount":102},[6275],{"nctId":6276,"briefTitle":6277,"status":308,"phases":6278,"primaryCompletion":1289,"completion":1289,"start":6279,"enrollment":166,"conditions":6280,"interventions":6282},"NCT02829151","Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)",[93],"2017-02-21",[6281],"Critical Limb Ischemia",[6263,6283,6284],"Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel","Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol",{"trials":6286,"activeCount":102},[],{"intervention":6283,"totalTrials":213,"cells":6288},{"EARLY_PHASE1":6289,"PHASE1":6291,"PHASE2":6293,"PHASE3":6295,"PHASE4":6297,"NA":6303},{"trials":6290,"activeCount":102},[],{"trials":6292,"activeCount":102},[],{"trials":6294,"activeCount":102},[],{"trials":6296,"activeCount":102},[],{"trials":6298,"activeCount":102},[6299],{"nctId":6276,"briefTitle":6277,"status":308,"phases":6300,"primaryCompletion":1289,"completion":1289,"start":6279,"enrollment":166,"conditions":6301,"interventions":6302},[93],[6281],[6263,6283,6284],{"trials":6304,"activeCount":102},[],{"intervention":6284,"totalTrials":213,"cells":6306},{"EARLY_PHASE1":6307,"PHASE1":6309,"PHASE2":6311,"PHASE3":6313,"PHASE4":6315,"NA":6321},{"trials":6308,"activeCount":102},[],{"trials":6310,"activeCount":102},[],{"trials":6312,"activeCount":102},[],{"trials":6314,"activeCount":102},[],{"trials":6316,"activeCount":102},[6317],{"nctId":6276,"briefTitle":6277,"status":308,"phases":6318,"primaryCompletion":1289,"completion":1289,"start":6279,"enrollment":166,"conditions":6319,"interventions":6320},[93],[6281],[6263,6283,6284],{"trials":6322,"activeCount":102},[],{"intervention":6324,"totalTrials":213,"cells":6325},"Everolimus + Low dose CsA +PD",{"EARLY_PHASE1":6326,"PHASE1":6328,"PHASE2":6330,"PHASE3":6332,"PHASE4":6334,"NA":6346},{"trials":6327,"activeCount":102},[],{"trials":6329,"activeCount":102},[],{"trials":6331,"activeCount":102},[],{"trials":6333,"activeCount":102},[],{"trials":6335,"activeCount":102},[6336],{"nctId":6337,"briefTitle":6338,"status":204,"phases":6339,"primaryCompletion":3657,"completion":6340,"start":6341,"enrollment":344,"conditions":6342,"interventions":6344},"NCT01706471","Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation",[93],"2013-04","2009-06",[6343],"Planned Kidney Transplantation",[6324,6345],"Myfortic+ Standard CsA + PD",{"trials":6347,"activeCount":102},[],{"intervention":6345,"totalTrials":213,"cells":6349},{"EARLY_PHASE1":6350,"PHASE1":6352,"PHASE2":6354,"PHASE3":6356,"PHASE4":6358,"NA":6364},{"trials":6351,"activeCount":102},[],{"trials":6353,"activeCount":102},[],{"trials":6355,"activeCount":102},[],{"trials":6357,"activeCount":102},[],{"trials":6359,"activeCount":102},[6360],{"nctId":6337,"briefTitle":6338,"status":204,"phases":6361,"primaryCompletion":3657,"completion":6340,"start":6341,"enrollment":344,"conditions":6362,"interventions":6363},[93],[6343],[6324,6345],{"trials":6365,"activeCount":102},[],{"intervention":6367,"totalTrials":213,"cells":6368},"Aflibercept + FOLFIRI",{"EARLY_PHASE1":6369,"PHASE1":6371,"PHASE2":6373,"PHASE3":6375,"PHASE4":6377,"NA":6389},{"trials":6370,"activeCount":102},[],{"trials":6372,"activeCount":102},[],{"trials":6374,"activeCount":102},[],{"trials":6376,"activeCount":102},[],{"trials":6378,"activeCount":102},[6379],{"nctId":6380,"briefTitle":6381,"status":308,"phases":6382,"primaryCompletion":6383,"completion":6383,"start":6384,"enrollment":6385,"conditions":6386,"interventions":6388},"NCT04810585","Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer",[93],"2025-10","2020-04-20",153,[6387],"Recurrent or Metastatic Colorectal Cancer",[6367],{"trials":6390,"activeCount":102},[],{"intervention":6392,"totalTrials":213,"cells":6393},"Rosuvastatin Immediate-Release Tablet (IRT) 10mg",{"EARLY_PHASE1":6394,"PHASE1":6396,"PHASE2":6398,"PHASE3":6400,"PHASE4":6402,"NA":6414},{"trials":6395,"activeCount":102},[],{"trials":6397,"activeCount":102},[],{"trials":6399,"activeCount":102},[],{"trials":6401,"activeCount":102},[],{"trials":6403,"activeCount":102},[6404],{"nctId":6405,"briefTitle":6406,"status":308,"phases":6407,"primaryCompletion":6408,"completion":6409,"start":6410,"enrollment":1010,"conditions":6411,"interventions":6412},"NCT06153433","Clinical Trial to Evaluate the Efficacy and Safety of Suvaro®OD Tablet in Patients With Dyslipidemia",[93],"2024-07","2024-08","2023-11-06",[2593],[6392,6413],"Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg",{"trials":6415,"activeCount":102},[],{"intervention":6413,"totalTrials":213,"cells":6417},{"EARLY_PHASE1":6418,"PHASE1":6420,"PHASE2":6422,"PHASE3":6424,"PHASE4":6426,"NA":6432},{"trials":6419,"activeCount":102},[],{"trials":6421,"activeCount":102},[],{"trials":6423,"activeCount":102},[],{"trials":6425,"activeCount":102},[],{"trials":6427,"activeCount":102},[6428],{"nctId":6405,"briefTitle":6406,"status":308,"phases":6429,"primaryCompletion":6408,"completion":6409,"start":6410,"enrollment":1010,"conditions":6430,"interventions":6431},[93],[2593],[6392,6413],{"trials":6433,"activeCount":102},[],{"intervention":6435,"totalTrials":213,"cells":6436},"Iron isomaltoside",{"EARLY_PHASE1":6437,"PHASE1":6439,"PHASE2":6441,"PHASE3":6443,"PHASE4":6445,"NA":6457},{"trials":6438,"activeCount":102},[],{"trials":6440,"activeCount":102},[],{"trials":6442,"activeCount":102},[],{"trials":6444,"activeCount":102},[],{"trials":6446,"activeCount":102},[6447],{"nctId":6448,"briefTitle":6449,"status":308,"phases":6450,"primaryCompletion":4563,"completion":4563,"start":6451,"enrollment":6452,"conditions":6453,"interventions":6455},"NCT04346004","Effect of Preoperative Iron Isomaltoside 1000 Administration on Hemoglobin Concentration in Patients Undergoing Transcatheter Aortic Valve Implantation",[93],"2020-04-27",214,[6454],"Aortic Stenosis (Treated With TAVI)",[6456,6435],"Normal saline",{"trials":6458,"activeCount":102},[],{"intervention":6460,"totalTrials":213,"cells":6461},"Elravie Re2O",{"EARLY_PHASE1":6462,"PHASE1":6464,"PHASE2":6466,"PHASE3":6468,"PHASE4":6470,"NA":6485},{"trials":6463,"activeCount":102},[],{"trials":6465,"activeCount":102},[],{"trials":6467,"activeCount":102},[],{"trials":6469,"activeCount":102},[],{"trials":6471,"activeCount":102},[6472],{"nctId":6473,"briefTitle":6474,"status":204,"phases":6475,"primaryCompletion":6476,"completion":6476,"start":6477,"enrollment":25,"conditions":6478,"interventions":6483},"NCT07155278","Efficacy & Safety of hADM Skin Booster",[93],"2025-05-07","2024-11-21",[6479,6480,6481,6482],"Rhytides","Skin Texture Irregularities","Photoaged Facial Skin","Skin Lifting and Tightening",[6460,6484],"Elravie Balance",{"trials":6486,"activeCount":102},[],{"intervention":6484,"totalTrials":213,"cells":6488},{"EARLY_PHASE1":6489,"PHASE1":6491,"PHASE2":6493,"PHASE3":6495,"PHASE4":6497,"NA":6503},{"trials":6490,"activeCount":102},[],{"trials":6492,"activeCount":102},[],{"trials":6494,"activeCount":102},[],{"trials":6496,"activeCount":102},[],{"trials":6498,"activeCount":102},[6499],{"nctId":6473,"briefTitle":6474,"status":204,"phases":6500,"primaryCompletion":6476,"completion":6476,"start":6477,"enrollment":25,"conditions":6501,"interventions":6502},[93],[6479,6480,6481,6482],[6460,6484],{"trials":6504,"activeCount":102},[],{"intervention":6506,"totalTrials":213,"cells":6507},"ramosetron with saline",{"EARLY_PHASE1":6508,"PHASE1":6510,"PHASE2":6512,"PHASE3":6514,"PHASE4":6516,"NA":6529},{"trials":6509,"activeCount":102},[],{"trials":6511,"activeCount":102},[],{"trials":6513,"activeCount":102},[],{"trials":6515,"activeCount":102},[],{"trials":6517,"activeCount":102},[6518],{"nctId":6519,"briefTitle":6520,"status":204,"phases":6521,"primaryCompletion":6522,"completion":6522,"start":6523,"enrollment":1343,"conditions":6524,"interventions":6527},"NCT01013012","Efficacy of Dexamethasone Added to Ramosetron for Preventing Postoperative Nausea and Vomiting in Highly Susceptible Patients Following Spine Surgery",[93],"2008-11","2008-01",[6525,6526],"Nausea","Vomiting",[6506,6528],"ramosetron with dexamethasone",{"trials":6530,"activeCount":102},[],{"intervention":6528,"totalTrials":213,"cells":6532},{"EARLY_PHASE1":6533,"PHASE1":6535,"PHASE2":6537,"PHASE3":6539,"PHASE4":6541,"NA":6547},{"trials":6534,"activeCount":102},[],{"trials":6536,"activeCount":102},[],{"trials":6538,"activeCount":102},[],{"trials":6540,"activeCount":102},[],{"trials":6542,"activeCount":102},[6543],{"nctId":6519,"briefTitle":6520,"status":204,"phases":6544,"primaryCompletion":6522,"completion":6522,"start":6523,"enrollment":1343,"conditions":6545,"interventions":6546},[93],[6525,6526],[6506,6528],{"trials":6548,"activeCount":102},[],{"intervention":6550,"totalTrials":213,"cells":6551},"N-acetylcysteine",{"EARLY_PHASE1":6552,"PHASE1":6554,"PHASE2":6556,"PHASE3":6558,"PHASE4":6560,"NA":6573},{"trials":6553,"activeCount":102},[],{"trials":6555,"activeCount":102},[],{"trials":6557,"activeCount":102},[],{"trials":6559,"activeCount":102},[],{"trials":6561,"activeCount":102},[6562],{"nctId":6563,"briefTitle":6564,"status":204,"phases":6565,"primaryCompletion":6566,"completion":6566,"start":6567,"enrollment":6568,"conditions":6569,"interventions":6571},"NCT01394419","Effect of N-acetylcysteine on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass Graft",[93],"2012-04","2010-09",115,[6570],"Postoperative Acute Kidney Injury After Off-pump Coronary Artery Bypass Graft",[6550,6572],"Saline",{"trials":6574,"activeCount":102},[],{"intervention":6576,"totalTrials":213,"cells":6577},"6% hydroxyethyl Stach 130\u002F0.4",{"EARLY_PHASE1":6578,"PHASE1":6580,"PHASE2":6582,"PHASE3":6584,"PHASE4":6586,"NA":6594},{"trials":6579,"activeCount":102},[],{"trials":6581,"activeCount":102},[],{"trials":6583,"activeCount":102},[],{"trials":6585,"activeCount":102},[],{"trials":6587,"activeCount":102},[6588],{"nctId":6589,"briefTitle":6590,"status":204,"phases":6591,"primaryCompletion":3937,"completion":3937,"start":4611,"enrollment":5220,"conditions":6592,"interventions":6593},"NCT01051206","The Effect of 6% Hydroxyethyl Starch 130\u002F0.4 on Blood Loss and Coagulation in Patients Medicated With Antiplatelet Agents Prior to Off-Pump Coronary Bypass Graft Surgery",[93],[5831],[6576],{"trials":6595,"activeCount":102},[],{"intervention":6597,"totalTrials":213,"cells":6598},"remifentanil, MgSO4",{"EARLY_PHASE1":6599,"PHASE1":6601,"PHASE2":6603,"PHASE3":6605,"PHASE4":6607,"NA":6616},{"trials":6600,"activeCount":102},[],{"trials":6602,"activeCount":102},[],{"trials":6604,"activeCount":102},[],{"trials":6606,"activeCount":102},[],{"trials":6608,"activeCount":102},[6609],{"nctId":6610,"briefTitle":6611,"status":204,"phases":6612,"primaryCompletion":3584,"completion":3584,"start":3451,"enrollment":2998,"conditions":6613,"interventions":6615},"NCT01025245","Effect of Intraoperative Magnesium on Remifentanil-induced Postoperative Hyperalgesia After Thyroidectomy",[93],[6614],"Hyperalgesia",[6597],{"trials":6617,"activeCount":102},[],{"intervention":6619,"totalTrials":213,"cells":6620},"conventional blood pressure control",{"EARLY_PHASE1":6621,"PHASE1":6623,"PHASE2":6625,"PHASE3":6627,"PHASE4":6629,"NA":6642},{"trials":6622,"activeCount":102},[],{"trials":6624,"activeCount":102},[],{"trials":6626,"activeCount":102},[],{"trials":6628,"activeCount":102},[],{"trials":6630,"activeCount":102},[6631],{"nctId":6632,"briefTitle":6633,"status":204,"phases":6634,"primaryCompletion":6635,"completion":6635,"start":6636,"enrollment":6637,"conditions":6638,"interventions":6640},"NCT04205305","Outcome in Patients Treated with Intraarterial Thrombectomy - OptiMAL Blood Pressure Control (OPTIMAL-BP)",[93],"2023-07-23","2020-06-18",306,[6639],"Ischemic Stroke",[6619,6641],"intensive blood pressure control",{"trials":6643,"activeCount":102},[],{"intervention":6641,"totalTrials":213,"cells":6645},{"EARLY_PHASE1":6646,"PHASE1":6648,"PHASE2":6650,"PHASE3":6652,"PHASE4":6654,"NA":6660},{"trials":6647,"activeCount":102},[],{"trials":6649,"activeCount":102},[],{"trials":6651,"activeCount":102},[],{"trials":6653,"activeCount":102},[],{"trials":6655,"activeCount":102},[6656],{"nctId":6632,"briefTitle":6633,"status":204,"phases":6657,"primaryCompletion":6635,"completion":6635,"start":6636,"enrollment":6637,"conditions":6658,"interventions":6659},[93],[6639],[6619,6641],{"trials":6661,"activeCount":102},[],{"intervention":6663,"totalTrials":213,"cells":6664},"Group R",{"EARLY_PHASE1":6665,"PHASE1":6667,"PHASE2":6669,"PHASE3":6671,"PHASE4":6673,"NA":6686},{"trials":6666,"activeCount":102},[],{"trials":6668,"activeCount":102},[],{"trials":6670,"activeCount":102},[],{"trials":6672,"activeCount":102},[],{"trials":6674,"activeCount":102},[6675],{"nctId":6676,"briefTitle":6677,"status":204,"phases":6678,"primaryCompletion":6679,"completion":6679,"start":5166,"enrollment":3775,"conditions":6680,"interventions":6683},"NCT01634594","The Effect of Deliberate Hypotension on QTc, Tp-e Intervals and Heart Rate Variability",[93],"2013-02",[6681,6682],"Mandibular Prognathism","Mandibular Retrognathism",[6663,6684,6685],"Group N","Group D",{"trials":6687,"activeCount":102},[],{"intervention":6684,"totalTrials":213,"cells":6689},{"EARLY_PHASE1":6690,"PHASE1":6692,"PHASE2":6694,"PHASE3":6696,"PHASE4":6698,"NA":6704},{"trials":6691,"activeCount":102},[],{"trials":6693,"activeCount":102},[],{"trials":6695,"activeCount":102},[],{"trials":6697,"activeCount":102},[],{"trials":6699,"activeCount":102},[6700],{"nctId":6676,"briefTitle":6677,"status":204,"phases":6701,"primaryCompletion":6679,"completion":6679,"start":5166,"enrollment":3775,"conditions":6702,"interventions":6703},[93],[6681,6682],[6663,6684,6685],{"trials":6705,"activeCount":102},[],{"intervention":6685,"totalTrials":213,"cells":6707},{"EARLY_PHASE1":6708,"PHASE1":6710,"PHASE2":6712,"PHASE3":6714,"PHASE4":6716,"NA":6722},{"trials":6709,"activeCount":102},[],{"trials":6711,"activeCount":102},[],{"trials":6713,"activeCount":102},[],{"trials":6715,"activeCount":102},[],{"trials":6717,"activeCount":102},[6718],{"nctId":6676,"briefTitle":6677,"status":204,"phases":6719,"primaryCompletion":6679,"completion":6679,"start":5166,"enrollment":3775,"conditions":6720,"interventions":6721},[93],[6681,6682],[6663,6684,6685],{"trials":6723,"activeCount":102},[],{"intervention":6725,"totalTrials":213,"cells":6726},"Carbamazepine",{"EARLY_PHASE1":6727,"PHASE1":6729,"PHASE2":6731,"PHASE3":6733,"PHASE4":6735,"NA":6747},{"trials":6728,"activeCount":102},[],{"trials":6730,"activeCount":102},[],{"trials":6732,"activeCount":102},[],{"trials":6734,"activeCount":102},[],{"trials":6736,"activeCount":102},[6737],{"nctId":6738,"briefTitle":6739,"status":204,"phases":6740,"primaryCompletion":3889,"completion":3889,"start":6741,"enrollment":6742,"conditions":6743,"interventions":6745},"NCT00807989","The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy",[93],"2008-03",207,[6744],"Epilepsy",[6725,6746],"Lamotrigine\u002FValproate",{"trials":6748,"activeCount":102},[],{"intervention":6746,"totalTrials":213,"cells":6750},{"EARLY_PHASE1":6751,"PHASE1":6753,"PHASE2":6755,"PHASE3":6757,"PHASE4":6759,"NA":6765},{"trials":6752,"activeCount":102},[],{"trials":6754,"activeCount":102},[],{"trials":6756,"activeCount":102},[],{"trials":6758,"activeCount":102},[],{"trials":6760,"activeCount":102},[6761],{"nctId":6738,"briefTitle":6739,"status":204,"phases":6762,"primaryCompletion":3889,"completion":3889,"start":6741,"enrollment":6742,"conditions":6763,"interventions":6764},[93],[6744],[6725,6746],{"trials":6766,"activeCount":102},[],{"intervention":6768,"totalTrials":213,"cells":6769},"Collastat",{"EARLY_PHASE1":6770,"PHASE1":6772,"PHASE2":6774,"PHASE3":6776,"PHASE4":6778,"NA":6789},{"trials":6771,"activeCount":102},[],{"trials":6773,"activeCount":102},[],{"trials":6775,"activeCount":102},[],{"trials":6777,"activeCount":102},[],{"trials":6779,"activeCount":102},[6780],{"nctId":6781,"briefTitle":6782,"status":204,"phases":6783,"primaryCompletion":6784,"completion":6785,"start":6786,"enrollment":233,"conditions":6787,"interventions":6788},"NCT04310150","Collagen-thrombin Matrix Efficacy During Cardiac Surgery: a Prospective Randomized Controlled Trial",[93],"2020-03-17","2020-03-31","2018-02-05",[15],[6768],{"trials":6790,"activeCount":102},[],{"intervention":6792,"totalTrials":213,"cells":6793},"Ilaprazole",{"EARLY_PHASE1":6794,"PHASE1":6796,"PHASE2":6798,"PHASE3":6800,"PHASE4":6802,"NA":6811},{"trials":6795,"activeCount":102},[],{"trials":6797,"activeCount":102},[],{"trials":6799,"activeCount":102},[],{"trials":6801,"activeCount":102},[],{"trials":6803,"activeCount":102},[6804],{"nctId":6805,"briefTitle":6806,"status":204,"phases":6807,"primaryCompletion":5743,"completion":3729,"start":3468,"enrollment":25,"conditions":6808,"interventions":6810},"NCT02666976","The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker",[93],[6809],"Gastrointestinal Subepithelial Tumors",[6792],{"trials":6812,"activeCount":102},[],{"intervention":6814,"totalTrials":213,"cells":6815},"Switching from adefovir",{"EARLY_PHASE1":6816,"PHASE1":6818,"PHASE2":6820,"PHASE3":6822,"PHASE4":6824,"NA":6833},{"trials":6817,"activeCount":102},[],{"trials":6819,"activeCount":102},[],{"trials":6821,"activeCount":102},[],{"trials":6823,"activeCount":102},[],{"trials":6825,"activeCount":102},[6826],{"nctId":6827,"briefTitle":6828,"status":308,"phases":6829,"primaryCompletion":3797,"completion":3797,"start":4751,"enrollment":6830,"conditions":6831,"interventions":6832},"NCT01595633","Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy",[93],124,[3228],[6814],{"trials":6834,"activeCount":102},[],{"intervention":6836,"totalTrials":213,"cells":6837},"epidural 250mL of 0.2% ropivacaine and 2 μg\u002FmL of fentanyl, 5 mL\u002Fhr continuous infusion and 0.5 mL bolus dose",{"EARLY_PHASE1":6838,"PHASE1":6840,"PHASE2":6842,"PHASE3":6844,"PHASE4":6846,"NA":6856},{"trials":6839,"activeCount":102},[],{"trials":6841,"activeCount":102},[],{"trials":6843,"activeCount":102},[],{"trials":6845,"activeCount":102},[],{"trials":6847,"activeCount":102},[6848],{"nctId":6849,"briefTitle":6850,"status":204,"phases":6851,"primaryCompletion":4751,"completion":3889,"start":6852,"enrollment":1243,"conditions":6853,"interventions":6854},"NCT01547416","The Effect of Combined General\u002FEpidural Anesthesia Versus General Anesthesia on Diaphragmatic Function",[93],"2011-11",[35],[6836,6855],"no epidural drug administered",{"trials":6857,"activeCount":102},[],{"intervention":6855,"totalTrials":213,"cells":6859},{"EARLY_PHASE1":6860,"PHASE1":6862,"PHASE2":6864,"PHASE3":6866,"PHASE4":6868,"NA":6874},{"trials":6861,"activeCount":102},[],{"trials":6863,"activeCount":102},[],{"trials":6865,"activeCount":102},[],{"trials":6867,"activeCount":102},[],{"trials":6869,"activeCount":102},[6870],{"nctId":6849,"briefTitle":6850,"status":204,"phases":6871,"primaryCompletion":4751,"completion":3889,"start":6852,"enrollment":1243,"conditions":6872,"interventions":6873},[93],[35],[6836,6855],{"trials":6875,"activeCount":102},[],{"intervention":325,"totalTrials":213,"cells":6877},{"EARLY_PHASE1":6878,"PHASE1":6880,"PHASE2":6882,"PHASE3":6884,"PHASE4":6886,"NA":6892},{"trials":6879,"activeCount":102},[],{"trials":6881,"activeCount":102},[],{"trials":6883,"activeCount":102},[],{"trials":6885,"activeCount":102},[],{"trials":6887,"activeCount":102},[6888],{"nctId":317,"briefTitle":318,"status":204,"phases":6889,"primaryCompletion":320,"completion":320,"start":321,"enrollment":322,"conditions":6890,"interventions":6891},[93],[15],[325,326,266],{"trials":6893,"activeCount":102},[],{"intervention":6895,"totalTrials":213,"cells":6896},"Masibone S",{"EARLY_PHASE1":6897,"PHASE1":6899,"PHASE2":6901,"PHASE3":6903,"PHASE4":6905,"NA":6916},{"trials":6898,"activeCount":102},[],{"trials":6900,"activeCount":102},[],{"trials":6902,"activeCount":102},[],{"trials":6904,"activeCount":102},[],{"trials":6906,"activeCount":102},[6907],{"nctId":6908,"briefTitle":6909,"status":308,"phases":6910,"primaryCompletion":1268,"completion":1268,"start":6911,"enrollment":6912,"conditions":6913,"interventions":6914},"NCT05387200","Phase IV Clinical Trial to Evaluate Efficacy and Safety of MASI BONE S (Alendronate Sodium Trihydrate) in Postmenopausal Women With Osteoporosis",[93],"2021-07-02",170,[5083],[6895,6915],"Fosamax",{"trials":6917,"activeCount":102},[],{"intervention":6915,"totalTrials":213,"cells":6919},{"EARLY_PHASE1":6920,"PHASE1":6922,"PHASE2":6924,"PHASE3":6926,"PHASE4":6928,"NA":6934},{"trials":6921,"activeCount":102},[],{"trials":6923,"activeCount":102},[],{"trials":6925,"activeCount":102},[],{"trials":6927,"activeCount":102},[],{"trials":6929,"activeCount":102},[6930],{"nctId":6908,"briefTitle":6909,"status":308,"phases":6931,"primaryCompletion":1268,"completion":1268,"start":6911,"enrollment":6912,"conditions":6932,"interventions":6933},[93],[5083],[6895,6915],{"trials":6935,"activeCount":102},[],{"intervention":6937,"totalTrials":213,"cells":6938},"Valsaltan, amlodipine",{"EARLY_PHASE1":6939,"PHASE1":6941,"PHASE2":6943,"PHASE3":6945,"PHASE4":6947,"NA":6955},{"trials":6940,"activeCount":102},[],{"trials":6942,"activeCount":102},[],{"trials":6944,"activeCount":102},[],{"trials":6946,"activeCount":102},[],{"trials":6948,"activeCount":102},[6949],{"nctId":6950,"briefTitle":6951,"status":204,"phases":6952,"primaryCompletion":4611,"completion":207,"start":6741,"enrollment":1166,"conditions":6953,"interventions":6954},"NCT01091753","Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers",[93],[3375],[6937],{"trials":6956,"activeCount":102},[],{"intervention":6958,"totalTrials":213,"cells":6959},"Cyclosporine 0.1% (Ikervis®) eye drop",{"EARLY_PHASE1":6960,"PHASE1":6962,"PHASE2":6964,"PHASE3":6966,"PHASE4":6968,"NA":6979},{"trials":6961,"activeCount":102},[],{"trials":6963,"activeCount":102},[],{"trials":6965,"activeCount":102},[],{"trials":6967,"activeCount":102},[],{"trials":6969,"activeCount":102},[6970],{"nctId":6971,"briefTitle":6972,"status":308,"phases":6973,"primaryCompletion":6974,"completion":6974,"start":6975,"enrollment":2661,"conditions":6976,"interventions":6978},"NCT04775303","A Clinical Trial to Evaluate the Clinical Efficacy of Cyclosporine 0.1% (Ikervis®) for Moderate to Severe Dry Eye Patients. (IKE-03-SWITCHING)",[93],"2022-01","2020-09-25",[6977],"Moderate to Severe Dry Eye",[6958],{"trials":6980,"activeCount":102},[],{"intervention":6982,"totalTrials":213,"cells":6983},"ESP block",{"EARLY_PHASE1":6984,"PHASE1":6986,"PHASE2":6988,"PHASE3":6990,"PHASE4":6992,"NA":7003},{"trials":6985,"activeCount":102},[],{"trials":6987,"activeCount":102},[],{"trials":6989,"activeCount":102},[],{"trials":6991,"activeCount":102},[],{"trials":6993,"activeCount":102},[6994],{"nctId":6995,"briefTitle":6996,"status":308,"phases":6997,"primaryCompletion":5262,"completion":6998,"start":6999,"enrollment":1501,"conditions":7000,"interventions":7002},"NCT04208542","Effects of Thoracic Erector Spinae Plane Blockade on Acute and Chronic Pain After Video Assisted Thoracoscopic Surgery (VATS)",[93],"2021-12","2019-04-01",[7001],"Thoracic",[6982],{"trials":7004,"activeCount":102},[],{"intervention":7006,"totalTrials":213,"cells":7007},"Mycophenolate Mofetil",{"EARLY_PHASE1":7008,"PHASE1":7010,"PHASE2":7012,"PHASE3":7014,"PHASE4":7016,"NA":7030},{"trials":7009,"activeCount":102},[],{"trials":7011,"activeCount":102},[],{"trials":7013,"activeCount":102},[],{"trials":7015,"activeCount":102},[],{"trials":7017,"activeCount":102},[7018],{"nctId":7019,"briefTitle":7020,"status":308,"phases":7021,"primaryCompletion":7022,"completion":7023,"start":980,"enrollment":222,"conditions":7024,"interventions":7026},"NCT02981212","Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy",[93],"2018-08","2018-10",[7025],"IgA Nephropathy",[7006,7027,7028,7029],"ACE inhibitor","Corticosteroid","ARB",{"trials":7031,"activeCount":102},[],{"intervention":7028,"totalTrials":213,"cells":7033},{"EARLY_PHASE1":7034,"PHASE1":7036,"PHASE2":7038,"PHASE3":7040,"PHASE4":7042,"NA":7048},{"trials":7035,"activeCount":102},[],{"trials":7037,"activeCount":102},[],{"trials":7039,"activeCount":102},[],{"trials":7041,"activeCount":102},[],{"trials":7043,"activeCount":102},[7044],{"nctId":7019,"briefTitle":7020,"status":308,"phases":7045,"primaryCompletion":7022,"completion":7023,"start":980,"enrollment":222,"conditions":7046,"interventions":7047},[93],[7025],[7006,7027,7028,7029],{"trials":7049,"activeCount":102},[],{"intervention":7029,"totalTrials":213,"cells":7051},{"EARLY_PHASE1":7052,"PHASE1":7054,"PHASE2":7056,"PHASE3":7058,"PHASE4":7060,"NA":7066},{"trials":7053,"activeCount":102},[],{"trials":7055,"activeCount":102},[],{"trials":7057,"activeCount":102},[],{"trials":7059,"activeCount":102},[],{"trials":7061,"activeCount":102},[7062],{"nctId":7019,"briefTitle":7020,"status":308,"phases":7063,"primaryCompletion":7022,"completion":7023,"start":980,"enrollment":222,"conditions":7064,"interventions":7065},[93],[7025],[7006,7027,7028,7029],{"trials":7067,"activeCount":102},[],{"intervention":7069,"totalTrials":213,"cells":7070},"Group A",{"EARLY_PHASE1":7071,"PHASE1":7073,"PHASE2":7075,"PHASE3":7077,"PHASE4":7079,"NA":7090},{"trials":7072,"activeCount":102},[],{"trials":7074,"activeCount":102},[],{"trials":7076,"activeCount":102},[],{"trials":7078,"activeCount":102},[],{"trials":7080,"activeCount":102},[7081],{"nctId":7082,"briefTitle":7083,"status":308,"phases":7084,"primaryCompletion":7085,"completion":7085,"start":3866,"enrollment":7086,"conditions":7087,"interventions":7088},"NCT01597934","Antiviral Efficacy of Switching to ETV Plus TDF",[93],"2014-05",104,[3228],[7069,7089],"Group B",{"trials":7091,"activeCount":102},[],{"intervention":7089,"totalTrials":213,"cells":7093},{"EARLY_PHASE1":7094,"PHASE1":7096,"PHASE2":7098,"PHASE3":7100,"PHASE4":7102,"NA":7108},{"trials":7095,"activeCount":102},[],{"trials":7097,"activeCount":102},[],{"trials":7099,"activeCount":102},[],{"trials":7101,"activeCount":102},[],{"trials":7103,"activeCount":102},[7104],{"nctId":7082,"briefTitle":7083,"status":308,"phases":7105,"primaryCompletion":7085,"completion":7085,"start":3866,"enrollment":7086,"conditions":7106,"interventions":7107},[93],[3228],[7069,7089],{"trials":7109,"activeCount":102},[],{"intervention":7111,"totalTrials":213,"cells":7112},"Raloxifene plus cholecalciferol",{"EARLY_PHASE1":7113,"PHASE1":7115,"PHASE2":7117,"PHASE3":7119,"PHASE4":7121,"NA":7133},{"trials":7114,"activeCount":102},[],{"trials":7116,"activeCount":102},[],{"trials":7118,"activeCount":102},[],{"trials":7120,"activeCount":102},[],{"trials":7122,"activeCount":102},[7123],{"nctId":7124,"briefTitle":7125,"status":204,"phases":7126,"primaryCompletion":7127,"completion":7127,"start":7128,"enrollment":1010,"conditions":7129,"interventions":7131},"NCT05386784","Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia",[93],"2022-07-14","2020-12-16",[7130],"Postemenopusal Women With Osteopenia",[7111,7132],"Cholecalciferol",{"trials":7134,"activeCount":102},[],{"intervention":7132,"totalTrials":213,"cells":7136},{"EARLY_PHASE1":7137,"PHASE1":7139,"PHASE2":7141,"PHASE3":7143,"PHASE4":7145,"NA":7151},{"trials":7138,"activeCount":102},[],{"trials":7140,"activeCount":102},[],{"trials":7142,"activeCount":102},[],{"trials":7144,"activeCount":102},[],{"trials":7146,"activeCount":102},[7147],{"nctId":7124,"briefTitle":7125,"status":204,"phases":7148,"primaryCompletion":7127,"completion":7127,"start":7128,"enrollment":1010,"conditions":7149,"interventions":7150},[93],[7130],[7111,7132],{"trials":7152,"activeCount":102},[],{"intervention":7154,"totalTrials":98,"cells":7155},"Vinorelbine, cisplatin",{"EARLY_PHASE1":7156,"PHASE1":7158,"PHASE2":7160,"PHASE3":7162,"PHASE4":7180,"NA":7182},{"trials":7157,"activeCount":102},[],{"trials":7159,"activeCount":102},[],{"trials":7161,"activeCount":102},[],{"trials":7163,"activeCount":102},[7164,7173],{"nctId":7165,"briefTitle":7166,"status":308,"phases":7167,"primaryCompletion":5984,"completion":5984,"start":4478,"enrollment":7168,"conditions":7169,"interventions":7171},"NCT03381066","A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.",[92],225,[7170],"Completely Resected NSCLC With Common EGFR Mutations",[7172,7154],"gefitinib, pemetrexed,cisplatin",{"nctId":7174,"briefTitle":7175,"status":1475,"phases":7176,"primaryCompletion":1046,"completion":1046,"start":980,"enrollment":102,"conditions":7177,"interventions":7178},"NCT02795884","Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation",[92],[1559],[7179,7154],"intercalation therapy using pemetrexed, cisplatin and erlotinib",{"trials":7181,"activeCount":102},[],{"trials":7183,"activeCount":102},[],{"intervention":7185,"totalTrials":98,"cells":7186},"SP",{"EARLY_PHASE1":7187,"PHASE1":7189,"PHASE2":7191,"PHASE3":7205,"PHASE4":7217,"NA":7219},{"trials":7188,"activeCount":102},[],{"trials":7190,"activeCount":102},[],{"trials":7192,"activeCount":102},[7193],{"nctId":7194,"briefTitle":7195,"status":204,"phases":7196,"primaryCompletion":7197,"completion":7197,"start":7198,"enrollment":369,"conditions":7199,"interventions":7201},"NCT01283204","Trial of 4-regimen (SP, FL\u002FTax, FL\u002FDoc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer",[91],"2016-07-25","2010-03-09",[7200],"Recurrent or Metastatic Gastric Cancer",[7185,7202,7203,7204],"FL\u002FTax","FL\u002FDoc","FOLFOX",{"trials":7206,"activeCount":102},[7207],{"nctId":7208,"briefTitle":7209,"status":308,"phases":7210,"primaryCompletion":7211,"completion":7211,"start":321,"enrollment":7212,"conditions":7213,"interventions":7215},"NCT01283217","Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB\u002FIV Gastric Cancer",[92],"2016-03",166,[7214],"Gastric Adenocarcinoma",[7216,7185],"DS",{"trials":7218,"activeCount":102},[],{"trials":7220,"activeCount":102},[],{"intervention":7222,"totalTrials":98,"cells":7223},"Endo-Clot",{"EARLY_PHASE1":7224,"PHASE1":7226,"PHASE2":7228,"PHASE3":7240,"PHASE4":7251,"NA":7253},{"trials":7225,"activeCount":102},[],{"trials":7227,"activeCount":102},[],{"trials":7229,"activeCount":102},[7230],{"nctId":7231,"briefTitle":7232,"status":308,"phases":7233,"primaryCompletion":7234,"completion":7234,"start":7235,"enrollment":7236,"conditions":7237,"interventions":7239},"NCT02732483","Role of Hemostatic Powder (Endo-clotTM) in Success and Prevention of Bleeding Within Gastric Cancer Patients With Bleeding",[91],"2018-04","2016-04",32,[7238],"Bleeding at Gastric Cancer",[7222],{"trials":7241,"activeCount":102},[7242],{"nctId":7243,"briefTitle":7244,"status":204,"phases":7245,"primaryCompletion":7246,"completion":7246,"start":5123,"enrollment":7247,"conditions":7248,"interventions":7250},"NCT02625792","Role of Hemostatic Powder (Endo-clotTM) in Prevention of Bleeding Within High Risk Patients After ESD",[92],"2016-10",45,[7249],"Iatrogenic Ulcer After ESD",[7222],{"trials":7252,"activeCount":102},[],{"trials":7254,"activeCount":102},[],{"intervention":7256,"totalTrials":98,"cells":7257},"mesenchymal stem cell",{"EARLY_PHASE1":7258,"PHASE1":7260,"PHASE2":7262,"PHASE3":7271,"PHASE4":7277,"NA":7279},{"trials":7259,"activeCount":102},[],{"trials":7261,"activeCount":102},[],{"trials":7263,"activeCount":102},[7264],{"nctId":7265,"briefTitle":7266,"status":308,"phases":7267,"primaryCompletion":3658,"completion":3841,"start":207,"enrollment":36,"conditions":7268,"interventions":7270},"NCT01741090","The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis",[91],[7269],"Alcoholic Liver Cirrhosis",[7256],{"trials":7272,"activeCount":102},[7273],{"nctId":896,"briefTitle":897,"status":204,"phases":7274,"primaryCompletion":899,"completion":899,"start":900,"enrollment":233,"conditions":7275,"interventions":7276},[91,92],[288],[903,904],{"trials":7278,"activeCount":102},[],{"trials":7280,"activeCount":102},[],{"intervention":7282,"totalTrials":213,"cells":7283},"Preoperative Gabexate Mesilate group",{"EARLY_PHASE1":7284,"PHASE1":7286,"PHASE2":7288,"PHASE3":7290,"PHASE4":7303,"NA":7305},{"trials":7285,"activeCount":102},[],{"trials":7287,"activeCount":102},[],{"trials":7289,"activeCount":102},[],{"trials":7291,"activeCount":102},[7292],{"nctId":7293,"briefTitle":7294,"status":243,"phases":7295,"primaryCompletion":7296,"completion":7296,"start":7297,"enrollment":98,"conditions":7298,"interventions":7300},"NCT02710266","Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection",[92],"2017-02-25","2012-02-24",[7299],"Liver Disease",[7282,7301,7302],"Intraoperative Gabexate Mesilate group","hepatectomy with dextrose water",{"trials":7304,"activeCount":102},[],{"trials":7306,"activeCount":102},[],{"intervention":7301,"totalTrials":213,"cells":7308},{"EARLY_PHASE1":7309,"PHASE1":7311,"PHASE2":7313,"PHASE3":7315,"PHASE4":7321,"NA":7323},{"trials":7310,"activeCount":102},[],{"trials":7312,"activeCount":102},[],{"trials":7314,"activeCount":102},[],{"trials":7316,"activeCount":102},[7317],{"nctId":7293,"briefTitle":7294,"status":243,"phases":7318,"primaryCompletion":7296,"completion":7296,"start":7297,"enrollment":98,"conditions":7319,"interventions":7320},[92],[7299],[7282,7301,7302],{"trials":7322,"activeCount":102},[],{"trials":7324,"activeCount":102},[],{"intervention":7302,"totalTrials":213,"cells":7326},{"EARLY_PHASE1":7327,"PHASE1":7329,"PHASE2":7331,"PHASE3":7333,"PHASE4":7339,"NA":7341},{"trials":7328,"activeCount":102},[],{"trials":7330,"activeCount":102},[],{"trials":7332,"activeCount":102},[],{"trials":7334,"activeCount":102},[7335],{"nctId":7293,"briefTitle":7294,"status":243,"phases":7336,"primaryCompletion":7296,"completion":7296,"start":7297,"enrollment":98,"conditions":7337,"interventions":7338},[92],[7299],[7282,7301,7302],{"trials":7340,"activeCount":102},[],{"trials":7342,"activeCount":102},[],{"intervention":7344,"totalTrials":213,"cells":7345},"Ertugliflozin",{"EARLY_PHASE1":7346,"PHASE1":7348,"PHASE2":7350,"PHASE3":7352,"PHASE4":7362,"NA":7364},{"trials":7347,"activeCount":102},[],{"trials":7349,"activeCount":102},[],{"trials":7351,"activeCount":102},[],{"trials":7353,"activeCount":102},[7354],{"nctId":7355,"briefTitle":7356,"status":308,"phases":7357,"primaryCompletion":6998,"completion":5984,"start":7358,"enrollment":16,"conditions":7359,"interventions":7361},"NCT04490681","Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)",[92],"2020-08",[7360],"Heart Failure With Nonischemic Cardiomyopathy",[7344],{"trials":7363,"activeCount":102},[],{"trials":7365,"activeCount":102},[],{"intervention":7367,"totalTrials":213,"cells":7368},"Rifaximin + propranolol",{"EARLY_PHASE1":7369,"PHASE1":7371,"PHASE2":7373,"PHASE3":7375,"PHASE4":7390,"NA":7392},{"trials":7370,"activeCount":102},[],{"trials":7372,"activeCount":102},[],{"trials":7374,"activeCount":102},[],{"trials":7376,"activeCount":102},[7377],{"nctId":7378,"briefTitle":7379,"status":308,"phases":7380,"primaryCompletion":7381,"completion":7382,"start":7383,"enrollment":7384,"conditions":7385,"interventions":7388},"NCT01897051","Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients",[91,92],"2017-02","2017-06","2013-07",140,[7386,7387],"Liver Cirrhosis","Portal Hypertension",[7367,7389],"Propranolol + Placebo",{"trials":7391,"activeCount":102},[],{"trials":7393,"activeCount":102},[],{"intervention":7389,"totalTrials":213,"cells":7395},{"EARLY_PHASE1":7396,"PHASE1":7398,"PHASE2":7400,"PHASE3":7402,"PHASE4":7408,"NA":7410},{"trials":7397,"activeCount":102},[],{"trials":7399,"activeCount":102},[],{"trials":7401,"activeCount":102},[],{"trials":7403,"activeCount":102},[7404],{"nctId":7378,"briefTitle":7379,"status":308,"phases":7405,"primaryCompletion":7381,"completion":7382,"start":7383,"enrollment":7384,"conditions":7406,"interventions":7407},[91,92],[7386,7387],[7367,7389],{"trials":7409,"activeCount":102},[],{"trials":7411,"activeCount":102},[],{"intervention":7413,"totalTrials":213,"cells":7414},"telbivudine",{"EARLY_PHASE1":7415,"PHASE1":7417,"PHASE2":7419,"PHASE3":7421,"PHASE4":7429,"NA":7431},{"trials":7416,"activeCount":102},[],{"trials":7418,"activeCount":102},[],{"trials":7420,"activeCount":102},[],{"trials":7422,"activeCount":102},[7423],{"nctId":7424,"briefTitle":7425,"status":308,"phases":7426,"primaryCompletion":3889,"completion":3889,"start":206,"enrollment":834,"conditions":7427,"interventions":7428},"NCT01270165","Lamivudine Plus Adefovir Versus Telbivudine Plus Adefovir in Lamivudine Resistant Chronic Hepatitis B",[92],[3228],[7413],{"trials":7430,"activeCount":102},[],{"trials":7432,"activeCount":102},[],{"intervention":7172,"totalTrials":213,"cells":7434},{"EARLY_PHASE1":7435,"PHASE1":7437,"PHASE2":7439,"PHASE3":7441,"PHASE4":7447,"NA":7449},{"trials":7436,"activeCount":102},[],{"trials":7438,"activeCount":102},[],{"trials":7440,"activeCount":102},[],{"trials":7442,"activeCount":102},[7443],{"nctId":7165,"briefTitle":7166,"status":308,"phases":7444,"primaryCompletion":5984,"completion":5984,"start":4478,"enrollment":7168,"conditions":7445,"interventions":7446},[92],[7170],[7172,7154],{"trials":7448,"activeCount":102},[],{"trials":7450,"activeCount":102},[],{"intervention":1073,"totalTrials":213,"cells":7452},{"EARLY_PHASE1":7453,"PHASE1":7455,"PHASE2":7457,"PHASE3":7459,"PHASE4":7465,"NA":7467},{"trials":7454,"activeCount":102},[],{"trials":7456,"activeCount":102},[],{"trials":7458,"activeCount":102},[],{"trials":7460,"activeCount":102},[7461],{"nctId":1064,"briefTitle":1065,"status":243,"phases":7462,"primaryCompletion":1067,"completion":1068,"start":1069,"enrollment":946,"conditions":7463,"interventions":7464},[92],[1071],[1073,1053],{"trials":7466,"activeCount":102},[],{"trials":7468,"activeCount":102},[],{"intervention":7216,"totalTrials":213,"cells":7470},{"EARLY_PHASE1":7471,"PHASE1":7473,"PHASE2":7475,"PHASE3":7477,"PHASE4":7483,"NA":7485},{"trials":7472,"activeCount":102},[],{"trials":7474,"activeCount":102},[],{"trials":7476,"activeCount":102},[],{"trials":7478,"activeCount":102},[7479],{"nctId":7208,"briefTitle":7209,"status":308,"phases":7480,"primaryCompletion":7211,"completion":7211,"start":321,"enrollment":7212,"conditions":7481,"interventions":7482},[92],[7214],[7216,7185],{"trials":7484,"activeCount":102},[],{"trials":7486,"activeCount":102},[],{"intervention":7488,"totalTrials":213,"cells":7489},"topical ketorolac 0.5%",{"EARLY_PHASE1":7490,"PHASE1":7492,"PHASE2":7494,"PHASE3":7496,"PHASE4":7508,"NA":7510},{"trials":7491,"activeCount":102},[],{"trials":7493,"activeCount":102},[],{"trials":7495,"activeCount":102},[],{"trials":7497,"activeCount":102},[7498],{"nctId":7499,"briefTitle":7500,"status":204,"phases":7501,"primaryCompletion":7502,"completion":320,"start":7503,"enrollment":1343,"conditions":7504,"interventions":7506},"NCT01761071","Time Serial Analysis on Preemptive Analgesia of Preoperative Topical Diclofenac and Ketorolac in Photorefractive Keratectomy(PRK)",[92],"2012-11","2012-01",[7505],"Myopes Who Have Undergone PRK.",[7488,7507],"topical diclofenac 0.1%",{"trials":7509,"activeCount":102},[],{"trials":7511,"activeCount":102},[],{"intervention":7507,"totalTrials":213,"cells":7513},{"EARLY_PHASE1":7514,"PHASE1":7516,"PHASE2":7518,"PHASE3":7520,"PHASE4":7526,"NA":7528},{"trials":7515,"activeCount":102},[],{"trials":7517,"activeCount":102},[],{"trials":7519,"activeCount":102},[],{"trials":7521,"activeCount":102},[7522],{"nctId":7499,"briefTitle":7500,"status":204,"phases":7523,"primaryCompletion":7502,"completion":320,"start":7503,"enrollment":1343,"conditions":7524,"interventions":7525},[92],[7505],[7488,7507],{"trials":7527,"activeCount":102},[],{"trials":7529,"activeCount":102},[],{"intervention":7531,"totalTrials":213,"cells":7532},"Edoxaban",{"EARLY_PHASE1":7533,"PHASE1":7535,"PHASE2":7537,"PHASE3":7539,"PHASE4":7553,"NA":7555},{"trials":7534,"activeCount":102},[],{"trials":7536,"activeCount":102},[],{"trials":7538,"activeCount":102},[],{"trials":7540,"activeCount":102},[7541],{"nctId":7542,"briefTitle":7543,"status":204,"phases":7544,"primaryCompletion":7545,"completion":7545,"start":7546,"enrollment":7547,"conditions":7548,"interventions":7550},"NCT03244319","Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)",[92],"2019-09-30","2017-12-01",220,[7549],"MV(Mitral Valve) Repair",[7531,7551,7552],"Warfarin","parenteral anti-coagulant",{"trials":7554,"activeCount":102},[],{"trials":7556,"activeCount":102},[],{"intervention":7551,"totalTrials":213,"cells":7558},{"EARLY_PHASE1":7559,"PHASE1":7561,"PHASE2":7563,"PHASE3":7565,"PHASE4":7571,"NA":7573},{"trials":7560,"activeCount":102},[],{"trials":7562,"activeCount":102},[],{"trials":7564,"activeCount":102},[],{"trials":7566,"activeCount":102},[7567],{"nctId":7542,"briefTitle":7543,"status":204,"phases":7568,"primaryCompletion":7545,"completion":7545,"start":7546,"enrollment":7547,"conditions":7569,"interventions":7570},[92],[7549],[7531,7551,7552],{"trials":7572,"activeCount":102},[],{"trials":7574,"activeCount":102},[],{"intervention":7552,"totalTrials":213,"cells":7576},{"EARLY_PHASE1":7577,"PHASE1":7579,"PHASE2":7581,"PHASE3":7583,"PHASE4":7589,"NA":7591},{"trials":7578,"activeCount":102},[],{"trials":7580,"activeCount":102},[],{"trials":7582,"activeCount":102},[],{"trials":7584,"activeCount":102},[7585],{"nctId":7542,"briefTitle":7543,"status":204,"phases":7586,"primaryCompletion":7545,"completion":7545,"start":7546,"enrollment":7547,"conditions":7587,"interventions":7588},[92],[7549],[7531,7551,7552],{"trials":7590,"activeCount":102},[],{"trials":7592,"activeCount":102},[],{"intervention":7594,"totalTrials":213,"cells":7595},"taxane plus carboplatin",{"EARLY_PHASE1":7596,"PHASE1":7598,"PHASE2":7600,"PHASE3":7602,"PHASE4":7613,"NA":7615},{"trials":7597,"activeCount":102},[],{"trials":7599,"activeCount":102},[],{"trials":7601,"activeCount":102},[],{"trials":7603,"activeCount":102},[7604],{"nctId":7605,"briefTitle":7606,"status":308,"phases":7607,"primaryCompletion":66,"completion":66,"start":7608,"enrollment":7609,"conditions":7610,"interventions":7611},"NCT02441933","Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)",[92],"2015-09-01",878,[30],[7594,7612],"Taxane",{"trials":7614,"activeCount":102},[],{"trials":7616,"activeCount":102},[],{"intervention":7612,"totalTrials":213,"cells":7618},{"EARLY_PHASE1":7619,"PHASE1":7621,"PHASE2":7623,"PHASE3":7625,"PHASE4":7631,"NA":7633},{"trials":7620,"activeCount":102},[],{"trials":7622,"activeCount":102},[],{"trials":7624,"activeCount":102},[],{"trials":7626,"activeCount":102},[7627],{"nctId":7605,"briefTitle":7606,"status":308,"phases":7628,"primaryCompletion":66,"completion":66,"start":7608,"enrollment":7609,"conditions":7629,"interventions":7630},[92],[30],[7594,7612],{"trials":7632,"activeCount":102},[],{"trials":7634,"activeCount":102},[],{"intervention":7636,"totalTrials":213,"cells":7637},"Cannabidiol",{"EARLY_PHASE1":7638,"PHASE1":7640,"PHASE2":7642,"PHASE3":7644,"PHASE4":7657,"NA":7659},{"trials":7639,"activeCount":102},[],{"trials":7641,"activeCount":102},[],{"trials":7643,"activeCount":102},[],{"trials":7645,"activeCount":102},[7646],{"nctId":7647,"briefTitle":7648,"status":308,"phases":7649,"primaryCompletion":7650,"completion":6109,"start":7651,"enrollment":7652,"conditions":7653,"interventions":7656},"NCT04611438","Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome",[92],"2021-03","2020-03-30",107,[7654,7655],"Dravet Syndrome","Lennox Gastaut Syndrome",[7636],{"trials":7658,"activeCount":102},[],{"trials":7660,"activeCount":102},[],{"intervention":7662,"totalTrials":213,"cells":7663},"5-fluorouracil, irinotecan and leucovorin",{"EARLY_PHASE1":7664,"PHASE1":7666,"PHASE2":7668,"PHASE3":7670,"PHASE4":7682,"NA":7684},{"trials":7665,"activeCount":102},[],{"trials":7667,"activeCount":102},[],{"trials":7669,"activeCount":102},[],{"trials":7671,"activeCount":102},[7672],{"nctId":7673,"briefTitle":7674,"status":204,"phases":7675,"primaryCompletion":7676,"completion":7676,"start":7677,"enrollment":16,"conditions":7678,"interventions":7680},"NCT03067792","FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer",[92],"2016-10-17","2014-12",[7679],"Inoperable Gastric Cancer",[7662,7681],"docetaxel and cisplatin",{"trials":7683,"activeCount":102},[],{"trials":7685,"activeCount":102},[],{"intervention":7681,"totalTrials":213,"cells":7687},{"EARLY_PHASE1":7688,"PHASE1":7690,"PHASE2":7692,"PHASE3":7694,"PHASE4":7700,"NA":7702},{"trials":7689,"activeCount":102},[],{"trials":7691,"activeCount":102},[],{"trials":7693,"activeCount":102},[],{"trials":7695,"activeCount":102},[7696],{"nctId":7673,"briefTitle":7674,"status":204,"phases":7697,"primaryCompletion":7676,"completion":7676,"start":7677,"enrollment":16,"conditions":7698,"interventions":7699},[92],[7679],[7662,7681],{"trials":7701,"activeCount":102},[],{"trials":7703,"activeCount":102},[],{"intervention":7705,"totalTrials":213,"cells":7706},"Vedolizumab",{"EARLY_PHASE1":7707,"PHASE1":7709,"PHASE2":7711,"PHASE3":7713,"PHASE4":7724,"NA":7726},{"trials":7708,"activeCount":102},[],{"trials":7710,"activeCount":102},[],{"trials":7712,"activeCount":102},[],{"trials":7714,"activeCount":102},[7715],{"nctId":7716,"briefTitle":7717,"status":308,"phases":7718,"primaryCompletion":5533,"completion":7719,"start":7720,"enrollment":344,"conditions":7721,"interventions":7723},"NCT04919252","Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease",[92],"2023-01-31","2021-06-01",[7722],"Crohn's Disease and Ulcerative Colitis",[7705],{"trials":7725,"activeCount":102},[],{"trials":7727,"activeCount":102},[],{"intervention":7179,"totalTrials":213,"cells":7729},{"EARLY_PHASE1":7730,"PHASE1":7732,"PHASE2":7734,"PHASE3":7736,"PHASE4":7742,"NA":7744},{"trials":7731,"activeCount":102},[],{"trials":7733,"activeCount":102},[],{"trials":7735,"activeCount":102},[],{"trials":7737,"activeCount":102},[7738],{"nctId":7174,"briefTitle":7175,"status":1475,"phases":7739,"primaryCompletion":1046,"completion":1046,"start":980,"enrollment":102,"conditions":7740,"interventions":7741},[92],[1559],[7179,7154],{"trials":7743,"activeCount":102},[],{"trials":7745,"activeCount":102},[],{"intervention":7747,"totalTrials":213,"cells":7748},"Adjuvant group",{"EARLY_PHASE1":7749,"PHASE1":7751,"PHASE2":7753,"PHASE3":7755,"PHASE4":7766,"NA":7768},{"trials":7750,"activeCount":102},[],{"trials":7752,"activeCount":102},[],{"trials":7754,"activeCount":102},[],{"trials":7756,"activeCount":102},[7757],{"nctId":7758,"briefTitle":7759,"status":204,"phases":7760,"primaryCompletion":7761,"completion":1477,"start":7762,"enrollment":7763,"conditions":7764,"interventions":7765},"NCT01088581","Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular Carcinoma",[92],"2007-12","2006-01",101,[2365],[7747],{"trials":7767,"activeCount":102},[],{"trials":7769,"activeCount":102},[],{"intervention":7771,"totalTrials":885,"cells":7772},"cisplatin",{"EARLY_PHASE1":7773,"PHASE1":7775,"PHASE2":7777,"PHASE3":7818,"PHASE4":7820,"NA":7822},{"trials":7774,"activeCount":102},[],{"trials":7776,"activeCount":102},[],{"trials":7778,"activeCount":102},[7779,7787,7796,7805,7814],{"nctId":7780,"briefTitle":7781,"status":308,"phases":7782,"start":6741,"enrollment":7236,"conditions":7783,"interventions":7785},"NCT00659113","S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery",[91],[7784],"Esophageal Cancer",[7771,7786],"tegafur-gimeracil-oteracil potassium",{"nctId":7788,"briefTitle":7789,"status":308,"phases":7790,"primaryCompletion":3452,"start":7791,"enrollment":7792,"conditions":7793,"interventions":7794},"NCT00625937","Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer",[91],"2006-11",46,[1334],[7771,7795,7786],"docetaxel",{"nctId":7797,"briefTitle":7798,"status":204,"phases":7799,"primaryCompletion":899,"completion":5166,"start":7800,"enrollment":1513,"conditions":7801,"interventions":7803},"NCT00754858","Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer",[91],"2008-10",[7802],"Lung Cancer",[7804,7771],"belotecan hydrochloride",{"nctId":7806,"briefTitle":7807,"status":308,"phases":7808,"primaryCompletion":3452,"start":7809,"enrollment":1291,"conditions":7810,"interventions":7811},"NCT00616785","Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",[91],"2007-06",[7802],[7771,7812,7813],"etoposide","irinotecan hydrochloride",{"nctId":1285,"briefTitle":1286,"status":308,"phases":7815,"primaryCompletion":1288,"completion":1289,"start":1290,"enrollment":1291,"conditions":7816,"interventions":7817},[90,91],[21],[87,1294,1295,1296],{"trials":7819,"activeCount":102},[],{"trials":7821,"activeCount":102},[],{"trials":7823,"activeCount":102},[],{"intervention":7786,"totalTrials":267,"cells":7825},{"EARLY_PHASE1":7826,"PHASE1":7828,"PHASE2":7830,"PHASE3":7858,"PHASE4":7860,"NA":7862},{"trials":7827,"activeCount":102},[],{"trials":7829,"activeCount":102},[],{"trials":7831,"activeCount":102},[7832,7836,7840,7850],{"nctId":7780,"briefTitle":7781,"status":308,"phases":7833,"start":6741,"enrollment":7236,"conditions":7834,"interventions":7835},[91],[7784],[7771,7786],{"nctId":7788,"briefTitle":7789,"status":308,"phases":7837,"primaryCompletion":3452,"start":7791,"enrollment":7792,"conditions":7838,"interventions":7839},[91],[1334],[7771,7795,7786],{"nctId":7841,"briefTitle":7842,"status":308,"phases":7843,"start":7844,"enrollment":7845,"conditions":7846,"interventions":7847},"NCT00994968","Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer",[91],"2009-07",49,[30],[7848,7795,7849,7786],"cyclophosphamide","doxorubicin hydrochloride",{"nctId":7851,"briefTitle":7852,"status":308,"phases":7853,"start":3470,"enrollment":11,"conditions":7854,"interventions":7855},"NCT00985556","Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer",[91],[21],[7856,7857,7786],"capecitabine","oxaliplatin",{"trials":7859,"activeCount":102},[],{"trials":7861,"activeCount":102},[],{"trials":7863,"activeCount":102},[],{"intervention":7795,"totalTrials":946,"cells":7865},{"EARLY_PHASE1":7866,"PHASE1":7868,"PHASE2":7870,"PHASE3":7891,"PHASE4":7893,"NA":7895},{"trials":7867,"activeCount":102},[],{"trials":7869,"activeCount":102},[],{"trials":7871,"activeCount":102},[7872,7876,7880],{"nctId":7788,"briefTitle":7789,"status":308,"phases":7873,"primaryCompletion":3452,"start":7791,"enrollment":7792,"conditions":7874,"interventions":7875},[91],[1334],[7771,7795,7786],{"nctId":7841,"briefTitle":7842,"status":308,"phases":7877,"start":7844,"enrollment":7845,"conditions":7878,"interventions":7879},[91],[30],[7848,7795,7849,7786],{"nctId":7881,"briefTitle":7882,"status":308,"phases":7883,"start":7884,"enrollment":7885,"conditions":7886,"interventions":7887},"NCT00736814","First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",[91],"2008-06",117,[7802],[7888,7795,7889,7890],"carboplatin","gemcitabine hydrochloride","vinorelbine tartrate",{"trials":7892,"activeCount":102},[],{"trials":7894,"activeCount":102},[],{"trials":7896,"activeCount":102},[],{"intervention":7856,"totalTrials":946,"cells":7898},{"EARLY_PHASE1":7899,"PHASE1":7901,"PHASE2":7903,"PHASE3":7921,"PHASE4":7923,"NA":7925},{"trials":7900,"activeCount":102},[],{"trials":7902,"activeCount":102},[],{"trials":7904,"activeCount":102},[7905,7913,7917],{"nctId":7906,"briefTitle":7907,"status":308,"phases":7908,"primaryCompletion":7909,"start":7910,"enrollment":1980,"conditions":7911,"interventions":7912},"NCT00496704","Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan",[90,91],"2009-08","2007-01",[32],[7856,7889,7857],{"nctId":1285,"briefTitle":1286,"status":308,"phases":7914,"primaryCompletion":1288,"completion":1289,"start":1290,"enrollment":1291,"conditions":7915,"interventions":7916},[90,91],[21],[87,1294,1295,1296],{"nctId":7851,"briefTitle":7852,"status":308,"phases":7918,"start":3470,"enrollment":11,"conditions":7919,"interventions":7920},[91],[21],[7856,7857,7786],{"trials":7922,"activeCount":102},[],{"trials":7924,"activeCount":102},[],{"trials":7926,"activeCount":102},[],{"intervention":7928,"totalTrials":98,"cells":7929},"gefitinib",{"EARLY_PHASE1":7930,"PHASE1":7932,"PHASE2":7934,"PHASE3":7952,"PHASE4":7954,"NA":7956},{"trials":7931,"activeCount":102},[],{"trials":7933,"activeCount":102},[],{"trials":7935,"activeCount":102},[7936,7943],{"nctId":7937,"briefTitle":7938,"status":308,"phases":7939,"primaryCompletion":3452,"start":7791,"enrollment":7940,"conditions":7941,"interventions":7942},"NCT00616499","Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer",[91],35,[7802],[7928],{"nctId":7944,"briefTitle":7945,"status":204,"phases":7946,"primaryCompletion":981,"completion":981,"start":5398,"enrollment":1538,"conditions":7947,"interventions":7949},"NCT01498562","Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer",[91],[7948],"Non Small Cell Lung Cancer (NSCLC)",[7950,7951],"Gefitinib and Nimotuzumab","Gefitinib",{"trials":7953,"activeCount":102},[],{"trials":7955,"activeCount":102},[],{"trials":7957,"activeCount":102},[],{"intervention":7889,"totalTrials":98,"cells":7959},{"EARLY_PHASE1":7960,"PHASE1":7962,"PHASE2":7964,"PHASE3":7974,"PHASE4":7976,"NA":7978},{"trials":7961,"activeCount":102},[],{"trials":7963,"activeCount":102},[],{"trials":7965,"activeCount":102},[7966,7970],{"nctId":7906,"briefTitle":7907,"status":308,"phases":7967,"primaryCompletion":7909,"start":7910,"enrollment":1980,"conditions":7968,"interventions":7969},[90,91],[32],[7856,7889,7857],{"nctId":7881,"briefTitle":7882,"status":308,"phases":7971,"start":7884,"enrollment":7885,"conditions":7972,"interventions":7973},[91],[7802],[7888,7795,7889,7890],{"trials":7975,"activeCount":102},[],{"trials":7977,"activeCount":102},[],{"trials":7979,"activeCount":102},[],{"intervention":7857,"totalTrials":98,"cells":7981},{"EARLY_PHASE1":7982,"PHASE1":7984,"PHASE2":7986,"PHASE3":7996,"PHASE4":7998,"NA":8000},{"trials":7983,"activeCount":102},[],{"trials":7985,"activeCount":102},[],{"trials":7987,"activeCount":102},[7988,7992],{"nctId":7906,"briefTitle":7907,"status":308,"phases":7989,"primaryCompletion":7909,"start":7910,"enrollment":1980,"conditions":7990,"interventions":7991},[90,91],[32],[7856,7889,7857],{"nctId":7851,"briefTitle":7852,"status":308,"phases":7993,"start":3470,"enrollment":11,"conditions":7994,"interventions":7995},[91],[21],[7856,7857,7786],{"trials":7997,"activeCount":102},[],{"trials":7999,"activeCount":102},[],{"trials":8001,"activeCount":102},[],{"intervention":8003,"totalTrials":98,"cells":8004},"folfox",{"EARLY_PHASE1":8005,"PHASE1":8007,"PHASE2":8009,"PHASE3":8023,"PHASE4":8025,"NA":8027},{"trials":8006,"activeCount":102},[],{"trials":8008,"activeCount":102},[],{"trials":8010,"activeCount":102},[8011,8019],{"nctId":8012,"briefTitle":8013,"status":204,"phases":8014,"primaryCompletion":8015,"completion":8015,"start":3584,"enrollment":7236,"conditions":8016,"interventions":8018},"NCT01269229","A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis",[91],"2015-04",[8017],"Rectal Cancer",[8003],{"nctId":7194,"briefTitle":7195,"status":204,"phases":8020,"primaryCompletion":7197,"completion":7197,"start":7198,"enrollment":369,"conditions":8021,"interventions":8022},[91],[7200],[7185,7202,7203,7204],{"trials":8024,"activeCount":102},[],{"trials":8026,"activeCount":102},[],{"trials":8028,"activeCount":102},[],{"intervention":8030,"totalTrials":98,"cells":8031},"LDK378",{"EARLY_PHASE1":8032,"PHASE1":8034,"PHASE2":8036,"PHASE3":8057,"PHASE4":8059,"NA":8061},{"trials":8033,"activeCount":102},[],{"trials":8035,"activeCount":102},[],{"trials":8037,"activeCount":102},[8038,8047],{"nctId":8039,"briefTitle":8040,"status":308,"phases":8041,"primaryCompletion":8042,"completion":8042,"start":8043,"enrollment":7236,"conditions":8044,"interventions":8046},"NCT01964157","An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement",[91],"2019-12","2013-09-01",[8045],"Non-small Cell Lung Cancer (NSCLC)",[8030],{"nctId":8048,"briefTitle":8049,"status":308,"phases":8050,"primaryCompletion":8051,"completion":8052,"start":8053,"enrollment":7792,"conditions":8054,"interventions":8056},"NCT03399487","A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement",[91],"2020-05","2020-10","2018-07-24",[8055],"Non-small Cell Lung Cancer Harboring ROS1 Rearrangement",[8030],{"trials":8058,"activeCount":102},[],{"trials":8060,"activeCount":102},[],{"trials":8062,"activeCount":102},[],{"intervention":8064,"totalTrials":213,"cells":8065},"Combination injection of EPO and G-CSF",{"EARLY_PHASE1":8066,"PHASE1":8068,"PHASE2":8070,"PHASE3":8084,"PHASE4":8086,"NA":8088},{"trials":8067,"activeCount":102},[],{"trials":8069,"activeCount":102},[],{"trials":8071,"activeCount":102},[8072],{"nctId":8073,"briefTitle":8074,"status":308,"phases":8075,"primaryCompletion":191,"completion":191,"start":8076,"enrollment":344,"conditions":8077,"interventions":8082},"NCT02018406","Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury",[90,91],"2011-07-05",[8078,6639,8079,8080,8081],"Neurological Diseases","Hemorrhagic Stroke","Cerebral Palsy","Atypical Parkinson Disease",[8064,8083],"Injection of normal saline",{"trials":8085,"activeCount":102},[],{"trials":8087,"activeCount":102},[],{"trials":8089,"activeCount":102},[],{"intervention":8083,"totalTrials":213,"cells":8091},{"EARLY_PHASE1":8092,"PHASE1":8094,"PHASE2":8096,"PHASE3":8102,"PHASE4":8104,"NA":8106},{"trials":8093,"activeCount":102},[],{"trials":8095,"activeCount":102},[],{"trials":8097,"activeCount":102},[8098],{"nctId":8073,"briefTitle":8074,"status":308,"phases":8099,"primaryCompletion":191,"completion":191,"start":8076,"enrollment":344,"conditions":8100,"interventions":8101},[90,91],[8078,6639,8079,8080,8081],[8064,8083],{"trials":8103,"activeCount":102},[],{"trials":8105,"activeCount":102},[],{"trials":8107,"activeCount":102},[],{"intervention":8109,"totalTrials":213,"cells":8110},"Orevogomab+PLD",{"EARLY_PHASE1":8111,"PHASE1":8113,"PHASE2":8115,"PHASE3":8128,"PHASE4":8130,"NA":8132},{"trials":8112,"activeCount":102},[],{"trials":8114,"activeCount":102},[],{"trials":8116,"activeCount":102},[8117],{"nctId":8118,"briefTitle":8119,"status":308,"phases":8120,"primaryCompletion":8121,"completion":8122,"start":8123,"enrollment":1980,"conditions":8124,"interventions":8126},"NCT05407584","Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment",[91],"2024-05","2024-11","2022-07-05",[8125],"PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment",[8109,8127],"Orevogomab+Paclitaxel",{"trials":8129,"activeCount":102},[],{"trials":8131,"activeCount":102},[],{"trials":8133,"activeCount":102},[],{"intervention":8127,"totalTrials":213,"cells":8135},{"EARLY_PHASE1":8136,"PHASE1":8138,"PHASE2":8140,"PHASE3":8146,"PHASE4":8148,"NA":8150},{"trials":8137,"activeCount":102},[],{"trials":8139,"activeCount":102},[],{"trials":8141,"activeCount":102},[8142],{"nctId":8118,"briefTitle":8119,"status":308,"phases":8143,"primaryCompletion":8121,"completion":8122,"start":8123,"enrollment":1980,"conditions":8144,"interventions":8145},[91],[8125],[8109,8127],{"trials":8147,"activeCount":102},[],{"trials":8149,"activeCount":102},[],{"trials":8151,"activeCount":102},[],{"intervention":8153,"totalTrials":213,"cells":8154},"Trastuzumab + Ramucirumab + Paclitaxel",{"EARLY_PHASE1":8155,"PHASE1":8157,"PHASE2":8159,"PHASE3":8170,"PHASE4":8172,"NA":8174},{"trials":8156,"activeCount":102},[],{"trials":8158,"activeCount":102},[],{"trials":8160,"activeCount":102},[8161],{"nctId":8162,"briefTitle":8163,"status":308,"phases":8164,"primaryCompletion":8165,"completion":8165,"start":8166,"enrollment":1243,"conditions":8167,"interventions":8169},"NCT04888663","Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent\u002FMetastatic Gastric Cancer (HER-RAM Study)",[90,91],"2021-09-02","2018-02-13",[8168],"Recurrent\u002FMetastatic Gastric Cancer",[8153],{"trials":8171,"activeCount":102},[],{"trials":8173,"activeCount":102},[],{"trials":8175,"activeCount":102},[],{"intervention":8177,"totalTrials":213,"cells":8178},"A-FOLFOXIRI",{"EARLY_PHASE1":8179,"PHASE1":8181,"PHASE2":8183,"PHASE3":8196,"PHASE4":8198,"NA":8200},{"trials":8180,"activeCount":102},[],{"trials":8182,"activeCount":102},[],{"trials":8184,"activeCount":102},[8185],{"nctId":8186,"briefTitle":8187,"status":308,"phases":8188,"primaryCompletion":8189,"completion":8189,"start":8190,"enrollment":4776,"conditions":8191,"interventions":8194},"NCT03641976","A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan\u002FOxaliplatin (A-FOLFIRI\u002FFOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer",[91],"2024-06","2019-01-03",[8192,8193],"Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy","Unresectable Metastatic Right-sided Colon Cancer, Stage IV",[8177,8195],"Arm II",{"trials":8197,"activeCount":102},[],{"trials":8199,"activeCount":102},[],{"trials":8201,"activeCount":102},[],{"intervention":8195,"totalTrials":213,"cells":8203},{"EARLY_PHASE1":8204,"PHASE1":8206,"PHASE2":8208,"PHASE3":8214,"PHASE4":8216,"NA":8218},{"trials":8205,"activeCount":102},[],{"trials":8207,"activeCount":102},[],{"trials":8209,"activeCount":102},[8210],{"nctId":8186,"briefTitle":8187,"status":308,"phases":8211,"primaryCompletion":8189,"completion":8189,"start":8190,"enrollment":4776,"conditions":8212,"interventions":8213},[91],[8192,8193],[8177,8195],{"trials":8215,"activeCount":102},[],{"trials":8217,"activeCount":102},[],{"trials":8219,"activeCount":102},[],{"intervention":8221,"totalTrials":213,"cells":8222},"BIBW2992",{"EARLY_PHASE1":8223,"PHASE1":8225,"PHASE2":8227,"PHASE3":8236,"PHASE4":8238,"NA":8240},{"trials":8224,"activeCount":102},[],{"trials":8226,"activeCount":102},[],{"trials":8228,"activeCount":102},[8229],{"nctId":8230,"briefTitle":8231,"status":308,"phases":8232,"primaryCompletion":4477,"completion":4477,"start":5575,"enrollment":22,"conditions":8233,"interventions":8235},"NCT02353936","A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus",[91],[8234],"Squamous Cell Carcinoma of Esophagus",[8221],{"trials":8237,"activeCount":102},[],{"trials":8239,"activeCount":102},[],{"trials":8241,"activeCount":102},[],{"intervention":8243,"totalTrials":213,"cells":8244},"Neulapeg",{"EARLY_PHASE1":8245,"PHASE1":8247,"PHASE2":8249,"PHASE3":8261,"PHASE4":8263,"NA":8265},{"trials":8246,"activeCount":102},[],{"trials":8248,"activeCount":102},[],{"trials":8250,"activeCount":102},[8251],{"nctId":8252,"briefTitle":8253,"status":308,"phases":8254,"primaryCompletion":8255,"completion":8255,"start":8256,"enrollment":1909,"conditions":8257,"interventions":8260},"NCT06353581","Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX",[91],"2024-05-08","2022-02-16",[8258,8259],"Locally Advanced Pancreatic Cancer","Metastatic Pancreatic Cancer",[8243],{"trials":8262,"activeCount":102},[],{"trials":8264,"activeCount":102},[],{"trials":8266,"activeCount":102},[],{"intervention":8268,"totalTrials":213,"cells":8269},"1) Inosine 5'-monophosphate",{"EARLY_PHASE1":8270,"PHASE1":8272,"PHASE2":8274,"PHASE3":8286,"PHASE4":8288,"NA":8290},{"trials":8271,"activeCount":102},[],{"trials":8273,"activeCount":102},[],{"trials":8275,"activeCount":102},[8276],{"nctId":8277,"briefTitle":8278,"status":204,"phases":8279,"primaryCompletion":8280,"completion":8280,"start":8281,"enrollment":8282,"conditions":8283,"interventions":8285},"NCT03403309","Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial",[91],"2019-06-10","2018-05-02",43,[8284],"Multiple System Atrophy",[8268],{"trials":8287,"activeCount":102},[],{"trials":8289,"activeCount":102},[],{"trials":8291,"activeCount":102},[],{"intervention":8293,"totalTrials":213,"cells":8294},"high dose dexamethsone",{"EARLY_PHASE1":8295,"PHASE1":8297,"PHASE2":8299,"PHASE3":8310,"PHASE4":8312,"NA":8314},{"trials":8296,"activeCount":102},[],{"trials":8298,"activeCount":102},[],{"trials":8300,"activeCount":102},[8301],{"nctId":8302,"briefTitle":8303,"status":204,"phases":8304,"primaryCompletion":8305,"completion":8305,"start":8306,"enrollment":22,"conditions":8307,"interventions":8309},"NCT01255514","Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma",[91],"2014-12-31","2008-10-30",[8308],"Multiple Myeloma",[8293],{"trials":8311,"activeCount":102},[],{"trials":8313,"activeCount":102},[],{"trials":8315,"activeCount":102},[],{"intervention":8317,"totalTrials":213,"cells":8318},"Gemcitabine, Oxaliplatin",{"EARLY_PHASE1":8319,"PHASE1":8321,"PHASE2":8323,"PHASE3":8334,"PHASE4":8336,"NA":8338},{"trials":8320,"activeCount":102},[],{"trials":8322,"activeCount":102},[],{"trials":8324,"activeCount":102},[8325],{"nctId":8326,"briefTitle":8327,"status":204,"phases":8328,"primaryCompletion":7545,"completion":8329,"start":8330,"enrollment":7236,"conditions":8331,"interventions":8333},"NCT05517239","Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment",[91],"2020-09-30","2015-05-01",[8332],"Hepatocellular Carcinoma, Unresectable, Advanced",[8317],{"trials":8335,"activeCount":102},[],{"trials":8337,"activeCount":102},[],{"trials":8339,"activeCount":102},[],{"intervention":8341,"totalTrials":213,"cells":8342},"5-FU with leucovorin",{"EARLY_PHASE1":8343,"PHASE1":8345,"PHASE2":8347,"PHASE3":8357,"PHASE4":8359,"NA":8361},{"trials":8344,"activeCount":102},[],{"trials":8346,"activeCount":102},[],{"trials":8348,"activeCount":102},[8349],{"nctId":8350,"briefTitle":8351,"status":204,"phases":8352,"primaryCompletion":8353,"completion":8353,"start":7800,"enrollment":3530,"conditions":8354,"interventions":8355},"NCT01269216","A Study of Neoadjuvant Chemoradiotherapy With 5-FU\u002FLeucovorin (FL) vs. TS-1\u002FIrinotecan in Patients With Locally Advanced Rectal Cancer",[91],"2014-09",[8017],[8341,8356],"TS-1 with Irinotecan",{"trials":8358,"activeCount":102},[],{"trials":8360,"activeCount":102},[],{"trials":8362,"activeCount":102},[],{"intervention":8356,"totalTrials":213,"cells":8364},{"EARLY_PHASE1":8365,"PHASE1":8367,"PHASE2":8369,"PHASE3":8375,"PHASE4":8377,"NA":8379},{"trials":8366,"activeCount":102},[],{"trials":8368,"activeCount":102},[],{"trials":8370,"activeCount":102},[8371],{"nctId":8350,"briefTitle":8351,"status":204,"phases":8372,"primaryCompletion":8353,"completion":8353,"start":7800,"enrollment":3530,"conditions":8373,"interventions":8374},[91],[8017],[8341,8356],{"trials":8376,"activeCount":102},[],{"trials":8378,"activeCount":102},[],{"trials":8380,"activeCount":102},[],{"intervention":8382,"totalTrials":213,"cells":8383},"PF-00299804",{"EARLY_PHASE1":8384,"PHASE1":8386,"PHASE2":8388,"PHASE3":8398,"PHASE4":8400,"NA":8402},{"trials":8385,"activeCount":102},[],{"trials":8387,"activeCount":102},[],{"trials":8389,"activeCount":102},[8390],{"nctId":8391,"briefTitle":8392,"status":204,"phases":8393,"primaryCompletion":5852,"completion":962,"start":6131,"enrollment":7845,"conditions":8394,"interventions":8397},"NCT01449201","PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma",[91],[8395,8396],"Head Neck Cancer Squamous Cell Metastatic","Head Neck Cancer Squamous Cell Recurrent",[8382],{"trials":8399,"activeCount":102},[],{"trials":8401,"activeCount":102},[],{"trials":8403,"activeCount":102},[],{"intervention":8405,"totalTrials":213,"cells":8406},"INCB054828, Paclitaxel",{"EARLY_PHASE1":8407,"PHASE1":8409,"PHASE2":8411,"PHASE3":8422,"PHASE4":8424,"NA":8426},{"trials":8408,"activeCount":102},[],{"trials":8410,"activeCount":102},[],{"trials":8412,"activeCount":102},[8413],{"nctId":8414,"briefTitle":8415,"status":204,"phases":8416,"primaryCompletion":8417,"completion":8417,"start":8418,"enrollment":28,"conditions":8419,"interventions":8421},"NCT05529667","Fibroblast Growth Factor (FGFs) \u002F Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent \u002F Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.",[90,91],"2023-08-30","2019-05-27",[8420],"Fibroblast Growth Factors (FGFs)\u002FFibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel",[8405],{"trials":8423,"activeCount":102},[],{"trials":8425,"activeCount":102},[],{"trials":8427,"activeCount":102},[],{"intervention":8429,"totalTrials":213,"cells":8430},"Docetaxel and epirubicin",{"EARLY_PHASE1":8431,"PHASE1":8433,"PHASE2":8435,"PHASE3":8446,"PHASE4":8448,"NA":8450},{"trials":8432,"activeCount":102},[],{"trials":8434,"activeCount":102},[],{"trials":8436,"activeCount":102},[8437],{"nctId":8438,"briefTitle":8439,"status":204,"phases":8440,"primaryCompletion":1467,"completion":1467,"start":8441,"enrollment":8442,"conditions":8443,"interventions":8445},"NCT00375999","Docetaxel and Epirubicin in Advanced Gastric Cancer",[91],"2006-09",34,[8444],"Stomach Neoplasms",[8429],{"trials":8447,"activeCount":102},[],{"trials":8449,"activeCount":102},[],{"trials":8451,"activeCount":102},[],{"intervention":8453,"totalTrials":213,"cells":8454},"DCS",{"EARLY_PHASE1":8455,"PHASE1":8457,"PHASE2":8459,"PHASE3":8468,"PHASE4":8470,"NA":8472},{"trials":8456,"activeCount":102},[],{"trials":8458,"activeCount":102},[],{"trials":8460,"activeCount":102},[8461],{"nctId":8462,"briefTitle":8463,"status":204,"phases":8464,"primaryCompletion":5166,"completion":5166,"start":207,"enrollment":173,"conditions":8465,"interventions":8466},"NCT01286766","Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma",[91],[21],[8453,8467],"DCF",{"trials":8469,"activeCount":102},[],{"trials":8471,"activeCount":102},[],{"trials":8473,"activeCount":102},[],{"intervention":8467,"totalTrials":213,"cells":8475},{"EARLY_PHASE1":8476,"PHASE1":8478,"PHASE2":8480,"PHASE3":8486,"PHASE4":8488,"NA":8490},{"trials":8477,"activeCount":102},[],{"trials":8479,"activeCount":102},[],{"trials":8481,"activeCount":102},[8482],{"nctId":8462,"briefTitle":8463,"status":204,"phases":8483,"primaryCompletion":5166,"completion":5166,"start":207,"enrollment":173,"conditions":8484,"interventions":8485},[91],[21],[8453,8467],{"trials":8487,"activeCount":102},[],{"trials":8489,"activeCount":102},[],{"trials":8491,"activeCount":102},[],{"intervention":2617,"totalTrials":213,"cells":8493},{"EARLY_PHASE1":8494,"PHASE1":8496,"PHASE2":8498,"PHASE3":8504,"PHASE4":8506,"NA":8508},{"trials":8495,"activeCount":102},[],{"trials":8497,"activeCount":102},[],{"trials":8499,"activeCount":102},[8500],{"nctId":2608,"briefTitle":2609,"status":204,"phases":8501,"primaryCompletion":2611,"completion":2612,"start":2613,"enrollment":2614,"conditions":8502,"interventions":8503},[91],[30],[2599,2617],{"trials":8505,"activeCount":102},[],{"trials":8507,"activeCount":102},[],{"trials":8509,"activeCount":102},[],{"intervention":8511,"totalTrials":213,"cells":8512},"mecobalamin",{"EARLY_PHASE1":8513,"PHASE1":8515,"PHASE2":8517,"PHASE3":8528,"PHASE4":8530,"NA":8532},{"trials":8514,"activeCount":102},[],{"trials":8516,"activeCount":102},[],{"trials":8518,"activeCount":102},[8519],{"nctId":8520,"briefTitle":8521,"status":204,"phases":8522,"primaryCompletion":8523,"completion":6522,"start":8524,"enrollment":22,"conditions":8525,"interventions":8527},"NCT00699478","Oral Vitamin B12 Administration for Vitamin B12 Deficiency After Total Gastrectomy",[91],"2008-09","2008-04",[8526],"Vitamin B12 Deficiency",[8511],{"trials":8529,"activeCount":102},[],{"trials":8531,"activeCount":102},[],{"trials":8533,"activeCount":102},[],{"intervention":8535,"totalTrials":213,"cells":8536},"Nivolumab, Paclitaxel",{"EARLY_PHASE1":8537,"PHASE1":8539,"PHASE2":8541,"PHASE3":8551,"PHASE4":8553,"NA":8555},{"trials":8538,"activeCount":102},[],{"trials":8540,"activeCount":102},[],{"trials":8542,"activeCount":102},[8543],{"nctId":8544,"briefTitle":8545,"status":204,"phases":8546,"primaryCompletion":8547,"completion":8547,"start":8548,"enrollment":1243,"conditions":8549,"interventions":8550},"NCT05535569","Phase Ib\u002FII Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer",[90,91],"2021-11-22","2017-07-17",[8168],[8535],{"trials":8552,"activeCount":102},[],{"trials":8554,"activeCount":102},[],{"trials":8556,"activeCount":102},[],{"intervention":1377,"totalTrials":213,"cells":8558},{"EARLY_PHASE1":8559,"PHASE1":8561,"PHASE2":8563,"PHASE3":8569,"PHASE4":8571,"NA":8573},{"trials":8560,"activeCount":102},[],{"trials":8562,"activeCount":102},[],{"trials":8564,"activeCount":102},[8565],{"nctId":1364,"briefTitle":1365,"status":308,"phases":8566,"primaryCompletion":1367,"completion":1367,"start":1368,"enrollment":1369,"conditions":8567,"interventions":8568},[91],[1371,1372,1373,1374],[1376,1377],{"trials":8570,"activeCount":102},[],{"trials":8572,"activeCount":102},[],{"trials":8574,"activeCount":102},[],{"intervention":8576,"totalTrials":213,"cells":8577},"MK-3475",{"EARLY_PHASE1":8578,"PHASE1":8580,"PHASE2":8582,"PHASE3":8594,"PHASE4":8596,"NA":8598},{"trials":8579,"activeCount":102},[],{"trials":8581,"activeCount":102},[],{"trials":8583,"activeCount":102},[8584],{"nctId":8585,"briefTitle":8586,"status":204,"phases":8587,"primaryCompletion":8588,"completion":8589,"start":8590,"enrollment":1166,"conditions":8591,"interventions":8593},"NCT02844075","Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)",[91],"2021-03-09","2021-04-26","2017-01",[8592],"Esophageal Squamous Cell Carcinoma",[8576],{"trials":8595,"activeCount":102},[],{"trials":8597,"activeCount":102},[],{"trials":8599,"activeCount":102},[],{"intervention":8601,"totalTrials":213,"cells":8602},"modified FOLFIRINOX regimen",{"EARLY_PHASE1":8603,"PHASE1":8605,"PHASE2":8607,"PHASE3":8617,"PHASE4":8619,"NA":8621},{"trials":8604,"activeCount":102},[],{"trials":8606,"activeCount":102},[],{"trials":8608,"activeCount":102},[8609],{"nctId":8610,"briefTitle":8611,"status":204,"phases":8612,"primaryCompletion":8613,"completion":8613,"start":8614,"enrollment":1243,"conditions":8615,"interventions":8616},"NCT02440958","Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial",[91],"2017-03-02","2015-08-28",[4277],[8601],{"trials":8618,"activeCount":102},[],{"trials":8620,"activeCount":102},[],{"trials":8622,"activeCount":102},[],{"intervention":7804,"totalTrials":213,"cells":8624},{"EARLY_PHASE1":8625,"PHASE1":8627,"PHASE2":8629,"PHASE3":8635,"PHASE4":8637,"NA":8639},{"trials":8626,"activeCount":102},[],{"trials":8628,"activeCount":102},[],{"trials":8630,"activeCount":102},[8631],{"nctId":7797,"briefTitle":7798,"status":204,"phases":8632,"primaryCompletion":899,"completion":5166,"start":7800,"enrollment":1513,"conditions":8633,"interventions":8634},[91],[7802],[7804,7771],{"trials":8636,"activeCount":102},[],{"trials":8638,"activeCount":102},[],{"trials":8640,"activeCount":102},[],{"intervention":8642,"totalTrials":213,"cells":8643},"Pembrolizumab, Vactosertib",{"EARLY_PHASE1":8644,"PHASE1":8646,"PHASE2":8648,"PHASE3":8661,"PHASE4":8663,"NA":8665},{"trials":8645,"activeCount":102},[],{"trials":8647,"activeCount":102},[],{"trials":8649,"activeCount":102},[8650],{"nctId":8651,"briefTitle":8652,"status":243,"phases":8653,"primaryCompletion":8654,"completion":8654,"start":8655,"enrollment":8656,"conditions":8657,"interventions":8660},"NCT05436990","Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor",[91],"2025-03-10","2023-02-09",14,[8658,8659],"Acral Melanoma","Mucosal Melanoma",[8642],{"trials":8662,"activeCount":102},[],{"trials":8664,"activeCount":102},[],{"trials":8666,"activeCount":102},[],{"intervention":8668,"totalTrials":213,"cells":8669},"candesartan for hepatic fibrosis",{"EARLY_PHASE1":8670,"PHASE1":8672,"PHASE2":8674,"PHASE3":8684,"PHASE4":8686,"NA":8688},{"trials":8671,"activeCount":102},[],{"trials":8673,"activeCount":102},[],{"trials":8675,"activeCount":102},[8676],{"nctId":8677,"briefTitle":8678,"status":204,"phases":8679,"primaryCompletion":1477,"completion":3576,"start":8680,"enrollment":1954,"conditions":8681,"interventions":8683},"NCT00990639","Effect of Candesartan in Alcoholic Liver Fibrosis",[90,91],"2005-09",[8682],"Alcoholic Liver Disease",[8668],{"trials":8685,"activeCount":102},[],{"trials":8687,"activeCount":102},[],{"trials":8689,"activeCount":102},[],{"intervention":7848,"totalTrials":213,"cells":8691},{"EARLY_PHASE1":8692,"PHASE1":8694,"PHASE2":8696,"PHASE3":8702,"PHASE4":8704,"NA":8706},{"trials":8693,"activeCount":102},[],{"trials":8695,"activeCount":102},[],{"trials":8697,"activeCount":102},[8698],{"nctId":7841,"briefTitle":7842,"status":308,"phases":8699,"start":7844,"enrollment":7845,"conditions":8700,"interventions":8701},[91],[30],[7848,7795,7849,7786],{"trials":8703,"activeCount":102},[],{"trials":8705,"activeCount":102},[],{"trials":8707,"activeCount":102},[],{"intervention":7849,"totalTrials":213,"cells":8709},{"EARLY_PHASE1":8710,"PHASE1":8712,"PHASE2":8714,"PHASE3":8720,"PHASE4":8722,"NA":8724},{"trials":8711,"activeCount":102},[],{"trials":8713,"activeCount":102},[],{"trials":8715,"activeCount":102},[8716],{"nctId":7841,"briefTitle":7842,"status":308,"phases":8717,"start":7844,"enrollment":7845,"conditions":8718,"interventions":8719},[91],[30],[7848,7795,7849,7786],{"trials":8721,"activeCount":102},[],{"trials":8723,"activeCount":102},[],{"trials":8725,"activeCount":102},[],{"intervention":8727,"totalTrials":213,"cells":8728},"atezolizumab \u002F tiragolumab",{"EARLY_PHASE1":8729,"PHASE1":8731,"PHASE2":8733,"PHASE3":8741,"PHASE4":8743,"NA":8745},{"trials":8730,"activeCount":102},[],{"trials":8732,"activeCount":102},[],{"trials":8734,"activeCount":102},[8735],{"nctId":8736,"briefTitle":8737,"status":308,"phases":8738,"primaryCompletion":310,"completion":310,"start":6998,"enrollment":7247,"conditions":8739,"interventions":8740},"NCT05034055","Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab \u002F Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer",[91],[1540],[8727],{"trials":8742,"activeCount":102},[],{"trials":8744,"activeCount":102},[],{"trials":8746,"activeCount":102},[],{"intervention":8748,"totalTrials":213,"cells":8749},"abemaciclib+paclitaxel",{"EARLY_PHASE1":8750,"PHASE1":8752,"PHASE2":8754,"PHASE3":8766,"PHASE4":8768,"NA":8770},{"trials":8751,"activeCount":102},[],{"trials":8753,"activeCount":102},[],{"trials":8755,"activeCount":102},[8756],{"nctId":8757,"briefTitle":8758,"status":204,"phases":8759,"primaryCompletion":8760,"completion":8761,"start":8762,"enrollment":22,"conditions":8763,"interventions":8765},"NCT04594005","CDK4\u002F6 Tumor, Abemaciclib, Paclitaxel",[90,91],"2024-07-16","2024-08-10","2021-02-25",[8764],"Tumors",[8748],{"trials":8767,"activeCount":102},[],{"trials":8769,"activeCount":102},[],{"trials":8771,"activeCount":102},[],{"intervention":8773,"totalTrials":213,"cells":8774},"BYL719",{"EARLY_PHASE1":8775,"PHASE1":8777,"PHASE2":8779,"PHASE3":8788,"PHASE4":8790,"NA":8792},{"trials":8776,"activeCount":102},[],{"trials":8778,"activeCount":102},[],{"trials":8780,"activeCount":102},[8781],{"nctId":8782,"briefTitle":8783,"status":308,"phases":8784,"primaryCompletion":5375,"completion":5375,"start":257,"enrollment":8282,"conditions":8785,"interventions":8787},"NCT02145312","An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.",[91],[8786],"Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck",[8773],{"trials":8789,"activeCount":102},[],{"trials":8791,"activeCount":102},[],{"trials":8793,"activeCount":102},[],{"intervention":8795,"totalTrials":213,"cells":8796},"Pemetrexed",{"EARLY_PHASE1":8797,"PHASE1":8799,"PHASE2":8801,"PHASE3":8813,"PHASE4":8815,"NA":8817},{"trials":8798,"activeCount":102},[],{"trials":8800,"activeCount":102},[],{"trials":8802,"activeCount":102},[8803],{"nctId":8804,"briefTitle":8805,"status":204,"phases":8806,"primaryCompletion":7022,"completion":8807,"start":8808,"enrollment":1243,"conditions":8809,"interventions":8811},"NCT02723578","Pemetrexed and Erlotinib for Metastatic Colorectal Cancer",[91],"2018-12","2015-12-01",[8810],"Metastatic Colorectal Cancer",[8795,8812],"Erlotinib",{"trials":8814,"activeCount":102},[],{"trials":8816,"activeCount":102},[],{"trials":8818,"activeCount":102},[],{"intervention":8812,"totalTrials":213,"cells":8820},{"EARLY_PHASE1":8821,"PHASE1":8823,"PHASE2":8825,"PHASE3":8831,"PHASE4":8833,"NA":8835},{"trials":8822,"activeCount":102},[],{"trials":8824,"activeCount":102},[],{"trials":8826,"activeCount":102},[8827],{"nctId":8804,"briefTitle":8805,"status":204,"phases":8828,"primaryCompletion":7022,"completion":8807,"start":8808,"enrollment":1243,"conditions":8829,"interventions":8830},[91],[8810],[8795,8812],{"trials":8832,"activeCount":102},[],{"trials":8834,"activeCount":102},[],{"trials":8836,"activeCount":102},[],{"intervention":8838,"totalTrials":213,"cells":8839},"regorafenib",{"EARLY_PHASE1":8840,"PHASE1":8842,"PHASE2":8844,"PHASE3":8855,"PHASE4":8857,"NA":8859},{"trials":8841,"activeCount":102},[],{"trials":8843,"activeCount":102},[],{"trials":8845,"activeCount":102},[8846],{"nctId":8847,"briefTitle":8848,"status":308,"phases":8849,"primaryCompletion":4341,"completion":8850,"start":8851,"enrollment":1557,"conditions":8852,"interventions":8854},"NCT02501551","Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy",[91],"2022-06","2015-02",[8853],"Melanoma",[8838],{"trials":8856,"activeCount":102},[],{"trials":8858,"activeCount":102},[],{"trials":8860,"activeCount":102},[],{"intervention":8862,"totalTrials":213,"cells":8863},"Irinotecan and Gemcitabine",{"EARLY_PHASE1":8864,"PHASE1":8866,"PHASE2":8868,"PHASE3":8877,"PHASE4":8879,"NA":8881},{"trials":8865,"activeCount":102},[],{"trials":8867,"activeCount":102},[],{"trials":8869,"activeCount":102},[8870],{"nctId":8871,"briefTitle":8872,"status":204,"phases":8873,"primaryCompletion":3937,"completion":321,"start":7884,"enrollment":9,"conditions":8874,"interventions":8876},"NCT00832689","Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer",[91],[8875],"Biliary Tract Cancer",[8862],{"trials":8878,"activeCount":102},[],{"trials":8880,"activeCount":102},[],{"trials":8882,"activeCount":102},[],{"intervention":8884,"totalTrials":213,"cells":8885},"Ribociclib, Trastuzumab, Letrozole",{"EARLY_PHASE1":8886,"PHASE1":8888,"PHASE2":8890,"PHASE3":8902,"PHASE4":8904,"NA":8906},{"trials":8887,"activeCount":102},[],{"trials":8889,"activeCount":102},[],{"trials":8891,"activeCount":102},[8892],{"nctId":8893,"briefTitle":8894,"status":308,"phases":8895,"primaryCompletion":8896,"completion":8896,"start":8280,"enrollment":8897,"conditions":8898,"interventions":8901},"NCT03913234","Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients",[90,91],"2023-10-30",95,[8899,8900,1271],"HER2-positive Breast Cancer","Postmenopausal",[8884],{"trials":8903,"activeCount":102},[],{"trials":8905,"activeCount":102},[],{"trials":8907,"activeCount":102},[],{"intervention":8909,"totalTrials":213,"cells":8910},"intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks",{"EARLY_PHASE1":8911,"PHASE1":8913,"PHASE2":8915,"PHASE3":8925,"PHASE4":8927,"NA":8929},{"trials":8912,"activeCount":102},[],{"trials":8914,"activeCount":102},[],{"trials":8916,"activeCount":102},[8917],{"nctId":8918,"briefTitle":8919,"status":308,"phases":8920,"primaryCompletion":4563,"completion":3292,"start":8921,"enrollment":222,"conditions":8922,"interventions":8923},"NCT05103020","Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases",[91],"2021-11-01",[8810],[8909,8924],"IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks",{"trials":8926,"activeCount":102},[],{"trials":8928,"activeCount":102},[],{"trials":8930,"activeCount":102},[],{"intervention":8924,"totalTrials":213,"cells":8932},{"EARLY_PHASE1":8933,"PHASE1":8935,"PHASE2":8937,"PHASE3":8943,"PHASE4":8945,"NA":8947},{"trials":8934,"activeCount":102},[],{"trials":8936,"activeCount":102},[],{"trials":8938,"activeCount":102},[8939],{"nctId":8918,"briefTitle":8919,"status":308,"phases":8940,"primaryCompletion":4563,"completion":3292,"start":8921,"enrollment":222,"conditions":8941,"interventions":8942},[91],[8810],[8909,8924],{"trials":8944,"activeCount":102},[],{"trials":8946,"activeCount":102},[],{"trials":8948,"activeCount":102},[],{"intervention":8950,"totalTrials":213,"cells":8951},"paclitaxel\u002Fcarboplatin",{"EARLY_PHASE1":8952,"PHASE1":8954,"PHASE2":8956,"PHASE3":8967,"PHASE4":8969,"NA":8971},{"trials":8953,"activeCount":102},[],{"trials":8955,"activeCount":102},[],{"trials":8957,"activeCount":102},[8958],{"nctId":8959,"briefTitle":8960,"status":204,"phases":8961,"primaryCompletion":8962,"completion":8962,"start":8963,"enrollment":8964,"conditions":8965,"interventions":8966},"NCT05294900","Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients",[91],"2025-10-22","2023-05-26",79,[1631],[8950],{"trials":8968,"activeCount":102},[],{"trials":8970,"activeCount":102},[],{"trials":8972,"activeCount":102},[],{"intervention":8974,"totalTrials":213,"cells":8975},"neoadjuvant modified FOLFIRINOX",{"EARLY_PHASE1":8976,"PHASE1":8978,"PHASE2":8980,"PHASE3":8992,"PHASE4":8994,"NA":8996},{"trials":8977,"activeCount":102},[],{"trials":8979,"activeCount":102},[],{"trials":8981,"activeCount":102},[8982],{"nctId":8983,"briefTitle":8984,"status":308,"phases":8985,"primaryCompletion":8986,"completion":8987,"start":8988,"enrollment":2343,"conditions":8989,"interventions":8991},"NCT05066802","A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma",[91],"2022-05-31","2023-05-31","2020-05-11",[8990],"Resectable Pancreatic Adenocarcinoma",[8974],{"trials":8993,"activeCount":102},[],{"trials":8995,"activeCount":102},[],{"trials":8997,"activeCount":102},[],{"intervention":8999,"totalTrials":213,"cells":9000},"Eribulin, gemcitabine",{"EARLY_PHASE1":9001,"PHASE1":9003,"PHASE2":9005,"PHASE3":9017,"PHASE4":9019,"NA":9021},{"trials":9002,"activeCount":102},[],{"trials":9004,"activeCount":102},[],{"trials":9006,"activeCount":102},[9007],{"nctId":9008,"briefTitle":9009,"status":204,"phases":9010,"primaryCompletion":9011,"completion":9011,"start":9012,"enrollment":9013,"conditions":9014,"interventions":9016},"NCT03810976","A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma",[91],"2022-05-30","2018-03-27",37,[9015],"Sarcoma",[8999],{"trials":9018,"activeCount":102},[],{"trials":9020,"activeCount":102},[],{"trials":9022,"activeCount":102},[],{"intervention":7812,"totalTrials":213,"cells":9024},{"EARLY_PHASE1":9025,"PHASE1":9027,"PHASE2":9029,"PHASE3":9035,"PHASE4":9037,"NA":9039},{"trials":9026,"activeCount":102},[],{"trials":9028,"activeCount":102},[],{"trials":9030,"activeCount":102},[9031],{"nctId":7806,"briefTitle":7807,"status":308,"phases":9032,"primaryCompletion":3452,"start":7809,"enrollment":1291,"conditions":9033,"interventions":9034},[91],[7802],[7771,7812,7813],{"trials":9036,"activeCount":102},[],{"trials":9038,"activeCount":102},[],{"trials":9040,"activeCount":102},[],{"intervention":7813,"totalTrials":213,"cells":9042},{"EARLY_PHASE1":9043,"PHASE1":9045,"PHASE2":9047,"PHASE3":9053,"PHASE4":9055,"NA":9057},{"trials":9044,"activeCount":102},[],{"trials":9046,"activeCount":102},[],{"trials":9048,"activeCount":102},[9049],{"nctId":7806,"briefTitle":7807,"status":308,"phases":9050,"primaryCompletion":3452,"start":7809,"enrollment":1291,"conditions":9051,"interventions":9052},[91],[7802],[7771,7812,7813],{"trials":9054,"activeCount":102},[],{"trials":9056,"activeCount":102},[],{"trials":9058,"activeCount":102},[],{"intervention":9060,"totalTrials":213,"cells":9061},"standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001",{"EARLY_PHASE1":9062,"PHASE1":9064,"PHASE2":9066,"PHASE3":9077,"PHASE4":9079,"NA":9081},{"trials":9063,"activeCount":102},[],{"trials":9065,"activeCount":102},[],{"trials":9067,"activeCount":102},[9068],{"nctId":9069,"briefTitle":9070,"status":1475,"phases":9071,"primaryCompletion":6974,"completion":6974,"start":9072,"enrollment":102,"conditions":9073,"interventions":9075},"NCT03945227","Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)",[91],"2019-06",[9074],"Stage III NSCLC",[9060,9076],"PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001",{"trials":9078,"activeCount":102},[],{"trials":9080,"activeCount":102},[],{"trials":9082,"activeCount":102},[],{"intervention":9076,"totalTrials":213,"cells":9084},{"EARLY_PHASE1":9085,"PHASE1":9087,"PHASE2":9089,"PHASE3":9095,"PHASE4":9097,"NA":9099},{"trials":9086,"activeCount":102},[],{"trials":9088,"activeCount":102},[],{"trials":9090,"activeCount":102},[9091],{"nctId":9069,"briefTitle":9070,"status":1475,"phases":9092,"primaryCompletion":6974,"completion":6974,"start":9072,"enrollment":102,"conditions":9093,"interventions":9094},[91],[9074],[9060,9076],{"trials":9096,"activeCount":102},[],{"trials":9098,"activeCount":102},[],{"trials":9100,"activeCount":102},[],{"intervention":9102,"totalTrials":213,"cells":9103},"CRS+HIPEC",{"EARLY_PHASE1":9104,"PHASE1":9106,"PHASE2":9108,"PHASE3":9120,"PHASE4":9122,"NA":9124},{"trials":9105,"activeCount":102},[],{"trials":9107,"activeCount":102},[],{"trials":9109,"activeCount":102},[9110],{"nctId":9111,"briefTitle":9112,"status":204,"phases":9113,"primaryCompletion":9114,"completion":9115,"start":9116,"enrollment":1394,"conditions":9117,"interventions":9119},"NCT02995850","A Phase Ib\u002FII Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis",[90,91],"2022-04-19","2022-05-05","2017-02-22",[9118],"Gastric Cancer With Peritoneal Metastasis (PCI\u003C12)",[9102],{"trials":9121,"activeCount":102},[],{"trials":9123,"activeCount":102},[],{"trials":9125,"activeCount":102},[],{"intervention":9127,"totalTrials":213,"cells":9128},"Micafungin sodium",{"EARLY_PHASE1":9129,"PHASE1":9131,"PHASE2":9133,"PHASE3":9144,"PHASE4":9146,"NA":9148},{"trials":9130,"activeCount":102},[],{"trials":9132,"activeCount":102},[],{"trials":9134,"activeCount":102},[9135],{"nctId":9136,"briefTitle":9137,"status":204,"phases":9138,"primaryCompletion":962,"completion":962,"start":4201,"enrollment":6385,"conditions":9139,"interventions":9142},"NCT01344681","Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases",[91],[9140,9141],"Febrile Neutropenia","Hematological Diseases",[9127,9143],"Itraconazole",{"trials":9145,"activeCount":102},[],{"trials":9147,"activeCount":102},[],{"trials":9149,"activeCount":102},[],{"intervention":9143,"totalTrials":213,"cells":9151},{"EARLY_PHASE1":9152,"PHASE1":9154,"PHASE2":9156,"PHASE3":9162,"PHASE4":9164,"NA":9166},{"trials":9153,"activeCount":102},[],{"trials":9155,"activeCount":102},[],{"trials":9157,"activeCount":102},[9158],{"nctId":9136,"briefTitle":9137,"status":204,"phases":9159,"primaryCompletion":962,"completion":962,"start":4201,"enrollment":6385,"conditions":9160,"interventions":9161},[91],[9140,9141],[9127,9143],{"trials":9163,"activeCount":102},[],{"trials":9165,"activeCount":102},[],{"trials":9167,"activeCount":102},[],{"intervention":9169,"totalTrials":213,"cells":9170},"Bevacizumab + modified FOLFIRINOX",{"EARLY_PHASE1":9171,"PHASE1":9173,"PHASE2":9175,"PHASE3":9188,"PHASE4":9190,"NA":9192},{"trials":9172,"activeCount":102},[],{"trials":9174,"activeCount":102},[],{"trials":9176,"activeCount":102},[9177],{"nctId":9178,"briefTitle":9179,"status":308,"phases":9180,"primaryCompletion":859,"completion":9181,"start":9182,"enrollment":9013,"conditions":9183,"interventions":9187},"NCT05665023","Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma",[91],"2025-02-01","2022-10-28",[9184,9185,9186],"Mucinous Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer",[9169],{"trials":9189,"activeCount":102},[],{"trials":9191,"activeCount":102},[],{"trials":9193,"activeCount":102},[],{"intervention":9195,"totalTrials":213,"cells":9196},"Tislelizumab+Zanidatamab",{"EARLY_PHASE1":9197,"PHASE1":9199,"PHASE2":9201,"PHASE3":9210,"PHASE4":9212,"NA":9214},{"trials":9198,"activeCount":102},[],{"trials":9200,"activeCount":102},[],{"trials":9202,"activeCount":102},[9203],{"nctId":9204,"briefTitle":9205,"status":308,"phases":9206,"primaryCompletion":8189,"completion":8189,"start":1269,"enrollment":1243,"conditions":9207,"interventions":9209},"NCT05270889","Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial",[91],[9208],"HER2-positive Gastric Cancer",[9195],{"trials":9211,"activeCount":102},[],{"trials":9213,"activeCount":102},[],{"trials":9215,"activeCount":102},[],{"intervention":9217,"totalTrials":213,"cells":9218},"The combination of radiotherapy with anti-PD1",{"EARLY_PHASE1":9219,"PHASE1":9221,"PHASE2":9223,"PHASE3":9233,"PHASE4":9235,"NA":9237},{"trials":9220,"activeCount":102},[],{"trials":9222,"activeCount":102},[],{"trials":9224,"activeCount":102},[9225],{"nctId":9226,"briefTitle":9227,"status":308,"phases":9228,"primaryCompletion":9229,"completion":9229,"start":9230,"enrollment":16,"conditions":9231,"interventions":9232},"NCT04017897","The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma",[91],"2022-07","2019-07-03",[8853],[9217],{"trials":9234,"activeCount":102},[],{"trials":9236,"activeCount":102},[],{"trials":9238,"activeCount":102},[],{"intervention":9240,"totalTrials":213,"cells":9241},"Durvalumab with Tremelimumab",{"EARLY_PHASE1":9242,"PHASE1":9244,"PHASE2":9246,"PHASE3":9256,"PHASE4":9258,"NA":9260},{"trials":9243,"activeCount":102},[],{"trials":9245,"activeCount":102},[],{"trials":9247,"activeCount":102},[9248],{"nctId":9249,"briefTitle":9250,"status":204,"phases":9251,"primaryCompletion":9252,"completion":9252,"start":9253,"enrollment":22,"conditions":9254,"interventions":9255},"NCT03608865","Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing",[91],"2021-11-24","2017-09-19",[1271],[9240],{"trials":9257,"activeCount":102},[],{"trials":9259,"activeCount":102},[],{"trials":9261,"activeCount":102},[],{"intervention":9263,"totalTrials":213,"cells":9264},"EPO group",{"EARLY_PHASE1":9265,"PHASE1":9267,"PHASE2":9269,"PHASE3":9280,"PHASE4":9282,"NA":9284},{"trials":9266,"activeCount":102},[],{"trials":9268,"activeCount":102},[],{"trials":9270,"activeCount":102},[9271],{"nctId":9272,"briefTitle":9273,"status":204,"phases":9274,"primaryCompletion":3730,"completion":9275,"start":9276,"enrollment":9277,"conditions":9278,"interventions":9279},"NCT01758861","Effect of Erythropoietin on the Incidence of Acute Kidney Injury Following Complex Valvular Heart Surgery",[91],"2012-10","2011-07",98,[4252],[9263],{"trials":9281,"activeCount":102},[],{"trials":9283,"activeCount":102},[],{"trials":9285,"activeCount":102},[],{"intervention":9287,"totalTrials":213,"cells":9288},"Brigatinib",{"EARLY_PHASE1":9289,"PHASE1":9291,"PHASE2":9293,"PHASE3":9301,"PHASE4":9303,"NA":9305},{"trials":9290,"activeCount":102},[],{"trials":9292,"activeCount":102},[],{"trials":9294,"activeCount":102},[9295],{"nctId":9296,"briefTitle":9297,"status":308,"phases":9298,"primaryCompletion":8189,"completion":8189,"start":8850,"enrollment":36,"conditions":9299,"interventions":9300},"NCT05361564","A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.",[91],[1540],[9287],{"trials":9302,"activeCount":102},[],{"trials":9304,"activeCount":102},[],{"trials":9306,"activeCount":102},[],{"intervention":9308,"totalTrials":213,"cells":9309},"Talazoparib",{"EARLY_PHASE1":9310,"PHASE1":9312,"PHASE2":9314,"PHASE3":9324,"PHASE4":9326,"NA":9328},{"trials":9311,"activeCount":102},[],{"trials":9313,"activeCount":102},[],{"trials":9315,"activeCount":102},[9316],{"nctId":9317,"briefTitle":9318,"status":308,"phases":9319,"primaryCompletion":6108,"completion":1652,"start":7650,"enrollment":9320,"conditions":9321,"interventions":9323},"NCT04755868","Talazoparib Maintenance Therapy in Triple-negative Breast Cancer",[91],206,[9322],"TNBC - Triple-Negative Breast Cancer",[9308],{"trials":9325,"activeCount":102},[],{"trials":9327,"activeCount":102},[],{"trials":9329,"activeCount":102},[],{"intervention":9331,"totalTrials":213,"cells":9332},"Variltinib, Paclitaxel",{"EARLY_PHASE1":9333,"PHASE1":9335,"PHASE2":9337,"PHASE3":9347,"PHASE4":9349,"NA":9351},{"trials":9334,"activeCount":102},[],{"trials":9336,"activeCount":102},[],{"trials":9338,"activeCount":102},[9339],{"nctId":9340,"briefTitle":9341,"status":204,"phases":9342,"primaryCompletion":9343,"completion":5331,"start":9344,"enrollment":2343,"conditions":9345,"interventions":9346},"NCT05400915","Two-Part, Phase Ib\u002FII, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR\u002FHER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients",[90,91],"2021-12-13","2019-07-23",[21],[9331],{"trials":9348,"activeCount":102},[],{"trials":9350,"activeCount":102},[],{"trials":9352,"activeCount":102},[],{"intervention":9354,"totalTrials":213,"cells":9355},"Niraparib-Bevacizumab",{"EARLY_PHASE1":9356,"PHASE1":9358,"PHASE2":9360,"PHASE3":9372,"PHASE4":9374,"NA":9376},{"trials":9357,"activeCount":102},[],{"trials":9359,"activeCount":102},[],{"trials":9361,"activeCount":102},[9362],{"nctId":9363,"briefTitle":9364,"status":308,"phases":9365,"primaryCompletion":9366,"completion":9367,"start":9368,"enrollment":1678,"conditions":9369,"interventions":9371},"NCT04734665","Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor",[91],"2023-03-31","2024-03-31","2021-07-05",[9370],"Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor",[9354],{"trials":9373,"activeCount":102},[],{"trials":9375,"activeCount":102},[],{"trials":9377,"activeCount":102},[],{"intervention":9379,"totalTrials":213,"cells":9380},"TS-1 + cisplatin",{"EARLY_PHASE1":9381,"PHASE1":9383,"PHASE2":9385,"PHASE3":9396,"PHASE4":9398,"NA":9400},{"trials":9382,"activeCount":102},[],{"trials":9384,"activeCount":102},[],{"trials":9386,"activeCount":102},[9387],{"nctId":9388,"briefTitle":9389,"status":204,"phases":9390,"primaryCompletion":1498,"completion":9391,"start":9392,"enrollment":9393,"conditions":9394,"interventions":9395},"NCT03814759","Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma",[91],"2022-07-31","2016-12-12",102,[7214],[9379],{"trials":9397,"activeCount":102},[],{"trials":9399,"activeCount":102},[],{"trials":9401,"activeCount":102},[],{"intervention":9403,"totalTrials":213,"cells":9404},"Arm A : standard neoadjuvant chemoradiotherapy group",{"EARLY_PHASE1":9405,"PHASE1":9407,"PHASE2":9409,"PHASE3":9419,"PHASE4":9421,"NA":9423},{"trials":9406,"activeCount":102},[],{"trials":9408,"activeCount":102},[],{"trials":9410,"activeCount":102},[9411],{"nctId":9412,"briefTitle":9413,"status":308,"phases":9414,"primaryCompletion":5375,"completion":2776,"start":7677,"enrollment":2661,"conditions":9415,"interventions":9417},"NCT02167321","Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil\u002FLeucovorin\u002FOxaliplatin), Total Mesorectal Excision",[91],[9416],"Locally Advanced Rectal Cancer",[9403,9418],"Arm B : adjuvant FOLFOX group",{"trials":9420,"activeCount":102},[],{"trials":9422,"activeCount":102},[],{"trials":9424,"activeCount":102},[],{"intervention":9418,"totalTrials":213,"cells":9426},{"EARLY_PHASE1":9427,"PHASE1":9429,"PHASE2":9431,"PHASE3":9437,"PHASE4":9439,"NA":9441},{"trials":9428,"activeCount":102},[],{"trials":9430,"activeCount":102},[],{"trials":9432,"activeCount":102},[9433],{"nctId":9412,"briefTitle":9413,"status":308,"phases":9434,"primaryCompletion":5375,"completion":2776,"start":7677,"enrollment":2661,"conditions":9435,"interventions":9436},[91],[9416],[9403,9418],{"trials":9438,"activeCount":102},[],{"trials":9440,"activeCount":102},[],{"trials":9442,"activeCount":102},[],{"intervention":9444,"totalTrials":213,"cells":9445},"Imatinib",{"EARLY_PHASE1":9446,"PHASE1":9448,"PHASE2":9450,"PHASE3":9460,"PHASE4":9462,"NA":9464},{"trials":9447,"activeCount":102},[],{"trials":9449,"activeCount":102},[],{"trials":9451,"activeCount":102},[9452],{"nctId":9453,"briefTitle":9454,"status":204,"phases":9455,"primaryCompletion":9456,"completion":9456,"start":3865,"enrollment":1629,"conditions":9457,"interventions":9459},"NCT02495519","A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)",[91],"2018-06",[9458],"Fibromatosis",[9444],{"trials":9461,"activeCount":102},[],{"trials":9463,"activeCount":102},[],{"trials":9465,"activeCount":102},[],{"intervention":9467,"totalTrials":213,"cells":9468},"Dovitinib",{"EARLY_PHASE1":9469,"PHASE1":9471,"PHASE2":9473,"PHASE3":9482,"PHASE4":9484,"NA":9486},{"trials":9470,"activeCount":102},[],{"trials":9472,"activeCount":102},[],{"trials":9474,"activeCount":102},[9475],{"nctId":9476,"briefTitle":9477,"status":204,"phases":9478,"primaryCompletion":963,"completion":963,"start":3657,"enrollment":458,"conditions":9479,"interventions":9481},"NCT01964144","An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer",[91],[9480],"Thyroid Cancer",[9467],{"trials":9483,"activeCount":102},[],{"trials":9485,"activeCount":102},[],{"trials":9487,"activeCount":102},[],{"intervention":9489,"totalTrials":213,"cells":9490},"PF804",{"EARLY_PHASE1":9491,"PHASE1":9493,"PHASE2":9495,"PHASE3":9504,"PHASE4":9506,"NA":9508},{"trials":9492,"activeCount":102},[],{"trials":9494,"activeCount":102},[],{"trials":9496,"activeCount":102},[9497],{"nctId":9498,"briefTitle":9499,"status":204,"phases":9500,"primaryCompletion":8015,"completion":4275,"start":9501,"enrollment":1369,"conditions":9502,"interventions":9503},"NCT01608022","A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus",[91],"2012-07",[8592],[9489],{"trials":9505,"activeCount":102},[],{"trials":9507,"activeCount":102},[],{"trials":9509,"activeCount":102},[],{"intervention":9511,"totalTrials":213,"cells":9512},"sotorasib",{"EARLY_PHASE1":9513,"PHASE1":9515,"PHASE2":9517,"PHASE3":9527,"PHASE4":9529,"NA":9531},{"trials":9514,"activeCount":102},[],{"trials":9516,"activeCount":102},[],{"trials":9518,"activeCount":102},[9519],{"nctId":9520,"briefTitle":9521,"status":308,"phases":9522,"primaryCompletion":9523,"completion":2511,"start":9524,"enrollment":9013,"conditions":9525,"interventions":9526},"NCT05451056","An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib",[91],"2026-01","2022-08-01",[1396],[9511],{"trials":9528,"activeCount":102},[],{"trials":9530,"activeCount":102},[],{"trials":9532,"activeCount":102},[],{"intervention":9534,"totalTrials":213,"cells":9535},"Avelumab",{"EARLY_PHASE1":9536,"PHASE1":9538,"PHASE2":9540,"PHASE3":9554,"PHASE4":9556,"NA":9558},{"trials":9537,"activeCount":102},[],{"trials":9539,"activeCount":102},[],{"trials":9541,"activeCount":102},[9542],{"nctId":9543,"briefTitle":9544,"status":308,"phases":9545,"primaryCompletion":9546,"completion":5984,"start":9547,"enrollment":344,"conditions":9548,"interventions":9553},"NCT03491345","K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor",[91],"2022-08","2017-08-01",[9549,9550,9551,9552],"PD-L1 Positive Mutation Tumor","EBV Positive Mutation Tumor","MSI-H Mutation Tumor","POLE\u002FPOLD1 Mutation Tumor",[9534],{"trials":9555,"activeCount":102},[],{"trials":9557,"activeCount":102},[],{"trials":9559,"activeCount":102},[],{"intervention":9561,"totalTrials":213,"cells":9562},"PDR001",{"EARLY_PHASE1":9563,"PHASE1":9565,"PHASE2":9567,"PHASE3":9578,"PHASE4":9580,"NA":9582},{"trials":9564,"activeCount":102},[],{"trials":9566,"activeCount":102},[],{"trials":9568,"activeCount":102},[9569],{"nctId":9570,"briefTitle":9571,"status":308,"phases":9572,"primaryCompletion":6974,"completion":9573,"start":9574,"enrollment":1678,"conditions":9575,"interventions":9577},"NCT03785496","Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus",[91],"2024-01","2020-02-18",[9576],"Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment",[9561],{"trials":9579,"activeCount":102},[],{"trials":9581,"activeCount":102},[],{"trials":9583,"activeCount":102},[],{"intervention":1294,"totalTrials":213,"cells":9585},{"EARLY_PHASE1":9586,"PHASE1":9588,"PHASE2":9590,"PHASE3":9596,"PHASE4":9598,"NA":9600},{"trials":9587,"activeCount":102},[],{"trials":9589,"activeCount":102},[],{"trials":9591,"activeCount":102},[9592],{"nctId":1285,"briefTitle":1286,"status":308,"phases":9593,"primaryCompletion":1288,"completion":1289,"start":1290,"enrollment":1291,"conditions":9594,"interventions":9595},[90,91],[21],[87,1294,1295,1296],{"trials":9597,"activeCount":102},[],{"trials":9599,"activeCount":102},[],{"trials":9601,"activeCount":102},[],{"intervention":9603,"totalTrials":213,"cells":9604},"TAS-117",{"EARLY_PHASE1":9605,"PHASE1":9607,"PHASE2":9609,"PHASE3":9620,"PHASE4":9622,"NA":9624},{"trials":9606,"activeCount":102},[],{"trials":9608,"activeCount":102},[],{"trials":9610,"activeCount":102},[9611],{"nctId":9612,"briefTitle":9613,"status":204,"phases":9614,"primaryCompletion":9615,"completion":9615,"start":9616,"enrollment":33,"conditions":9617,"interventions":9619},"NCT03017521","K-BASKET, TAS-117, PI3K\u002FAKT Gene Aberration",[91],"2019-12-31","2017-11-21",[9618],"Solid Tumor, Adult",[9603],{"trials":9621,"activeCount":102},[],{"trials":9623,"activeCount":102},[],{"trials":9625,"activeCount":102},[],{"intervention":7950,"totalTrials":213,"cells":9627},{"EARLY_PHASE1":9628,"PHASE1":9630,"PHASE2":9632,"PHASE3":9638,"PHASE4":9640,"NA":9642},{"trials":9629,"activeCount":102},[],{"trials":9631,"activeCount":102},[],{"trials":9633,"activeCount":102},[9634],{"nctId":7944,"briefTitle":7945,"status":204,"phases":9635,"primaryCompletion":981,"completion":981,"start":5398,"enrollment":1538,"conditions":9636,"interventions":9637},[91],[7948],[7950,7951],{"trials":9639,"activeCount":102},[],{"trials":9641,"activeCount":102},[],{"trials":9643,"activeCount":102},[],{"intervention":9645,"totalTrials":213,"cells":9646},"Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy",{"EARLY_PHASE1":9647,"PHASE1":9649,"PHASE2":9651,"PHASE3":9662,"PHASE4":9664,"NA":9666},{"trials":9648,"activeCount":102},[],{"trials":9650,"activeCount":102},[],{"trials":9652,"activeCount":102},[9653],{"nctId":9654,"briefTitle":9655,"status":308,"phases":9656,"primaryCompletion":9657,"completion":9658,"start":9659,"enrollment":16,"conditions":9660,"interventions":9661},"NCT03502343","Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer",[91],"2020-04","2020-06","2018-04-01",[8259],[9645],{"trials":9663,"activeCount":102},[],{"trials":9665,"activeCount":102},[],{"trials":9667,"activeCount":102},[],{"intervention":7202,"totalTrials":213,"cells":9669},{"EARLY_PHASE1":9670,"PHASE1":9672,"PHASE2":9674,"PHASE3":9680,"PHASE4":9682,"NA":9684},{"trials":9671,"activeCount":102},[],{"trials":9673,"activeCount":102},[],{"trials":9675,"activeCount":102},[9676],{"nctId":7194,"briefTitle":7195,"status":204,"phases":9677,"primaryCompletion":7197,"completion":7197,"start":7198,"enrollment":369,"conditions":9678,"interventions":9679},[91],[7200],[7185,7202,7203,7204],{"trials":9681,"activeCount":102},[],{"trials":9683,"activeCount":102},[],{"trials":9685,"activeCount":102},[],{"intervention":7203,"totalTrials":213,"cells":9687},{"EARLY_PHASE1":9688,"PHASE1":9690,"PHASE2":9692,"PHASE3":9698,"PHASE4":9700,"NA":9702},{"trials":9689,"activeCount":102},[],{"trials":9691,"activeCount":102},[],{"trials":9693,"activeCount":102},[9694],{"nctId":7194,"briefTitle":7195,"status":204,"phases":9695,"primaryCompletion":7197,"completion":7197,"start":7198,"enrollment":369,"conditions":9696,"interventions":9697},[91],[7200],[7185,7202,7203,7204],{"trials":9699,"activeCount":102},[],{"trials":9701,"activeCount":102},[],{"trials":9703,"activeCount":102},[],{"intervention":9705,"totalTrials":213,"cells":9706},"autologous mesenchymal stem cells",{"EARLY_PHASE1":9707,"PHASE1":9709,"PHASE2":9711,"PHASE3":9720,"PHASE4":9722,"NA":9724},{"trials":9708,"activeCount":102},[],{"trials":9710,"activeCount":102},[],{"trials":9712,"activeCount":102},[9713],{"nctId":9714,"briefTitle":9715,"status":204,"phases":9716,"primaryCompletion":4201,"completion":4201,"start":9717,"enrollment":2343,"conditions":9718,"interventions":9719},"NCT00911365","Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy",[91],"2008-05",[8284],[9705,4996],{"trials":9721,"activeCount":102},[],{"trials":9723,"activeCount":102},[],{"trials":9725,"activeCount":102},[],{"intervention":9727,"totalTrials":213,"cells":9728},"Lazertinib , a combination group of SBRT",{"EARLY_PHASE1":9729,"PHASE1":9731,"PHASE2":9733,"PHASE3":9743,"PHASE4":9745,"NA":9747},{"trials":9730,"activeCount":102},[],{"trials":9732,"activeCount":102},[],{"trials":9734,"activeCount":102},[9735],{"nctId":9736,"briefTitle":9737,"status":308,"phases":9738,"primaryCompletion":191,"completion":191,"start":6998,"enrollment":9739,"conditions":9740,"interventions":9741},"NCT05167851","The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer",[91],68,[1396],[9727,9742],"Lazertinib single administration group",{"trials":9744,"activeCount":102},[],{"trials":9746,"activeCount":102},[],{"trials":9748,"activeCount":102},[],{"intervention":9742,"totalTrials":213,"cells":9750},{"EARLY_PHASE1":9751,"PHASE1":9753,"PHASE2":9755,"PHASE3":9761,"PHASE4":9763,"NA":9765},{"trials":9752,"activeCount":102},[],{"trials":9754,"activeCount":102},[],{"trials":9756,"activeCount":102},[9757],{"nctId":9736,"briefTitle":9737,"status":308,"phases":9758,"primaryCompletion":191,"completion":191,"start":6998,"enrollment":9739,"conditions":9759,"interventions":9760},[91],[1396],[9727,9742],{"trials":9762,"activeCount":102},[],{"trials":9764,"activeCount":102},[],{"trials":9766,"activeCount":102},[],{"intervention":9768,"totalTrials":213,"cells":9769},"docetaxel 35mg\u002Fm2",{"EARLY_PHASE1":9770,"PHASE1":9772,"PHASE2":9774,"PHASE3":9784,"PHASE4":9786,"NA":9788},{"trials":9771,"activeCount":102},[],{"trials":9773,"activeCount":102},[],{"trials":9775,"activeCount":102},[9776],{"nctId":9777,"briefTitle":9778,"status":204,"phases":9779,"primaryCompletion":3888,"completion":3888,"start":9276,"enrollment":22,"conditions":9780,"interventions":9782},"NCT02223884","A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy",[91],[9781],"Malignant Melanoma",[9768,9783],"Carboplatin AUC3",{"trials":9785,"activeCount":102},[],{"trials":9787,"activeCount":102},[],{"trials":9789,"activeCount":102},[],{"intervention":9783,"totalTrials":213,"cells":9791},{"EARLY_PHASE1":9792,"PHASE1":9794,"PHASE2":9796,"PHASE3":9802,"PHASE4":9804,"NA":9806},{"trials":9793,"activeCount":102},[],{"trials":9795,"activeCount":102},[],{"trials":9797,"activeCount":102},[9798],{"nctId":9777,"briefTitle":9778,"status":204,"phases":9799,"primaryCompletion":3888,"completion":3888,"start":9276,"enrollment":22,"conditions":9800,"interventions":9801},[91],[9781],[9768,9783],{"trials":9803,"activeCount":102},[],{"trials":9805,"activeCount":102},[],{"trials":9807,"activeCount":102},[],{"intervention":9809,"totalTrials":213,"cells":9810},"Neoadjuvant chemotherapy+Durvalumab+Tremelimumab",{"EARLY_PHASE1":9811,"PHASE1":9813,"PHASE2":9815,"PHASE3":9827,"PHASE4":9829,"NA":9831},{"trials":9812,"activeCount":102},[],{"trials":9814,"activeCount":102},[],{"trials":9816,"activeCount":102},[9817],{"nctId":9818,"briefTitle":9819,"status":308,"phases":9820,"primaryCompletion":9821,"completion":9821,"start":9822,"enrollment":5016,"conditions":9823,"interventions":9826},"NCT03899610","A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)",[91],"2021-05","2019-07-04",[9824,9825],"Ovarian Cancer Stage IIIC","Ovarian Cancer Stage IV",[9809],{"trials":9828,"activeCount":102},[],{"trials":9830,"activeCount":102},[],{"trials":9832,"activeCount":102},[],{"intervention":9834,"totalTrials":213,"cells":9835},"BKM120",{"EARLY_PHASE1":9836,"PHASE1":9838,"PHASE2":9840,"PHASE3":9849,"PHASE4":9851,"NA":9853},{"trials":9837,"activeCount":102},[],{"trials":9839,"activeCount":102},[],{"trials":9841,"activeCount":102},[9842],{"nctId":9843,"briefTitle":9844,"status":308,"phases":9845,"primaryCompletion":3520,"completion":3888,"start":3730,"enrollment":9846,"conditions":9847,"interventions":9848},"NCT01527877","Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck",[91],53,[8395,8396],[9834],{"trials":9850,"activeCount":102},[],{"trials":9852,"activeCount":102},[],{"trials":9854,"activeCount":102},[],{"intervention":9856,"totalTrials":213,"cells":9857},"Afinitor",{"EARLY_PHASE1":9858,"PHASE1":9860,"PHASE2":9862,"PHASE3":9874,"PHASE4":9876,"NA":9878},{"trials":9859,"activeCount":102},[],{"trials":9861,"activeCount":102},[],{"trials":9863,"activeCount":102},[9864],{"nctId":9865,"briefTitle":9866,"status":204,"phases":9867,"primaryCompletion":9868,"completion":9868,"start":9869,"enrollment":9870,"conditions":9871,"interventions":9873},"NCT03198949","A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)",[91],"2020-09-11","2018-05-24",23,[9872],"Epilepsy and Focal Cortical Dysplasia II",[9856],{"trials":9875,"activeCount":102},[],{"trials":9877,"activeCount":102},[],{"trials":9879,"activeCount":102},[],{"intervention":9881,"totalTrials":213,"cells":9882},"M7824+paclitaxel",{"EARLY_PHASE1":9883,"PHASE1":9885,"PHASE2":9887,"PHASE3":9897,"PHASE4":9899,"NA":9901},{"trials":9884,"activeCount":102},[],{"trials":9886,"activeCount":102},[],{"trials":9888,"activeCount":102},[9889],{"nctId":9890,"briefTitle":9891,"status":204,"phases":9892,"primaryCompletion":9893,"completion":9893,"start":9894,"enrollment":7845,"conditions":9895,"interventions":9896},"NCT04835896","Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent\u002FMetastatic Gastric Cancer",[90,91],"2023-10-27","2021-06-02",[8168],[9881],{"trials":9898,"activeCount":102},[],{"trials":9900,"activeCount":102},[],{"trials":9902,"activeCount":102},[],{"intervention":9904,"totalTrials":213,"cells":9905},"Durvalumab+doxorubicin cobination",{"EARLY_PHASE1":9906,"PHASE1":9908,"PHASE2":9910,"PHASE3":9919,"PHASE4":9921,"NA":9923},{"trials":9907,"activeCount":102},[],{"trials":9909,"activeCount":102},[],{"trials":9911,"activeCount":102},[9912],{"nctId":9913,"briefTitle":9914,"status":204,"phases":9915,"primaryCompletion":1018,"completion":1018,"start":9916,"enrollment":1678,"conditions":9917,"interventions":9918},"NCT03802071","A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma",[90,91],"2019-09-16",[9015],[9904],{"trials":9920,"activeCount":102},[],{"trials":9922,"activeCount":102},[],{"trials":9924,"activeCount":102},[],{"intervention":9926,"totalTrials":213,"cells":9927},"Treatment with Poziotinib",{"EARLY_PHASE1":9928,"PHASE1":9930,"PHASE2":9932,"PHASE3":9942,"PHASE4":9944,"NA":9946},{"trials":9929,"activeCount":102},[],{"trials":9931,"activeCount":102},[],{"trials":9933,"activeCount":102},[9934],{"nctId":9935,"briefTitle":9936,"status":308,"phases":9937,"primaryCompletion":9938,"completion":9938,"start":6999,"enrollment":7845,"conditions":9939,"interventions":9941},"NCT03770988","A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent\u002FMetastatic Esophageal Cancer (R\u002FM ESCC)",[91],"2020-08-31",[9940],"Inoperable or Recurrent or Metastatic Esophageal Squamous Carcinoma",[9926],{"trials":9943,"activeCount":102},[],{"trials":9945,"activeCount":102},[],{"trials":9947,"activeCount":102},[],{"intervention":9949,"totalTrials":213,"cells":9950},"Bortezomib",{"EARLY_PHASE1":9951,"PHASE1":9953,"PHASE2":9955,"PHASE3":9964,"PHASE4":9966,"NA":9968},{"trials":9952,"activeCount":102},[],{"trials":9954,"activeCount":102},[],{"trials":9956,"activeCount":102},[9957],{"nctId":9958,"briefTitle":9959,"status":308,"phases":9960,"primaryCompletion":7677,"completion":7677,"start":3912,"enrollment":9846,"conditions":9961,"interventions":9963},"NCT01255527","Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study",[90,91],[9962],"Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation",[9949],{"trials":9965,"activeCount":102},[],{"trials":9967,"activeCount":102},[],{"trials":9969,"activeCount":102},[],{"intervention":9971,"totalTrials":213,"cells":9972},"Niclosamide",{"EARLY_PHASE1":9973,"PHASE1":9975,"PHASE2":9977,"PHASE3":9986,"PHASE4":9988,"NA":9990},{"trials":9974,"activeCount":102},[],{"trials":9976,"activeCount":102},[],{"trials":9978,"activeCount":102},[9979],{"nctId":9980,"briefTitle":9981,"status":308,"phases":9982,"primaryCompletion":5984,"completion":609,"start":9983,"enrollment":1501,"conditions":9984,"interventions":9985},"NCT04296851","Niclosamide for Familial Adenomatous Polyposis",[91],"2020-02-14",[1168],[9971],{"trials":9987,"activeCount":102},[],{"trials":9989,"activeCount":102},[],{"trials":9991,"activeCount":102},[],{"intervention":9993,"totalTrials":213,"cells":9994},"HM781-36B",{"EARLY_PHASE1":9995,"PHASE1":9997,"PHASE2":9999,"PHASE3":10009,"PHASE4":10011,"NA":10013},{"trials":9996,"activeCount":102},[],{"trials":9998,"activeCount":102},[],{"trials":10000,"activeCount":102},[10001],{"nctId":10002,"briefTitle":10003,"status":308,"phases":10004,"primaryCompletion":10005,"completion":10005,"start":3888,"enrollment":7845,"conditions":10006,"interventions":10008},"NCT02216916","Phase II Trial of HM781-36B in Patients With Metastatic\u002FRecurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy",[91],"2019-07",[10007],"HNSCC",[9993],{"trials":10010,"activeCount":102},[],{"trials":10012,"activeCount":102},[],{"trials":10014,"activeCount":102},[],{"intervention":10016,"totalTrials":213,"cells":10017},"Bevacizumab, mFOLFOX, FOLFIRI",{"EARLY_PHASE1":10018,"PHASE1":10020,"PHASE2":10022,"PHASE3":10032,"PHASE4":10034,"NA":10036},{"trials":10019,"activeCount":102},[],{"trials":10021,"activeCount":102},[],{"trials":10023,"activeCount":102},[10024],{"nctId":10025,"briefTitle":10026,"status":204,"phases":10027,"primaryCompletion":10028,"completion":9456,"start":5166,"enrollment":8964,"conditions":10029,"interventions":10031},"NCT01632722","Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets",[91],"2018-05",[32,10030],"Liver Metastasis",[10016,10016],{"trials":10033,"activeCount":102},[],{"trials":10035,"activeCount":102},[],{"trials":10037,"activeCount":102},[],{"intervention":10039,"totalTrials":213,"cells":10040},"Pemetrexed, cisplatin",{"EARLY_PHASE1":10041,"PHASE1":10043,"PHASE2":10045,"PHASE3":10055,"PHASE4":10057,"NA":10059},{"trials":10042,"activeCount":102},[],{"trials":10044,"activeCount":102},[],{"trials":10046,"activeCount":102},[10047],{"nctId":10048,"briefTitle":10049,"status":204,"phases":10050,"primaryCompletion":10051,"completion":10051,"start":10052,"enrollment":9013,"conditions":10053,"interventions":10054},"NCT03809637","A Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma",[91],"2021-06-30","2017-01-10",[9015],[10039],{"trials":10056,"activeCount":102},[],{"trials":10058,"activeCount":102},[],{"trials":10060,"activeCount":102},[],{"intervention":1505,"totalTrials":213,"cells":10062},{"EARLY_PHASE1":10063,"PHASE1":10065,"PHASE2":10067,"PHASE3":10073,"PHASE4":10075,"NA":10077},{"trials":10064,"activeCount":102},[],{"trials":10066,"activeCount":102},[],{"trials":10068,"activeCount":102},[10069],{"nctId":1495,"briefTitle":1496,"status":204,"phases":10070,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":10071,"interventions":10072},[91],[21,1503],[1505,1506],{"trials":10074,"activeCount":102},[],{"trials":10076,"activeCount":102},[],{"trials":10078,"activeCount":102},[],{"intervention":10080,"totalTrials":213,"cells":10081},"Pembrolizumab 200mg +Paclitaxel 80mg\u002Fm2",{"EARLY_PHASE1":10082,"PHASE1":10084,"PHASE2":10086,"PHASE3":10095,"PHASE4":10097,"NA":10099},{"trials":10083,"activeCount":102},[],{"trials":10085,"activeCount":102},[],{"trials":10087,"activeCount":102},[10088],{"nctId":10089,"briefTitle":10090,"status":308,"phases":10091,"primaryCompletion":5984,"completion":5984,"start":10092,"enrollment":16,"conditions":10093,"interventions":10094},"NCT04946227","Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')",[91],"2021-07",[30],[10080],{"trials":10096,"activeCount":102},[],{"trials":10098,"activeCount":102},[],{"trials":10100,"activeCount":102},[],{"intervention":10102,"totalTrials":213,"cells":10103},"sorafenib",{"EARLY_PHASE1":10104,"PHASE1":10106,"PHASE2":10108,"PHASE3":10119,"PHASE4":10121,"NA":10123},{"trials":10105,"activeCount":102},[],{"trials":10107,"activeCount":102},[],{"trials":10109,"activeCount":102},[10110],{"nctId":10111,"briefTitle":10112,"status":204,"phases":10113,"primaryCompletion":10114,"completion":10114,"start":10115,"enrollment":10116,"conditions":10117,"interventions":10118},"NCT02425605","Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma",[91],"2017-09-22","2014-12-03",47,[2365],[10102],{"trials":10120,"activeCount":102},[],{"trials":10122,"activeCount":102},[],{"trials":10124,"activeCount":102},[],{"intervention":10126,"totalTrials":213,"cells":10127},"S-1 plus oxaliplatin",{"EARLY_PHASE1":10128,"PHASE1":10130,"PHASE2":10132,"PHASE3":10141,"PHASE4":10143,"NA":10145},{"trials":10129,"activeCount":102},[],{"trials":10131,"activeCount":102},[],{"trials":10133,"activeCount":102},[10134],{"nctId":10135,"briefTitle":10136,"status":243,"phases":10137,"primaryCompletion":7211,"completion":7211,"start":4775,"enrollment":946,"conditions":10138,"interventions":10140},"NCT01946061","A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer",[91],[10139],"Advanced Gastric Cancer",[10126],{"trials":10142,"activeCount":102},[],{"trials":10144,"activeCount":102},[],{"trials":10146,"activeCount":102},[],{"intervention":10148,"totalTrials":213,"cells":10149},"BAY 1000394 (Roniciclib) in combination with docetaxel",{"EARLY_PHASE1":10150,"PHASE1":10152,"PHASE2":10154,"PHASE3":10164,"PHASE4":10166,"NA":10168},{"trials":10151,"activeCount":102},[],{"trials":10153,"activeCount":102},[],{"trials":10155,"activeCount":102},[10156],{"nctId":10157,"briefTitle":10158,"status":1475,"phases":10159,"primaryCompletion":10160,"completion":10160,"start":5743,"enrollment":102,"conditions":10161,"interventions":10163},"NCT02522910","An Open-label Phase Ib\u002FII Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)",[90,91],"2016-08",[10162],"NSCLC (Non-Small Cell Lung Cancer)",[10148],{"trials":10165,"activeCount":102},[],{"trials":10167,"activeCount":102},[],{"trials":10169,"activeCount":102},[],{"intervention":10171,"totalTrials":213,"cells":10172},"HERZUMA+mFOLFOX",{"EARLY_PHASE1":10173,"PHASE1":10175,"PHASE2":10177,"PHASE3":10187,"PHASE4":10189,"NA":10191},{"trials":10174,"activeCount":102},[],{"trials":10176,"activeCount":102},[],{"trials":10178,"activeCount":102},[10179],{"nctId":10180,"briefTitle":10181,"status":204,"phases":10182,"primaryCompletion":10183,"completion":10183,"start":10184,"enrollment":1557,"conditions":10185,"interventions":10186},"NCT04722133","Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy",[91],"2023-06-14","2020-06-23",[1680],[10171],{"trials":10188,"activeCount":102},[],{"trials":10190,"activeCount":102},[],{"trials":10192,"activeCount":102},[],{"intervention":10194,"totalTrials":213,"cells":10195},"Durvalumab, pazopanib",{"EARLY_PHASE1":10196,"PHASE1":10198,"PHASE2":10200,"PHASE3":10209,"PHASE4":10211,"NA":10213},{"trials":10197,"activeCount":102},[],{"trials":10199,"activeCount":102},[],{"trials":10201,"activeCount":102},[10202],{"nctId":10203,"briefTitle":10204,"status":204,"phases":10205,"primaryCompletion":1018,"completion":1018,"start":10206,"enrollment":7792,"conditions":10207,"interventions":10208},"NCT03798106","A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma",[91],"2019-04-10",[9015],[10194],{"trials":10210,"activeCount":102},[],{"trials":10212,"activeCount":102},[],{"trials":10214,"activeCount":102},[],{"intervention":10216,"totalTrials":213,"cells":10217},"Induction DCS chemotherapy",{"EARLY_PHASE1":10218,"PHASE1":10220,"PHASE2":10222,"PHASE3":10230,"PHASE4":10232,"NA":10234},{"trials":10219,"activeCount":102},[],{"trials":10221,"activeCount":102},[],{"trials":10223,"activeCount":102},[10224],{"nctId":10225,"briefTitle":10226,"status":204,"phases":10227,"primaryCompletion":4856,"completion":10005,"start":7383,"enrollment":1513,"conditions":10228,"interventions":10229},"NCT02495493","S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma",[91],[7214],[10216],{"trials":10231,"activeCount":102},[],{"trials":10233,"activeCount":102},[],{"trials":10235,"activeCount":102},[],{"intervention":10237,"totalTrials":213,"cells":10238},"Acetazolamide group",{"EARLY_PHASE1":10239,"PHASE1":10241,"PHASE2":10243,"PHASE3":10253,"PHASE4":10255,"NA":10257},{"trials":10240,"activeCount":102},[],{"trials":10242,"activeCount":102},[],{"trials":10244,"activeCount":102},[10245],{"nctId":10246,"briefTitle":10247,"status":1475,"phases":10248,"primaryCompletion":7677,"start":962,"enrollment":102,"conditions":10249,"interventions":10251},"NCT02090738","A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide",[91],[10250],"H. Pylori Infection",[10237,10252],"Standard regimen group",{"trials":10254,"activeCount":102},[],{"trials":10256,"activeCount":102},[],{"trials":10258,"activeCount":102},[],{"intervention":10252,"totalTrials":213,"cells":10260},{"EARLY_PHASE1":10261,"PHASE1":10263,"PHASE2":10265,"PHASE3":10271,"PHASE4":10273,"NA":10275},{"trials":10262,"activeCount":102},[],{"trials":10264,"activeCount":102},[],{"trials":10266,"activeCount":102},[10267],{"nctId":10246,"briefTitle":10247,"status":1475,"phases":10268,"primaryCompletion":7677,"start":962,"enrollment":102,"conditions":10269,"interventions":10270},[91],[10250],[10237,10252],{"trials":10272,"activeCount":102},[],{"trials":10274,"activeCount":102},[],{"trials":10276,"activeCount":102},[],{"intervention":7888,"totalTrials":213,"cells":10278},{"EARLY_PHASE1":10279,"PHASE1":10281,"PHASE2":10283,"PHASE3":10289,"PHASE4":10291,"NA":10293},{"trials":10280,"activeCount":102},[],{"trials":10282,"activeCount":102},[],{"trials":10284,"activeCount":102},[10285],{"nctId":7881,"briefTitle":7882,"status":308,"phases":10286,"start":7884,"enrollment":7885,"conditions":10287,"interventions":10288},[91],[7802],[7888,7795,7889,7890],{"trials":10290,"activeCount":102},[],{"trials":10292,"activeCount":102},[],{"trials":10294,"activeCount":102},[],{"intervention":7890,"totalTrials":213,"cells":10296},{"EARLY_PHASE1":10297,"PHASE1":10299,"PHASE2":10301,"PHASE3":10307,"PHASE4":10309,"NA":10311},{"trials":10298,"activeCount":102},[],{"trials":10300,"activeCount":102},[],{"trials":10302,"activeCount":102},[10303],{"nctId":7881,"briefTitle":7882,"status":308,"phases":10304,"start":7884,"enrollment":7885,"conditions":10305,"interventions":10306},[91],[7802],[7888,7795,7889,7890],{"trials":10308,"activeCount":102},[],{"trials":10310,"activeCount":102},[],{"trials":10312,"activeCount":102},[],{"intervention":10314,"totalTrials":213,"cells":10315},"olaparib+cediranib combination therapy",{"EARLY_PHASE1":10316,"PHASE1":10318,"PHASE2":10320,"PHASE3":10336,"PHASE4":10338,"NA":10340},{"trials":10317,"activeCount":102},[],{"trials":10319,"activeCount":102},[],{"trials":10321,"activeCount":102},[10322],{"nctId":10323,"briefTitle":10324,"status":308,"phases":10325,"primaryCompletion":10326,"completion":10326,"start":10327,"enrollment":7086,"conditions":10328,"interventions":10330},"NCT03699449","An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)",[91],"2022-09","2018-11-26",[10329],"Platinum-resistant Recurrent Ovarian Cancer",[10314,10331,10332,10333,10334,10335],"durvalumab + olaparib combination therapy","durvalumab + chemotherapy treatment","durvalumab + tremelimumab + chemotherapy treatment","durvalumab + tremelimumab + paclitaxel treatment","durvalumab +chemotherapy treatment",{"trials":10337,"activeCount":102},[],{"trials":10339,"activeCount":102},[],{"trials":10341,"activeCount":102},[],{"intervention":10331,"totalTrials":213,"cells":10343},{"EARLY_PHASE1":10344,"PHASE1":10346,"PHASE2":10348,"PHASE3":10354,"PHASE4":10356,"NA":10358},{"trials":10345,"activeCount":102},[],{"trials":10347,"activeCount":102},[],{"trials":10349,"activeCount":102},[10350],{"nctId":10323,"briefTitle":10324,"status":308,"phases":10351,"primaryCompletion":10326,"completion":10326,"start":10327,"enrollment":7086,"conditions":10352,"interventions":10353},[91],[10329],[10314,10331,10332,10333,10334,10335],{"trials":10355,"activeCount":102},[],{"trials":10357,"activeCount":102},[],{"trials":10359,"activeCount":102},[],{"intervention":10332,"totalTrials":213,"cells":10361},{"EARLY_PHASE1":10362,"PHASE1":10364,"PHASE2":10366,"PHASE3":10372,"PHASE4":10374,"NA":10376},{"trials":10363,"activeCount":102},[],{"trials":10365,"activeCount":102},[],{"trials":10367,"activeCount":102},[10368],{"nctId":10323,"briefTitle":10324,"status":308,"phases":10369,"primaryCompletion":10326,"completion":10326,"start":10327,"enrollment":7086,"conditions":10370,"interventions":10371},[91],[10329],[10314,10331,10332,10333,10334,10335],{"trials":10373,"activeCount":102},[],{"trials":10375,"activeCount":102},[],{"trials":10377,"activeCount":102},[],{"intervention":10333,"totalTrials":213,"cells":10379},{"EARLY_PHASE1":10380,"PHASE1":10382,"PHASE2":10384,"PHASE3":10390,"PHASE4":10392,"NA":10394},{"trials":10381,"activeCount":102},[],{"trials":10383,"activeCount":102},[],{"trials":10385,"activeCount":102},[10386],{"nctId":10323,"briefTitle":10324,"status":308,"phases":10387,"primaryCompletion":10326,"completion":10326,"start":10327,"enrollment":7086,"conditions":10388,"interventions":10389},[91],[10329],[10314,10331,10332,10333,10334,10335],{"trials":10391,"activeCount":102},[],{"trials":10393,"activeCount":102},[],{"trials":10395,"activeCount":102},[],{"intervention":10334,"totalTrials":213,"cells":10397},{"EARLY_PHASE1":10398,"PHASE1":10400,"PHASE2":10402,"PHASE3":10408,"PHASE4":10410,"NA":10412},{"trials":10399,"activeCount":102},[],{"trials":10401,"activeCount":102},[],{"trials":10403,"activeCount":102},[10404],{"nctId":10323,"briefTitle":10324,"status":308,"phases":10405,"primaryCompletion":10326,"completion":10326,"start":10327,"enrollment":7086,"conditions":10406,"interventions":10407},[91],[10329],[10314,10331,10332,10333,10334,10335],{"trials":10409,"activeCount":102},[],{"trials":10411,"activeCount":102},[],{"trials":10413,"activeCount":102},[],{"intervention":10335,"totalTrials":213,"cells":10415},{"EARLY_PHASE1":10416,"PHASE1":10418,"PHASE2":10420,"PHASE3":10426,"PHASE4":10428,"NA":10430},{"trials":10417,"activeCount":102},[],{"trials":10419,"activeCount":102},[],{"trials":10421,"activeCount":102},[10422],{"nctId":10323,"briefTitle":10324,"status":308,"phases":10423,"primaryCompletion":10326,"completion":10326,"start":10327,"enrollment":7086,"conditions":10424,"interventions":10425},[91],[10329],[10314,10331,10332,10333,10334,10335],{"trials":10427,"activeCount":102},[],{"trials":10429,"activeCount":102},[],{"trials":10431,"activeCount":102},[],{"intervention":10433,"totalTrials":213,"cells":10434},"erlotinib hydrochloride",{"EARLY_PHASE1":10435,"PHASE1":10437,"PHASE2":10439,"PHASE3":10453,"PHASE4":10455,"NA":10457},{"trials":10436,"activeCount":102},[],{"trials":10438,"activeCount":102},[],{"trials":10440,"activeCount":102},[10441],{"nctId":10442,"briefTitle":10443,"status":308,"phases":10444,"primaryCompletion":6341,"start":8523,"enrollment":10116,"conditions":10445,"interventions":10446},"NCT00801385","Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy",[91],[7802],[10433,10447,10448,10449,10450,10451,10452],"sorafenib tosylate","DNA analysis","mutation analysis","polymerase chain reaction","protein analysis","protein expression analysis",{"trials":10454,"activeCount":102},[],{"trials":10456,"activeCount":102},[],{"trials":10458,"activeCount":102},[],{"intervention":10447,"totalTrials":213,"cells":10460},{"EARLY_PHASE1":10461,"PHASE1":10463,"PHASE2":10465,"PHASE3":10471,"PHASE4":10473,"NA":10475},{"trials":10462,"activeCount":102},[],{"trials":10464,"activeCount":102},[],{"trials":10466,"activeCount":102},[10467],{"nctId":10442,"briefTitle":10443,"status":308,"phases":10468,"primaryCompletion":6341,"start":8523,"enrollment":10116,"conditions":10469,"interventions":10470},[91],[7802],[10433,10447,10448,10449,10450,10451,10452],{"trials":10472,"activeCount":102},[],{"trials":10474,"activeCount":102},[],{"trials":10476,"activeCount":102},[],{"intervention":10448,"totalTrials":213,"cells":10478},{"EARLY_PHASE1":10479,"PHASE1":10481,"PHASE2":10483,"PHASE3":10489,"PHASE4":10491,"NA":10493},{"trials":10480,"activeCount":102},[],{"trials":10482,"activeCount":102},[],{"trials":10484,"activeCount":102},[10485],{"nctId":10442,"briefTitle":10443,"status":308,"phases":10486,"primaryCompletion":6341,"start":8523,"enrollment":10116,"conditions":10487,"interventions":10488},[91],[7802],[10433,10447,10448,10449,10450,10451,10452],{"trials":10490,"activeCount":102},[],{"trials":10492,"activeCount":102},[],{"trials":10494,"activeCount":102},[],{"intervention":10449,"totalTrials":213,"cells":10496},{"EARLY_PHASE1":10497,"PHASE1":10499,"PHASE2":10501,"PHASE3":10507,"PHASE4":10509,"NA":10511},{"trials":10498,"activeCount":102},[],{"trials":10500,"activeCount":102},[],{"trials":10502,"activeCount":102},[10503],{"nctId":10442,"briefTitle":10443,"status":308,"phases":10504,"primaryCompletion":6341,"start":8523,"enrollment":10116,"conditions":10505,"interventions":10506},[91],[7802],[10433,10447,10448,10449,10450,10451,10452],{"trials":10508,"activeCount":102},[],{"trials":10510,"activeCount":102},[],{"trials":10512,"activeCount":102},[],{"intervention":10450,"totalTrials":213,"cells":10514},{"EARLY_PHASE1":10515,"PHASE1":10517,"PHASE2":10519,"PHASE3":10525,"PHASE4":10527,"NA":10529},{"trials":10516,"activeCount":102},[],{"trials":10518,"activeCount":102},[],{"trials":10520,"activeCount":102},[10521],{"nctId":10442,"briefTitle":10443,"status":308,"phases":10522,"primaryCompletion":6341,"start":8523,"enrollment":10116,"conditions":10523,"interventions":10524},[91],[7802],[10433,10447,10448,10449,10450,10451,10452],{"trials":10526,"activeCount":102},[],{"trials":10528,"activeCount":102},[],{"trials":10530,"activeCount":102},[],{"intervention":10451,"totalTrials":213,"cells":10532},{"EARLY_PHASE1":10533,"PHASE1":10535,"PHASE2":10537,"PHASE3":10543,"PHASE4":10545,"NA":10547},{"trials":10534,"activeCount":102},[],{"trials":10536,"activeCount":102},[],{"trials":10538,"activeCount":102},[10539],{"nctId":10442,"briefTitle":10443,"status":308,"phases":10540,"primaryCompletion":6341,"start":8523,"enrollment":10116,"conditions":10541,"interventions":10542},[91],[7802],[10433,10447,10448,10449,10450,10451,10452],{"trials":10544,"activeCount":102},[],{"trials":10546,"activeCount":102},[],{"trials":10548,"activeCount":102},[],{"intervention":10452,"totalTrials":213,"cells":10550},{"EARLY_PHASE1":10551,"PHASE1":10553,"PHASE2":10555,"PHASE3":10561,"PHASE4":10563,"NA":10565},{"trials":10552,"activeCount":102},[],{"trials":10554,"activeCount":102},[],{"trials":10556,"activeCount":102},[10557],{"nctId":10442,"briefTitle":10443,"status":308,"phases":10558,"primaryCompletion":6341,"start":8523,"enrollment":10116,"conditions":10559,"interventions":10560},[91],[7802],[10433,10447,10448,10449,10450,10451,10452],{"trials":10562,"activeCount":102},[],{"trials":10564,"activeCount":102},[],{"trials":10566,"activeCount":102},[],{"intervention":1517,"totalTrials":213,"cells":10568},{"EARLY_PHASE1":10569,"PHASE1":10571,"PHASE2":10573,"PHASE3":10579,"PHASE4":10581,"NA":10583},{"trials":10570,"activeCount":102},[],{"trials":10572,"activeCount":102},[],{"trials":10574,"activeCount":102},[10575],{"nctId":1508,"briefTitle":1509,"status":204,"phases":10576,"primaryCompletion":1511,"completion":1511,"start":1512,"enrollment":1513,"conditions":10577,"interventions":10578},[90,91],[1515],[1517,1445],{"trials":10580,"activeCount":102},[],{"trials":10582,"activeCount":102},[],{"trials":10584,"activeCount":102},[],{"intervention":10586,"totalTrials":213,"cells":10587},"Donepezil",{"EARLY_PHASE1":10588,"PHASE1":10590,"PHASE2":10592,"PHASE3":10602,"PHASE4":10604,"NA":10606},{"trials":10589,"activeCount":102},[],{"trials":10591,"activeCount":102},[],{"trials":10593,"activeCount":102},[10594],{"nctId":10595,"briefTitle":10596,"status":308,"phases":10597,"primaryCompletion":10598,"completion":10598,"start":4225,"enrollment":233,"conditions":10599,"interventions":10601},"NCT02450786","Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)",[91],"2019-08",[10600],"Parkinson's Disease",[10586],{"trials":10603,"activeCount":102},[],{"trials":10605,"activeCount":102},[],{"trials":10607,"activeCount":102},[],{"intervention":10609,"totalTrials":213,"cells":10610},"0.5% ropivacaine",{"EARLY_PHASE1":10611,"PHASE1":10613,"PHASE2":10615,"PHASE3":10627,"PHASE4":10629,"NA":10631},{"trials":10612,"activeCount":102},[],{"trials":10614,"activeCount":102},[],{"trials":10616,"activeCount":102},[10617],{"nctId":10618,"briefTitle":10619,"status":204,"phases":10620,"primaryCompletion":10621,"completion":10621,"start":10622,"enrollment":8964,"conditions":10623,"interventions":10625},"NCT01703351","Prospective Randomized Trial Comparing the Effectiveness of Continuous Paravertebral Infusion of Local Anesthetics Versus Intravenous Patient-controlled Analgesia on Acute and Chronic Neuropathic Pain After VATS Lobectomy",[91],"2015-11-06","2012-10-04",[10624,2918],"Lung Neoplasms",[10609,10626],"Fentanyl 500mcg + acupan 160mg + nasea 0.6mg",{"trials":10628,"activeCount":102},[],{"trials":10630,"activeCount":102},[],{"trials":10632,"activeCount":102},[],{"intervention":10626,"totalTrials":213,"cells":10634},{"EARLY_PHASE1":10635,"PHASE1":10637,"PHASE2":10639,"PHASE3":10645,"PHASE4":10647,"NA":10649},{"trials":10636,"activeCount":102},[],{"trials":10638,"activeCount":102},[],{"trials":10640,"activeCount":102},[10641],{"nctId":10618,"briefTitle":10619,"status":204,"phases":10642,"primaryCompletion":10621,"completion":10621,"start":10622,"enrollment":8964,"conditions":10643,"interventions":10644},[91],[10624,2918],[10609,10626],{"trials":10646,"activeCount":102},[],{"trials":10648,"activeCount":102},[],{"trials":10650,"activeCount":102},[],{"intervention":10652,"totalTrials":213,"cells":10653},"Natural killer cell",{"EARLY_PHASE1":10654,"PHASE1":10656,"PHASE2":10667,"PHASE3":10669,"PHASE4":10671,"NA":10673},{"trials":10655,"activeCount":102},[],{"trials":10657,"activeCount":102},[10658],{"nctId":10659,"briefTitle":10660,"status":204,"phases":10661,"primaryCompletion":10662,"completion":10662,"start":10663,"enrollment":2295,"conditions":10664,"interventions":10666},"NCT03358849","Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell (\"SMT-NK\") Cell Therapy in Advanced Biliary Tract Cancer",[90],"2018-09-27","2017-10-17",[10665],"Advanced Biliary Tract Cancer",[10652],{"trials":10668,"activeCount":102},[],{"trials":10670,"activeCount":102},[],{"trials":10672,"activeCount":102},[],{"trials":10674,"activeCount":102},[],{"intervention":10676,"totalTrials":213,"cells":10677},"ALLO-ASC",{"EARLY_PHASE1":10678,"PHASE1":10680,"PHASE2":10690,"PHASE3":10692,"PHASE4":10694,"NA":10696},{"trials":10679,"activeCount":102},[],{"trials":10681,"activeCount":102},[10682],{"nctId":10683,"briefTitle":10684,"status":204,"phases":10685,"primaryCompletion":10686,"completion":10686,"start":7677,"enrollment":1629,"conditions":10687,"interventions":10689},"NCT02384499","Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study",[90],"2017-06-30",[10688],"Fecal Incontinence",[10676],{"trials":10691,"activeCount":102},[],{"trials":10693,"activeCount":102},[],{"trials":10695,"activeCount":102},[],{"trials":10697,"activeCount":102},[],{"intervention":10699,"totalTrials":213,"cells":10700},"Afatinib plus Ruxolitinib combination therapy",{"EARLY_PHASE1":10701,"PHASE1":10703,"PHASE2":10713,"PHASE3":10715,"PHASE4":10717,"NA":10719},{"trials":10702,"activeCount":102},[],{"trials":10704,"activeCount":102},[10705],{"nctId":10706,"briefTitle":10707,"status":204,"phases":10708,"primaryCompletion":10709,"completion":10709,"start":10710,"enrollment":22,"conditions":10711,"interventions":10712},"NCT02145637","Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)",[90],"2017-11-09","2015-05-07",[1559],[10699],{"trials":10714,"activeCount":102},[],{"trials":10716,"activeCount":102},[],{"trials":10718,"activeCount":102},[],{"trials":10720,"activeCount":102},[],{"intervention":10722,"totalTrials":213,"cells":10723},"multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide",{"EARLY_PHASE1":10724,"PHASE1":10726,"PHASE2":10735,"PHASE3":10737,"PHASE4":10739,"NA":10741},{"trials":10725,"activeCount":102},[],{"trials":10727,"activeCount":102},[10728],{"nctId":10729,"briefTitle":10730,"status":204,"phases":10731,"primaryCompletion":3774,"completion":5399,"start":6567,"enrollment":9870,"conditions":10732,"interventions":10734},"NCT01198249","Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension",[90],[10733],"Essential Hypertension",[10722],{"trials":10736,"activeCount":102},[],{"trials":10738,"activeCount":102},[],{"trials":10740,"activeCount":102},[],{"trials":10742,"activeCount":102},[],{"intervention":10744,"totalTrials":213,"cells":10745},"TS-1 with Cisplatin",{"EARLY_PHASE1":10746,"PHASE1":10748,"PHASE2":10756,"PHASE3":10758,"PHASE4":10760,"NA":10762},{"trials":10747,"activeCount":102},[],{"trials":10749,"activeCount":102},[10750],{"nctId":10751,"briefTitle":10752,"status":204,"phases":10753,"primaryCompletion":7503,"completion":7503,"start":4538,"enrollment":173,"conditions":10754,"interventions":10755},"NCT01269255","A Trial of Induction Chemotherapy and Chemoradiotherapy With TS-1 and Cisplatin (SP) as First-line Treatment in Patients With High Risk Advanced Gastric Cancer",[90],[21],[10744],{"trials":10757,"activeCount":102},[],{"trials":10759,"activeCount":102},[],{"trials":10761,"activeCount":102},[],{"trials":10763,"activeCount":102},[],{"intervention":10765,"totalTrials":213,"cells":10766},"GX-70 by electroporation",{"EARLY_PHASE1":10767,"PHASE1":10769,"PHASE2":10781,"PHASE3":10783,"PHASE4":10785,"NA":10787},{"trials":10768,"activeCount":102},[],{"trials":10770,"activeCount":102},[10771],{"nctId":10772,"briefTitle":10773,"status":1475,"phases":10774,"primaryCompletion":7022,"completion":7022,"start":10775,"enrollment":102,"conditions":10776,"interventions":10780},"NCT03159975","Safety and Immunogenicity Study of GX-70 in TB Patient",[90],"2018-03",[10777,10778,10779],"Pulmonary Tuberculoses","High Risk Factors for Relapse","Treatment Failure",[10765,10765,10765],{"trials":10782,"activeCount":102},[],{"trials":10784,"activeCount":102},[],{"trials":10786,"activeCount":102},[],{"trials":10788,"activeCount":102},[],{"intervention":4996,"totalTrials":22,"cells":10790},{"EARLY_PHASE1":10791,"PHASE1":10793,"PHASE2":10795,"PHASE3":10801,"PHASE4":10803,"NA":10821},{"trials":10792,"activeCount":102},[],{"trials":10794,"activeCount":102},[],{"trials":10796,"activeCount":102},[10797],{"nctId":9714,"briefTitle":9715,"status":204,"phases":10798,"primaryCompletion":4201,"completion":4201,"start":9717,"enrollment":2343,"conditions":10799,"interventions":10800},[91],[8284],[9705,4996],{"trials":10802,"activeCount":102},[],{"trials":10804,"activeCount":102},[10805,10813,10817],{"nctId":10806,"briefTitle":10807,"status":204,"phases":10808,"primaryCompletion":5575,"completion":8851,"start":963,"enrollment":344,"conditions":10809,"interventions":10811},"NCT02235246","The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study",[93],[10810],"Gastric Neoplasm",[10812,6456],"Magnesium Sulfate",{"nctId":4986,"briefTitle":4987,"status":204,"phases":10814,"primaryCompletion":4989,"completion":4990,"start":4991,"enrollment":4992,"conditions":10815,"interventions":10816},[93],[4994],[4973,4996],{"nctId":6448,"briefTitle":6449,"status":308,"phases":10818,"primaryCompletion":4563,"completion":4563,"start":6451,"enrollment":6452,"conditions":10819,"interventions":10820},[93],[6454],[6456,6435],{"trials":10822,"activeCount":102},[10823,10834,10842,10849,10856,10863,10872,10879,10887,10894,10904,10911,10918,10926,10935,10943,10953,10962,10970,10978,10988,10996,11005,11012,11022,11030],{"nctId":10824,"briefTitle":10825,"status":204,"phases":10826,"primaryCompletion":10827,"completion":10827,"start":10828,"enrollment":10829,"conditions":10830,"interventions":10832},"NCT01717599","Intramuscular Diclofenac in the Prevention of Post-ERCP Pancreatitis",[94],"2013-08-28","2012-08-29",343,[10831],"Post ERCP Pancreatitis",[10833,4996],"Diclofenac",{"nctId":10835,"briefTitle":10836,"status":204,"phases":10837,"primaryCompletion":7211,"completion":7211,"start":3658,"enrollment":1243,"conditions":10838,"interventions":10840},"NCT02180321","Effect of Tranexamic Acid Based on Pharmacokinetics in Pediatric Patients Undergoing Craniosynostosis Surgery: Randomized Controlled Trial",[94],[10839],"Craniosynostosis Patients Undergoing Distraction Osteotomy",[10841,4996],"Tranexamic Acid",{"nctId":10843,"briefTitle":10844,"status":204,"phases":10845,"primaryCompletion":4453,"completion":4775,"start":7383,"enrollment":2661,"conditions":10846,"interventions":10847},"NCT01907997","Effects of Systemic Lidocaine on Postoperative Quality of Recovery After Robot-assisted Thyroidectomy",[94],[9480],[10848,4996],"Systemic intravenous lidocaine",{"nctId":10850,"briefTitle":10851,"status":204,"phases":10852,"primaryCompletion":3519,"completion":5575,"start":3631,"enrollment":3775,"conditions":10853,"interventions":10855},"NCT02007330","The Effect of Systemic Lidocaine Infusion to Postoperative Pain and Quality of Recovery After Laparoscopic Hernia Repair in Children",[94],[10854],"Inguinal Hernia",[10848,6456],{"nctId":10857,"briefTitle":10858,"status":204,"phases":10859,"primaryCompletion":3658,"completion":3841,"start":3773,"enrollment":4177,"conditions":10860,"interventions":10861},"NCT01857141","Comparative Study on the Effects of Epidural Dexmedetomidine on Heart Rate Variability During General Anesthesia in Patients Undergoing Gastrectomy",[94],[21],[10862,4996],"preemptive dexmedetomidine epidural bolus",{"nctId":10864,"briefTitle":10865,"status":204,"phases":10866,"primaryCompletion":10867,"completion":10867,"start":284,"enrollment":5124,"conditions":10868,"interventions":10871},"NCT02006966","The Impact of Intraoperative Systemic Lidocaine Infusion on Chronic Postoperative Pain After Video-assisted Thoracic Surgery (VATS)",[94],"2016-08-22",[10869,10870],"Lung Cancer(Primary, Metastatic)","Benign Lung Mass Requiring Operation",[10848,6456],{"nctId":10873,"briefTitle":10874,"status":204,"phases":10875,"primaryCompletion":5743,"completion":5743,"start":3469,"enrollment":458,"conditions":10876,"interventions":10878},"NCT02490072","Echocardiographic Evaluation of the Effects of Dexmedetomidine in Diastolic Dysfunction",[94],[10877],"Under General Anesthesia",[5197,4996],{"nctId":10880,"briefTitle":10881,"status":204,"phases":10882,"primaryCompletion":10883,"completion":10883,"start":3730,"enrollment":5660,"conditions":10884,"interventions":10886},"NCT01840254","Effect of Combination Dexmedetomidine Added to Fentanyl-based Intravenous Patient-controlled Analgesia on Nausea Vomiting in Highly Susceptible Patients Undergoing Lumbar Spinal Surgery: Prospective Double Blinded Randomized Controlled Trial",[94],"2013-09",[10885],"PONV",[262,4996],{"nctId":10888,"briefTitle":10889,"status":204,"phases":10890,"primaryCompletion":4751,"completion":4751,"start":964,"enrollment":458,"conditions":10891,"interventions":10893},"NCT01691001","Effect of Dexmedetomidine on Sevoflurane Requirements and Emergence Agitation in Children Undergoing Ambulatory Surgery",[94],[10892],"Ambulation Difficulty",[5197,4996],{"nctId":10895,"briefTitle":10896,"status":204,"phases":10897,"primaryCompletion":10898,"completion":10898,"start":10899,"enrollment":7792,"conditions":10900,"interventions":10902},"NCT04836962","Does the Single Use of Intravenous Dexamethasone Enhance Analgesic Quality of Pudendal Analgesia in Children Undergoing Hypospadias Surgery?",[94],"2022-01-31","2021-05-07",[10901],"Pediatric Patients Undergoing Hypospadias Surgery",[4996,10903],"dexamethasone",{"nctId":10905,"briefTitle":10906,"status":204,"phases":10907,"primaryCompletion":8418,"completion":8418,"start":7546,"enrollment":1980,"conditions":10908,"interventions":10910},"NCT03370588","The Influence of Perioperative Administration of Dexmedetomidine on Inflammation Response and Postoperative Outcomes in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Double Blind Randomized Controlled Trial",[94],[10909],"Colon Cancer",[262,6456],{"nctId":10912,"briefTitle":10913,"status":308,"phases":10914,"primaryCompletion":8052,"completion":8052,"start":10160,"enrollment":1343,"conditions":10915,"interventions":10917},"NCT02698930","Effect of Dexmedetomidine on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery",[94],[10916],"Infective Endocarditis",[262,6456],{"nctId":10919,"briefTitle":10920,"status":204,"phases":10921,"primaryCompletion":6852,"completion":6852,"start":4201,"enrollment":10922,"conditions":10923,"interventions":10924},"NCT01617694","Comparison Between Remifentanil Target-controlled Infusion and Dexmedetomidine Bolus Administration for Smooth Emergence From General Sevoflurane Anesthesia",[94],65,[3939],[262,10925],"Normal Saline",{"nctId":10927,"briefTitle":10928,"status":204,"phases":10929,"primaryCompletion":10930,"completion":10930,"start":10931,"enrollment":2661,"conditions":10932,"interventions":10934},"NCT02311517","The Effects of Serratus Anterior Plane Block on Postoperative Quality of Recovery and Analgesia After Video-assisted Thoracoscopic Surgery",[94],"2016-07-28","2014-01-28",[10933],"Postoperative Quality of Recovery and Analgesia After Video-assisted Thoracoscopic Surgery",[5198,10925],{"nctId":10936,"briefTitle":10937,"status":204,"phases":10938,"primaryCompletion":979,"completion":979,"start":3469,"enrollment":1678,"conditions":10939,"interventions":10941},"NCT02490657","Effects of Iloprost on Pulmonary Hemodynamics and Oxygenation in Patients of Chronic Obstructive Pulmonary Disease During One-lung Ventilation",[94],[10940,2664],"Video-assisted Thoracoscopic Surgery",[10942,4996],"Inhaled iloprost",{"nctId":10944,"briefTitle":10945,"status":204,"phases":10946,"primaryCompletion":10947,"completion":10947,"start":10948,"enrollment":10949,"conditions":10950,"interventions":10951},"NCT01840241","Effect of Sodium Bicarbonate on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass (OPCAB)",[94],"2015-10-20","2013-04-01",162,[4252],[10952,4996],"sodium bicarbonate",{"nctId":10954,"briefTitle":10955,"status":204,"phases":10956,"primaryCompletion":10957,"completion":10957,"start":10958,"enrollment":233,"conditions":10959,"interventions":10961},"NCT02643017","Effect of Dexmedetomidine on Postoperative Cognitive Function in Patients Undergoing Shoulder Arthroscopy With Beach Chair Position Under Desflurane Anesthesia",[94],"2018-08-16","2015-12-11",[10960],"Rotator Cuff Tear",[5197,4996],{"nctId":10963,"briefTitle":10964,"status":204,"phases":10965,"primaryCompletion":10966,"completion":10966,"start":3729,"enrollment":9739,"conditions":10967,"interventions":10969},"NCT02648958","Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations",[94],"2017-07-31",[10968],"Arthroplasty, Replacement",[5197,4996],{"nctId":10971,"briefTitle":10972,"status":204,"phases":10973,"primaryCompletion":10686,"completion":10686,"start":10974,"enrollment":458,"conditions":10975,"interventions":10976},"NCT02784899","Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung Ventilation",[94],"2015-10-08",[7802],[10977,4996],"iloprost",{"nctId":10979,"briefTitle":10980,"status":204,"phases":10981,"primaryCompletion":10982,"completion":10983,"start":9547,"enrollment":10984,"conditions":10985,"interventions":10986},"NCT03232125","Effect of Ramosetron on Heart Rate-corrected QT Interval During Robot-assisted Laparoscopic Prostatectomy With Steep Trendelenburg Position",[94],"2020-06-09","2020-06-12",54,[35],[10987,6456],"Ramosetron",{"nctId":10989,"briefTitle":10990,"status":204,"phases":10991,"primaryCompletion":1500,"completion":1500,"start":963,"enrollment":3775,"conditions":10992,"interventions":10994},"NCT02258906","Effect of Ulinastatin on Postoperative Renal Function in Patients Undergoing Robot-assisted Laparoscopic Partial Nephrectomy",[94],[10993],"Renal Mass",[10995,4996],"ulinastatin",{"nctId":10997,"briefTitle":10998,"status":308,"phases":10999,"primaryCompletion":5123,"completion":3729,"start":7085,"enrollment":2661,"conditions":11000,"interventions":11002},"NCT02152787","Comparison of Propofol 1mg\u002Fkg and Propofol 0.5mg\u002Fkg for Prevention of Emergence Agitation in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia",[94],[11001],"Strabismus",[11003,11004,4996],"Injection of propofol 1.0mg\u002Fkg","propofol 0.5mg\u002Fkg",{"nctId":11006,"briefTitle":11007,"status":204,"phases":11008,"primaryCompletion":1047,"completion":1047,"start":5743,"enrollment":11009,"conditions":11010,"interventions":11011},"NCT02537249","Effects of Dexmedetomidine on Quality of Recovery and Analgesia After Video-assisted Thoracoscopic Surgery",[94],111,[7802,10940],[5197,6456],{"nctId":11013,"briefTitle":11014,"status":204,"phases":11015,"primaryCompletion":11016,"completion":11016,"start":11017,"enrollment":9277,"conditions":11018,"interventions":11020},"NCT04061057","Effect of Perioperative Intravenous Lidocaine Infusion on Postoperative Recovery in Patients Undergoing Arthroscopic Rotator Cuff Repair Under General Anesthesia",[94],"2019-02-11","2018-03-19",[11019],"Rotator Cuff Tears",[11021,6456],"Lidocaine",{"nctId":11023,"briefTitle":11024,"status":308,"phases":11025,"primaryCompletion":10005,"completion":10005,"start":4727,"enrollment":222,"conditions":11026,"interventions":11028},"NCT03588988","Effect of Dexmedetomidine on Postoperative Delirium Inflammasome Activation Inhibition",[94],[11027],"Patients Under Hip, Femur, Spine Operation",[11029,6456],"Dexmedetomidine IV",{"nctId":11031,"briefTitle":11032,"status":308,"phases":11033,"primaryCompletion":10598,"completion":10598,"start":8613,"enrollment":1886,"conditions":11034,"interventions":11038},"NCT03094182","Efficacy of Intravenous Iron Therapy in Maintaining Hemoglobin Concentration on Patients Undergoing Bimaxillary Orthognathic Surgery",[94],[11035,11036,11037],"Facial Asymmetry","Retrognathism","Prognathism",[11039,6456],"Iron Isomaltoside 1000",{"intervention":5197,"totalTrials":1166,"cells":11041},{"EARLY_PHASE1":11042,"PHASE1":11044,"PHASE2":11046,"PHASE3":11048,"PHASE4":11050,"NA":11077},{"trials":11043,"activeCount":102},[],{"trials":11045,"activeCount":102},[],{"trials":11047,"activeCount":102},[],{"trials":11049,"activeCount":102},[],{"trials":11051,"activeCount":102},[11052,11059,11066,11073],{"nctId":11053,"briefTitle":11054,"status":204,"phases":11055,"primaryCompletion":3657,"completion":3658,"start":320,"enrollment":1842,"conditions":11056,"interventions":11058},"NCT01774305","Effect of Single-dose Dexmedetomidine on Airway Reflex in Adult With Oral Intubation After Thyroidectomy",[93],[11057],"Coughing",[5197,6572],{"nctId":11060,"briefTitle":11061,"status":204,"phases":11062,"primaryCompletion":3657,"completion":3657,"start":6131,"enrollment":4966,"conditions":11063,"interventions":11065},"NCT01524367","Effect of Single-dose Dexmedetomidine on Emergence Excitement in Adults With Nasotracheal Intubation After Orthognathic Surgery",[93],[11064],"Agitation",[3941,5197],{"nctId":11067,"briefTitle":11068,"status":308,"phases":11069,"primaryCompletion":4775,"completion":4775,"start":11070,"enrollment":522,"conditions":11071,"interventions":11072},"NCT01886079","The Effects of Dexmedetomidine on Postoperative Renal Function in Valvular Heart Surgery",[93],"2013-05",[4252],[262,6572],{"nctId":5186,"briefTitle":5187,"status":204,"phases":11074,"primaryCompletion":5189,"completion":5189,"start":5190,"enrollment":458,"conditions":11075,"interventions":11076},[93],[5192,5193,5194,5195],[5197,5173,5198],{"trials":11078,"activeCount":102},[11079,11087,11097,11104,11113,11117,11126,11130,11134,11141,11149,11155,11159,11163,11167,11176,11183,11187,11191,11195,11202,11209,11218,11222],{"nctId":11080,"briefTitle":11081,"status":204,"phases":11082,"primaryCompletion":11083,"completion":3774,"start":3452,"enrollment":2363,"conditions":11084,"interventions":11086},"NCT01224470","The Effects of Intravenous Dexmedetomidine on Spinal Anesthesia Using Low Dose Diluted Bupivacaine for Transurethral Resection of Prostate",[94],"2011-01",[11085],"Transurethral Prostatectomy",[5197],{"nctId":11088,"briefTitle":11089,"status":204,"phases":11090,"primaryCompletion":11091,"completion":11091,"start":11092,"enrollment":458,"conditions":11093,"interventions":11095},"NCT06037135","Dexmedetomidine Infusion During Laparoscopic Adrenalectomy",[94],"2021-03-26","2012-12-03",[11094],"Pheochromocytoma",[262,11096],"0.9% normal saline",{"nctId":11098,"briefTitle":11099,"status":204,"phases":11100,"primaryCompletion":9501,"completion":3866,"start":3798,"enrollment":11101,"conditions":11102,"interventions":11103},"NCT01548209","Effects of a Dexmedetomidine on Quality of Recovery 40 and Postoperative Nausea and Vomiting in Breast Cancer Surgery",[94],97,[30],[5197],{"nctId":11105,"briefTitle":11106,"status":204,"phases":11107,"primaryCompletion":10883,"completion":10883,"start":4751,"enrollment":11108,"conditions":11109,"interventions":11112},"NCT01665586","Effective Dose of Dexmedetomidine for Sedation in Patients Undergoing TURP\u002FTURB Under Spinal Anesthesia With or Without Fentanyl by Age Groups: Randomized Comparative Study",[94],82,[11110,11111],"Benign Prostate Hyperplasia","Bladder Tumor",[262],{"nctId":10873,"briefTitle":10874,"status":204,"phases":11114,"primaryCompletion":5743,"completion":5743,"start":3469,"enrollment":458,"conditions":11115,"interventions":11116},[94],[10877],[5197,4996],{"nctId":11118,"briefTitle":11119,"status":204,"phases":11120,"primaryCompletion":11121,"completion":11121,"start":11122,"enrollment":5660,"conditions":11123,"interventions":11125},"NCT02607163","The Effect of Dexmedetomidine on Prevention of Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery",[94],"2019-03-06","2015-09",[11124],"Acute Kidney Injury(Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery)",[262,3941],{"nctId":10880,"briefTitle":10881,"status":204,"phases":11127,"primaryCompletion":10883,"completion":10883,"start":3730,"enrollment":5660,"conditions":11128,"interventions":11129},[94],[10885],[262,4996],{"nctId":10888,"briefTitle":10889,"status":204,"phases":11131,"primaryCompletion":4751,"completion":4751,"start":964,"enrollment":458,"conditions":11132,"interventions":11133},[94],[10892],[5197,4996],{"nctId":11135,"briefTitle":11136,"status":204,"phases":11137,"primaryCompletion":11070,"completion":11070,"start":9501,"enrollment":3687,"conditions":11138,"interventions":11140},"NCT01687868","Evaluation of Efficacy and Safety of General Anesthesia Using Dexmedetomidine With Sevoflurane in Patients Undergoing Arthroscopic Shoulder Surgery: Preliminary Study",[94],[11139],"Arthroscopic Shoulder Surgery in the Beach-chair Position",[5197],{"nctId":11142,"briefTitle":11143,"status":204,"phases":11144,"primaryCompletion":980,"completion":980,"start":5575,"enrollment":1886,"conditions":11145,"interventions":11147},"NCT02375191","A Comparative Study of the Effect of Epidural Dexmedetomidine Versus Fentanyl Added to Ropivacaine in Pediatric Orthopedic Surgery",[94],[11146],"Congenital Skelectal Anomaly",[11148,262,5198],"fentanyl",{"nctId":11150,"briefTitle":11151,"status":204,"phases":11152,"primaryCompletion":4751,"completion":4751,"start":3798,"enrollment":929,"conditions":11153,"interventions":11154},"NCT01512355","The Effect of Dexmedetomidine on Decreasing Emergence Agitation and Delirium in Pediatric Patients Undergoing Strabismus Surgery",[94],[11001],[5197],{"nctId":10905,"briefTitle":10906,"status":204,"phases":11156,"primaryCompletion":8418,"completion":8418,"start":7546,"enrollment":1980,"conditions":11157,"interventions":11158},[94],[10909],[262,6456],{"nctId":10912,"briefTitle":10913,"status":308,"phases":11160,"primaryCompletion":8052,"completion":8052,"start":10160,"enrollment":1343,"conditions":11161,"interventions":11162},[94],[10916],[262,6456],{"nctId":10919,"briefTitle":10920,"status":204,"phases":11164,"primaryCompletion":6852,"completion":6852,"start":4201,"enrollment":10922,"conditions":11165,"interventions":11166},[94],[3939],[262,10925],{"nctId":11168,"briefTitle":11169,"status":308,"phases":11170,"primaryCompletion":11171,"completion":11171,"start":11172,"enrollment":7086,"conditions":11173,"interventions":11175},"NCT03327389","Effect of Dexmedetomidine on Renal Function and Delayed Graft Function After Kidney Transplantation",[94],"2019-09-28","2017-11-01",[11174],"Kidney Transplantation",[5197],{"nctId":11177,"briefTitle":11178,"status":204,"phases":11179,"primaryCompletion":8015,"completion":8015,"start":3468,"enrollment":2614,"conditions":11180,"interventions":11182},"NCT02185430","Effects of Dexmedetomidine on Respiratory Mechanics and Oxygenation During One Lung Ventilation With Chronic Obstructive Lung Disease",[94],[11181],"COPD, One Lung Ventilation",[3941,262],{"nctId":10954,"briefTitle":10955,"status":204,"phases":11184,"primaryCompletion":10957,"completion":10957,"start":10958,"enrollment":233,"conditions":11185,"interventions":11186},[94],[10960],[5197,4996],{"nctId":253,"briefTitle":254,"status":204,"phases":11188,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":11189,"interventions":11190},[94],[260],[262,263,264],{"nctId":10963,"briefTitle":10964,"status":204,"phases":11192,"primaryCompletion":10966,"completion":10966,"start":3729,"enrollment":9739,"conditions":11193,"interventions":11194},[94],[10968],[5197,4996],{"nctId":11196,"briefTitle":11197,"status":204,"phases":11198,"primaryCompletion":3520,"completion":3520,"start":7383,"enrollment":258,"conditions":11199,"interventions":11201},"NCT01898819","The Effect of Dexmedetomidine in Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy",[94],[11200],"Steep Trendelenburg Position With Penumoperitoneum in Robot Assisted Laparoscopic Prostatectomy",[5197,3941],{"nctId":11203,"briefTitle":11204,"status":204,"phases":11205,"primaryCompletion":3729,"completion":3729,"start":5743,"enrollment":1243,"conditions":11206,"interventions":11208},"NCT02536014","Effect of Dexmedetomidine on Heart-rate Corrected QT(QTc) Interval Prolongation During Robotic-assisted Laparoscopic Radical Prostatectomy -Randomized Blind Clinical Trial-",[94],[35,11207],"Robotic Surgery",[5197,6572],{"nctId":11210,"briefTitle":11211,"status":204,"phases":11212,"primaryCompletion":11213,"completion":11213,"start":11214,"enrollment":2998,"conditions":11215,"interventions":11217},"NCT03960775","The Influence of Perioperative Administration of Dexmedetomidine on Inflammation Response and Postoperative Recovery in Patients Undergoing Robot or Laparoscopic Assisted Gastrectomy",[94],"2019-11-29","2019-04-30",[21,11216],"Gastrostomy",[262,3941],{"nctId":11006,"briefTitle":11007,"status":204,"phases":11219,"primaryCompletion":1047,"completion":1047,"start":5743,"enrollment":11009,"conditions":11220,"interventions":11221},[94],[7802,10940],[5197,6456],{"nctId":11223,"briefTitle":11224,"status":204,"phases":11225,"primaryCompletion":7211,"completion":7211,"start":4453,"enrollment":11226,"conditions":11227,"interventions":11228},"NCT02325882","The Postoperative Analgesic Effect of Combination With Dexmedetomidine in Fentanyl-based Intravenous Patient Controlled Analgesia Compared With Conventional Thoracic Epidural and Intravenous Patient Controlled Analgesia After Radical Open Gastrectomy",[94],171,[2918],[5197,11229,11230],"Fentanyl 1","Fentanyl 2",{"intervention":212,"totalTrials":3687,"cells":11232},{"EARLY_PHASE1":11233,"PHASE1":11235,"PHASE2":11237,"PHASE3":11239,"PHASE4":11241,"NA":11278},{"trials":11234,"activeCount":102},[],{"trials":11236,"activeCount":102},[],{"trials":11238,"activeCount":102},[],{"trials":11240,"activeCount":102},[],{"trials":11242,"activeCount":102},[11243,11247,11254,11262,11269],{"nctId":202,"briefTitle":203,"status":204,"phases":11244,"primaryCompletion":206,"completion":206,"start":207,"enrollment":208,"conditions":11245,"interventions":11246},[93],[210],[212,172],{"nctId":11248,"briefTitle":11249,"status":204,"phases":11250,"primaryCompletion":8851,"completion":8851,"start":7085,"enrollment":1243,"conditions":11251,"interventions":11252},"NCT02149628","The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide",[93],[35],[1023,11253],"Desflurane",{"nctId":11255,"briefTitle":11256,"status":204,"phases":11257,"primaryCompletion":7503,"completion":7503,"start":321,"enrollment":11258,"conditions":11259,"interventions":11261},"NCT01132157","Comparison of the Protective Effect of Desflurane and Propofol in Patients With Renal Transplantation",[93],99,[11260,3522],"Healthy",[11253,212],{"nctId":11263,"briefTitle":11264,"status":204,"phases":11265,"primaryCompletion":3889,"completion":3889,"start":4900,"enrollment":1010,"conditions":11266,"interventions":11268},"NCT01384643","Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery",[93],[11267],"Heart Valve Disease",[212],{"nctId":11270,"briefTitle":11271,"status":204,"phases":11272,"primaryCompletion":4775,"completion":4775,"start":9501,"enrollment":344,"conditions":11273,"interventions":11275},"NCT01895348","A Comparison of Surgical Outcome Following Drug-induced Sleep Endoscopic Diagnosis Using Propofol or Dexmedetomidine for Sedation : A Prospective Randomized Trial",[93],[11274],"Obstructive Sleep Apnea",[212,11276,11277],"propofol-remifentanil","Dexmedetomidine-remifentanil",{"trials":11279,"activeCount":102},[11280,11286,11296,11303,11312,11322,11326,11332,11339,11348,11355,11366,11375,11384],{"nctId":11281,"briefTitle":11282,"status":204,"phases":11283,"primaryCompletion":3452,"completion":3452,"start":3936,"enrollment":25,"conditions":11284,"interventions":11285},"NCT01244113","Optimal Dose of Propofol for Induction of Deep Sedation for Brain MRI Scanning in Children With Cerebral Palsy",[94],[8080],[1023],{"nctId":11287,"briefTitle":11288,"status":204,"phases":11289,"primaryCompletion":11290,"completion":11290,"start":11291,"enrollment":1243,"conditions":11292,"interventions":11294},"NCT05136508","The Effect of Volatile Anesthesia and Total Intravenous Anesthesia on Shedding of the Endothelial Glycocalyx in Patients Undergoing Mastectomy and Breast Reconstruction Using Deep Inferior Epigastric Artery Perforator Free Flap",[94],"2021-11-13","2021-05-21",[11293],"Deep Inferior Epigastric Artery Perforator Flap Breast Reconstruction",[212,11295],"Sevoflurane",{"nctId":11297,"briefTitle":11298,"status":1475,"phases":11299,"primaryCompletion":4225,"completion":4275,"start":5852,"enrollment":102,"conditions":11300,"interventions":11302},"NCT02003768","The Effect of Pnemoperitoneum on Intracranial Pressure and Cerebral Oxygenation During Laparoscopic Surgery According to Anesthesia Agents: Propofol Based Total Intravenous Anesthesia vs Desflurane Anesthesia",[94],[11301],"Optic Nerve Sheath",[212,11253],{"nctId":11304,"briefTitle":11305,"status":204,"phases":11306,"primaryCompletion":11307,"completion":11307,"start":11308,"enrollment":344,"conditions":11309,"interventions":11311},"NCT04415905","Comparison of Optic Nerve Sheath Diameter in Children Receiving Caudal Block According to Anesthetic Agents: Total Intravenous Anesthesia vs. Volatile Anesthesia",[94],"2022-03-02","2020-06-22",[11310],"Caudal Block for Postoperative Analgesia",[212,11295],{"nctId":11313,"briefTitle":11314,"status":204,"phases":11315,"primaryCompletion":11316,"completion":11316,"start":4775,"enrollment":11317,"conditions":11318,"interventions":11320},"NCT02458547","Effect of Anesthesia Technique on Outcome After Hip Fracture Surgery in Elderly Adult Patients",[94],"2019-01-21",186,[11319],"Hip Fracture",[11253,212,11321],"Bupivacaine",{"nctId":1005,"briefTitle":1006,"status":204,"phases":11323,"primaryCompletion":1008,"completion":1008,"start":1009,"enrollment":1010,"conditions":11324,"interventions":11325},[94],[1012],[986,212],{"nctId":11327,"briefTitle":11328,"status":1475,"phases":11329,"primaryCompletion":11122,"completion":11122,"start":5743,"enrollment":102,"conditions":11330,"interventions":11331},"NCT02515968","Comparison of Desflurane and Propofol on Quality of Recovery in Patients Undergoing Robotic or Laparoscopic Gastrectomy",[94],[24],[11253,212],{"nctId":11333,"briefTitle":11334,"status":204,"phases":11335,"primaryCompletion":3937,"completion":5399,"start":3451,"enrollment":1243,"conditions":11336,"interventions":11338},"NCT01084031","Dose Titration of Propofol for Tracheal Intubation in Children With Sevoflurane Inhalation Induction",[94],[11337],"Pediatric Urinary Disorders",[1023],{"nctId":11340,"briefTitle":11341,"status":204,"phases":11342,"primaryCompletion":11343,"completion":11343,"start":11344,"enrollment":1010,"conditions":11345,"interventions":11347},"NCT06359834","Comparison of Remimazolam and Propofol Effect on Oxygen Reserve During Endoscopic Retrograde Cholangiopancreatography",[94],"2024-08-29","2024-04-11",[11346],"Hepatobiiliary Diseases Requiring Endoscopic Retrograde Cholangiopancreatography",[239,212],{"nctId":11349,"briefTitle":11350,"status":204,"phases":11351,"primaryCompletion":9276,"completion":9276,"start":3912,"enrollment":8282,"conditions":11352,"interventions":11354},"NCT01232270","The Optimal Effect Site Concentration of Propofol for Conscious Sedation in Elderly Male Patients Undergoing Urologic Surgery Under Spinal Anesthesia With or Without Intrathecal Fentanyl",[94],[11353],"Conscious Sedation Under Spinal Anesthesia",[1023],{"nctId":11356,"briefTitle":11357,"status":204,"phases":11358,"primaryCompletion":11359,"completion":11359,"start":11360,"enrollment":11361,"conditions":11362,"interventions":11364},"NCT02174588","Moderate Sedation for Elective Upper Endoscopy With Balanced Propofol Versus Propofol Alone: a Randomized Clinical Trial",[94],"2015-02-04","2013-01-07",22,[11363],"EGD Procedure",[11365,1023],"Midazolam + propofol",{"nctId":11367,"briefTitle":11368,"status":204,"phases":11369,"primaryCompletion":11370,"completion":11370,"start":11371,"enrollment":258,"conditions":11372,"interventions":11374},"NCT05723627","Comparison of Remimazolam and Propofol Effect on Oxygenation Reservoir During Diagnostic Gastric Endoscopy",[94],"2023-09-21","2023-04-06",[11373],"Diagnostic Gastric Endoscopy",[239,212],{"nctId":11376,"briefTitle":11377,"status":204,"phases":11378,"primaryCompletion":11379,"completion":11379,"start":11380,"enrollment":3530,"conditions":11381,"interventions":11382},"NCT04183296","The Effect of Total Intravenous Anesthesia and Volatile Anesthesia on Shedding of the Endothelial Glycocalyx in Patients Undergoing Laparoscopic or Robotic Assisted Gastrectomy",[94],"2020-08-03","2019-11-28",[11216],[1023,11383],"sevoflurane",{"nctId":1015,"briefTitle":1016,"status":204,"phases":11385,"primaryCompletion":1018,"completion":1018,"start":1019,"enrollment":222,"conditions":11386,"interventions":11387},[94],[1021],[1023,986],{"intervention":6572,"totalTrials":3842,"cells":11389},{"EARLY_PHASE1":11390,"PHASE1":11392,"PHASE2":11394,"PHASE3":11396,"PHASE4":11398,"NA":11439},{"trials":11391,"activeCount":102},[],{"trials":11393,"activeCount":102},[],{"trials":11395,"activeCount":102},[],{"trials":11397,"activeCount":102},[],{"trials":11399,"activeCount":102},[11400,11404,11408,11412,11419,11423,11427,11435],{"nctId":11053,"briefTitle":11054,"status":204,"phases":11401,"primaryCompletion":3657,"completion":3658,"start":320,"enrollment":1842,"conditions":11402,"interventions":11403},[93],[11057],[5197,6572],{"nctId":3933,"briefTitle":3934,"status":204,"phases":11405,"primaryCompletion":3936,"completion":3936,"start":3937,"enrollment":1513,"conditions":11406,"interventions":11407},[93],[3939],[3920,3941],{"nctId":11060,"briefTitle":11061,"status":204,"phases":11409,"primaryCompletion":3657,"completion":3657,"start":6131,"enrollment":4966,"conditions":11410,"interventions":11411},[93],[11064],[3941,5197],{"nctId":11413,"briefTitle":11414,"status":204,"phases":11415,"primaryCompletion":6566,"completion":6566,"start":3584,"enrollment":1243,"conditions":11416,"interventions":11417},"NCT01394406","Effect of Ketamine Added to Intravenous Patient-controlled Analgesia on Postoperative Pain, Nausea and Vomiting in Patients Undergoing Lumbar Spinal Surgery",[93],[4009],[11418,6572],"Ketamine",{"nctId":11067,"briefTitle":11068,"status":308,"phases":11420,"primaryCompletion":4775,"completion":4775,"start":11070,"enrollment":522,"conditions":11421,"interventions":11422},[93],[4252],[262,6572],{"nctId":4897,"briefTitle":4898,"status":204,"phases":11424,"primaryCompletion":3657,"completion":3657,"start":4900,"enrollment":3775,"conditions":11425,"interventions":11426},[93],[4902],[4884,3941],{"nctId":11428,"briefTitle":11429,"status":204,"phases":11430,"primaryCompletion":11431,"completion":11431,"start":11432,"enrollment":258,"conditions":11433,"interventions":11434},"NCT01920126","The Effect of Sodium Bicarbonate on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery",[93],"2016-08-23","2013-08-13",[4252],[10952,6572],{"nctId":6563,"briefTitle":6564,"status":204,"phases":11436,"primaryCompletion":6566,"completion":6566,"start":6567,"enrollment":6568,"conditions":11437,"interventions":11438},[93],[6570],[6550,6572],{"trials":11440,"activeCount":102},[11441,11447,11451,11455,11459,11463,11470,11479],{"nctId":11442,"briefTitle":11443,"status":204,"phases":11444,"primaryCompletion":11122,"completion":11122,"start":3468,"enrollment":5921,"conditions":11445,"interventions":11446},"NCT02185859","Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Mastectomy",[94],[30],[11021,10812,6572],{"nctId":11118,"briefTitle":11119,"status":204,"phases":11448,"primaryCompletion":11121,"completion":11121,"start":11122,"enrollment":5660,"conditions":11449,"interventions":11450},[94],[11124],[262,3941],{"nctId":11177,"briefTitle":11178,"status":204,"phases":11452,"primaryCompletion":8015,"completion":8015,"start":3468,"enrollment":2614,"conditions":11453,"interventions":11454},[94],[11181],[3941,262],{"nctId":11196,"briefTitle":11197,"status":204,"phases":11456,"primaryCompletion":3520,"completion":3520,"start":7383,"enrollment":258,"conditions":11457,"interventions":11458},[94],[11200],[5197,3941],{"nctId":11203,"briefTitle":11204,"status":204,"phases":11460,"primaryCompletion":3729,"completion":3729,"start":5743,"enrollment":1243,"conditions":11461,"interventions":11462},[94],[35,11207],[5197,6572],{"nctId":11464,"briefTitle":11465,"status":308,"phases":11466,"primaryCompletion":11467,"completion":11467,"start":1458,"enrollment":222,"conditions":11468,"interventions":11469},"NCT03273231","The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection",[94],"2020-07",[32],[11418,6572],{"nctId":11471,"briefTitle":11472,"status":204,"phases":11473,"primaryCompletion":6340,"completion":6340,"start":9501,"enrollment":11009,"conditions":11474,"interventions":11476},"NCT01961752","The Efficacy of Topical Bupivacaine and Triamcinolone Acetonide Injection in the Relief of Pain After Endoscopic Submucosal Dissection for Gastric Neoplasia: A Randomized Double-blind, Placebo-controlled Trial",[94],[21,11475],"Gastric Adenoma",[6572,11477,11478],"Bupivacaine + saline","Bupivacaine + triamcinolone acetonide",{"nctId":11210,"briefTitle":11211,"status":204,"phases":11480,"primaryCompletion":11213,"completion":11213,"start":11214,"enrollment":2998,"conditions":11481,"interventions":11482},[94],[21,11216],[262,3941],{"intervention":5747,"totalTrials":11484,"cells":11485},7,{"EARLY_PHASE1":11486,"PHASE1":11488,"PHASE2":11490,"PHASE3":11492,"PHASE4":11494,"NA":11533},{"trials":11487,"activeCount":102},[],{"trials":11489,"activeCount":102},[],{"trials":11491,"activeCount":102},[],{"trials":11493,"activeCount":102},[],{"trials":11495,"activeCount":102},[11496,11503,11507,11516,11525],{"nctId":11497,"briefTitle":11498,"status":308,"phases":11499,"primaryCompletion":7502,"completion":3658,"start":6341,"enrollment":208,"conditions":11500,"interventions":11502},"NCT00917527","Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease",[93],[11501],"Coronary Heart Disease",[5747],{"nctId":5740,"briefTitle":5741,"status":308,"phases":11504,"primaryCompletion":5743,"completion":5743,"start":3936,"enrollment":3226,"conditions":11505,"interventions":11506},[93],[5745],[5747,5727],{"nctId":11508,"briefTitle":11509,"status":204,"phases":11510,"primaryCompletion":11511,"completion":11511,"start":11512,"enrollment":9870,"conditions":11513,"interventions":11515},"NCT02157337","The Effect of Atorvastatin on Prevention of Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery",[93],"2015-05-29","2014-03-12",[11514,4252],"Aortic Surgery",[5747],{"nctId":11517,"briefTitle":11518,"status":204,"phases":11519,"primaryCompletion":7844,"completion":7844,"start":11520,"enrollment":11521,"conditions":11522,"interventions":11523},"NCT01081548","A Clinical Trial Study to Evaluate Efficacy and Safety of Atorvastatin in Korean Patients With Hypercholesterolemia",[93],"2008-08",17,[2594],[11524,11524],"atorvastatin",{"nctId":11526,"briefTitle":11527,"status":204,"phases":11528,"primaryCompletion":1477,"start":4539,"enrollment":6912,"conditions":11529,"interventions":11532},"NCT00808717","Efficacy of High Dose atorvaSTATIN Loading Before Primary Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction (STATIN STEMI)",[93],[4542,11530,11531],"Angioplasty","Percutaneous Coronary",[5747],{"trials":11534,"activeCount":102},[11535,11545],{"nctId":11536,"briefTitle":11537,"status":308,"phases":11538,"primaryCompletion":11539,"completion":1288,"start":9659,"enrollment":11540,"conditions":11541,"interventions":11544},"NCT03414840","Assessment of Change in Atherosclerotic Plaque by Serial CCTA",[],"2020-02-28",400,[15,11542,11543],"Hydroxymethylglutaryl-CoA Reductase Inhibitors","Coronary Arteriosclerosis",[5747],{"nctId":11546,"briefTitle":11547,"status":308,"phases":11548,"primaryCompletion":1079,"completion":46,"start":11549,"enrollment":11550,"conditions":11551,"interventions":11553},"NCT05705804","Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial",[94],"2023-06-13",250,[664,11552],"Atherosclerotic Cardiovascular Disease",[11554,11555,5747],"Pitavastatin","Pitavastatin plus Ezetemibe",{"intervention":11253,"totalTrials":11484,"cells":11557},{"EARLY_PHASE1":11558,"PHASE1":11560,"PHASE2":11562,"PHASE3":11564,"PHASE4":11566,"NA":11576},{"trials":11559,"activeCount":102},[],{"trials":11561,"activeCount":102},[],{"trials":11563,"activeCount":102},[],{"trials":11565,"activeCount":102},[],{"trials":11567,"activeCount":102},[11568,11572],{"nctId":11248,"briefTitle":11249,"status":204,"phases":11569,"primaryCompletion":8851,"completion":8851,"start":7085,"enrollment":1243,"conditions":11570,"interventions":11571},[93],[35],[1023,11253],{"nctId":11255,"briefTitle":11256,"status":204,"phases":11573,"primaryCompletion":7503,"completion":7503,"start":321,"enrollment":11258,"conditions":11574,"interventions":11575},[93],[11260,3522],[11253,212],{"trials":11577,"activeCount":102},[11578,11587,11591,11595,11599],{"nctId":11579,"briefTitle":11580,"status":204,"phases":11581,"primaryCompletion":9275,"completion":9275,"start":3773,"enrollment":11582,"conditions":11583,"interventions":11585},"NCT01549990","A Comparison of Kidney Function After Nephrectomy in Living Donors Under Sevoflurane and Desflurane Anesthesia",[],236,[11584],"Nephrectomy,Kidney Donation",[11295,11586],"desflurane",{"nctId":11297,"briefTitle":11298,"status":1475,"phases":11588,"primaryCompletion":4225,"completion":4275,"start":5852,"enrollment":102,"conditions":11589,"interventions":11590},[94],[11301],[212,11253],{"nctId":11313,"briefTitle":11314,"status":204,"phases":11592,"primaryCompletion":11316,"completion":11316,"start":4775,"enrollment":11317,"conditions":11593,"interventions":11594},[94],[11319],[11253,212,11321],{"nctId":11327,"briefTitle":11328,"status":1475,"phases":11596,"primaryCompletion":11122,"completion":11122,"start":5743,"enrollment":102,"conditions":11597,"interventions":11598},[94],[24],[11253,212],{"nctId":11600,"briefTitle":11601,"status":204,"phases":11602,"primaryCompletion":11603,"completion":11603,"start":11604,"enrollment":11605,"conditions":11606,"interventions":11608},"NCT03539003","The Comparison of Changes of QTc, Tp-e Interval, and Tp-e\u002FQT Ratio, Tp-e\u002FQTc Ratio on the ECG During Robotic-assisted Laparoscopic Radical Prostatectomy Under Sevoflurane, Desflurane and Total Intravenous Anesthesia -Randomized Controlled Trial",[94],"2019-01-22","2018-05-31",69,[11607],"Robotic-assisted Laparoscopic Radical Prostatectomy",[11383,11586,4755],{"intervention":264,"totalTrials":173,"cells":11610},{"EARLY_PHASE1":11611,"PHASE1":11613,"PHASE2":11615,"PHASE3":11617,"PHASE4":11619,"NA":11642},{"trials":11612,"activeCount":102},[],{"trials":11614,"activeCount":102},[],{"trials":11616,"activeCount":102},[],{"trials":11618,"activeCount":102},[],{"trials":11620,"activeCount":102},[11621,11631,11638],{"nctId":11622,"briefTitle":11623,"status":204,"phases":11624,"primaryCompletion":3452,"completion":3452,"start":321,"enrollment":3687,"conditions":11625,"interventions":11629},"NCT01052324","The Effect Site Concentration of Remifentanil for Conscious Sedation During Awake Nasotracheal Fiberoptic Intubation",[93],[11626,11627,11628],"Cervical Disc Herniation","Cervical Spinal Stenosis","Cervical Spine Damage",[11630],"Remifentanil",{"nctId":11632,"briefTitle":11633,"status":204,"phases":11634,"primaryCompletion":11083,"completion":3774,"start":6567,"enrollment":258,"conditions":11635,"interventions":11637},"NCT01240109","Effect of Remifentanil on Cough During Emergence From General Anesthesia : Trial to Compare Between Sevoflurane Anesthesia and Propofol Anesthesia",[93],[11636],"Elective Thyroidectomy",[11630],{"nctId":4963,"briefTitle":4964,"status":204,"phases":11639,"primaryCompletion":3730,"completion":3730,"start":4900,"enrollment":4966,"conditions":11640,"interventions":11641},[93],[4968],[264,4950],{"trials":11643,"activeCount":102},[11644,11652,11656],{"nctId":11645,"briefTitle":11646,"status":204,"phases":11647,"primaryCompletion":4201,"completion":5398,"start":4249,"enrollment":7792,"conditions":11648,"interventions":11650},"NCT01175746","The Effect of Nicardipine on Kidney Function During Orthognathic Surgery Under Hypotensive Anesthesia",[94],[11649],"Healthy Subjects",[11651,264],"Nicardipine",{"nctId":253,"briefTitle":254,"status":204,"phases":11653,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":11654,"interventions":11655},[94],[260],[262,263,264],{"nctId":11657,"briefTitle":11658,"status":308,"phases":11659,"primaryCompletion":5166,"completion":5166,"start":206,"enrollment":344,"conditions":11660,"interventions":11662},"NCT01147757","Effect of Intraoperative Remifentanil Infusion Rate on Postoperative Tolerance and Analgesic Consumption in Pediatric Laparoscopic Ureteroneocystostomy",[94],[11661],"Pediatrics",[264],{"intervention":10903,"totalTrials":173,"cells":11664},{"EARLY_PHASE1":11665,"PHASE1":11667,"PHASE2":11669,"PHASE3":11671,"PHASE4":11673,"NA":11684},{"trials":11666,"activeCount":102},[],{"trials":11668,"activeCount":102},[],{"trials":11670,"activeCount":102},[],{"trials":11672,"activeCount":102},[],{"trials":11674,"activeCount":102},[11675],{"nctId":11676,"briefTitle":11677,"status":204,"phases":11678,"primaryCompletion":3936,"completion":6567,"start":207,"enrollment":11679,"conditions":11680,"interventions":11681},"NCT01007500","Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery",[93],123,[6525,6526],[11682,11683],"Dexamethasone","Ondansetron",{"trials":11685,"activeCount":102},[11686,11695,11703,11707,11714],{"nctId":11687,"briefTitle":11688,"status":243,"phases":11689,"primaryCompletion":4453,"completion":4453,"start":3519,"enrollment":11690,"conditions":11691,"interventions":11694},"NCT02224170","Comparison of Effect on Quality of Recovery Outcome Between Systemic Lidocaine and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy",[94],8,[11692,11693],"Gallbladder Polyp","Asymptomatic Gallstones Without Cholecystitis",[11021,11682],{"nctId":11696,"briefTitle":11697,"status":204,"phases":11698,"primaryCompletion":8353,"completion":8353,"start":3841,"enrollment":11699,"conditions":11700,"interventions":11702},"NCT01923831","Comparison of the Effect of Magnesium Sulfate and Dexamethasone on Postoperative Sore Throat After Spinal Surgery in Prone Position With Tracheal Intubation: a Double-blind, Randomized, Noninferiority Clinical Trial",[94],146,[11701],"Post Operative Sore Throat",[10812,10903],{"nctId":10895,"briefTitle":10896,"status":204,"phases":11704,"primaryCompletion":10898,"completion":10898,"start":10899,"enrollment":7792,"conditions":11705,"interventions":11706},[94],[10901],[4996,10903],{"nctId":11708,"briefTitle":11709,"status":204,"phases":11710,"primaryCompletion":899,"completion":899,"start":3584,"enrollment":233,"conditions":11711,"interventions":11713},"NCT01041378","Efficacy of Intravenous Dexamethasone on Postoperative Caudal Analgesia in Pediatric Orchiopexy",[94],[11712],"Pain",[10903],{"nctId":11715,"briefTitle":11716,"status":204,"phases":11717,"primaryCompletion":5399,"completion":5399,"start":4538,"enrollment":5660,"conditions":11718,"interventions":11719},"NCT01168531","The Effect of Pregabalin and Dexamethasone on Acute and Chronic Pain After Lumbar Spinal Surgery",[94],[11712],[11720,10903],"Pregabalin",{"intervention":10987,"totalTrials":885,"cells":11722},{"EARLY_PHASE1":11723,"PHASE1":11725,"PHASE2":11727,"PHASE3":11729,"PHASE4":11731,"NA":11742},{"trials":11724,"activeCount":102},[],{"trials":11726,"activeCount":102},[],{"trials":11728,"activeCount":102},[],{"trials":11730,"activeCount":102},[],{"trials":11732,"activeCount":102},[11733],{"nctId":11734,"briefTitle":11735,"status":204,"phases":11736,"primaryCompletion":11737,"completion":11737,"start":11738,"enrollment":192,"conditions":11739,"interventions":11740},"NCT02480088","Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 Polymorphism",[93],"2015-03-11","2014-09-22",[4009],[10987,11741],"Palonosetron",{"trials":11743,"activeCount":102},[11744,11753,11762,11766],{"nctId":11745,"briefTitle":11746,"status":204,"phases":11747,"primaryCompletion":9501,"completion":9501,"start":964,"enrollment":11748,"conditions":11749,"interventions":11750},"NCT01825733","Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery",[94],196,[4009],[11751,11752],"ramosetron","palonosetron",{"nctId":11754,"briefTitle":11755,"status":204,"phases":11756,"primaryCompletion":4201,"completion":4201,"start":4249,"enrollment":11757,"conditions":11758,"interventions":11760},"NCT01169805","Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery",[94],105,[11759],"Laparoscopic Marsupialization of Renal Cyst",[11683,10987,11741,11761],"Normal saline inj",{"nctId":10979,"briefTitle":10980,"status":204,"phases":11763,"primaryCompletion":10982,"completion":10983,"start":9547,"enrollment":10984,"conditions":11764,"interventions":11765},[94],[35],[10987,6456],{"nctId":11767,"briefTitle":11768,"status":204,"phases":11769,"primaryCompletion":11770,"completion":11770,"start":11771,"enrollment":233,"conditions":11772,"interventions":11774},"NCT03017222","Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery",[94],"2016-04-02","2015-09-07",[11773],"Abdominal Mass",[11683,10987],{"intervention":11295,"totalTrials":885,"cells":11776},{"EARLY_PHASE1":11777,"PHASE1":11779,"PHASE2":11781,"PHASE3":11783,"PHASE4":11785,"NA":11787},{"trials":11778,"activeCount":102},[],{"trials":11780,"activeCount":102},[],{"trials":11782,"activeCount":102},[],{"trials":11784,"activeCount":102},[],{"trials":11786,"activeCount":102},[],{"trials":11788,"activeCount":102},[11789,11793,11797,11801,11805],{"nctId":11579,"briefTitle":11580,"status":204,"phases":11790,"primaryCompletion":9275,"completion":9275,"start":3773,"enrollment":11582,"conditions":11791,"interventions":11792},[],[11584],[11295,11586],{"nctId":11287,"briefTitle":11288,"status":204,"phases":11794,"primaryCompletion":11290,"completion":11290,"start":11291,"enrollment":1243,"conditions":11795,"interventions":11796},[94],[11293],[212,11295],{"nctId":11304,"briefTitle":11305,"status":204,"phases":11798,"primaryCompletion":11307,"completion":11307,"start":11308,"enrollment":344,"conditions":11799,"interventions":11800},[94],[11310],[212,11295],{"nctId":11600,"briefTitle":11601,"status":204,"phases":11802,"primaryCompletion":11603,"completion":11603,"start":11604,"enrollment":11605,"conditions":11803,"interventions":11804},[94],[11607],[11383,11586,4755],{"nctId":11376,"briefTitle":11377,"status":204,"phases":11806,"primaryCompletion":11379,"completion":11379,"start":11380,"enrollment":3530,"conditions":11807,"interventions":11808},[94],[11216],[1023,11383],{"intervention":4683,"totalTrials":267,"cells":11810},{"EARLY_PHASE1":11811,"PHASE1":11813,"PHASE2":11815,"PHASE3":11817,"PHASE4":11830,"NA":11840},{"trials":11812,"activeCount":102},[],{"trials":11814,"activeCount":102},[],{"trials":11816,"activeCount":102},[],{"trials":11818,"activeCount":102},[11819],{"nctId":11820,"briefTitle":11821,"status":308,"phases":11822,"primaryCompletion":10092,"completion":10092,"start":5123,"enrollment":11823,"conditions":11824,"interventions":11827},"NCT02614339","Effect of Adjunctive Metformin on Recurrence of Non-DM Colorectal Cancer Stage II High-risk\u002F III Colorectal Cancer",[92],593,[11825,11826],"Non-DM Stage II High-risk Colorectal Cancer","Non-DM Stage III Colorectal Cancer",[11828,11829],"metformin","control",{"trials":11831,"activeCount":102},[11832,11836],{"nctId":4674,"briefTitle":4675,"status":204,"phases":11833,"primaryCompletion":4677,"completion":4678,"start":4679,"enrollment":222,"conditions":11834,"interventions":11835},[93],[4681,664],[4661,4683],{"nctId":5981,"briefTitle":5982,"status":308,"phases":11837,"primaryCompletion":5984,"completion":5984,"start":5985,"enrollment":5986,"conditions":11838,"interventions":11839},[93],[4252],[5968,4683],{"trials":11841,"activeCount":102},[11842],{"nctId":11843,"briefTitle":11844,"status":308,"phases":11845,"primaryCompletion":5984,"completion":5984,"start":11846,"enrollment":222,"conditions":11847,"interventions":11848},"NCT04598191","Effect of Intraoperative Iloprost Inhalant on Hemodynamic Stability in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery",[94],"2020-11-04",[5831],[11849,4683],"Iloprost",{"intervention":11741,"totalTrials":267,"cells":11851},{"EARLY_PHASE1":11852,"PHASE1":11854,"PHASE2":11856,"PHASE3":11858,"PHASE4":11860,"NA":11866},{"trials":11853,"activeCount":102},[],{"trials":11855,"activeCount":102},[],{"trials":11857,"activeCount":102},[],{"trials":11859,"activeCount":102},[],{"trials":11861,"activeCount":102},[11862],{"nctId":11734,"briefTitle":11735,"status":204,"phases":11863,"primaryCompletion":11737,"completion":11737,"start":11738,"enrollment":192,"conditions":11864,"interventions":11865},[93],[4009],[10987,11741],{"trials":11867,"activeCount":102},[11868,11872,11876],{"nctId":11745,"briefTitle":11746,"status":204,"phases":11869,"primaryCompletion":9501,"completion":9501,"start":964,"enrollment":11748,"conditions":11870,"interventions":11871},[94],[4009],[11751,11752],{"nctId":11754,"briefTitle":11755,"status":204,"phases":11873,"primaryCompletion":4201,"completion":4201,"start":4249,"enrollment":11757,"conditions":11874,"interventions":11875},[94],[11759],[11683,10987,11741,11761],{"nctId":11877,"briefTitle":11878,"status":204,"phases":11879,"primaryCompletion":11880,"completion":11880,"start":11881,"enrollment":11882,"conditions":11883,"interventions":11885},"NCT02744508","Comparison of Palonosetron Versus Combination of Palonosetron and Dexamethasone for Preventing Postoperative Vomiting in Patients Receiving Fentanyl by Patient-controlled Analgesia After Minor Orthopedic Surgery",[94],"2017-03-20","2015-07-24",202,[11884],"Orthopedic Surgery",[11752,11886],"palonosetron with dexamethasone",{"intervention":11888,"totalTrials":267,"cells":11889},"Sugammadex",{"EARLY_PHASE1":11890,"PHASE1":11892,"PHASE2":11894,"PHASE3":11896,"PHASE4":11898,"NA":11900},{"trials":11891,"activeCount":102},[],{"trials":11893,"activeCount":102},[],{"trials":11895,"activeCount":102},[],{"trials":11897,"activeCount":102},[],{"trials":11899,"activeCount":102},[],{"trials":11901,"activeCount":102},[11902,11911,11920,11929],{"nctId":11903,"briefTitle":11904,"status":308,"phases":11905,"primaryCompletion":10326,"completion":10326,"start":11906,"enrollment":2998,"conditions":11907,"interventions":11909},"NCT04545099","Comparison of the Impacts of Sugammadex With Neostigmine on Patency of Laryngeal Opening (Glottic Aperture Angle)",[94],"2020-09",[11908],"Supraglottic Airway Device Insertion",[11888,11910],"Neostigmine",{"nctId":11912,"briefTitle":11913,"status":204,"phases":11914,"primaryCompletion":7677,"completion":7677,"start":7085,"enrollment":1319,"conditions":11915,"interventions":11917},"NCT02109133","The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy",[94],[11916],"Robot-Assisted Laparoscopic Radical Prostatectomy",[11918,11888,11919,11910],"Rocuronium","Atracurium",{"nctId":11921,"briefTitle":11922,"status":204,"phases":11923,"primaryCompletion":11924,"completion":11924,"start":11925,"enrollment":2661,"conditions":11926,"interventions":11928},"NCT03108989","Comparison the Postoperative Quality of Recovery Between Neostigmine and Sugammadex in Elderly Patients Undergoing Trans Pars Plana Vitrectomy With General Anesthesia -Randomized Controlled Trial-",[94],"2017-07-25","2017-02-08",[11927],"Elderly Patients Undergoing Trans Pars Plana Vitrectomy With General Anesthesia",[11888,11910],{"nctId":11930,"briefTitle":11931,"status":204,"phases":11932,"primaryCompletion":963,"completion":963,"start":3631,"enrollment":1501,"conditions":11933,"interventions":11934},"NCT01980069","A Double-blind, Randomized, Parallel Design Study to Compare the Effectiveness of Sugammadex Versus Neostigmine in Improving Surgical Condition in Subjects Undergoing Laryngeal Microsurgery",[94],[24],[11888,11910],{"intervention":11910,"totalTrials":267,"cells":11936},{"EARLY_PHASE1":11937,"PHASE1":11939,"PHASE2":11941,"PHASE3":11943,"PHASE4":11945,"NA":11947},{"trials":11938,"activeCount":102},[],{"trials":11940,"activeCount":102},[],{"trials":11942,"activeCount":102},[],{"trials":11944,"activeCount":102},[],{"trials":11946,"activeCount":102},[],{"trials":11948,"activeCount":102},[11949,11953,11957,11961],{"nctId":11903,"briefTitle":11904,"status":308,"phases":11950,"primaryCompletion":10326,"completion":10326,"start":11906,"enrollment":2998,"conditions":11951,"interventions":11952},[94],[11908],[11888,11910],{"nctId":11912,"briefTitle":11913,"status":204,"phases":11954,"primaryCompletion":7677,"completion":7677,"start":7085,"enrollment":1319,"conditions":11955,"interventions":11956},[94],[11916],[11918,11888,11919,11910],{"nctId":11921,"briefTitle":11922,"status":204,"phases":11958,"primaryCompletion":11924,"completion":11924,"start":11925,"enrollment":2661,"conditions":11959,"interventions":11960},[94],[11927],[11888,11910],{"nctId":11930,"briefTitle":11931,"status":204,"phases":11962,"primaryCompletion":963,"completion":963,"start":3631,"enrollment":1501,"conditions":11963,"interventions":11964},[94],[24],[11888,11910],{"intervention":11966,"totalTrials":267,"cells":11967},"Propacetamol",{"EARLY_PHASE1":11968,"PHASE1":11970,"PHASE2":11972,"PHASE3":11974,"PHASE4":11976,"NA":11978},{"trials":11969,"activeCount":102},[],{"trials":11971,"activeCount":102},[],{"trials":11973,"activeCount":102},[],{"trials":11975,"activeCount":102},[],{"trials":11977,"activeCount":102},[],{"trials":11979,"activeCount":102},[11980,11988,11995,12008],{"nctId":11981,"briefTitle":11982,"status":204,"phases":11983,"primaryCompletion":11431,"completion":11431,"start":11984,"enrollment":2998,"conditions":11985,"interventions":11986},"NCT02577068","Combination Effect of Nefopam With Propacetamol for Postoperative Pain After Thyroidectomy",[94],"2015-11-15",[5126,11712],[11987,11966],"Nefopam",{"nctId":11989,"briefTitle":11990,"status":204,"phases":11991,"primaryCompletion":4453,"completion":4453,"start":3631,"enrollment":5660,"conditions":11992,"interventions":11993},"NCT02116257","The Opioid-sparing Effect and Reduced PONV Using Propacetamol in PCA Among Patients With High Risk of PONV",[94],[10885,11966],[11966,11994],"PCA regimen",{"nctId":11996,"briefTitle":11997,"status":204,"phases":11998,"primaryCompletion":11999,"completion":12000,"start":12001,"enrollment":12002,"conditions":12003,"interventions":12004},"NCT03352362","Comparison of the Effect of Propacetamol, Ibuprofen or Their Combination on Postoperative Pain and Quality of Recovery After Laparoscopic Hernia Repair in Children",[94],"2019-03-08","2019-03-09","2017-12-15",159,[10854],[12005,12006,12007],"ibuprofen","propacetamol","ibuprofen + propacetamol",{"nctId":12009,"briefTitle":12010,"status":204,"phases":12011,"primaryCompletion":12012,"completion":12012,"start":12013,"enrollment":9277,"conditions":12014,"interventions":12016},"NCT02515188","The Effect of Additional Propacetamol Infusion on Post Procedural Outcome and Opioid Consumption During Catheter Ablation of Atrial Fibrillation.",[94],"2016-06-23","2015-08-07",[12015],"Arrhythmia",[11966],{"intervention":4431,"totalTrials":267,"cells":12018},{"EARLY_PHASE1":12019,"PHASE1":12021,"PHASE2":12023,"PHASE3":12025,"PHASE4":12027,"NA":12043},{"trials":12020,"activeCount":102},[],{"trials":12022,"activeCount":102},[],{"trials":12024,"activeCount":102},[],{"trials":12026,"activeCount":102},[],{"trials":12028,"activeCount":102},[12029,12033],{"nctId":4422,"briefTitle":4423,"status":204,"phases":12030,"primaryCompletion":4425,"completion":4425,"start":4426,"enrollment":4427,"conditions":12031,"interventions":12032},[93],[4429,664],[4431,4409],{"nctId":12034,"briefTitle":12035,"status":204,"phases":12036,"primaryCompletion":5166,"completion":12037,"start":12038,"enrollment":12039,"conditions":12040,"interventions":12042},"NCT01971606","Impact of High-dose Pretreatment of Rosuvastatin in Patients With Acute Coronary Syndrome Following Off-pump Coronary Artery Bypass: Results From the HIROP-ACS (HIgh-dose Pretreatment of Rosuvastatin During Off-Pump Coronary Bypass in Acute Coronary Syndrome) Study",[93],"2013-03","2007-10",234,[12041],"A Total of 234 Patients With Acute Coronary Syndrome Who Will Undergo OPCAB.",[4431],{"trials":12044,"activeCount":102},[12045,12057],{"nctId":12046,"briefTitle":12047,"status":308,"phases":12048,"primaryCompletion":12049,"completion":12050,"start":2612,"enrollment":12051,"conditions":12052,"interventions":12055},"NCT03044665","RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin\u002FEzetimibe Combination for High-risk Cardiovascular Diseases (RACING Trial)",[94],"2022-01-15","2023-02-15",3780,[156,12053,12054],"Cerebrovascular Disease","Peripheral Atherosclerotic Disease",[4431,12056],"Rosuvastatin plus ezetimibe",{"nctId":12058,"briefTitle":12059,"status":204,"phases":12060,"primaryCompletion":12061,"completion":12061,"start":12062,"enrollment":12063,"conditions":12064,"interventions":12065},"NCT01872845","A Trial Comparing the Effect of Pravastatin and Rosuvastatin on Atherosclerosis Progression Measured by Carotid Intima Media Thickness in Patients With Coronary Artery Disease After Biolimus Eluting Stent (Nobori®) Implantation: CPR IMT",[94],"2017-05-25","2013-06-12",671,[5831],[12066,4431],"Pravastatin 40mg",{"intervention":11021,"totalTrials":267,"cells":12068},{"EARLY_PHASE1":12069,"PHASE1":12071,"PHASE2":12073,"PHASE3":12075,"PHASE4":12077,"NA":12079},{"trials":12070,"activeCount":102},[],{"trials":12072,"activeCount":102},[],{"trials":12074,"activeCount":102},[],{"trials":12076,"activeCount":102},[],{"trials":12078,"activeCount":102},[],{"trials":12080,"activeCount":102},[12081,12085,12089,12093],{"nctId":11442,"briefTitle":11443,"status":204,"phases":12082,"primaryCompletion":11122,"completion":11122,"start":3468,"enrollment":5921,"conditions":12083,"interventions":12084},[94],[30],[11021,10812,6572],{"nctId":11687,"briefTitle":11688,"status":243,"phases":12086,"primaryCompletion":4453,"completion":4453,"start":3519,"enrollment":11690,"conditions":12087,"interventions":12088},[94],[11692,11693],[11021,11682],{"nctId":11013,"briefTitle":11014,"status":204,"phases":12090,"primaryCompletion":11016,"completion":11016,"start":11017,"enrollment":9277,"conditions":12091,"interventions":12092},[94],[11019],[11021,6456],{"nctId":12094,"briefTitle":12095,"status":204,"phases":12096,"primaryCompletion":963,"completion":963,"start":3520,"enrollment":3250,"conditions":12097,"interventions":12098},"NCT02018276","Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Thyroid Surgery",[94],[9480],[11021,12099],"Magnesium",{"intervention":12101,"totalTrials":267,"cells":12102},"Metformin",{"EARLY_PHASE1":12103,"PHASE1":12105,"PHASE2":12107,"PHASE3":12116,"PHASE4":12122,"NA":12124},{"trials":12104,"activeCount":102},[],{"trials":12106,"activeCount":102},[],{"trials":12108,"activeCount":102},[12109],{"nctId":12110,"briefTitle":12111,"status":204,"phases":12112,"primaryCompletion":1242,"completion":1242,"start":12113,"enrollment":8442,"conditions":12114,"interventions":12115},"NCT01725490","The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study",[91],"2013-02-15",[1168],[12101,12101],{"trials":12117,"activeCount":102},[12118],{"nctId":11820,"briefTitle":11821,"status":308,"phases":12119,"primaryCompletion":10092,"completion":10092,"start":5123,"enrollment":11823,"conditions":12120,"interventions":12121},[92],[11825,11826],[11828,11829],{"trials":12123,"activeCount":102},[],{"trials":12125,"activeCount":102},[12126,12133],{"nctId":12127,"briefTitle":12128,"status":204,"phases":12129,"primaryCompletion":3798,"completion":3798,"start":4703,"enrollment":22,"conditions":12130,"interventions":12132},"NCT01274130","Investigatory Study of Metformin's Pharmacokinetics, Pharmacodynamics and Drug Drug Interactions Classifying the Group by MATE1 Genotype in Healthy Volunteers",[94],[12131],"Healthy Adult",[12101],{"nctId":12134,"briefTitle":12135,"status":308,"phases":12136,"primaryCompletion":3249,"completion":3249,"start":7677,"enrollment":233,"conditions":12137,"interventions":12139},"NCT02535975","The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy",[94],[12138],"Mild Graves' Ophthalmopathy",[12101],{"intervention":12141,"totalTrials":267,"cells":12142},"chemotherapy",{"EARLY_PHASE1":12143,"PHASE1":12145,"PHASE2":12147,"PHASE3":12174,"PHASE4":12176,"NA":12178},{"trials":12144,"activeCount":102},[],{"trials":12146,"activeCount":102},[],{"trials":12148,"activeCount":102},[12149,12158,12167],{"nctId":12150,"briefTitle":12151,"status":204,"phases":12152,"primaryCompletion":12153,"completion":12153,"start":12154,"enrollment":344,"conditions":12155,"interventions":12157},"NCT01648517","Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy",[91],"2015-06-30","2012-07-27",[12156],"Non-small Cell Lung Carcinoma",[12141,12141],{"nctId":12159,"briefTitle":12160,"status":1475,"phases":12161,"primaryCompletion":8896,"completion":8896,"start":12162,"enrollment":102,"conditions":12163,"interventions":12165},"NCT05512182","Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent\u002FAdvanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification\u002FOverexpression",[91],"2022-09-15",[12164],"Recurrent\u002FAdvanced Gastric Cancer",[12166],"Chemotherapy",{"nctId":12168,"briefTitle":12169,"status":308,"phases":12170,"primaryCompletion":5374,"completion":6109,"start":4451,"enrollment":458,"conditions":12171,"interventions":12173},"NCT03022734","Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis",[91],[12172],"Rectal Cancer, Metastatic",[12141],{"trials":12175,"activeCount":102},[],{"trials":12177,"activeCount":102},[],{"trials":12179,"activeCount":102},[12180],{"nctId":12181,"briefTitle":12182,"status":204,"phases":12183,"primaryCompletion":12184,"completion":12184,"start":4857,"enrollment":11550,"conditions":12185,"interventions":12187},"NCT03491033","Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy",[],"2017-10-31",[12186],"Advanced-stage Ovarian Cancer",[12141],{"intervention":11683,"totalTrials":267,"cells":12189},{"EARLY_PHASE1":12190,"PHASE1":12192,"PHASE2":12194,"PHASE3":12196,"PHASE4":12198,"NA":12204},{"trials":12191,"activeCount":102},[],{"trials":12193,"activeCount":102},[],{"trials":12195,"activeCount":102},[],{"trials":12197,"activeCount":102},[],{"trials":12199,"activeCount":102},[12200],{"nctId":11676,"briefTitle":11677,"status":204,"phases":12201,"primaryCompletion":3936,"completion":6567,"start":207,"enrollment":11679,"conditions":12202,"interventions":12203},[93],[6525,6526],[11682,11683],{"trials":12205,"activeCount":102},[12206,12216,12220],{"nctId":12207,"briefTitle":12208,"status":204,"phases":12209,"primaryCompletion":12210,"completion":12210,"start":3520,"enrollment":5124,"conditions":12211,"interventions":12213},"NCT02026778","Comparison of the Effect of Ondansetron and Combined Ondansetron and Betahistine on Postoperative Nausea and Vomiting After Gynecological Laparoscopy",[94],"2014-11-11",[12212],"Nausea and Vomiting",[12214,12215],"ondansetron","ondansetron-betahistine",{"nctId":11754,"briefTitle":11755,"status":204,"phases":12217,"primaryCompletion":4201,"completion":4201,"start":4249,"enrollment":11757,"conditions":12218,"interventions":12219},[94],[11759],[11683,10987,11741,11761],{"nctId":11767,"briefTitle":11768,"status":204,"phases":12221,"primaryCompletion":11770,"completion":11770,"start":11771,"enrollment":233,"conditions":12222,"interventions":12223},[94],[11773],[11683,10987],{"intervention":5198,"totalTrials":267,"cells":12225},{"EARLY_PHASE1":12226,"PHASE1":12228,"PHASE2":12230,"PHASE3":12232,"PHASE4":12234,"NA":12248},{"trials":12227,"activeCount":102},[],{"trials":12229,"activeCount":102},[],{"trials":12231,"activeCount":102},[],{"trials":12233,"activeCount":102},[],{"trials":12235,"activeCount":102},[12236,12244],{"nctId":12237,"briefTitle":12238,"status":204,"phases":12239,"primaryCompletion":11083,"completion":4201,"start":4249,"enrollment":12240,"conditions":12241,"interventions":12242},"NCT01234272","Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study-",[93],59,[21],[12243,5198],"morphine",{"nctId":5186,"briefTitle":5187,"status":204,"phases":12245,"primaryCompletion":5189,"completion":5189,"start":5190,"enrollment":458,"conditions":12246,"interventions":12247},[93],[5192,5193,5194,5195],[5197,5173,5198],{"trials":12249,"activeCount":102},[12250,12254],{"nctId":11142,"briefTitle":11143,"status":204,"phases":12251,"primaryCompletion":980,"completion":980,"start":5575,"enrollment":1886,"conditions":12252,"interventions":12253},[94],[11146],[11148,262,5198],{"nctId":10927,"briefTitle":10928,"status":204,"phases":12255,"primaryCompletion":10930,"completion":10930,"start":10931,"enrollment":2661,"conditions":12256,"interventions":12257},[94],[10933],[5198,10925],{"intervention":10841,"totalTrials":946,"cells":12259},{"EARLY_PHASE1":12260,"PHASE1":12262,"PHASE2":12264,"PHASE3":12266,"PHASE4":12268,"NA":12276},{"trials":12261,"activeCount":102},[],{"trials":12263,"activeCount":102},[],{"trials":12265,"activeCount":102},[],{"trials":12267,"activeCount":102},[],{"trials":12269,"activeCount":102},[12270],{"nctId":12271,"briefTitle":12272,"status":204,"phases":12273,"primaryCompletion":6567,"completion":6567,"start":3451,"enrollment":2661,"conditions":12274,"interventions":12275},"NCT01067638","The Effect of Tranexamic Acid on Postoperative Blood Loss and Coagulation in Patients With Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft; Double Blind Randomized Control Study",[93],[5831],[10841],{"trials":12277,"activeCount":102},[12278,12282],{"nctId":10835,"briefTitle":10836,"status":204,"phases":12279,"primaryCompletion":7211,"completion":7211,"start":3658,"enrollment":1243,"conditions":12280,"interventions":12281},[94],[10839],[10841,4996],{"nctId":12283,"briefTitle":12284,"status":204,"phases":12285,"primaryCompletion":12286,"completion":12286,"start":12287,"enrollment":12288,"conditions":12289,"interventions":12291},"NCT03697681","Protective Effect of Tranexamic Acid on Shedding of the Endothelial Glycocalyx in Patients Undergoing Spinal Fusion Surgery",[94],"2020-08-12","2018-10-16",128,[12290],"Posterior Lumbar Spinal Fusion Surgery",[12292,12293],"Tranexamic acid","0.9% NaCl",{"intervention":10848,"totalTrials":946,"cells":12295},{"EARLY_PHASE1":12296,"PHASE1":12298,"PHASE2":12300,"PHASE3":12302,"PHASE4":12304,"NA":12306},{"trials":12297,"activeCount":102},[],{"trials":12299,"activeCount":102},[],{"trials":12301,"activeCount":102},[],{"trials":12303,"activeCount":102},[],{"trials":12305,"activeCount":102},[],{"trials":12307,"activeCount":102},[12308,12312,12316],{"nctId":10843,"briefTitle":10844,"status":204,"phases":12309,"primaryCompletion":4453,"completion":4775,"start":7383,"enrollment":2661,"conditions":12310,"interventions":12311},[94],[9480],[10848,4996],{"nctId":10850,"briefTitle":10851,"status":204,"phases":12313,"primaryCompletion":3519,"completion":5575,"start":3631,"enrollment":3775,"conditions":12314,"interventions":12315},[94],[10854],[10848,6456],{"nctId":10864,"briefTitle":10865,"status":204,"phases":12317,"primaryCompletion":10867,"completion":10867,"start":284,"enrollment":5124,"conditions":12318,"interventions":12319},[94],[10869,10870],[10848,6456],{"intervention":11987,"totalTrials":946,"cells":12321},{"EARLY_PHASE1":12322,"PHASE1":12324,"PHASE2":12326,"PHASE3":12328,"PHASE4":12330,"NA":12332},{"trials":12323,"activeCount":102},[],{"trials":12325,"activeCount":102},[],{"trials":12327,"activeCount":102},[],{"trials":12329,"activeCount":102},[],{"trials":12331,"activeCount":102},[],{"trials":12333,"activeCount":102},[12334,12338,12347],{"nctId":11981,"briefTitle":11982,"status":204,"phases":12335,"primaryCompletion":11431,"completion":11431,"start":11984,"enrollment":2998,"conditions":12336,"interventions":12337},[94],[5126,11712],[11987,11966],{"nctId":12339,"briefTitle":12340,"status":204,"phases":12341,"primaryCompletion":3730,"completion":3730,"start":3889,"enrollment":1394,"conditions":12342,"interventions":12344},"NCT01732666","Effect of Nefopam on Remifentanil Induced Postoperative Hyperalgesia",[94],[12343],"Patients Undergoing Laparoscopic Gastrectomy",[11987,12345,12346],"low dose remifentanil","high dose remifentanil",{"nctId":12348,"briefTitle":12349,"status":308,"phases":12350,"primaryCompletion":962,"completion":981,"start":6679,"enrollment":10984,"conditions":12351,"interventions":12353},"NCT01808014","The Analgesic Effect of Nefopam on the Fentanyl Based PCA (Patient-controlled Analgesia) After Lumbar Spinal Surgery",[94],[12352],"Lumbar Spinal Stenisis or Lumbar Herniated Intervertebral Disc",[12354],"nefopam",{"intervention":11918,"totalTrials":946,"cells":12356},{"EARLY_PHASE1":12357,"PHASE1":12359,"PHASE2":12361,"PHASE3":12363,"PHASE4":12365,"NA":12374},{"trials":12358,"activeCount":102},[],{"trials":12360,"activeCount":102},[],{"trials":12362,"activeCount":102},[],{"trials":12364,"activeCount":102},[],{"trials":12366,"activeCount":102},[12367],{"nctId":12368,"briefTitle":12369,"status":204,"phases":12370,"primaryCompletion":5575,"completion":5575,"start":3520,"enrollment":5660,"conditions":12371,"interventions":12373},"NCT02036827","The Effect of Deep Neuromuscular Blockade on Postoperative Shoulder Tip Pain After Laparoscopic Cholecystectomy",[93],[12372],"Pain, Postoperative",[11918],{"trials":12375,"activeCount":102},[12376,12380],{"nctId":11912,"briefTitle":11913,"status":204,"phases":12377,"primaryCompletion":7677,"completion":7677,"start":7085,"enrollment":1319,"conditions":12378,"interventions":12379},[94],[11916],[11918,11888,11919,11910],{"nctId":12381,"briefTitle":12382,"status":204,"phases":12383,"primaryCompletion":12384,"completion":12384,"start":12385,"enrollment":12386,"conditions":12387,"interventions":12388},"NCT02400931","The Necessity of Routine Mask Ventilation in Adults",[94],"2015-11-23","2015-04-28",288,[24],[11918],{"intervention":10812,"totalTrials":946,"cells":12390},{"EARLY_PHASE1":12391,"PHASE1":12393,"PHASE2":12395,"PHASE3":12397,"PHASE4":12399,"NA":12405},{"trials":12392,"activeCount":102},[],{"trials":12394,"activeCount":102},[],{"trials":12396,"activeCount":102},[],{"trials":12398,"activeCount":102},[],{"trials":12400,"activeCount":102},[12401],{"nctId":10806,"briefTitle":10807,"status":204,"phases":12402,"primaryCompletion":5575,"completion":8851,"start":963,"enrollment":344,"conditions":12403,"interventions":12404},[93],[10810],[10812,6456],{"trials":12406,"activeCount":102},[12407,12411],{"nctId":11442,"briefTitle":11443,"status":204,"phases":12408,"primaryCompletion":11122,"completion":11122,"start":3468,"enrollment":5921,"conditions":12409,"interventions":12410},[94],[30],[11021,10812,6572],{"nctId":11696,"briefTitle":11697,"status":204,"phases":12412,"primaryCompletion":8353,"completion":8353,"start":3841,"enrollment":11699,"conditions":12413,"interventions":12414},[94],[11701],[10812,10903],{"intervention":11418,"totalTrials":946,"cells":12416},{"EARLY_PHASE1":12417,"PHASE1":12419,"PHASE2":12421,"PHASE3":12423,"PHASE4":12425,"NA":12438},{"trials":12418,"activeCount":102},[],{"trials":12420,"activeCount":102},[],{"trials":12422,"activeCount":102},[],{"trials":12424,"activeCount":102},[],{"trials":12426,"activeCount":102},[12427,12434],{"nctId":12428,"briefTitle":12429,"status":308,"phases":12430,"primaryCompletion":8015,"completion":8015,"start":7085,"enrollment":1980,"conditions":12431,"interventions":12433},"NCT02154438","The Effect of Ketamine Infusion on Lumbar Surgery",[93],[12432],"Chronic Low Back Pain",[11418],{"nctId":11413,"briefTitle":11414,"status":204,"phases":12435,"primaryCompletion":6566,"completion":6566,"start":3584,"enrollment":1243,"conditions":12436,"interventions":12437},[93],[4009],[11418,6572],{"trials":12439,"activeCount":102},[12440],{"nctId":11464,"briefTitle":11465,"status":308,"phases":12441,"primaryCompletion":11467,"completion":11467,"start":1458,"enrollment":222,"conditions":12442,"interventions":12443},[94],[32],[11418,6572],{"intervention":4755,"totalTrials":946,"cells":12445},{"EARLY_PHASE1":12446,"PHASE1":12448,"PHASE2":12450,"PHASE3":12452,"PHASE4":12454,"NA":12460},{"trials":12447,"activeCount":102},[],{"trials":12449,"activeCount":102},[],{"trials":12451,"activeCount":102},[],{"trials":12453,"activeCount":102},[],{"trials":12455,"activeCount":102},[12456],{"nctId":4748,"briefTitle":4749,"status":204,"phases":12457,"primaryCompletion":3797,"completion":3797,"start":4751,"enrollment":3775,"conditions":12458,"interventions":12459},[93],[4753],[4735,4755],{"trials":12461,"activeCount":102},[12462,12472],{"nctId":12463,"briefTitle":12464,"status":204,"phases":12465,"primaryCompletion":12466,"completion":12466,"start":918,"enrollment":4992,"conditions":12467,"interventions":12470},"NCT02826902","Effect of Anesthesia on Quality of Recovery in Patients Undergoing Correctional Tibial Osteotomy - A Randomized Controlled Trial",[94],"2019-11-09",[12468,12469],"Short Stature","Osteoarthritis",[4755,12471],"desflurane and remifentanil",{"nctId":11600,"briefTitle":11601,"status":204,"phases":12473,"primaryCompletion":11603,"completion":11603,"start":11604,"enrollment":11605,"conditions":12474,"interventions":12475},[94],[11607],[11383,11586,4755],{"intervention":12477,"totalTrials":946,"cells":12478},"Fentanyl",{"EARLY_PHASE1":12479,"PHASE1":12481,"PHASE2":12483,"PHASE3":12485,"PHASE4":12487,"NA":12489},{"trials":12480,"activeCount":102},[],{"trials":12482,"activeCount":102},[],{"trials":12484,"activeCount":102},[],{"trials":12486,"activeCount":102},[],{"trials":12488,"activeCount":102},[],{"trials":12490,"activeCount":102},[12491,12495,12503],{"nctId":11142,"briefTitle":11143,"status":204,"phases":12492,"primaryCompletion":980,"completion":980,"start":5575,"enrollment":1886,"conditions":12493,"interventions":12494},[94],[11146],[11148,262,5198],{"nctId":12496,"briefTitle":12497,"status":204,"phases":12498,"primaryCompletion":7503,"completion":7503,"start":964,"enrollment":1980,"conditions":12499,"interventions":12501},"NCT01608334","Comparison of Intrathecal Fentanyl or Sufentanil in 1 mg Bupivacaine Spinal Anesthesia for TURP in Elderly Patients",[94],[12500],"Adequate Anesthesia With Unimpaired Motor Strength",[12477,12502],"Sufentanil",{"nctId":12504,"briefTitle":12505,"status":308,"phases":12506,"primaryCompletion":3730,"completion":9275,"start":3773,"enrollment":3226,"conditions":12507,"interventions":12508},"NCT01527890","Effect of Intravenous Patient-controlled Analgesia (IV-PCA) With Fentanyl in Adults for Acute Postoperative Pain Control",[],[6525,6526],[12477],{"intervention":239,"totalTrials":946,"cells":12510},{"EARLY_PHASE1":12511,"PHASE1":12513,"PHASE2":12515,"PHASE3":12517,"PHASE4":12519,"NA":12521},{"trials":12512,"activeCount":102},[],{"trials":12514,"activeCount":102},[],{"trials":12516,"activeCount":102},[],{"trials":12518,"activeCount":102},[],{"trials":12520,"activeCount":102},[],{"trials":12522,"activeCount":102},[12523,12527,12531],{"nctId":228,"briefTitle":229,"status":204,"phases":12524,"primaryCompletion":231,"completion":232,"start":231,"enrollment":233,"conditions":12525,"interventions":12526},[94],[235,236,237],[239,172],{"nctId":11340,"briefTitle":11341,"status":204,"phases":12528,"primaryCompletion":11343,"completion":11343,"start":11344,"enrollment":1010,"conditions":12529,"interventions":12530},[94],[11346],[239,212],{"nctId":11367,"briefTitle":11368,"status":204,"phases":12532,"primaryCompletion":11370,"completion":11370,"start":11371,"enrollment":258,"conditions":12533,"interventions":12534},[94],[11373],[239,212],{"intervention":12536,"totalTrials":946,"cells":12537},"dexmedetomidine-remifentanil",{"EARLY_PHASE1":12538,"PHASE1":12540,"PHASE2":12542,"PHASE3":12544,"PHASE4":12546,"NA":12552},{"trials":12539,"activeCount":102},[],{"trials":12541,"activeCount":102},[],{"trials":12543,"activeCount":102},[],{"trials":12545,"activeCount":102},[],{"trials":12547,"activeCount":102},[12548],{"nctId":11270,"briefTitle":11271,"status":204,"phases":12549,"primaryCompletion":4775,"completion":4775,"start":9501,"enrollment":344,"conditions":12550,"interventions":12551},[93],[11274],[212,11276,11277],{"trials":12553,"activeCount":102},[12554,12562],{"nctId":12555,"briefTitle":12556,"status":204,"phases":12557,"primaryCompletion":5398,"completion":5398,"start":3575,"enrollment":2661,"conditions":12558,"interventions":12560},"NCT01652586","Sedation Regimen in Patients Undergoing Cardiac Electrophysiology Study and Ablation : a Comparison Between Dexmedetomidine-remifentanil and Midazolam-remifentanil Combinations",[94],[12559],"Cardiac Arrhythmia",[12536,12561],"midazolam-remifentanil",{"nctId":12563,"briefTitle":12564,"status":308,"phases":12565,"primaryCompletion":12566,"completion":12566,"start":12567,"enrollment":4612,"conditions":12568,"interventions":12570},"NCT05864404","Comparison of Patients' Satisfaction Between Dexmedetomidine and Remimazolam Anesthesia in Patients With Atrial Fibrillation Undergoing Catheter Ablation",[94],"2024-10-09","2023-05-24",[12569],"Patients With Atrial Fibrillation Undergoing Catheter Ablation",[12571,12536],"remimazolam-remifentanil",{"intervention":11849,"totalTrials":98,"cells":12573},{"EARLY_PHASE1":12574,"PHASE1":12576,"PHASE2":12578,"PHASE3":12580,"PHASE4":12582,"NA":12584},{"trials":12575,"activeCount":102},[],{"trials":12577,"activeCount":102},[],{"trials":12579,"activeCount":102},[],{"trials":12581,"activeCount":102},[],{"trials":12583,"activeCount":102},[],{"trials":12585,"activeCount":102},[12586,12590],{"nctId":11843,"briefTitle":11844,"status":308,"phases":12587,"primaryCompletion":5984,"completion":5984,"start":11846,"enrollment":222,"conditions":12588,"interventions":12589},[94],[5831],[11849,4683],{"nctId":10971,"briefTitle":10972,"status":204,"phases":12591,"primaryCompletion":10686,"completion":10686,"start":10974,"enrollment":458,"conditions":12592,"interventions":12593},[94],[7802],[10977,4996],{"intervention":12595,"totalTrials":98,"cells":12596},"Morphine",{"EARLY_PHASE1":12597,"PHASE1":12599,"PHASE2":12601,"PHASE3":12603,"PHASE4":12605,"NA":12611},{"trials":12598,"activeCount":102},[],{"trials":12600,"activeCount":102},[],{"trials":12602,"activeCount":102},[],{"trials":12604,"activeCount":102},[],{"trials":12606,"activeCount":102},[12607],{"nctId":12237,"briefTitle":12238,"status":204,"phases":12608,"primaryCompletion":11083,"completion":4201,"start":4249,"enrollment":12240,"conditions":12609,"interventions":12610},[93],[21],[12243,5198],{"trials":12612,"activeCount":102},[12613],{"nctId":12614,"briefTitle":12615,"status":204,"phases":12616,"primaryCompletion":12617,"completion":12617,"start":12618,"enrollment":2661,"conditions":12619,"interventions":12621},"NCT05208801","Analgesic Effect of Intrathecal Morphine Combined With Low Dose Local Anesthetics on Postoperative Analgesia After Liver Resection",[94],"2020-04-18","2018-11-19",[12620],"Patients Receiving Hepatectomy Under General Anesthesia",[12622,12595,12623],"Percutaneous","Morphine+Bupivacaine",{"intervention":12625,"totalTrials":98,"cells":12626},"Atropine",{"EARLY_PHASE1":12627,"PHASE1":12629,"PHASE2":12631,"PHASE3":12633,"PHASE4":12635,"NA":12637},{"trials":12628,"activeCount":102},[],{"trials":12630,"activeCount":102},[],{"trials":12632,"activeCount":102},[],{"trials":12634,"activeCount":102},[],{"trials":12636,"activeCount":102},[],{"trials":12638,"activeCount":102},[12639,12648],{"nctId":12640,"briefTitle":12641,"status":204,"phases":12642,"primaryCompletion":12643,"completion":12643,"start":12644,"enrollment":10984,"conditions":12645,"interventions":12646},"NCT03322098","Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Geriatric Patients Undergoing Total Knee Replacement Under Spinal Anesthesia",[94],"2018-05-15","2017-10-16",[237],[12625,12647],"Glycopyrrolate",{"nctId":12649,"briefTitle":12650,"status":243,"phases":12651,"primaryCompletion":12652,"completion":12652,"start":12653,"enrollment":98,"conditions":12654,"interventions":12655},"NCT03322150","Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Adult Patients Undergoing Lower Extremity Surgery Under Spinal Anesthesia",[94],"2018-08-01","2017-10-01",[237],[12625,12647],{"intervention":12647,"totalTrials":98,"cells":12657},{"EARLY_PHASE1":12658,"PHASE1":12660,"PHASE2":12662,"PHASE3":12664,"PHASE4":12666,"NA":12668},{"trials":12659,"activeCount":102},[],{"trials":12661,"activeCount":102},[],{"trials":12663,"activeCount":102},[],{"trials":12665,"activeCount":102},[],{"trials":12667,"activeCount":102},[],{"trials":12669,"activeCount":102},[12670,12674],{"nctId":12640,"briefTitle":12641,"status":204,"phases":12671,"primaryCompletion":12643,"completion":12643,"start":12644,"enrollment":10984,"conditions":12672,"interventions":12673},[94],[237],[12625,12647],{"nctId":12649,"briefTitle":12650,"status":243,"phases":12675,"primaryCompletion":12652,"completion":12652,"start":12653,"enrollment":98,"conditions":12676,"interventions":12677},[94],[237],[12625,12647],{"intervention":922,"totalTrials":98,"cells":12679},{"EARLY_PHASE1":12680,"PHASE1":12682,"PHASE2":12684,"PHASE3":12686,"PHASE4":12688,"NA":12690},{"trials":12681,"activeCount":102},[],{"trials":12683,"activeCount":102},[],{"trials":12685,"activeCount":102},[],{"trials":12687,"activeCount":102},[],{"trials":12689,"activeCount":102},[],{"trials":12691,"activeCount":102},[12692,12696],{"nctId":914,"briefTitle":915,"status":204,"phases":12693,"primaryCompletion":917,"completion":917,"start":918,"enrollment":16,"conditions":12694,"interventions":12695},[94],[920],[922,614],{"nctId":936,"briefTitle":937,"status":204,"phases":12697,"primaryCompletion":939,"completion":939,"start":940,"enrollment":222,"conditions":12698,"interventions":12699},[94],[942],[944,904],{"intervention":10995,"totalTrials":98,"cells":12701},{"EARLY_PHASE1":12702,"PHASE1":12704,"PHASE2":12706,"PHASE3":12708,"PHASE4":12710,"NA":12719},{"trials":12703,"activeCount":102},[],{"trials":12705,"activeCount":102},[],{"trials":12707,"activeCount":102},[],{"trials":12709,"activeCount":102},[],{"trials":12711,"activeCount":102},[12712],{"nctId":12713,"briefTitle":12714,"status":204,"phases":12715,"primaryCompletion":3575,"completion":3575,"start":6341,"conditions":12716,"interventions":12718},"NCT00944385","Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement",[93],[12717],"Abnormal Aortic Valve",[10995],{"trials":12720,"activeCount":102},[12721],{"nctId":10989,"briefTitle":10990,"status":204,"phases":12722,"primaryCompletion":1500,"completion":1500,"start":963,"enrollment":3775,"conditions":12723,"interventions":12724},[94],[10993],[10995,4996],{"intervention":12726,"totalTrials":98,"cells":12727},"total intravenous anesthesia",{"EARLY_PHASE1":12728,"PHASE1":12730,"PHASE2":12732,"PHASE3":12734,"PHASE4":12736,"NA":12738},{"trials":12729,"activeCount":102},[],{"trials":12731,"activeCount":102},[],{"trials":12733,"activeCount":102},[],{"trials":12735,"activeCount":102},[],{"trials":12737,"activeCount":102},[],{"trials":12739,"activeCount":102},[12740,12750],{"nctId":12741,"briefTitle":12742,"status":204,"phases":12743,"primaryCompletion":12744,"completion":12744,"start":12745,"enrollment":11108,"conditions":12746,"interventions":12748},"NCT02813044","Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor",[94],"2018-06-15","2016-06-16",[12747],"Pituitary Tumor",[12726,12749],"inhalation anesthesia group",{"nctId":12751,"briefTitle":12752,"status":204,"phases":12753,"primaryCompletion":4751,"completion":4751,"start":4900,"enrollment":3775,"conditions":12754,"interventions":12755},"NCT01744262","A Comparison of Totally Intravenous and Inhalation Anesthesia for Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy",[94],[35],[12756,12757],"Total intravenous anesthesia","Inhalation Anesthesia",{"intervention":12759,"totalTrials":98,"cells":12760},"Statin",{"EARLY_PHASE1":12761,"PHASE1":12763,"PHASE2":12765,"PHASE3":12767,"PHASE4":12769,"NA":12771},{"trials":12762,"activeCount":102},[],{"trials":12764,"activeCount":102},[],{"trials":12766,"activeCount":102},[],{"trials":12768,"activeCount":102},[],{"trials":12770,"activeCount":102},[],{"trials":12772,"activeCount":102},[12773,12781],{"nctId":12774,"briefTitle":12775,"status":204,"phases":12776,"primaryCompletion":12777,"completion":12777,"start":12778,"enrollment":2687,"conditions":12779,"interventions":12780},"NCT03490461","Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation",[],"2018-03-01","2017-11-22",[2365],[12759],{"nctId":12782,"briefTitle":12783,"status":204,"phases":12784,"primaryCompletion":7383,"completion":3631,"start":899,"enrollment":1243,"conditions":12785,"interventions":12786},"NCT01127945","Study to Evaluate the Effectiveness of High Dose Statin Loading in Acute Heart Failure Patients",[94],[4480],[12787],"statin",{"intervention":12471,"totalTrials":98,"cells":12789},{"EARLY_PHASE1":12790,"PHASE1":12792,"PHASE2":12794,"PHASE3":12796,"PHASE4":12798,"NA":12800},{"trials":12791,"activeCount":102},[],{"trials":12793,"activeCount":102},[],{"trials":12795,"activeCount":102},[],{"trials":12797,"activeCount":102},[],{"trials":12799,"activeCount":102},[],{"trials":12801,"activeCount":102},[12802,12810],{"nctId":12803,"briefTitle":12804,"status":204,"phases":12805,"primaryCompletion":3729,"completion":7211,"start":3468,"enrollment":2998,"conditions":12806,"interventions":12808},"NCT02212340","Comparison Between Propofol-remifentanil Total Intravenous Anesthesia and Desflurane-remifentanil Balanced Anesthesia With Regard to Post-anesthetic Functional Recovery Measured With QoR-40 in Vitrectomy",[94],[12807],"Vitrectomy Operation Under General Anesthesia",[12809,12471],"fresofol and remifentanil",{"nctId":12463,"briefTitle":12464,"status":204,"phases":12811,"primaryCompletion":12466,"completion":12466,"start":918,"enrollment":4992,"conditions":12812,"interventions":12813},[94],[12468,12469],[4755,12471],{"intervention":12815,"totalTrials":98,"cells":12816},"propofol group",{"EARLY_PHASE1":12817,"PHASE1":12819,"PHASE2":12821,"PHASE3":12823,"PHASE4":12825,"NA":12827},{"trials":12818,"activeCount":102},[],{"trials":12820,"activeCount":102},[],{"trials":12822,"activeCount":102},[],{"trials":12824,"activeCount":102},[],{"trials":12826,"activeCount":102},[],{"trials":12828,"activeCount":102},[12829,12840],{"nctId":12830,"briefTitle":12831,"status":204,"phases":12832,"primaryCompletion":12833,"completion":12833,"start":12834,"enrollment":12835,"conditions":12836,"interventions":12838},"NCT05164159","The Comparison of Hemodynamic Effects Between Remimazolam-remifentanil and Propofol-remifentanil in Patients Undergoing Laparoscopic Cholecystectomy",[94],"2022-08-22","2022-02-20",274,[12837],"Acute Cholecystitis",[12815,12839],"remimazolam group",{"nctId":12841,"briefTitle":12842,"status":204,"phases":12843,"primaryCompletion":9893,"completion":9893,"start":12844,"enrollment":344,"conditions":12845,"interventions":12849},"NCT06178848","EEG Parameters Between Remimazolam- and Propofol-based Anesthesia",[94],"2023-06-26",[12846,12847,12848],"Cholecystitis, Acute","Gallbladder Neoplasms","Acalculous Cholecystitis",[12815,12839],{"intervention":12839,"totalTrials":98,"cells":12851},{"EARLY_PHASE1":12852,"PHASE1":12854,"PHASE2":12856,"PHASE3":12858,"PHASE4":12860,"NA":12862},{"trials":12853,"activeCount":102},[],{"trials":12855,"activeCount":102},[],{"trials":12857,"activeCount":102},[],{"trials":12859,"activeCount":102},[],{"trials":12861,"activeCount":102},[],{"trials":12863,"activeCount":102},[12864,12868],{"nctId":12830,"briefTitle":12831,"status":204,"phases":12865,"primaryCompletion":12833,"completion":12833,"start":12834,"enrollment":12835,"conditions":12866,"interventions":12867},[94],[12837],[12815,12839],{"nctId":12841,"briefTitle":12842,"status":204,"phases":12869,"primaryCompletion":9893,"completion":9893,"start":12844,"enrollment":344,"conditions":12870,"interventions":12871},[94],[12846,12847,12848],[12815,12839],{"intervention":12873,"totalTrials":98,"cells":12874},"furosemid\u002Fspironolactone",{"EARLY_PHASE1":12875,"PHASE1":12877,"PHASE2":12879,"PHASE3":12881,"PHASE4":12883,"NA":12885},{"trials":12876,"activeCount":102},[],{"trials":12878,"activeCount":102},[],{"trials":12880,"activeCount":102},[],{"trials":12882,"activeCount":102},[],{"trials":12884,"activeCount":102},[],{"trials":12886,"activeCount":102},[12887,12897],{"nctId":12888,"briefTitle":12889,"status":1475,"phases":12890,"primaryCompletion":4225,"completion":5123,"start":12037,"enrollment":102,"conditions":12891,"interventions":12893},"NCT01817803","A Prospective, Single-center, Open-label, Pilot Study to Compare the Effectiveness and Safety of Diuretics Add-On Strategy in Chronic Heart Failure Patients (DIOS 1)",[94],[12892],"Congestive Heart Failure",[12894,12895,12873,12896],"furosemide\u002Fno spironolactone","metolazone\u002Fno spironolactone","metolazone\u002Fspironolactone",{"nctId":12898,"briefTitle":12899,"status":1475,"phases":12900,"primaryCompletion":1512,"completion":1512,"start":284,"enrollment":102,"conditions":12901,"interventions":12902},"NCT02047422","A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)",[94],[12892],[12903,12904,12873,12896],"Furosemide","metolazone",{"intervention":12896,"totalTrials":98,"cells":12906},{"EARLY_PHASE1":12907,"PHASE1":12909,"PHASE2":12911,"PHASE3":12913,"PHASE4":12915,"NA":12917},{"trials":12908,"activeCount":102},[],{"trials":12910,"activeCount":102},[],{"trials":12912,"activeCount":102},[],{"trials":12914,"activeCount":102},[],{"trials":12916,"activeCount":102},[],{"trials":12918,"activeCount":102},[12919,12923],{"nctId":12888,"briefTitle":12889,"status":1475,"phases":12920,"primaryCompletion":4225,"completion":5123,"start":12037,"enrollment":102,"conditions":12921,"interventions":12922},[94],[12892],[12894,12895,12873,12896],{"nctId":12898,"briefTitle":12899,"status":1475,"phases":12924,"primaryCompletion":1512,"completion":1512,"start":284,"enrollment":102,"conditions":12925,"interventions":12926},[94],[12892],[12903,12904,12873,12896],{"intervention":11651,"totalTrials":98,"cells":12928},{"EARLY_PHASE1":12929,"PHASE1":12931,"PHASE2":12933,"PHASE3":12935,"PHASE4":12937,"NA":12945},{"trials":12930,"activeCount":102},[],{"trials":12932,"activeCount":102},[],{"trials":12934,"activeCount":102},[],{"trials":12936,"activeCount":102},[],{"trials":12938,"activeCount":102},[12939],{"nctId":12940,"briefTitle":12941,"status":204,"phases":12942,"primaryCompletion":3657,"completion":3657,"start":3889,"enrollment":4427,"conditions":12943,"interventions":12944},"NCT02271191","Effect of Nicardipine on Renal Function in Deliberate Hypotension",[93],[920],[11651],{"trials":12946,"activeCount":102},[12947],{"nctId":11645,"briefTitle":11646,"status":204,"phases":12948,"primaryCompletion":4201,"completion":5398,"start":4249,"enrollment":7792,"conditions":12949,"interventions":12950},[94],[11649],[11651,264],{"intervention":11321,"totalTrials":98,"cells":12952},{"EARLY_PHASE1":12953,"PHASE1":12955,"PHASE2":12957,"PHASE3":12959,"PHASE4":12961,"NA":12963},{"trials":12954,"activeCount":102},[],{"trials":12956,"activeCount":102},[],{"trials":12958,"activeCount":102},[],{"trials":12960,"activeCount":102},[],{"trials":12962,"activeCount":102},[],{"trials":12964,"activeCount":102},[12965,12969],{"nctId":11313,"briefTitle":11314,"status":204,"phases":12966,"primaryCompletion":11316,"completion":11316,"start":4775,"enrollment":11317,"conditions":12967,"interventions":12968},[94],[11319],[11253,212,11321],{"nctId":12970,"briefTitle":12971,"status":204,"phases":12972,"primaryCompletion":4703,"completion":4703,"start":206,"enrollment":4427,"conditions":12973,"interventions":12975},"NCT01147146","The Effects of Anesthetic Method on Cerebral Oxygen Saturation in Geriatric Patients Undergoing Transurethral Surgery",[94],[12974],"Surgery",[12976,12977,12978],"propofol, fentanyl, atracurium","bupivacaine","bupivacaine, Midazolam",{"intervention":12980,"totalTrials":98,"cells":12981},"Administration of propofol",{"EARLY_PHASE1":12982,"PHASE1":12984,"PHASE2":12986,"PHASE3":12988,"PHASE4":12990,"NA":12992},{"trials":12983,"activeCount":102},[],{"trials":12985,"activeCount":102},[],{"trials":12987,"activeCount":102},[],{"trials":12989,"activeCount":102},[],{"trials":12991,"activeCount":102},[],{"trials":12993,"activeCount":102},[12994,13004],{"nctId":12995,"briefTitle":12996,"status":204,"phases":12997,"primaryCompletion":5398,"completion":5398,"start":11083,"enrollment":12998,"conditions":12999,"interventions":13001},"NCT01506622","Comparison Between Propofol and Fentanyl for Prevention of Emergence Agitation in Children After Sevoflurane Anesthesia",[94],222,[13000],"Emergence Agitation",[12980,13002,13003],"Administration of fentanyl","Administration of saline",{"nctId":13005,"briefTitle":13006,"status":204,"phases":13007,"primaryCompletion":284,"completion":284,"start":3773,"enrollment":5081,"conditions":13008,"interventions":13010},"NCT01550354","Comparison Among Propofol, Alfentanil and Rocuronium as Adjunct to Sevoflurane Anesthesia for Endotracheal Intubation in Children With Frenectomy",[94],[13009],"Ankyloglossia",[13011,13012,13013],"administration of propofol","administration of alfentanil","administration of rocuronium",{"intervention":13015,"totalTrials":98,"cells":13016},"SGLT2 inhibitor",{"EARLY_PHASE1":13017,"PHASE1":13019,"PHASE2":13021,"PHASE3":13023,"PHASE4":13025,"NA":13038},{"trials":13018,"activeCount":102},[],{"trials":13020,"activeCount":102},[],{"trials":13022,"activeCount":102},[],{"trials":13024,"activeCount":102},[],{"trials":13026,"activeCount":102},[13027],{"nctId":13028,"briefTitle":13029,"status":308,"phases":13030,"primaryCompletion":1791,"completion":1791,"start":13031,"enrollment":1277,"conditions":13032,"interventions":13036},"NCT05975528","Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes",[93],"2023-06-01",[13033,13034,13035],"Diabetes Mellitus","Cellular Senescence","Sodium-Glucose Transporter 2 Inhibitors",[13015,13037],"Glimepiride",{"trials":13039,"activeCount":102},[13040],{"nctId":13041,"briefTitle":13042,"status":308,"phases":13043,"primaryCompletion":4476,"completion":13044,"start":13045,"enrollment":4300,"conditions":13046,"interventions":13047},"NCT03204799","Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes",[],"2019-12-16","2016-12-17",[3914,664],[13015,13048],"ezetimibe",{"intervention":13050,"totalTrials":98,"cells":13051},"pregabalin",{"EARLY_PHASE1":13052,"PHASE1":13054,"PHASE2":13056,"PHASE3":13058,"PHASE4":13060,"NA":13062},{"trials":13053,"activeCount":102},[],{"trials":13055,"activeCount":102},[],{"trials":13057,"activeCount":102},[],{"trials":13059,"activeCount":102},[],{"trials":13061,"activeCount":102},[],{"trials":13063,"activeCount":102},[13064,13073],{"nctId":13065,"briefTitle":13066,"status":204,"phases":13067,"primaryCompletion":13068,"completion":13068,"start":13069,"enrollment":4226,"conditions":13070,"interventions":13072},"NCT03211728","Does Perioperative Pregabalin Reduce Postoperative Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction Surgery Under Spinal Anesthesia?",[94],"2019-02-08","2017-07-19",[13071],"Anterior Cruciate Ligament (ACL) Reconstruction",[13050],{"nctId":11715,"briefTitle":11716,"status":204,"phases":13074,"primaryCompletion":5399,"completion":5399,"start":4538,"enrollment":5660,"conditions":13075,"interventions":13076},[94],[11712],[11720,10903],{"intervention":13078,"totalTrials":98,"cells":13079},"iron isomaltoside 1000",{"EARLY_PHASE1":13080,"PHASE1":13082,"PHASE2":13084,"PHASE3":13086,"PHASE4":13088,"NA":13090},{"trials":13081,"activeCount":102},[],{"trials":13083,"activeCount":102},[],{"trials":13085,"activeCount":102},[],{"trials":13087,"activeCount":102},[],{"trials":13089,"activeCount":102},[],{"trials":13091,"activeCount":102},[13092,13101],{"nctId":13093,"briefTitle":13094,"status":204,"phases":13095,"primaryCompletion":13096,"completion":13096,"start":10160,"enrollment":6452,"conditions":13097,"interventions":13099},"NCT02862665","Effect of Perioperative Iron Isomaltoside 1000 Administration on Transfusion Requirements in Patients Undergoing Complex Valvular Heart Surgery: a Randomized Clinical Trial",[94],"2020-05-07",[13098],"Complex Valvular Heart Surgery",[13078,13100],"normal saline 100 ml",{"nctId":11031,"briefTitle":11032,"status":308,"phases":13102,"primaryCompletion":10598,"completion":10598,"start":8613,"enrollment":1886,"conditions":13103,"interventions":13104},[94],[11035,11036,11037],[11039,6456],{"intervention":13037,"totalTrials":98,"cells":13106},{"EARLY_PHASE1":13107,"PHASE1":13109,"PHASE2":13111,"PHASE3":13113,"PHASE4":13115,"NA":13121},{"trials":13108,"activeCount":102},[],{"trials":13110,"activeCount":102},[],{"trials":13112,"activeCount":102},[],{"trials":13114,"activeCount":102},[],{"trials":13116,"activeCount":102},[13117],{"nctId":13028,"briefTitle":13029,"status":308,"phases":13118,"primaryCompletion":1791,"completion":1791,"start":13031,"enrollment":1277,"conditions":13119,"interventions":13120},[93],[13033,13034,13035],[13015,13037],{"trials":13122,"activeCount":102},[13123],{"nctId":13124,"briefTitle":13125,"status":204,"phases":13126,"primaryCompletion":13127,"completion":13127,"start":2889,"enrollment":13128,"conditions":13129,"interventions":13131},"NCT02964572","Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes",[94],"2017-07",61,[13130],"Type2 Diabetes Mellitus",[13037,6086],{"intervention":6086,"totalTrials":98,"cells":13133},{"EARLY_PHASE1":13134,"PHASE1":13136,"PHASE2":13138,"PHASE3":13140,"PHASE4":13142,"NA":13148},{"trials":13135,"activeCount":102},[],{"trials":13137,"activeCount":102},[],{"trials":13139,"activeCount":102},[],{"trials":13141,"activeCount":102},[],{"trials":13143,"activeCount":102},[13144],{"nctId":6069,"briefTitle":6070,"status":204,"phases":13145,"primaryCompletion":6072,"completion":6072,"start":6073,"enrollment":2363,"conditions":13146,"interventions":13147},[93],[6075,4179,6076,6077,6078,6079,6080,6081,6082,6083,6084,6085,6086,6087],[6084,6086,6056],{"trials":13149,"activeCount":102},[13150],{"nctId":13124,"briefTitle":13125,"status":204,"phases":13151,"primaryCompletion":13127,"completion":13127,"start":2889,"enrollment":13128,"conditions":13152,"interventions":13153},[94],[13130],[13037,6086],{"intervention":10952,"totalTrials":98,"cells":13155},{"EARLY_PHASE1":13156,"PHASE1":13158,"PHASE2":13160,"PHASE3":13162,"PHASE4":13164,"NA":13170},{"trials":13157,"activeCount":102},[],{"trials":13159,"activeCount":102},[],{"trials":13161,"activeCount":102},[],{"trials":13163,"activeCount":102},[],{"trials":13165,"activeCount":102},[13166],{"nctId":11428,"briefTitle":11429,"status":204,"phases":13167,"primaryCompletion":11431,"completion":11431,"start":11432,"enrollment":258,"conditions":13168,"interventions":13169},[93],[4252],[10952,6572],{"trials":13171,"activeCount":102},[13172],{"nctId":10944,"briefTitle":10945,"status":204,"phases":13173,"primaryCompletion":10947,"completion":10947,"start":10948,"enrollment":10949,"conditions":13174,"interventions":13175},[94],[4252],[10952,4996],{"intervention":7027,"totalTrials":98,"cells":13177},{"EARLY_PHASE1":13178,"PHASE1":13180,"PHASE2":13182,"PHASE3":13184,"PHASE4":13186,"NA":13192},{"trials":13179,"activeCount":102},[],{"trials":13181,"activeCount":102},[],{"trials":13183,"activeCount":102},[],{"trials":13185,"activeCount":102},[],{"trials":13187,"activeCount":102},[13188],{"nctId":7019,"briefTitle":7020,"status":308,"phases":13189,"primaryCompletion":7022,"completion":7023,"start":980,"enrollment":222,"conditions":13190,"interventions":13191},[93],[7025],[7006,7027,7028,7029],{"trials":13193,"activeCount":102},[13194],{"nctId":13195,"briefTitle":13196,"status":204,"phases":13197,"primaryCompletion":962,"completion":962,"start":3866,"enrollment":1259,"conditions":13198,"interventions":13200},"NCT01839253","The Effect of Antihypertensive Agents Concerning With Hemodynamics and Reduction of Anaesthetics in Orthognathic Surgery",[94],[13199],"Orthognathic Surgery",[13201,7027],"b-blocker",{"intervention":6084,"totalTrials":98,"cells":13203},{"EARLY_PHASE1":13204,"PHASE1":13206,"PHASE2":13208,"PHASE3":13210,"PHASE4":13212,"NA":13218},{"trials":13205,"activeCount":102},[],{"trials":13207,"activeCount":102},[],{"trials":13209,"activeCount":102},[],{"trials":13211,"activeCount":102},[],{"trials":13213,"activeCount":102},[13214],{"nctId":6069,"briefTitle":6070,"status":204,"phases":13215,"primaryCompletion":6072,"completion":6072,"start":6073,"enrollment":2363,"conditions":13216,"interventions":13217},[93],[6075,4179,6076,6077,6078,6079,6080,6081,6082,6083,6084,6085,6086,6087],[6084,6086,6056],{"trials":13219,"activeCount":102},[13220],{"nctId":13221,"briefTitle":13222,"status":204,"phases":13223,"primaryCompletion":13224,"completion":13224,"start":13225,"enrollment":13226,"conditions":13227,"interventions":13228},"NCT00598013","Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes",[94],"2007-11","2004-11",83,[11174,690,2592],[6084],{"intervention":11276,"totalTrials":98,"cells":13230},{"EARLY_PHASE1":13231,"PHASE1":13233,"PHASE2":13235,"PHASE3":13237,"PHASE4":13239,"NA":13245},{"trials":13232,"activeCount":102},[],{"trials":13234,"activeCount":102},[],{"trials":13236,"activeCount":102},[],{"trials":13238,"activeCount":102},[],{"trials":13240,"activeCount":102},[13241],{"nctId":11270,"briefTitle":11271,"status":204,"phases":13242,"primaryCompletion":4775,"completion":4775,"start":9501,"enrollment":344,"conditions":13243,"interventions":13244},[93],[11274],[212,11276,11277],{"trials":13246,"activeCount":102},[13247],{"nctId":13248,"briefTitle":13249,"status":243,"phases":13250,"primaryCompletion":13251,"completion":13251,"start":3797,"enrollment":1369,"conditions":13252,"interventions":13253},"NCT02089178","Comparison of the Effect of Total Intravenous Anesthesia and Inhalation Anesthesia on Cancer Cell Cytotoxicity, Micrometastasis and Recurrence of Tumor in Patients Undergoing Breast Tumor Resection",[94],"2014-12-30",[30],[11276,13254],"sevoflurane-remifentanil",{"intervention":1461,"totalTrials":213,"cells":13256},{"EARLY_PHASE1":13257,"PHASE1":13259,"PHASE2":13261,"PHASE3":13263,"PHASE4":13265,"NA":13267},{"trials":13258,"activeCount":102},[],{"trials":13260,"activeCount":102},[],{"trials":13262,"activeCount":102},[],{"trials":13264,"activeCount":102},[],{"trials":13266,"activeCount":102},[],{"trials":13268,"activeCount":102},[13269],{"nctId":1454,"briefTitle":1455,"status":204,"phases":13270,"primaryCompletion":1457,"completion":1457,"start":1458,"enrollment":1243,"conditions":13271,"interventions":13272},[],[1421],[1461,1462,1446,1405],{"intervention":1462,"totalTrials":213,"cells":13274},{"EARLY_PHASE1":13275,"PHASE1":13277,"PHASE2":13279,"PHASE3":13281,"PHASE4":13283,"NA":13285},{"trials":13276,"activeCount":102},[],{"trials":13278,"activeCount":102},[],{"trials":13280,"activeCount":102},[],{"trials":13282,"activeCount":102},[],{"trials":13284,"activeCount":102},[],{"trials":13286,"activeCount":102},[13287],{"nctId":1454,"briefTitle":1455,"status":204,"phases":13288,"primaryCompletion":1457,"completion":1457,"start":1458,"enrollment":1243,"conditions":13289,"interventions":13290},[],[1421],[1461,1462,1446,1405],{"intervention":13292,"totalTrials":213,"cells":13293},"B0 group: bolus 0.6mcg\u002Fkg without background",{"EARLY_PHASE1":13294,"PHASE1":13296,"PHASE2":13298,"PHASE3":13300,"PHASE4":13302,"NA":13304},{"trials":13295,"activeCount":102},[],{"trials":13297,"activeCount":102},[],{"trials":13299,"activeCount":102},[],{"trials":13301,"activeCount":102},[],{"trials":13303,"activeCount":102},[],{"trials":13305,"activeCount":102},[13306],{"nctId":13307,"briefTitle":13308,"status":308,"phases":13309,"primaryCompletion":963,"completion":7677,"start":11070,"enrollment":7168,"conditions":13310,"interventions":13312},"NCT01863355","Comparison of Analgesic Efficacy and Occurrence of Emesis Among Different Background Infusion and Bolus Administration Regimens of Fentanyl Based Intravenous Patient-controlled Analgesia in Patients After Laparoscopic Assisted Gastrectomy - a Randomized Blind Study -",[94],[13311],"The Patients With Gastric Cancer Who Are Scheduled to Receive Laparoscopy Assisted Gastrectomy",[13292,13313,13314],"BL group: bolus 0.4mcg\u002Fkg with background infusion rate 0.2mcg\u002Fkg\u002Fhr","BH group: bolus 0.2mcg\u002Fkg with background infusion rate 0.4mcg\u002Fkg\u002Fhr",{"intervention":13313,"totalTrials":213,"cells":13316},{"EARLY_PHASE1":13317,"PHASE1":13319,"PHASE2":13321,"PHASE3":13323,"PHASE4":13325,"NA":13327},{"trials":13318,"activeCount":102},[],{"trials":13320,"activeCount":102},[],{"trials":13322,"activeCount":102},[],{"trials":13324,"activeCount":102},[],{"trials":13326,"activeCount":102},[],{"trials":13328,"activeCount":102},[13329],{"nctId":13307,"briefTitle":13308,"status":308,"phases":13330,"primaryCompletion":963,"completion":7677,"start":11070,"enrollment":7168,"conditions":13331,"interventions":13332},[94],[13311],[13292,13313,13314],{"intervention":13314,"totalTrials":213,"cells":13334},{"EARLY_PHASE1":13335,"PHASE1":13337,"PHASE2":13339,"PHASE3":13341,"PHASE4":13343,"NA":13345},{"trials":13336,"activeCount":102},[],{"trials":13338,"activeCount":102},[],{"trials":13340,"activeCount":102},[],{"trials":13342,"activeCount":102},[],{"trials":13344,"activeCount":102},[],{"trials":13346,"activeCount":102},[13347],{"nctId":13307,"briefTitle":13308,"status":308,"phases":13348,"primaryCompletion":963,"completion":7677,"start":11070,"enrollment":7168,"conditions":13349,"interventions":13350},[94],[13311],[13292,13313,13314],{"intervention":12622,"totalTrials":213,"cells":13352},{"EARLY_PHASE1":13353,"PHASE1":13355,"PHASE2":13357,"PHASE3":13359,"PHASE4":13361,"NA":13363},{"trials":13354,"activeCount":102},[],{"trials":13356,"activeCount":102},[],{"trials":13358,"activeCount":102},[],{"trials":13360,"activeCount":102},[],{"trials":13362,"activeCount":102},[],{"trials":13364,"activeCount":102},[13365],{"nctId":12614,"briefTitle":12615,"status":204,"phases":13366,"primaryCompletion":12617,"completion":12617,"start":12618,"enrollment":2661,"conditions":13367,"interventions":13368},[94],[12620],[12622,12595,12623],{"intervention":12623,"totalTrials":213,"cells":13370},{"EARLY_PHASE1":13371,"PHASE1":13373,"PHASE2":13375,"PHASE3":13377,"PHASE4":13379,"NA":13381},{"trials":13372,"activeCount":102},[],{"trials":13374,"activeCount":102},[],{"trials":13376,"activeCount":102},[],{"trials":13378,"activeCount":102},[],{"trials":13380,"activeCount":102},[],{"trials":13382,"activeCount":102},[13383],{"nctId":12614,"briefTitle":12615,"status":204,"phases":13384,"primaryCompletion":12617,"completion":12617,"start":12618,"enrollment":2661,"conditions":13385,"interventions":13386},[94],[12620],[12622,12595,12623],{"intervention":13388,"totalTrials":213,"cells":13389},"1% Lidocaine",{"EARLY_PHASE1":13390,"PHASE1":13392,"PHASE2":13394,"PHASE3":13396,"PHASE4":13398,"NA":13400},{"trials":13391,"activeCount":102},[],{"trials":13393,"activeCount":102},[],{"trials":13395,"activeCount":102},[],{"trials":13397,"activeCount":102},[],{"trials":13399,"activeCount":102},[],{"trials":13401,"activeCount":102},[13402],{"nctId":13403,"briefTitle":13404,"status":204,"phases":13405,"primaryCompletion":13406,"completion":13406,"start":12644,"enrollment":9739,"conditions":13407,"interventions":13409},"NCT03308136","The Effect of Local Anesthetic Injection Depth on Procedural Pain and Discomfort During Fluoroscopically Guided Lumbar Transforaminal Epidural Injections",[94],"2018-02-28",[13408],"Lumbar Radiculopathy Due to Spinal Nerve Compression",[13388],{"intervention":10833,"totalTrials":213,"cells":13411},{"EARLY_PHASE1":13412,"PHASE1":13414,"PHASE2":13416,"PHASE3":13418,"PHASE4":13420,"NA":13422},{"trials":13413,"activeCount":102},[],{"trials":13415,"activeCount":102},[],{"trials":13417,"activeCount":102},[],{"trials":13419,"activeCount":102},[],{"trials":13421,"activeCount":102},[],{"trials":13423,"activeCount":102},[13424],{"nctId":10824,"briefTitle":10825,"status":204,"phases":13425,"primaryCompletion":10827,"completion":10827,"start":10828,"enrollment":10829,"conditions":13426,"interventions":13427},[94],[10831],[10833,4996],{"intervention":13429,"totalTrials":213,"cells":13430},"Antiarrhythmic drug",{"EARLY_PHASE1":13431,"PHASE1":13433,"PHASE2":13435,"PHASE3":13437,"PHASE4":13439,"NA":13441},{"trials":13432,"activeCount":102},[],{"trials":13434,"activeCount":102},[],{"trials":13436,"activeCount":102},[],{"trials":13438,"activeCount":102},[],{"trials":13440,"activeCount":102},[],{"trials":13442,"activeCount":102},[13443],{"nctId":13444,"briefTitle":13445,"status":308,"phases":13446,"primaryCompletion":4476,"completion":4476,"start":4727,"enrollment":25,"conditions":13447,"interventions":13449},"NCT02646501","Prospective Randomized Clinical Trial for Effect of Stellate Ganglion Block in Medically Refractory Ventricular Tachycardia",[94],[13448],"Refractory Ventricular Tachycardia",[13429],{"intervention":984,"totalTrials":213,"cells":13451},{"EARLY_PHASE1":13452,"PHASE1":13454,"PHASE2":13456,"PHASE3":13458,"PHASE4":13460,"NA":13462},{"trials":13453,"activeCount":102},[],{"trials":13455,"activeCount":102},[],{"trials":13457,"activeCount":102},[],{"trials":13459,"activeCount":102},[],{"trials":13461,"activeCount":102},[],{"trials":13463,"activeCount":102},[13464],{"nctId":976,"briefTitle":977,"status":204,"phases":13465,"primaryCompletion":979,"completion":980,"start":981,"enrollment":22,"conditions":13466,"interventions":13467},[94],[15],[77,984],{"intervention":13469,"totalTrials":213,"cells":13470},"remifentanil of the assigned dose",{"EARLY_PHASE1":13471,"PHASE1":13473,"PHASE2":13475,"PHASE3":13477,"PHASE4":13479,"NA":13481},{"trials":13472,"activeCount":102},[],{"trials":13474,"activeCount":102},[],{"trials":13476,"activeCount":102},[],{"trials":13478,"activeCount":102},[],{"trials":13480,"activeCount":102},[],{"trials":13482,"activeCount":102},[13483],{"nctId":13484,"briefTitle":13485,"status":308,"phases":13486,"primaryCompletion":13487,"completion":13487,"start":13488,"enrollment":1319,"conditions":13489,"interventions":13491},"NCT06289829","The Appropriate Remifentanil Dose for Optimal Insertion of Laryngeal Mask Airway in Adult Patients During Induction of General Anesthesia Using Remimazolam.",[94],"2025-07-29","2024-03-02",[13490],"Adult, Laryngeal Masks, Remimazolam, Remifentanil",[13469],{"intervention":13493,"totalTrials":213,"cells":13494},"Deep neuromuscular block using rocuronium and reversal with suggamadex",{"EARLY_PHASE1":13495,"PHASE1":13497,"PHASE2":13499,"PHASE3":13501,"PHASE4":13503,"NA":13505},{"trials":13496,"activeCount":102},[],{"trials":13498,"activeCount":102},[],{"trials":13500,"activeCount":102},[],{"trials":13502,"activeCount":102},[],{"trials":13504,"activeCount":102},[],{"trials":13506,"activeCount":102},[13507],{"nctId":13508,"briefTitle":13509,"status":204,"phases":13510,"primaryCompletion":11122,"completion":11122,"start":3888,"enrollment":1501,"conditions":13511,"interventions":13512},"NCT02266056","The Benefits of Deep Neuromuscular Block and Sugammadex in Laparoscopic Colorectal Surgery",[94],[32],[13493,13513],"Moderate neuromuscular block using rocuronium and reversal with suggamadex",{"intervention":13513,"totalTrials":213,"cells":13515},{"EARLY_PHASE1":13516,"PHASE1":13518,"PHASE2":13520,"PHASE3":13522,"PHASE4":13524,"NA":13526},{"trials":13517,"activeCount":102},[],{"trials":13519,"activeCount":102},[],{"trials":13521,"activeCount":102},[],{"trials":13523,"activeCount":102},[],{"trials":13525,"activeCount":102},[],{"trials":13527,"activeCount":102},[13528],{"nctId":13508,"briefTitle":13509,"status":204,"phases":13529,"primaryCompletion":11122,"completion":11122,"start":3888,"enrollment":1501,"conditions":13530,"interventions":13531},[94],[32],[13493,13513],{"intervention":13533,"totalTrials":213,"cells":13534},"Bolus group for epidural block",{"EARLY_PHASE1":13535,"PHASE1":13537,"PHASE2":13539,"PHASE3":13541,"PHASE4":13543,"NA":13545},{"trials":13536,"activeCount":102},[],{"trials":13538,"activeCount":102},[],{"trials":13540,"activeCount":102},[],{"trials":13542,"activeCount":102},[],{"trials":13544,"activeCount":102},[],{"trials":13546,"activeCount":102},[13547],{"nctId":13548,"briefTitle":13549,"status":204,"phases":13550,"primaryCompletion":11604,"completion":11604,"start":13551,"enrollment":458,"conditions":13552,"interventions":13553},"NCT03200951","The Effect of Epidural Analgesia on Intracranial Pressure by Measuring the Optic Nerve Sheath Diameter Using Ultrasound in Pediatric Patients With Cerebral Palsy",[94],"2017-08-22",[8080],[13533,13554],"Infusion group for epidural block",{"intervention":13554,"totalTrials":213,"cells":13556},{"EARLY_PHASE1":13557,"PHASE1":13559,"PHASE2":13561,"PHASE3":13563,"PHASE4":13565,"NA":13567},{"trials":13558,"activeCount":102},[],{"trials":13560,"activeCount":102},[],{"trials":13562,"activeCount":102},[],{"trials":13564,"activeCount":102},[],{"trials":13566,"activeCount":102},[],{"trials":13568,"activeCount":102},[13569],{"nctId":13548,"briefTitle":13549,"status":204,"phases":13570,"primaryCompletion":11604,"completion":11604,"start":13551,"enrollment":458,"conditions":13571,"interventions":13572},[94],[8080],[13533,13554],{"intervention":13574,"totalTrials":213,"cells":13575},"sedation with propofol",{"EARLY_PHASE1":13576,"PHASE1":13578,"PHASE2":13580,"PHASE3":13582,"PHASE4":13584,"NA":13586},{"trials":13577,"activeCount":102},[],{"trials":13579,"activeCount":102},[],{"trials":13581,"activeCount":102},[],{"trials":13583,"activeCount":102},[],{"trials":13585,"activeCount":102},[],{"trials":13587,"activeCount":102},[13588],{"nctId":13589,"briefTitle":13590,"status":204,"phases":13591,"primaryCompletion":3519,"completion":3519,"start":7502,"enrollment":13592,"conditions":13593,"interventions":13595},"NCT01855555","The Incidence and Nature of Adverse Events During Pediatric Sedation for MRI\u002FCT in One Korean University Hospital: Prospective Study",[],2948,[13594],"Children Requiring Sedation for MRI\u002FCT",[13574],{"intervention":13597,"totalTrials":213,"cells":13598},"Ketorolac tromethamine and remote ischemic preconditioning",{"EARLY_PHASE1":13599,"PHASE1":13601,"PHASE2":13603,"PHASE3":13605,"PHASE4":13607,"NA":13609},{"trials":13600,"activeCount":102},[],{"trials":13602,"activeCount":102},[],{"trials":13604,"activeCount":102},[],{"trials":13606,"activeCount":102},[],{"trials":13608,"activeCount":102},[],{"trials":13610,"activeCount":102},[13611],{"nctId":13612,"briefTitle":13613,"status":204,"phases":13614,"primaryCompletion":3658,"completion":3658,"start":320,"enrollment":3842,"conditions":13615,"interventions":13617},"NCT01836406","Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy",[94],[13616],"Renal Cell Carcinoma",[13597],{"intervention":13619,"totalTrials":213,"cells":13620},"tamoxifen",{"EARLY_PHASE1":13621,"PHASE1":13623,"PHASE2":13625,"PHASE3":13627,"PHASE4":13629,"NA":13631},{"trials":13622,"activeCount":102},[],{"trials":13624,"activeCount":102},[],{"trials":13626,"activeCount":102},[],{"trials":13628,"activeCount":102},[],{"trials":13630,"activeCount":102},[],{"trials":13632,"activeCount":102},[13633],{"nctId":13634,"briefTitle":13635,"status":204,"phases":13636,"conditions":13637,"interventions":13642},"NCT01169792","Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4\u002F5 and CYP2C19) in Breast Cancer Patients",[],[13638,13639,13640,13641],"Breast Neoplasms","Survival Analysis","Antineoplastic Agents","Therapeutic Uses",[13619],{"intervention":11096,"totalTrials":213,"cells":13644},{"EARLY_PHASE1":13645,"PHASE1":13647,"PHASE2":13649,"PHASE3":13651,"PHASE4":13653,"NA":13655},{"trials":13646,"activeCount":102},[],{"trials":13648,"activeCount":102},[],{"trials":13650,"activeCount":102},[],{"trials":13652,"activeCount":102},[],{"trials":13654,"activeCount":102},[],{"trials":13656,"activeCount":102},[13657],{"nctId":11088,"briefTitle":11089,"status":204,"phases":13658,"primaryCompletion":11091,"completion":11091,"start":11092,"enrollment":458,"conditions":13659,"interventions":13660},[94],[11094],[262,11096],{"intervention":13662,"totalTrials":213,"cells":13663},"Total intravenous anesthesia with Byfavo",{"EARLY_PHASE1":13664,"PHASE1":13666,"PHASE2":13668,"PHASE3":13670,"PHASE4":13672,"NA":13674},{"trials":13665,"activeCount":102},[],{"trials":13667,"activeCount":102},[],{"trials":13669,"activeCount":102},[],{"trials":13671,"activeCount":102},[],{"trials":13673,"activeCount":102},[],{"trials":13675,"activeCount":102},[13676],{"nctId":13677,"briefTitle":13678,"status":204,"phases":13679,"primaryCompletion":13680,"completion":13680,"start":13681,"enrollment":5220,"conditions":13682,"interventions":13683},"NCT06275425","Comparison of the Coughing Frequency of Remimazolam Total Intravenous Anesthesia Versus Inhalational Anesthesia",[94],"2023-11-29","2023-06-25",[3939,5018],[13662,13684],"Inhalation anesthesia with Sevoflurane",{"intervention":13684,"totalTrials":213,"cells":13686},{"EARLY_PHASE1":13687,"PHASE1":13689,"PHASE2":13691,"PHASE3":13693,"PHASE4":13695,"NA":13697},{"trials":13688,"activeCount":102},[],{"trials":13690,"activeCount":102},[],{"trials":13692,"activeCount":102},[],{"trials":13694,"activeCount":102},[],{"trials":13696,"activeCount":102},[],{"trials":13698,"activeCount":102},[13699],{"nctId":13677,"briefTitle":13678,"status":204,"phases":13700,"primaryCompletion":13680,"completion":13680,"start":13681,"enrollment":5220,"conditions":13701,"interventions":13702},[94],[3939,5018],[13662,13684],{"intervention":12749,"totalTrials":213,"cells":13704},{"EARLY_PHASE1":13705,"PHASE1":13707,"PHASE2":13709,"PHASE3":13711,"PHASE4":13713,"NA":13715},{"trials":13706,"activeCount":102},[],{"trials":13708,"activeCount":102},[],{"trials":13710,"activeCount":102},[],{"trials":13712,"activeCount":102},[],{"trials":13714,"activeCount":102},[],{"trials":13716,"activeCount":102},[13717],{"nctId":12741,"briefTitle":12742,"status":204,"phases":13718,"primaryCompletion":12744,"completion":12744,"start":12745,"enrollment":11108,"conditions":13719,"interventions":13720},[94],[12747],[12726,12749],{"intervention":12056,"totalTrials":213,"cells":13722},{"EARLY_PHASE1":13723,"PHASE1":13725,"PHASE2":13727,"PHASE3":13729,"PHASE4":13731,"NA":13733},{"trials":13724,"activeCount":102},[],{"trials":13726,"activeCount":102},[],{"trials":13728,"activeCount":102},[],{"trials":13730,"activeCount":102},[],{"trials":13732,"activeCount":102},[],{"trials":13734,"activeCount":102},[13735],{"nctId":12046,"briefTitle":12047,"status":308,"phases":13736,"primaryCompletion":12049,"completion":12050,"start":2612,"enrollment":12051,"conditions":13737,"interventions":13738},[94],[156,12053,12054],[4431,12056],{"intervention":13740,"totalTrials":213,"cells":13741},"Pacetin®",{"EARLY_PHASE1":13742,"PHASE1":13744,"PHASE2":13746,"PHASE3":13748,"PHASE4":13750,"NA":13752},{"trials":13743,"activeCount":102},[],{"trials":13745,"activeCount":102},[],{"trials":13747,"activeCount":102},[],{"trials":13749,"activeCount":102},[],{"trials":13751,"activeCount":102},[],{"trials":13753,"activeCount":102},[13754],{"nctId":13755,"briefTitle":13756,"status":308,"phases":13757,"primaryCompletion":7358,"completion":7358,"start":13758,"enrollment":11540,"conditions":13759,"interventions":13765},"NCT02958059","Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient",[94],"2016-12-01",[13760,13761,13762,13763,13764],"Biliary Obstructive Disease Such as Choledocholithiasis","Benign Biliary Stricture","Peri-ampullary Cancer","Bile Duct Cancer Resectable","Klatskin Tumor",[13740],{"intervention":11919,"totalTrials":213,"cells":13767},{"EARLY_PHASE1":13768,"PHASE1":13770,"PHASE2":13772,"PHASE3":13774,"PHASE4":13776,"NA":13778},{"trials":13769,"activeCount":102},[],{"trials":13771,"activeCount":102},[],{"trials":13773,"activeCount":102},[],{"trials":13775,"activeCount":102},[],{"trials":13777,"activeCount":102},[],{"trials":13779,"activeCount":102},[13780],{"nctId":11912,"briefTitle":11913,"status":204,"phases":13781,"primaryCompletion":7677,"completion":7677,"start":7085,"enrollment":1319,"conditions":13782,"interventions":13783},[94],[11916],[11918,11888,11919,11910],{"intervention":10862,"totalTrials":213,"cells":13785},{"EARLY_PHASE1":13786,"PHASE1":13788,"PHASE2":13790,"PHASE3":13792,"PHASE4":13794,"NA":13796},{"trials":13787,"activeCount":102},[],{"trials":13789,"activeCount":102},[],{"trials":13791,"activeCount":102},[],{"trials":13793,"activeCount":102},[],{"trials":13795,"activeCount":102},[],{"trials":13797,"activeCount":102},[13798],{"nctId":10857,"briefTitle":10858,"status":204,"phases":13799,"primaryCompletion":3658,"completion":3841,"start":3773,"enrollment":4177,"conditions":13800,"interventions":13801},[94],[21],[10862,4996],{"intervention":13803,"totalTrials":213,"cells":13804},"N(2)-L-Alanine L-Glutamine dipeptide",{"EARLY_PHASE1":13805,"PHASE1":13807,"PHASE2":13809,"PHASE3":13811,"PHASE4":13813,"NA":13815},{"trials":13806,"activeCount":102},[],{"trials":13808,"activeCount":102},[],{"trials":13810,"activeCount":102},[],{"trials":13812,"activeCount":102},[],{"trials":13814,"activeCount":102},[],{"trials":13816,"activeCount":102},[13817],{"nctId":13818,"briefTitle":13819,"status":308,"phases":13820,"primaryCompletion":11171,"completion":11171,"start":13821,"enrollment":5660,"conditions":13822,"interventions":13824},"NCT03341169","Impact of Perioperative Treatment With Intravenous Glutamine on Myocardial Protection in Cardiac Surgery Patients With Aortic Stenosis",[94],"2018-03-20",[13823],"Aortic Valve Stenois",[13803],{"intervention":13826,"totalTrials":213,"cells":13827},"Virtual AAD TEST group",{"EARLY_PHASE1":13828,"PHASE1":13830,"PHASE2":13832,"PHASE3":13834,"PHASE4":13836,"NA":13838},{"trials":13829,"activeCount":102},[],{"trials":13831,"activeCount":102},[],{"trials":13833,"activeCount":102},[],{"trials":13835,"activeCount":102},[],{"trials":13837,"activeCount":102},[],{"trials":13839,"activeCount":102},[13840],{"nctId":13841,"briefTitle":13842,"status":308,"phases":13843,"primaryCompletion":1556,"completion":1556,"start":11549,"enrollment":192,"conditions":13844,"interventions":13845},"NCT04223310","Clinical Usefulness of Virtual Antiarrhythmic Drug Test in Patients With Recurred AF After Catheter Ablation(CUVIA-AF3)",[94],[18],[13826,13846],"Empirical AAD group",{"intervention":13846,"totalTrials":213,"cells":13848},{"EARLY_PHASE1":13849,"PHASE1":13851,"PHASE2":13853,"PHASE3":13855,"PHASE4":13857,"NA":13859},{"trials":13850,"activeCount":102},[],{"trials":13852,"activeCount":102},[],{"trials":13854,"activeCount":102},[],{"trials":13856,"activeCount":102},[],{"trials":13858,"activeCount":102},[],{"trials":13860,"activeCount":102},[13861],{"nctId":13841,"briefTitle":13842,"status":308,"phases":13862,"primaryCompletion":1556,"completion":1556,"start":11549,"enrollment":192,"conditions":13863,"interventions":13864},[94],[18],[13826,13846],{"intervention":11994,"totalTrials":213,"cells":13866},{"EARLY_PHASE1":13867,"PHASE1":13869,"PHASE2":13871,"PHASE3":13873,"PHASE4":13875,"NA":13877},{"trials":13868,"activeCount":102},[],{"trials":13870,"activeCount":102},[],{"trials":13872,"activeCount":102},[],{"trials":13874,"activeCount":102},[],{"trials":13876,"activeCount":102},[],{"trials":13878,"activeCount":102},[13879],{"nctId":11989,"briefTitle":11990,"status":204,"phases":13880,"primaryCompletion":4453,"completion":4453,"start":3631,"enrollment":5660,"conditions":13881,"interventions":13882},[94],[10885,11966],[11966,11994],{"intervention":13884,"totalTrials":213,"cells":13885},"midazolam premedication",{"EARLY_PHASE1":13886,"PHASE1":13888,"PHASE2":13890,"PHASE3":13892,"PHASE4":13894,"NA":13896},{"trials":13887,"activeCount":102},[],{"trials":13889,"activeCount":102},[],{"trials":13891,"activeCount":102},[],{"trials":13893,"activeCount":102},[],{"trials":13895,"activeCount":102},[],{"trials":13897,"activeCount":102},[13898],{"nctId":13899,"briefTitle":13900,"status":204,"phases":13901,"primaryCompletion":3888,"completion":3888,"start":10883,"enrollment":11108,"conditions":13902,"interventions":13903},"NCT01945476","Effect of Midazolam Premedication Before Induction on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Surgery Due to Breast Cancer",[94],[30],[13884],{"intervention":12757,"totalTrials":213,"cells":13905},{"EARLY_PHASE1":13906,"PHASE1":13908,"PHASE2":13910,"PHASE3":13912,"PHASE4":13914,"NA":13916},{"trials":13907,"activeCount":102},[],{"trials":13909,"activeCount":102},[],{"trials":13911,"activeCount":102},[],{"trials":13913,"activeCount":102},[],{"trials":13915,"activeCount":102},[],{"trials":13917,"activeCount":102},[13918],{"nctId":12751,"briefTitle":12752,"status":204,"phases":13919,"primaryCompletion":4751,"completion":4751,"start":4900,"enrollment":3775,"conditions":13920,"interventions":13921},[94],[35],[12756,12757],{"intervention":13923,"totalTrials":213,"cells":13924},"Tenofovir disoproxil fumarate 300mg",{"EARLY_PHASE1":13925,"PHASE1":13927,"PHASE2":13929,"PHASE3":13931,"PHASE4":13933,"NA":13935},{"trials":13926,"activeCount":102},[],{"trials":13928,"activeCount":102},[],{"trials":13930,"activeCount":102},[],{"trials":13932,"activeCount":102},[],{"trials":13934,"activeCount":102},[],{"trials":13936,"activeCount":102},[13937],{"nctId":13938,"briefTitle":13939,"status":308,"phases":13940,"primaryCompletion":13941,"completion":9938,"start":13942,"enrollment":192,"conditions":13943,"interventions":13946},"NCT03566030","Switching From Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Antiviral Resistance",[],"2019-08-31","2018-09-01",[13944,13945],"Hepatitis B","Antiviral Drug Adverse Reaction",[13923,13947],"Tenofovir Alafenamide 25 mg",{"intervention":13947,"totalTrials":213,"cells":13949},{"EARLY_PHASE1":13950,"PHASE1":13952,"PHASE2":13954,"PHASE3":13956,"PHASE4":13958,"NA":13960},{"trials":13951,"activeCount":102},[],{"trials":13953,"activeCount":102},[],{"trials":13955,"activeCount":102},[],{"trials":13957,"activeCount":102},[],{"trials":13959,"activeCount":102},[],{"trials":13961,"activeCount":102},[13962],{"nctId":13938,"briefTitle":13939,"status":308,"phases":13963,"primaryCompletion":13941,"completion":9938,"start":13942,"enrollment":192,"conditions":13964,"interventions":13965},[],[13944,13945],[13923,13947],{"intervention":13967,"totalTrials":213,"cells":13968},"intravitreal bevacizumab and triamcinolone acetonide",{"EARLY_PHASE1":13969,"PHASE1":13971,"PHASE2":13973,"PHASE3":13975,"PHASE4":13977,"NA":13979},{"trials":13970,"activeCount":102},[],{"trials":13972,"activeCount":102},[],{"trials":13974,"activeCount":102},[],{"trials":13976,"activeCount":102},[],{"trials":13978,"activeCount":102},[],{"trials":13980,"activeCount":102},[13981],{"nctId":13982,"briefTitle":13983,"status":1475,"phases":13984,"completion":13224,"start":900,"enrollment":102,"conditions":13985,"interventions":13987},"NCT00447031","Combination Therapy for Neovascular Age Related Macular Degeneration",[94],[13986],"Macular Degeneration",[13967],{"intervention":13989,"totalTrials":213,"cells":13990},"1.0 ml\u002Fkg of 0.15% ropivacaine",{"EARLY_PHASE1":13991,"PHASE1":13993,"PHASE2":13995,"PHASE3":13997,"PHASE4":13999,"NA":14001},{"trials":13992,"activeCount":102},[],{"trials":13994,"activeCount":102},[],{"trials":13996,"activeCount":102},[],{"trials":13998,"activeCount":102},[],{"trials":14000,"activeCount":102},[],{"trials":14002,"activeCount":102},[14003],{"nctId":14004,"briefTitle":14005,"status":204,"phases":14006,"primaryCompletion":10160,"completion":10160,"start":979,"enrollment":233,"conditions":14007,"interventions":14014},"NCT02768493","Ultrasonographic Assessment of Optic Nerve Sheath Diameter in Children Receiving Caudal Block",[94],[14008,14009,14010,14011,14012,14013],"Orchiopexy","Inguinal Hernioplasty","Hydrocelectomy","Diverticulectomy","Fistula Repair","Penoplasty",[13989,14015],"1.5 ml\u002Fkg of 0.15% ropivacaine",{"intervention":14015,"totalTrials":213,"cells":14017},{"EARLY_PHASE1":14018,"PHASE1":14020,"PHASE2":14022,"PHASE3":14024,"PHASE4":14026,"NA":14028},{"trials":14019,"activeCount":102},[],{"trials":14021,"activeCount":102},[],{"trials":14023,"activeCount":102},[],{"trials":14025,"activeCount":102},[],{"trials":14027,"activeCount":102},[],{"trials":14029,"activeCount":102},[14030],{"nctId":14004,"briefTitle":14005,"status":204,"phases":14031,"primaryCompletion":10160,"completion":10160,"start":979,"enrollment":233,"conditions":14032,"interventions":14033},[94],[14008,14009,14010,14011,14012,14013],[13989,14015],{"intervention":14035,"totalTrials":213,"cells":14036},"Pregabalin_male",{"EARLY_PHASE1":14037,"PHASE1":14039,"PHASE2":14041,"PHASE3":14043,"PHASE4":14045,"NA":14047},{"trials":14038,"activeCount":102},[],{"trials":14040,"activeCount":102},[],{"trials":14042,"activeCount":102},[],{"trials":14044,"activeCount":102},[],{"trials":14046,"activeCount":102},[],{"trials":14048,"activeCount":102},[14049],{"nctId":14050,"briefTitle":14051,"status":1475,"phases":14052,"primaryCompletion":2889,"completion":4452,"start":7677,"enrollment":102,"conditions":14053,"interventions":14055},"NCT02340455","Effect of Oral Pregabalin on Hyperalgesia and Post-operative Pain in Patients Undergoing Nephrectomy Surgery: Sex Differential Study",[94],[14054],"Living Kidney Donors Undergoing VAMS-nephrectomy",[14035,14056,14057,14058],"Pregabalin_female","Placebo_Men","Placebo_Women",{"intervention":14056,"totalTrials":213,"cells":14060},{"EARLY_PHASE1":14061,"PHASE1":14063,"PHASE2":14065,"PHASE3":14067,"PHASE4":14069,"NA":14071},{"trials":14062,"activeCount":102},[],{"trials":14064,"activeCount":102},[],{"trials":14066,"activeCount":102},[],{"trials":14068,"activeCount":102},[],{"trials":14070,"activeCount":102},[],{"trials":14072,"activeCount":102},[14073],{"nctId":14050,"briefTitle":14051,"status":1475,"phases":14074,"primaryCompletion":2889,"completion":4452,"start":7677,"enrollment":102,"conditions":14075,"interventions":14076},[94],[14054],[14035,14056,14057,14058],{"intervention":14057,"totalTrials":213,"cells":14078},{"EARLY_PHASE1":14079,"PHASE1":14081,"PHASE2":14083,"PHASE3":14085,"PHASE4":14087,"NA":14089},{"trials":14080,"activeCount":102},[],{"trials":14082,"activeCount":102},[],{"trials":14084,"activeCount":102},[],{"trials":14086,"activeCount":102},[],{"trials":14088,"activeCount":102},[],{"trials":14090,"activeCount":102},[14091],{"nctId":14050,"briefTitle":14051,"status":1475,"phases":14092,"primaryCompletion":2889,"completion":4452,"start":7677,"enrollment":102,"conditions":14093,"interventions":14094},[94],[14054],[14035,14056,14057,14058],{"intervention":14058,"totalTrials":213,"cells":14096},{"EARLY_PHASE1":14097,"PHASE1":14099,"PHASE2":14101,"PHASE3":14103,"PHASE4":14105,"NA":14107},{"trials":14098,"activeCount":102},[],{"trials":14100,"activeCount":102},[],{"trials":14102,"activeCount":102},[],{"trials":14104,"activeCount":102},[],{"trials":14106,"activeCount":102},[],{"trials":14108,"activeCount":102},[14109],{"nctId":14050,"briefTitle":14051,"status":1475,"phases":14110,"primaryCompletion":2889,"completion":4452,"start":7677,"enrollment":102,"conditions":14111,"interventions":14112},[94],[14054],[14035,14056,14057,14058],{"intervention":14114,"totalTrials":213,"cells":14115},"inhalation (desflurane) group",{"EARLY_PHASE1":14116,"PHASE1":14118,"PHASE2":14120,"PHASE3":14122,"PHASE4":14124,"NA":14126},{"trials":14117,"activeCount":102},[],{"trials":14119,"activeCount":102},[],{"trials":14121,"activeCount":102},[],{"trials":14123,"activeCount":102},[],{"trials":14125,"activeCount":102},[],{"trials":14127,"activeCount":102},[14128],{"nctId":14129,"briefTitle":14130,"status":204,"phases":14131,"primaryCompletion":14132,"completion":14132,"start":14133,"enrollment":4776,"conditions":14134,"interventions":14136},"NCT03864276","The Comparison of Changes of QTc, Tp-e Interval, and Tp-e\u002FQT Ratio, Tp-e\u002FQTc Ratio on the ECG During Living Donor Liver Transplantation Under Desflurane and Total Intravenous Anesthesia -Randomized Controlled Trial",[94],"2020-12-31","2019-02-17",[14135],"Liver Cirrhosis(Who Will Undergo Planed Liver Transplantation)",[14114,14137],"total intravenous (propofol) anesthesia",{"intervention":14137,"totalTrials":213,"cells":14139},{"EARLY_PHASE1":14140,"PHASE1":14142,"PHASE2":14144,"PHASE3":14146,"PHASE4":14148,"NA":14150},{"trials":14141,"activeCount":102},[],{"trials":14143,"activeCount":102},[],{"trials":14145,"activeCount":102},[],{"trials":14147,"activeCount":102},[],{"trials":14149,"activeCount":102},[],{"trials":14151,"activeCount":102},[14152],{"nctId":14129,"briefTitle":14130,"status":204,"phases":14153,"primaryCompletion":14132,"completion":14132,"start":14133,"enrollment":4776,"conditions":14154,"interventions":14155},[94],[14135],[14114,14137],{"intervention":14157,"totalTrials":213,"cells":14158},"High-dose PPI",{"EARLY_PHASE1":14159,"PHASE1":14161,"PHASE2":14163,"PHASE3":14165,"PHASE4":14167,"NA":14169},{"trials":14160,"activeCount":102},[],{"trials":14162,"activeCount":102},[],{"trials":14164,"activeCount":102},[],{"trials":14166,"activeCount":102},[],{"trials":14168,"activeCount":102},[],{"trials":14170,"activeCount":102},[14171],{"nctId":14172,"briefTitle":14173,"status":204,"phases":14174,"primaryCompletion":1512,"completion":1512,"start":3773,"enrollment":1369,"conditions":14175,"interventions":14177},"NCT01888549","Efficacy of Proton Pump Inhibitor for Chronic Cough Caused by Gastroesophageal Reflux; Double-blind, Placebo-controlled, Randomized Clinical Trial",[94],[14176],"Chronic Cough Caused by Gastroesophageal Reflux",[14157,14178],"standard PPI",{"intervention":14178,"totalTrials":213,"cells":14180},{"EARLY_PHASE1":14181,"PHASE1":14183,"PHASE2":14185,"PHASE3":14187,"PHASE4":14189,"NA":14191},{"trials":14182,"activeCount":102},[],{"trials":14184,"activeCount":102},[],{"trials":14186,"activeCount":102},[],{"trials":14188,"activeCount":102},[],{"trials":14190,"activeCount":102},[],{"trials":14192,"activeCount":102},[14193],{"nctId":14172,"briefTitle":14173,"status":204,"phases":14194,"primaryCompletion":1512,"completion":1512,"start":3773,"enrollment":1369,"conditions":14195,"interventions":14196},[94],[14176],[14157,14178],{"intervention":12809,"totalTrials":213,"cells":14198},{"EARLY_PHASE1":14199,"PHASE1":14201,"PHASE2":14203,"PHASE3":14205,"PHASE4":14207,"NA":14209},{"trials":14200,"activeCount":102},[],{"trials":14202,"activeCount":102},[],{"trials":14204,"activeCount":102},[],{"trials":14206,"activeCount":102},[],{"trials":14208,"activeCount":102},[],{"trials":14210,"activeCount":102},[14211],{"nctId":12803,"briefTitle":12804,"status":204,"phases":14212,"primaryCompletion":3729,"completion":7211,"start":3468,"enrollment":2998,"conditions":14213,"interventions":14214},[94],[12807],[12809,12471],{"intervention":14216,"totalTrials":213,"cells":14217},"desflurane anesthetics",{"EARLY_PHASE1":14218,"PHASE1":14220,"PHASE2":14222,"PHASE3":14224,"PHASE4":14226,"NA":14228},{"trials":14219,"activeCount":102},[],{"trials":14221,"activeCount":102},[],{"trials":14223,"activeCount":102},[],{"trials":14225,"activeCount":102},[],{"trials":14227,"activeCount":102},[],{"trials":14229,"activeCount":102},[14230],{"nctId":14231,"briefTitle":14232,"status":204,"phases":14233,"primaryCompletion":3468,"completion":3468,"start":3798,"enrollment":458,"conditions":14234,"interventions":14237},"NCT01443572","The Comparison of Desflurane and Sevoflurane on Postoperative Recovery and Hepatic Function of Biliary Atresia Patients During Kasai Operation",[94],[14235,14236],"Kasai Operation","Biliary Atresia",[14216,14238],"sevoflurane anesthetics",{"intervention":14238,"totalTrials":213,"cells":14240},{"EARLY_PHASE1":14241,"PHASE1":14243,"PHASE2":14245,"PHASE3":14247,"PHASE4":14249,"NA":14251},{"trials":14242,"activeCount":102},[],{"trials":14244,"activeCount":102},[],{"trials":14246,"activeCount":102},[],{"trials":14248,"activeCount":102},[],{"trials":14250,"activeCount":102},[],{"trials":14252,"activeCount":102},[14253],{"nctId":14231,"briefTitle":14232,"status":204,"phases":14254,"primaryCompletion":3468,"completion":3468,"start":3798,"enrollment":458,"conditions":14255,"interventions":14256},[94],[14235,14236],[14216,14238],{"intervention":14258,"totalTrials":213,"cells":14259},"Pravastatin 20mg\u002Fday for 12 months after randomization",{"EARLY_PHASE1":14260,"PHASE1":14262,"PHASE2":14264,"PHASE3":14266,"PHASE4":14268,"NA":14270},{"trials":14261,"activeCount":102},[],{"trials":14263,"activeCount":102},[],{"trials":14265,"activeCount":102},[],{"trials":14267,"activeCount":102},[],{"trials":14269,"activeCount":102},[],{"trials":14271,"activeCount":102},[14272],{"nctId":14273,"briefTitle":14274,"status":204,"phases":14275,"primaryCompletion":14276,"completion":14276,"start":4703,"enrollment":14277,"conditions":14278,"interventions":14280},"NCT01857921","Combination Effects of High-dose Statin and Trimetazidine on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Coronary Artery Bypass Surgery",[94],"2018-04-08",290,[14279],"Coronary Artery",[14258,14281],"Atorvastatin 40 mg and trimetazidine MR 70 mg\u002Fday for 12 months after randomization",{"intervention":14281,"totalTrials":213,"cells":14283},{"EARLY_PHASE1":14284,"PHASE1":14286,"PHASE2":14288,"PHASE3":14290,"PHASE4":14292,"NA":14294},{"trials":14285,"activeCount":102},[],{"trials":14287,"activeCount":102},[],{"trials":14289,"activeCount":102},[],{"trials":14291,"activeCount":102},[],{"trials":14293,"activeCount":102},[],{"trials":14295,"activeCount":102},[14296],{"nctId":14273,"briefTitle":14274,"status":204,"phases":14297,"primaryCompletion":14276,"completion":14276,"start":4703,"enrollment":14277,"conditions":14298,"interventions":14299},[94],[14279],[14258,14281],{"intervention":2656,"totalTrials":213,"cells":14301},{"EARLY_PHASE1":14302,"PHASE1":14304,"PHASE2":14306,"PHASE3":14308,"PHASE4":14310,"NA":14312},{"trials":14303,"activeCount":102},[],{"trials":14305,"activeCount":102},[],{"trials":14307,"activeCount":102},[],{"trials":14309,"activeCount":102},[],{"trials":14311,"activeCount":102},[],{"trials":14313,"activeCount":102},[14314],{"nctId":2648,"briefTitle":2649,"status":308,"phases":14315,"primaryCompletion":2651,"completion":2651,"start":2652,"enrollment":344,"conditions":14316,"interventions":14317},[94],[2654],[62,2656],{"intervention":14319,"totalTrials":213,"cells":14320},"dexmedetomidine infusion rate, 0.5 mcg\u002Fkg\u002Fhr",{"EARLY_PHASE1":14321,"PHASE1":14323,"PHASE2":14325,"PHASE3":14327,"PHASE4":14329,"NA":14331},{"trials":14322,"activeCount":102},[],{"trials":14324,"activeCount":102},[],{"trials":14326,"activeCount":102},[],{"trials":14328,"activeCount":102},[],{"trials":14330,"activeCount":102},[],{"trials":14332,"activeCount":102},[14333],{"nctId":14334,"briefTitle":14335,"status":204,"phases":14336,"primaryCompletion":14337,"completion":14337,"start":14338,"enrollment":19,"conditions":14339,"interventions":14341},"NCT02148432","Establishment of Ideal IV Sedative Regimen for Successful Fiberoptic Bronchoscopy in Assessing the Site, Severity of Sleep Apnea Syndrome",[94],"2016-04-29","2014-05-19",[14340],"Sleep Apnea Syndrome",[14319,14342],"dexmedetomidine infusion rate, 1.0 mcg\u002Fkg\u002Fhr",{"intervention":14342,"totalTrials":213,"cells":14344},{"EARLY_PHASE1":14345,"PHASE1":14347,"PHASE2":14349,"PHASE3":14351,"PHASE4":14353,"NA":14355},{"trials":14346,"activeCount":102},[],{"trials":14348,"activeCount":102},[],{"trials":14350,"activeCount":102},[],{"trials":14352,"activeCount":102},[],{"trials":14354,"activeCount":102},[],{"trials":14356,"activeCount":102},[14357],{"nctId":14334,"briefTitle":14335,"status":204,"phases":14358,"primaryCompletion":14337,"completion":14337,"start":14338,"enrollment":19,"conditions":14359,"interventions":14360},[94],[14340],[14319,14342],{"intervention":933,"totalTrials":213,"cells":14362},{"EARLY_PHASE1":14363,"PHASE1":14365,"PHASE2":14367,"PHASE3":14369,"PHASE4":14371,"NA":14373},{"trials":14364,"activeCount":102},[],{"trials":14366,"activeCount":102},[],{"trials":14368,"activeCount":102},[],{"trials":14370,"activeCount":102},[],{"trials":14372,"activeCount":102},[],{"trials":14374,"activeCount":102},[14375],{"nctId":924,"briefTitle":925,"status":204,"phases":14376,"primaryCompletion":927,"completion":927,"start":928,"enrollment":929,"conditions":14377,"interventions":14378},[94],[931],[933,934],{"intervention":14380,"totalTrials":213,"cells":14381},"Administration of remifentanil with TCI system",{"EARLY_PHASE1":14382,"PHASE1":14384,"PHASE2":14386,"PHASE3":14388,"PHASE4":14390,"NA":14392},{"trials":14383,"activeCount":102},[],{"trials":14385,"activeCount":102},[],{"trials":14387,"activeCount":102},[],{"trials":14389,"activeCount":102},[],{"trials":14391,"activeCount":102},[],{"trials":14393,"activeCount":102},[14394],{"nctId":14395,"briefTitle":14396,"status":204,"phases":14397,"primaryCompletion":7383,"completion":7383,"start":7502,"enrollment":458,"conditions":14398,"interventions":14400},"NCT01735019","Estimating EC95 of Remifentanil for Cough Prevention During Emergence From Total Intravenous Anesthesia With Propofol and Remifentanil in Patients Undergoing Transsphenoidal Hypophysectomy",[94],[14399],"Hypophysectomy",[14380],{"intervention":14402,"totalTrials":213,"cells":14403},"norepinephrine",{"EARLY_PHASE1":14404,"PHASE1":14406,"PHASE2":14408,"PHASE3":14410,"PHASE4":14412,"NA":14414},{"trials":14405,"activeCount":102},[],{"trials":14407,"activeCount":102},[],{"trials":14409,"activeCount":102},[],{"trials":14411,"activeCount":102},[],{"trials":14413,"activeCount":102},[],{"trials":14415,"activeCount":102},[14416],{"nctId":14417,"briefTitle":14418,"status":308,"phases":14419,"primaryCompletion":1547,"completion":3292,"start":1268,"enrollment":258,"conditions":14420,"interventions":14422},"NCT05814601","Effect of Preemptive Low Dose Norepinephrine Infusion on Intraoperative Hemodynamic Stability and Postoperative Outcomes in Patients Undergoing Brain Tumor Resection With a Craniotomy",[94],[14421],"Brain Tumor",[14402],{"intervention":14424,"totalTrials":213,"cells":14425},"16 mcg \u002F cc of norepinephrine",{"EARLY_PHASE1":14426,"PHASE1":14428,"PHASE2":14430,"PHASE3":14432,"PHASE4":14434,"NA":14436},{"trials":14427,"activeCount":102},[],{"trials":14429,"activeCount":102},[],{"trials":14431,"activeCount":102},[],{"trials":14433,"activeCount":102},[],{"trials":14435,"activeCount":102},[],{"trials":14437,"activeCount":102},[14438],{"nctId":14439,"briefTitle":14440,"status":308,"phases":14441,"primaryCompletion":14442,"completion":14442,"start":14443,"enrollment":458,"conditions":14444,"interventions":14445},"NCT04170751","Effect of Vasopressin vs Norepinephrine on Pulmonary Oxygenation and Lung Mechanics in Patients With Hypertension Therapy During One-lung Ventilation : Preliminary Study",[94],"2021-09","2019-11-18",[3375],[14424,14446],"0.4 unit \u002F cc of vasopressin",{"intervention":14446,"totalTrials":213,"cells":14448},{"EARLY_PHASE1":14449,"PHASE1":14451,"PHASE2":14453,"PHASE3":14455,"PHASE4":14457,"NA":14459},{"trials":14450,"activeCount":102},[],{"trials":14452,"activeCount":102},[],{"trials":14454,"activeCount":102},[],{"trials":14456,"activeCount":102},[],{"trials":14458,"activeCount":102},[],{"trials":14460,"activeCount":102},[14461],{"nctId":14439,"briefTitle":14440,"status":308,"phases":14462,"primaryCompletion":14442,"completion":14442,"start":14443,"enrollment":458,"conditions":14463,"interventions":14464},[94],[3375],[14424,14446],{"intervention":14466,"totalTrials":213,"cells":14467},"1. Use of preservative free diquafosol ophthalmic solution after cataract surgery",{"EARLY_PHASE1":14468,"PHASE1":14470,"PHASE2":14472,"PHASE3":14474,"PHASE4":14476,"NA":14478},{"trials":14469,"activeCount":102},[],{"trials":14471,"activeCount":102},[],{"trials":14473,"activeCount":102},[],{"trials":14475,"activeCount":102},[],{"trials":14477,"activeCount":102},[],{"trials":14479,"activeCount":102},[14480],{"nctId":14481,"briefTitle":14482,"status":204,"phases":14483,"primaryCompletion":14484,"completion":14484,"start":14485,"enrollment":4300,"conditions":14486,"interventions":14489},"NCT03640351","Clinical Effects of Diquas-S for Patients With Dry Eye After Cataract Surgery",[94],"2019-02-13","2017-08-15",[14487,14488],"Dry Eye","Cataract Surgery",[14466,14490,14491],"2. Use of preservative containing diquafosol ophthalmic solution after cataract surgery","3. Use of preservative free sodium hyaluronate ophthalmic solution after cataract surgery",{"intervention":14490,"totalTrials":213,"cells":14493},{"EARLY_PHASE1":14494,"PHASE1":14496,"PHASE2":14498,"PHASE3":14500,"PHASE4":14502,"NA":14504},{"trials":14495,"activeCount":102},[],{"trials":14497,"activeCount":102},[],{"trials":14499,"activeCount":102},[],{"trials":14501,"activeCount":102},[],{"trials":14503,"activeCount":102},[],{"trials":14505,"activeCount":102},[14506],{"nctId":14481,"briefTitle":14482,"status":204,"phases":14507,"primaryCompletion":14484,"completion":14484,"start":14485,"enrollment":4300,"conditions":14508,"interventions":14509},[94],[14487,14488],[14466,14490,14491],{"intervention":14491,"totalTrials":213,"cells":14511},{"EARLY_PHASE1":14512,"PHASE1":14514,"PHASE2":14516,"PHASE3":14518,"PHASE4":14520,"NA":14522},{"trials":14513,"activeCount":102},[],{"trials":14515,"activeCount":102},[],{"trials":14517,"activeCount":102},[],{"trials":14519,"activeCount":102},[],{"trials":14521,"activeCount":102},[],{"trials":14523,"activeCount":102},[14524],{"nctId":14481,"briefTitle":14482,"status":204,"phases":14525,"primaryCompletion":14484,"completion":14484,"start":14485,"enrollment":4300,"conditions":14526,"interventions":14527},[94],[14487,14488],[14466,14490,14491],{"intervention":14529,"totalTrials":213,"cells":14530},"Zoledronic acid",{"EARLY_PHASE1":14531,"PHASE1":14533,"PHASE2":14535,"PHASE3":14537,"PHASE4":14539,"NA":14541},{"trials":14532,"activeCount":102},[],{"trials":14534,"activeCount":102},[],{"trials":14536,"activeCount":102},[],{"trials":14538,"activeCount":102},[],{"trials":14540,"activeCount":102},[],{"trials":14542,"activeCount":102},[14543],{"nctId":14544,"briefTitle":14545,"status":308,"phases":14546,"primaryCompletion":9229,"completion":609,"start":14547,"enrollment":1980,"conditions":14548,"interventions":14549},"NCT04652128","Effect of Zoledronic Acid on Prevention of Bone Loss in Acute Phase First-ever Stroke Patients",[94],"2019-07-15",[27],[14529],{"intervention":14551,"totalTrials":213,"cells":14552},"Conventional sedation",{"EARLY_PHASE1":14553,"PHASE1":14555,"PHASE2":14557,"PHASE3":14559,"PHASE4":14561,"NA":14563},{"trials":14554,"activeCount":102},[],{"trials":14556,"activeCount":102},[],{"trials":14558,"activeCount":102},[],{"trials":14560,"activeCount":102},[],{"trials":14562,"activeCount":102},[],{"trials":14564,"activeCount":102},[14565],{"nctId":14566,"briefTitle":14567,"status":204,"phases":14568,"primaryCompletion":962,"completion":962,"start":6340,"enrollment":7547,"conditions":14569,"interventions":14571},"NCT01840371","Randomized Controlled Study for Analyzing Clinical Benefit of Pain Focused Sedation With Combination of Fentanyl and Propofol During Endoscopic Retrograde Cholangiopancreatography (ERCP)",[94],[14570],"Endoscopic Retrograde Cholangiopancreatography",[14551,14572],"Experimental sedation",{"intervention":14572,"totalTrials":213,"cells":14574},{"EARLY_PHASE1":14575,"PHASE1":14577,"PHASE2":14579,"PHASE3":14581,"PHASE4":14583,"NA":14585},{"trials":14576,"activeCount":102},[],{"trials":14578,"activeCount":102},[],{"trials":14580,"activeCount":102},[],{"trials":14582,"activeCount":102},[],{"trials":14584,"activeCount":102},[],{"trials":14586,"activeCount":102},[14587],{"nctId":14566,"briefTitle":14567,"status":204,"phases":14588,"primaryCompletion":962,"completion":962,"start":6340,"enrollment":7547,"conditions":14589,"interventions":14590},[94],[14570],[14551,14572],{"intervention":14592,"totalTrials":213,"cells":14593},"IV ketamine\u002Flidocaine\u002FIV PCA apply",{"EARLY_PHASE1":14594,"PHASE1":14596,"PHASE2":14598,"PHASE3":14600,"PHASE4":14602,"NA":14604},{"trials":14595,"activeCount":102},[],{"trials":14597,"activeCount":102},[],{"trials":14599,"activeCount":102},[],{"trials":14601,"activeCount":102},[],{"trials":14603,"activeCount":102},[],{"trials":14605,"activeCount":102},[14606],{"nctId":14607,"briefTitle":14608,"status":1475,"phases":14609,"primaryCompletion":9615,"completion":14610,"start":4856,"enrollment":102,"conditions":14611,"interventions":14613},"NCT03462836","The Effects of Optimizing Post-operative Pain Management With Multi Modal Analgesia on Immune Suppression and Oncologic Outcome in Patients Undergoing Laparoscopic Colorectal Surgery",[94],"2021-09-28",[14612],"Laparoscopic Colorectal Resection Due to Cancer",[14592,14614],"IV PCA only apply",{"intervention":14614,"totalTrials":213,"cells":14616},{"EARLY_PHASE1":14617,"PHASE1":14619,"PHASE2":14621,"PHASE3":14623,"PHASE4":14625,"NA":14627},{"trials":14618,"activeCount":102},[],{"trials":14620,"activeCount":102},[],{"trials":14622,"activeCount":102},[],{"trials":14624,"activeCount":102},[],{"trials":14626,"activeCount":102},[],{"trials":14628,"activeCount":102},[14629],{"nctId":14607,"briefTitle":14608,"status":1475,"phases":14630,"primaryCompletion":9615,"completion":14610,"start":4856,"enrollment":102,"conditions":14631,"interventions":14632},[94],[14612],[14592,14614],{"intervention":14634,"totalTrials":213,"cells":14635},"Mirabegron (beta3-adrenoceptor agonist), Anticholinergics",{"EARLY_PHASE1":14636,"PHASE1":14638,"PHASE2":14640,"PHASE3":14642,"PHASE4":14644,"NA":14646},{"trials":14637,"activeCount":102},[],{"trials":14639,"activeCount":102},[],{"trials":14641,"activeCount":102},[],{"trials":14643,"activeCount":102},[],{"trials":14645,"activeCount":102},[],{"trials":14647,"activeCount":102},[14648],{"nctId":14649,"briefTitle":14650,"status":308,"phases":14651,"primaryCompletion":14652,"completion":14652,"start":14653,"enrollment":28,"conditions":14654,"interventions":14656},"NCT05745584","Effect of Mirabegron on Bladder Compliance",[94],"2023-03-02","2016-01-12",[14655],"Patients With Low Bladder Compliance of 20ml\u002FH2O or Less Despite Taking Anticholinergics",[14634],{"intervention":14658,"totalTrials":213,"cells":14659},"remimazolam based MAC",{"EARLY_PHASE1":14660,"PHASE1":14662,"PHASE2":14664,"PHASE3":14666,"PHASE4":14668,"NA":14670},{"trials":14661,"activeCount":102},[],{"trials":14663,"activeCount":102},[],{"trials":14665,"activeCount":102},[],{"trials":14667,"activeCount":102},[],{"trials":14669,"activeCount":102},[],{"trials":14671,"activeCount":102},[14672],{"nctId":14673,"briefTitle":14674,"status":308,"phases":14675,"primaryCompletion":14676,"completion":14676,"start":9573,"enrollment":7792,"conditions":14677,"interventions":14679},"NCT06217055","Comparison of Remimazolam-based MAC With Inhalation General Anesthesia Under the Guidance of an ANI Monitor During TURB",[94],"2024-10",[14678],"Patients Undergoing Transurethral Resection of Bladder",[14658,14680],"general anesthesia with sevoflurane",{"intervention":14680,"totalTrials":213,"cells":14682},{"EARLY_PHASE1":14683,"PHASE1":14685,"PHASE2":14687,"PHASE3":14689,"PHASE4":14691,"NA":14693},{"trials":14684,"activeCount":102},[],{"trials":14686,"activeCount":102},[],{"trials":14688,"activeCount":102},[],{"trials":14690,"activeCount":102},[],{"trials":14692,"activeCount":102},[],{"trials":14694,"activeCount":102},[14695],{"nctId":14673,"briefTitle":14674,"status":308,"phases":14696,"primaryCompletion":14676,"completion":14676,"start":9573,"enrollment":7792,"conditions":14697,"interventions":14698},[94],[14678],[14658,14680],{"intervention":14700,"totalTrials":213,"cells":14701},"Ultrasound guided serratus anterior block with ropivacaine",{"EARLY_PHASE1":14702,"PHASE1":14704,"PHASE2":14706,"PHASE3":14708,"PHASE4":14710,"NA":14712},{"trials":14703,"activeCount":102},[],{"trials":14705,"activeCount":102},[],{"trials":14707,"activeCount":102},[],{"trials":14709,"activeCount":102},[],{"trials":14711,"activeCount":102},[],{"trials":14713,"activeCount":102},[14714],{"nctId":14715,"briefTitle":14716,"status":204,"phases":14717,"primaryCompletion":14718,"completion":14718,"start":14719,"enrollment":458,"conditions":14720,"interventions":14721},"NCT02483923","Analgesic Effect to Postoperative Pain After Mastectomy: Ultrasound-guided Serratus Anterior Plane Block",[94],"2016-02-28","2015-06-16",[30],[14700,14722],"intravenous PCA only",{"intervention":14722,"totalTrials":213,"cells":14724},{"EARLY_PHASE1":14725,"PHASE1":14727,"PHASE2":14729,"PHASE3":14731,"PHASE4":14733,"NA":14735},{"trials":14726,"activeCount":102},[],{"trials":14728,"activeCount":102},[],{"trials":14730,"activeCount":102},[],{"trials":14732,"activeCount":102},[],{"trials":14734,"activeCount":102},[],{"trials":14736,"activeCount":102},[14737],{"nctId":14715,"briefTitle":14716,"status":204,"phases":14738,"primaryCompletion":14718,"completion":14718,"start":14719,"enrollment":458,"conditions":14739,"interventions":14740},[94],[30],[14700,14722],{"intervention":14742,"totalTrials":213,"cells":14743},"high-flow humidified oxygen-delivery system",{"EARLY_PHASE1":14744,"PHASE1":14746,"PHASE2":14748,"PHASE3":14750,"PHASE4":14752,"NA":14754},{"trials":14745,"activeCount":102},[],{"trials":14747,"activeCount":102},[],{"trials":14749,"activeCount":102},[],{"trials":14751,"activeCount":102},[],{"trials":14753,"activeCount":102},[],{"trials":14755,"activeCount":102},[14756],{"nctId":14757,"briefTitle":14758,"status":204,"phases":14759,"primaryCompletion":14760,"completion":14760,"start":6999,"enrollment":1501,"conditions":14761,"interventions":14763},"NCT03872674","A Trial Comparing High-flow Nasal Oxygen With Standard Management for Conscious Sedation During Endoscopic Retrograde Cholangiopancreatography in Prone Position",[94],"2019-04-18",[14762],"Patients Undergoing Endoscopic Retrograde Cholangiopancreatography in Prone Position",[14742],{"intervention":14765,"totalTrials":213,"cells":14766},"Dexmedetomidine - remifentanil group",{"EARLY_PHASE1":14767,"PHASE1":14769,"PHASE2":14771,"PHASE3":14773,"PHASE4":14775,"NA":14777},{"trials":14768,"activeCount":102},[],{"trials":14770,"activeCount":102},[],{"trials":14772,"activeCount":102},[],{"trials":14774,"activeCount":102},[],{"trials":14776,"activeCount":102},[],{"trials":14778,"activeCount":102},[14779],{"nctId":14780,"briefTitle":14781,"status":204,"phases":14782,"primaryCompletion":3657,"completion":12037,"start":9275,"enrollment":344,"conditions":14783,"interventions":14785},"NCT01920113","A Comparison of Efficacy and Safety During Endoscopic Submucosal Dissection Between Dexmedetomidine-remifentanil and Propofol-remifentanil",[94],[14784],"Early Gastric Cancer Patients Who Were Scheduled for Endoscopic Submucosal Dissection",[14765,14786],"Propofol - remifentanil group",{"intervention":14786,"totalTrials":213,"cells":14788},{"EARLY_PHASE1":14789,"PHASE1":14791,"PHASE2":14793,"PHASE3":14795,"PHASE4":14797,"NA":14799},{"trials":14790,"activeCount":102},[],{"trials":14792,"activeCount":102},[],{"trials":14794,"activeCount":102},[],{"trials":14796,"activeCount":102},[],{"trials":14798,"activeCount":102},[],{"trials":14800,"activeCount":102},[14801],{"nctId":14780,"briefTitle":14781,"status":204,"phases":14802,"primaryCompletion":3657,"completion":12037,"start":9275,"enrollment":344,"conditions":14803,"interventions":14804},[94],[14784],[14765,14786],{"intervention":14806,"totalTrials":213,"cells":14807},"NSAID patch",{"EARLY_PHASE1":14808,"PHASE1":14810,"PHASE2":14812,"PHASE3":14814,"PHASE4":14816,"NA":14818},{"trials":14809,"activeCount":102},[],{"trials":14811,"activeCount":102},[],{"trials":14813,"activeCount":102},[],{"trials":14815,"activeCount":102},[],{"trials":14817,"activeCount":102},[],{"trials":14819,"activeCount":102},[14820],{"nctId":14821,"briefTitle":14822,"status":204,"phases":14823,"primaryCompletion":4751,"completion":3866,"start":5399,"enrollment":222,"conditions":14824,"interventions":14826},"NCT01884116","Comparison of NSAID Patch Given in Monotherapy and NSAID Patch in Combination With Transcutaneous Electric Nerve Stimulation, Heating Pad, or Topical Capsaicin in the Treatment of Patients With Myofascial Pain Syndrome of the Upper Trapezius: A Pilot Study",[94],[14825],"Myofascial Pain Syndrome of the Upper Trapezius",[14806,14827,14828,14829],"NSAID patch + transcutaneous electric nerve stimulation","NSAID patch + heating pad","NSAID patch + topical capsaicin",{"intervention":14827,"totalTrials":213,"cells":14831},{"EARLY_PHASE1":14832,"PHASE1":14834,"PHASE2":14836,"PHASE3":14838,"PHASE4":14840,"NA":14842},{"trials":14833,"activeCount":102},[],{"trials":14835,"activeCount":102},[],{"trials":14837,"activeCount":102},[],{"trials":14839,"activeCount":102},[],{"trials":14841,"activeCount":102},[],{"trials":14843,"activeCount":102},[14844],{"nctId":14821,"briefTitle":14822,"status":204,"phases":14845,"primaryCompletion":4751,"completion":3866,"start":5399,"enrollment":222,"conditions":14846,"interventions":14847},[94],[14825],[14806,14827,14828,14829],{"intervention":14828,"totalTrials":213,"cells":14849},{"EARLY_PHASE1":14850,"PHASE1":14852,"PHASE2":14854,"PHASE3":14856,"PHASE4":14858,"NA":14860},{"trials":14851,"activeCount":102},[],{"trials":14853,"activeCount":102},[],{"trials":14855,"activeCount":102},[],{"trials":14857,"activeCount":102},[],{"trials":14859,"activeCount":102},[],{"trials":14861,"activeCount":102},[14862],{"nctId":14821,"briefTitle":14822,"status":204,"phases":14863,"primaryCompletion":4751,"completion":3866,"start":5399,"enrollment":222,"conditions":14864,"interventions":14865},[94],[14825],[14806,14827,14828,14829],{"intervention":14829,"totalTrials":213,"cells":14867},{"EARLY_PHASE1":14868,"PHASE1":14870,"PHASE2":14872,"PHASE3":14874,"PHASE4":14876,"NA":14878},{"trials":14869,"activeCount":102},[],{"trials":14871,"activeCount":102},[],{"trials":14873,"activeCount":102},[],{"trials":14875,"activeCount":102},[],{"trials":14877,"activeCount":102},[],{"trials":14879,"activeCount":102},[14880],{"nctId":14821,"briefTitle":14822,"status":204,"phases":14881,"primaryCompletion":4751,"completion":3866,"start":5399,"enrollment":222,"conditions":14882,"interventions":14883},[94],[14825],[14806,14827,14828,14829],{"intervention":14885,"totalTrials":213,"cells":14886},"remifentanil \u002F lidocaine",{"EARLY_PHASE1":14887,"PHASE1":14889,"PHASE2":14891,"PHASE3":14893,"PHASE4":14895,"NA":14897},{"trials":14888,"activeCount":102},[],{"trials":14890,"activeCount":102},[],{"trials":14892,"activeCount":102},[],{"trials":14894,"activeCount":102},[],{"trials":14896,"activeCount":102},[],{"trials":14898,"activeCount":102},[14899],{"nctId":14900,"briefTitle":14901,"status":204,"phases":14902,"primaryCompletion":3936,"completion":3936,"start":3937,"enrollment":1319,"conditions":14903,"interventions":14904},"NCT01082458","Comparison of Lidocaine and Remifentanil for the Effect on Responses to the Endotracheal Tube During Emergence From General Anesthesia",[94],[5126],[14885],{"intervention":14906,"totalTrials":213,"cells":14907},"sufentanil-remimazolam group",{"EARLY_PHASE1":14908,"PHASE1":14910,"PHASE2":14912,"PHASE3":14914,"PHASE4":14916,"NA":14918},{"trials":14909,"activeCount":102},[],{"trials":14911,"activeCount":102},[],{"trials":14913,"activeCount":102},[],{"trials":14915,"activeCount":102},[],{"trials":14917,"activeCount":102},[],{"trials":14919,"activeCount":102},[14920],{"nctId":14921,"briefTitle":14922,"status":308,"phases":14923,"primaryCompletion":3292,"completion":51,"start":1267,"enrollment":3775,"conditions":14924,"interventions":14925},"NCT05785234","The Effects of Sufentanil vs. Remifentanil in Total Intravenous Anesthesia With Remimazolam on Postoperative Pain",[94],[8444],[14906,14926],"remifentanil-remimazolam group",{"intervention":14926,"totalTrials":213,"cells":14928},{"EARLY_PHASE1":14929,"PHASE1":14931,"PHASE2":14933,"PHASE3":14935,"PHASE4":14937,"NA":14939},{"trials":14930,"activeCount":102},[],{"trials":14932,"activeCount":102},[],{"trials":14934,"activeCount":102},[],{"trials":14936,"activeCount":102},[],{"trials":14938,"activeCount":102},[],{"trials":14940,"activeCount":102},[14941],{"nctId":14921,"briefTitle":14922,"status":308,"phases":14942,"primaryCompletion":3292,"completion":51,"start":1267,"enrollment":3775,"conditions":14943,"interventions":14944},[94],[8444],[14906,14926],{"intervention":14946,"totalTrials":213,"cells":14947},"intravenous dexamethasone",{"EARLY_PHASE1":14948,"PHASE1":14950,"PHASE2":14952,"PHASE3":14954,"PHASE4":14956,"NA":14958},{"trials":14949,"activeCount":102},[],{"trials":14951,"activeCount":102},[],{"trials":14953,"activeCount":102},[],{"trials":14955,"activeCount":102},[],{"trials":14957,"activeCount":102},[],{"trials":14959,"activeCount":102},[14960],{"nctId":14961,"briefTitle":14962,"status":308,"phases":14963,"primaryCompletion":3797,"completion":3797,"start":7383,"enrollment":1243,"conditions":14964,"interventions":14966},"NCT02037399","Pilot Trial on Efficacy of Single Dose Perioperative Intravenous Dexamethasone for Pain Relief After Endoscopic Submucosal Dissection",[94],[14965],"Early Gastric Cancer or Gastric Adenoma",[14946,14967],"intravenous normal saline",{"intervention":14967,"totalTrials":213,"cells":14969},{"EARLY_PHASE1":14970,"PHASE1":14972,"PHASE2":14974,"PHASE3":14976,"PHASE4":14978,"NA":14980},{"trials":14971,"activeCount":102},[],{"trials":14973,"activeCount":102},[],{"trials":14975,"activeCount":102},[],{"trials":14977,"activeCount":102},[],{"trials":14979,"activeCount":102},[],{"trials":14981,"activeCount":102},[14982],{"nctId":14961,"briefTitle":14962,"status":308,"phases":14983,"primaryCompletion":3797,"completion":3797,"start":7383,"enrollment":1243,"conditions":14984,"interventions":14985},[94],[14965],[14946,14967],{"intervention":14987,"totalTrials":213,"cells":14988},"Hydroxyethyl starch 130\u002F0.4",{"EARLY_PHASE1":14989,"PHASE1":14991,"PHASE2":14993,"PHASE3":14995,"PHASE4":14997,"NA":14999},{"trials":14990,"activeCount":102},[],{"trials":14992,"activeCount":102},[],{"trials":14994,"activeCount":102},[],{"trials":14996,"activeCount":102},[],{"trials":14998,"activeCount":102},[],{"trials":15000,"activeCount":102},[15001],{"nctId":15002,"briefTitle":15003,"status":204,"phases":15004,"primaryCompletion":11083,"completion":3575,"start":6341,"enrollment":10984,"conditions":15005,"interventions":15007},"NCT01644084","A Comparison Between 5% Albumin and 6% Hydroxyethyl Starch 130\u002F0.4 in Priming Solution for Cardiopulmonary Bypass and Post-bypass Maintenance Fluid in High-risk Patients",[94],[15006],"Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass",[14987,14987,14987],{"intervention":15009,"totalTrials":213,"cells":15010},"epidural block with lidocaine and fentanyl",{"EARLY_PHASE1":15011,"PHASE1":15013,"PHASE2":15015,"PHASE3":15017,"PHASE4":15019,"NA":15021},{"trials":15012,"activeCount":102},[],{"trials":15014,"activeCount":102},[],{"trials":15016,"activeCount":102},[],{"trials":15018,"activeCount":102},[],{"trials":15020,"activeCount":102},[],{"trials":15022,"activeCount":102},[15023],{"nctId":15024,"briefTitle":15025,"status":204,"phases":15026,"primaryCompletion":284,"completion":962,"start":3658,"enrollment":25,"conditions":15027,"interventions":15030},"NCT01892332","The Effective Concentration of Lidocaine With Fentanyl in Lumbar Epidural Anesthesia for Transurethral Resection of Prostate(TURP) in Elderly Patients",[94],[15028,15029],"BPH( Benign Prostate Hyperplasia)","TURP(Transurethral Resection of Prostate)",[15009],{"intervention":15032,"totalTrials":213,"cells":15033},"Dual antiplatelet therapy including aspirin and clopidogrel after off-pump coronary bypass surgery",{"EARLY_PHASE1":15034,"PHASE1":15036,"PHASE2":15038,"PHASE3":15040,"PHASE4":15042,"NA":15044},{"trials":15035,"activeCount":102},[],{"trials":15037,"activeCount":102},[],{"trials":15039,"activeCount":102},[],{"trials":15041,"activeCount":102},[],{"trials":15043,"activeCount":102},[],{"trials":15045,"activeCount":102},[15046],{"nctId":15047,"briefTitle":15048,"status":204,"phases":15049,"primaryCompletion":3658,"completion":7383,"start":6523,"enrollment":15050,"conditions":15051,"interventions":15052},"NCT01959191","Clinical Significance of Platelet Reactivity on Clopidogrel During Off-pump Coronary Artery Bypass",[],859,[15],[15032],{"intervention":12894,"totalTrials":213,"cells":15054},{"EARLY_PHASE1":15055,"PHASE1":15057,"PHASE2":15059,"PHASE3":15061,"PHASE4":15063,"NA":15065},{"trials":15056,"activeCount":102},[],{"trials":15058,"activeCount":102},[],{"trials":15060,"activeCount":102},[],{"trials":15062,"activeCount":102},[],{"trials":15064,"activeCount":102},[],{"trials":15066,"activeCount":102},[15067],{"nctId":12888,"briefTitle":12889,"status":1475,"phases":15068,"primaryCompletion":4225,"completion":5123,"start":12037,"enrollment":102,"conditions":15069,"interventions":15070},[94],[12892],[12894,12895,12873,12896],{"intervention":12895,"totalTrials":213,"cells":15072},{"EARLY_PHASE1":15073,"PHASE1":15075,"PHASE2":15077,"PHASE3":15079,"PHASE4":15081,"NA":15083},{"trials":15074,"activeCount":102},[],{"trials":15076,"activeCount":102},[],{"trials":15078,"activeCount":102},[],{"trials":15080,"activeCount":102},[],{"trials":15082,"activeCount":102},[],{"trials":15084,"activeCount":102},[15085],{"nctId":12888,"briefTitle":12889,"status":1475,"phases":15086,"primaryCompletion":4225,"completion":5123,"start":12037,"enrollment":102,"conditions":15087,"interventions":15088},[94],[12892],[12894,12895,12873,12896],{"intervention":15090,"totalTrials":213,"cells":15091},"normal saline inhalation",{"EARLY_PHASE1":15092,"PHASE1":15094,"PHASE2":15096,"PHASE3":15098,"PHASE4":15100,"NA":15102},{"trials":15093,"activeCount":102},[],{"trials":15095,"activeCount":102},[],{"trials":15097,"activeCount":102},[],{"trials":15099,"activeCount":102},[],{"trials":15101,"activeCount":102},[],{"trials":15103,"activeCount":102},[15104],{"nctId":15105,"briefTitle":15106,"status":204,"phases":15107,"primaryCompletion":15108,"completion":15108,"start":15109,"enrollment":1909,"conditions":15110,"interventions":15113},"NCT04583046","Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation",[94],"2025-09-26","2020-11-02",[15111,15112],"Lung Cancer (Including Metastatic Cancer)","Pulmonary Infection",[15090,15114],"iloprost inhalation",{"intervention":15114,"totalTrials":213,"cells":15116},{"EARLY_PHASE1":15117,"PHASE1":15119,"PHASE2":15121,"PHASE3":15123,"PHASE4":15125,"NA":15127},{"trials":15118,"activeCount":102},[],{"trials":15120,"activeCount":102},[],{"trials":15122,"activeCount":102},[],{"trials":15124,"activeCount":102},[],{"trials":15126,"activeCount":102},[],{"trials":15128,"activeCount":102},[15129],{"nctId":15105,"briefTitle":15106,"status":204,"phases":15130,"primaryCompletion":15108,"completion":15108,"start":15109,"enrollment":1909,"conditions":15131,"interventions":15132},[94],[15111,15112],[15090,15114],{"intervention":15134,"totalTrials":213,"cells":15135},"Ezetimibe\u002FStatin Combination therarpy",{"EARLY_PHASE1":15136,"PHASE1":15138,"PHASE2":15140,"PHASE3":15142,"PHASE4":15144,"NA":15146},{"trials":15137,"activeCount":102},[],{"trials":15139,"activeCount":102},[],{"trials":15141,"activeCount":102},[],{"trials":15143,"activeCount":102},[],{"trials":15145,"activeCount":102},[],{"trials":15147,"activeCount":102},[15148],{"nctId":15149,"briefTitle":15150,"status":204,"phases":15151,"primaryCompletion":15152,"completion":15152,"start":15153,"enrollment":15154,"conditions":15155,"interventions":15156},"NCT04626973","Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting \u003C70 Versus \u003C55mg\u002FdL; Ez-PAVE Trial",[94],"2025-09-24","2021-01-15",3048,[11552],[15134,15157,15134,15157],"Statin monotherapy",{"intervention":15157,"totalTrials":213,"cells":15159},{"EARLY_PHASE1":15160,"PHASE1":15162,"PHASE2":15164,"PHASE3":15166,"PHASE4":15168,"NA":15170},{"trials":15161,"activeCount":102},[],{"trials":15163,"activeCount":102},[],{"trials":15165,"activeCount":102},[],{"trials":15167,"activeCount":102},[],{"trials":15169,"activeCount":102},[],{"trials":15171,"activeCount":102},[15172],{"nctId":15149,"briefTitle":15150,"status":204,"phases":15173,"primaryCompletion":15152,"completion":15152,"start":15153,"enrollment":15154,"conditions":15174,"interventions":15175},[94],[11552],[15134,15157,15134,15157],{"intervention":15177,"totalTrials":213,"cells":15178},"Treatment of pitavastatin 4 mg qd for 12 weeks",{"EARLY_PHASE1":15179,"PHASE1":15181,"PHASE2":15183,"PHASE3":15185,"PHASE4":15187,"NA":15189},{"trials":15180,"activeCount":102},[],{"trials":15182,"activeCount":102},[],{"trials":15184,"activeCount":102},[],{"trials":15186,"activeCount":102},[],{"trials":15188,"activeCount":102},[],{"trials":15190,"activeCount":102},[15191],{"nctId":15192,"briefTitle":15193,"status":204,"phases":15194,"primaryCompletion":15195,"completion":15195,"start":15196,"enrollment":1243,"conditions":15197,"interventions":15198},"NCT03730038","Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia",[94],"2020-02-13","2019-02-18",[664],[15177],{"intervention":1051,"totalTrials":213,"cells":15200},{"EARLY_PHASE1":15201,"PHASE1":15203,"PHASE2":15205,"PHASE3":15207,"PHASE4":15209,"NA":15211},{"trials":15202,"activeCount":102},[],{"trials":15204,"activeCount":102},[],{"trials":15206,"activeCount":102},[],{"trials":15208,"activeCount":102},[],{"trials":15210,"activeCount":102},[],{"trials":15212,"activeCount":102},[15213],{"nctId":1043,"briefTitle":1044,"status":308,"phases":15214,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":522,"conditions":15215,"interventions":15216},[94],[1049],[1051,304],{"intervention":15218,"totalTrials":213,"cells":15219},"Deep neuromuscular blockade",{"EARLY_PHASE1":15220,"PHASE1":15222,"PHASE2":15224,"PHASE3":15226,"PHASE4":15228,"NA":15230},{"trials":15221,"activeCount":102},[],{"trials":15223,"activeCount":102},[],{"trials":15225,"activeCount":102},[],{"trials":15227,"activeCount":102},[],{"trials":15229,"activeCount":102},[],{"trials":15231,"activeCount":102},[15232],{"nctId":15233,"briefTitle":15234,"status":204,"phases":15235,"primaryCompletion":15236,"completion":15236,"start":15237,"enrollment":1980,"conditions":15238,"interventions":15239},"NCT02762890","Comparison of Deep Neuromuscular Block and Moderate Neuromuscular Block on Quality of Recovery in Patients Undergoing Robotic Gastrectomy",[94],"2017-02-27","2016-10-06",[24],[15218,15240],"Moderate neuromuscular blockade",{"intervention":15240,"totalTrials":213,"cells":15242},{"EARLY_PHASE1":15243,"PHASE1":15245,"PHASE2":15247,"PHASE3":15249,"PHASE4":15251,"NA":15253},{"trials":15244,"activeCount":102},[],{"trials":15246,"activeCount":102},[],{"trials":15248,"activeCount":102},[],{"trials":15250,"activeCount":102},[],{"trials":15252,"activeCount":102},[],{"trials":15254,"activeCount":102},[15255],{"nctId":15233,"briefTitle":15234,"status":204,"phases":15256,"primaryCompletion":15236,"completion":15236,"start":15237,"enrollment":1980,"conditions":15257,"interventions":15258},[94],[24],[15218,15240],{"intervention":15260,"totalTrials":213,"cells":15261},"S1 transforaminal epidural steroid(dexamethasone)",{"EARLY_PHASE1":15262,"PHASE1":15264,"PHASE2":15266,"PHASE3":15268,"PHASE4":15270,"NA":15272},{"trials":15263,"activeCount":102},[],{"trials":15265,"activeCount":102},[],{"trials":15267,"activeCount":102},[],{"trials":15269,"activeCount":102},[],{"trials":15271,"activeCount":102},[],{"trials":15273,"activeCount":102},[15274],{"nctId":15275,"briefTitle":15276,"status":204,"phases":15277,"primaryCompletion":15278,"completion":15278,"start":15279,"enrollment":15280,"conditions":15281,"interventions":15283},"NCT02867046","The Incidence of the Intravascular Injection During S1 Transforaminal Epidural Steroid Injection in Two Approaches: Medial vs Lateral in Anteroposterior View",[94],"2016-11-28","2016-07-29",165,[15282],"Lumbosacral Radicular Pain",[15260],{"intervention":15285,"totalTrials":213,"cells":15286},"Des",{"EARLY_PHASE1":15287,"PHASE1":15289,"PHASE2":15291,"PHASE3":15293,"PHASE4":15295,"NA":15297},{"trials":15288,"activeCount":102},[],{"trials":15290,"activeCount":102},[],{"trials":15292,"activeCount":102},[],{"trials":15294,"activeCount":102},[],{"trials":15296,"activeCount":102},[],{"trials":15298,"activeCount":102},[15299],{"nctId":15300,"briefTitle":15301,"status":308,"phases":15302,"primaryCompletion":15303,"completion":15303,"start":15304,"enrollment":15305,"conditions":15306,"interventions":15308},"NCT03447691","Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery",[94],"2022-08-28","2017-08-27",132,[15307],"Pancreatic Cancer or Distal CBD Cancer",[15285,15309],"TIVA",{"intervention":15309,"totalTrials":213,"cells":15311},{"EARLY_PHASE1":15312,"PHASE1":15314,"PHASE2":15316,"PHASE3":15318,"PHASE4":15320,"NA":15322},{"trials":15313,"activeCount":102},[],{"trials":15315,"activeCount":102},[],{"trials":15317,"activeCount":102},[],{"trials":15319,"activeCount":102},[],{"trials":15321,"activeCount":102},[],{"trials":15323,"activeCount":102},[15324],{"nctId":15300,"briefTitle":15301,"status":308,"phases":15325,"primaryCompletion":15303,"completion":15303,"start":15304,"enrollment":15305,"conditions":15326,"interventions":15327},[94],[15307],[15285,15309],{"intervention":15329,"totalTrials":213,"cells":15330},"Motilitone",{"EARLY_PHASE1":15331,"PHASE1":15333,"PHASE2":15335,"PHASE3":15337,"PHASE4":15339,"NA":15341},{"trials":15332,"activeCount":102},[],{"trials":15334,"activeCount":102},[],{"trials":15336,"activeCount":102},[],{"trials":15338,"activeCount":102},[],{"trials":15340,"activeCount":102},[],{"trials":15342,"activeCount":102},[15343],{"nctId":15344,"briefTitle":15345,"status":308,"phases":15346,"primaryCompletion":14442,"completion":14442,"start":15347,"enrollment":258,"conditions":15348,"interventions":15350},"NCT04350346","The Comparative Analysis Between Motilitone and Gasmotin for the Symptom Relief in Gallstone Patients With Functional Dyspepsia",[94],"2020-03-25",[15349],"Gallstone",[15329,15351],"Gasmotin",{"intervention":15351,"totalTrials":213,"cells":15353},{"EARLY_PHASE1":15354,"PHASE1":15356,"PHASE2":15358,"PHASE3":15360,"PHASE4":15362,"NA":15364},{"trials":15355,"activeCount":102},[],{"trials":15357,"activeCount":102},[],{"trials":15359,"activeCount":102},[],{"trials":15361,"activeCount":102},[],{"trials":15363,"activeCount":102},[],{"trials":15365,"activeCount":102},[15366],{"nctId":15344,"briefTitle":15345,"status":308,"phases":15367,"primaryCompletion":14442,"completion":14442,"start":15347,"enrollment":258,"conditions":15368,"interventions":15369},[94],[15349],[15329,15351],{"intervention":15371,"totalTrials":213,"cells":15372},"scalp infiltration solution",{"EARLY_PHASE1":15373,"PHASE1":15375,"PHASE2":15377,"PHASE3":15379,"PHASE4":15381,"NA":15383},{"trials":15374,"activeCount":102},[],{"trials":15376,"activeCount":102},[],{"trials":15378,"activeCount":102},[],{"trials":15380,"activeCount":102},[],{"trials":15382,"activeCount":102},[],{"trials":15384,"activeCount":102},[15385],{"nctId":15386,"briefTitle":15387,"status":204,"phases":15388,"primaryCompletion":11070,"completion":11070,"start":5166,"enrollment":16,"conditions":15389,"interventions":15391},"NCT01606969","Comparison of Epinephrine-lidocaine Solution and Dexmedetomidine -Lidocaine Solution",[94],[15390],"Craniotomy",[15371,15371],{"intervention":15393,"totalTrials":213,"cells":15394},"fentanyl doses",{"EARLY_PHASE1":15395,"PHASE1":15397,"PHASE2":15399,"PHASE3":15401,"PHASE4":15403,"NA":15405},{"trials":15396,"activeCount":102},[],{"trials":15398,"activeCount":102},[],{"trials":15400,"activeCount":102},[],{"trials":15402,"activeCount":102},[],{"trials":15404,"activeCount":102},[],{"trials":15406,"activeCount":102},[15407],{"nctId":15408,"briefTitle":15409,"status":308,"phases":15410,"primaryCompletion":5743,"completion":5743,"start":10883,"enrollment":1538,"conditions":15411,"interventions":15413},"NCT02039453","Safety and Efficacy of Fentanyl Versus Pethidine During Propofol-based Sedated Colonoscopy: Prospective Randomized Study",[94],[15412],"Health Check up Colonoscopy",[15393,15414],"pethidine dose",{"intervention":15414,"totalTrials":213,"cells":15416},{"EARLY_PHASE1":15417,"PHASE1":15419,"PHASE2":15421,"PHASE3":15423,"PHASE4":15425,"NA":15427},{"trials":15418,"activeCount":102},[],{"trials":15420,"activeCount":102},[],{"trials":15422,"activeCount":102},[],{"trials":15424,"activeCount":102},[],{"trials":15426,"activeCount":102},[],{"trials":15428,"activeCount":102},[15429],{"nctId":15408,"briefTitle":15409,"status":308,"phases":15430,"primaryCompletion":5743,"completion":5743,"start":10883,"enrollment":1538,"conditions":15431,"interventions":15432},[94],[15412],[15393,15414],{"intervention":15434,"totalTrials":213,"cells":15435},"desflurane group",{"EARLY_PHASE1":15436,"PHASE1":15438,"PHASE2":15440,"PHASE3":15442,"PHASE4":15444,"NA":15446},{"trials":15437,"activeCount":102},[],{"trials":15439,"activeCount":102},[],{"trials":15441,"activeCount":102},[],{"trials":15443,"activeCount":102},[],{"trials":15445,"activeCount":102},[],{"trials":15447,"activeCount":102},[15448],{"nctId":15449,"briefTitle":15450,"status":204,"phases":15451,"primaryCompletion":3657,"completion":3657,"start":320,"enrollment":4992,"conditions":15452,"interventions":15454},"NCT01760018","Comparison Between Propofol-remifentanil Total Intravenous Anesthesia and Desflurane-remifentanil Balanced Anesthesia With Regard to Post-anesthetic Functional Recovery Measured With QoR-40",[94],[15453],"Thyroid Operation Under General Anesthesia",[15434,15455],"TIVA group",{"intervention":15455,"totalTrials":213,"cells":15457},{"EARLY_PHASE1":15458,"PHASE1":15460,"PHASE2":15462,"PHASE3":15464,"PHASE4":15466,"NA":15468},{"trials":15459,"activeCount":102},[],{"trials":15461,"activeCount":102},[],{"trials":15463,"activeCount":102},[],{"trials":15465,"activeCount":102},[],{"trials":15467,"activeCount":102},[],{"trials":15469,"activeCount":102},[15470],{"nctId":15449,"briefTitle":15450,"status":204,"phases":15471,"primaryCompletion":3657,"completion":3657,"start":320,"enrollment":4992,"conditions":15472,"interventions":15473},[94],[15453],[15434,15455],{"intervention":15475,"totalTrials":213,"cells":15476},"genotyping for three genes",{"EARLY_PHASE1":15477,"PHASE1":15479,"PHASE2":15481,"PHASE3":15483,"PHASE4":15485,"NA":15487},{"trials":15478,"activeCount":102},[],{"trials":15480,"activeCount":102},[],{"trials":15482,"activeCount":102},[],{"trials":15484,"activeCount":102},[],{"trials":15486,"activeCount":102},[],{"trials":15488,"activeCount":102},[15489],{"nctId":15490,"briefTitle":15491,"status":204,"phases":15492,"primaryCompletion":15493,"completion":15494,"start":15495,"enrollment":15496,"conditions":15497,"interventions":15499},"NCT03719118","Tailored Therapeutic Model According to the Expression of Genes in Inflammatory Bowel Disease Patients",[94],"2018-09-30","2018-10-05","2016-01-01",215,[15498],"Inflammatory Bowel Diseases",[15475],{"intervention":15501,"totalTrials":213,"cells":15502},"SVV",{"EARLY_PHASE1":15503,"PHASE1":15505,"PHASE2":15507,"PHASE3":15509,"PHASE4":15511,"NA":15513},{"trials":15504,"activeCount":102},[],{"trials":15506,"activeCount":102},[],{"trials":15508,"activeCount":102},[],{"trials":15510,"activeCount":102},[],{"trials":15512,"activeCount":102},[],{"trials":15514,"activeCount":102},[15515],{"nctId":15516,"briefTitle":15517,"status":204,"phases":15518,"primaryCompletion":981,"completion":3468,"start":320,"enrollment":1243,"conditions":15519,"interventions":15520},"NCT01738880","Effect of Goal-directed Fluid Therapy Based on Stroke Volume Variation on Metabolic Acidosis in Patients Undergoing Brain Tumor Surgery",[94],[14421],[15501,15521],"CVP",{"intervention":15521,"totalTrials":213,"cells":15523},{"EARLY_PHASE1":15524,"PHASE1":15526,"PHASE2":15528,"PHASE3":15530,"PHASE4":15532,"NA":15534},{"trials":15525,"activeCount":102},[],{"trials":15527,"activeCount":102},[],{"trials":15529,"activeCount":102},[],{"trials":15531,"activeCount":102},[],{"trials":15533,"activeCount":102},[],{"trials":15535,"activeCount":102},[15536],{"nctId":15516,"briefTitle":15517,"status":204,"phases":15537,"primaryCompletion":981,"completion":3468,"start":320,"enrollment":1243,"conditions":15538,"interventions":15539},[94],[14421],[15501,15521],{"intervention":15541,"totalTrials":213,"cells":15542},"pegylated Interferon-alpha 2a",{"EARLY_PHASE1":15543,"PHASE1":15545,"PHASE2":15547,"PHASE3":15549,"PHASE4":15551,"NA":15553},{"trials":15544,"activeCount":102},[],{"trials":15546,"activeCount":102},[],{"trials":15548,"activeCount":102},[],{"trials":15550,"activeCount":102},[],{"trials":15552,"activeCount":102},[],{"trials":15554,"activeCount":102},[15555],{"nctId":15556,"briefTitle":15557,"status":204,"phases":15558,"primaryCompletion":3888,"completion":963,"start":3798,"enrollment":15559,"conditions":15560,"interventions":15561},"NCT01531166","A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon",[],500,[3228],[15541],{"intervention":15563,"totalTrials":213,"cells":15564},"rs662799",{"EARLY_PHASE1":15565,"PHASE1":15567,"PHASE2":15569,"PHASE3":15571,"PHASE4":15573,"NA":15575},{"trials":15566,"activeCount":102},[],{"trials":15568,"activeCount":102},[],{"trials":15570,"activeCount":102},[],{"trials":15572,"activeCount":102},[],{"trials":15574,"activeCount":102},[],{"trials":15576,"activeCount":102},[15577],{"nctId":15578,"briefTitle":15579,"status":204,"phases":15580,"primaryCompletion":15581,"completion":15582,"start":15583,"enrollment":15584,"conditions":15585,"interventions":15587},"NCT03367598","Longitudinal Interaction Between APOA5 -1131T>C and Overweight Accelerates Arterial Stiffness",[],"2013-12-01","2013-12-31","2008-01-01",503,[15586],"Overweight and Obesity",[15563],{"intervention":15589,"totalTrials":213,"cells":15590},"Phenobarbital",{"EARLY_PHASE1":15591,"PHASE1":15593,"PHASE2":15595,"PHASE3":15597,"PHASE4":15599,"NA":15601},{"trials":15592,"activeCount":102},[],{"trials":15594,"activeCount":102},[],{"trials":15596,"activeCount":102},[],{"trials":15598,"activeCount":102},[],{"trials":15600,"activeCount":102},[],{"trials":15602,"activeCount":102},[15603],{"nctId":15604,"briefTitle":15605,"status":204,"phases":15606,"primaryCompletion":15607,"completion":899,"start":9717,"enrollment":16,"conditions":15608,"interventions":15610},"NCT01224457","Effect of CYP2C9\u002FCYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients.",[94],"2010-04",[15609],"Neonatal Seizure",[15589],{"intervention":15612,"totalTrials":213,"cells":15613},"Standard DAPT",{"EARLY_PHASE1":15614,"PHASE1":15616,"PHASE2":15618,"PHASE3":15620,"PHASE4":15622,"NA":15624},{"trials":15615,"activeCount":102},[],{"trials":15617,"activeCount":102},[],{"trials":15619,"activeCount":102},[],{"trials":15621,"activeCount":102},[],{"trials":15623,"activeCount":102},[],{"trials":15625,"activeCount":102},[15626],{"nctId":15627,"briefTitle":15628,"status":308,"phases":15629,"primaryCompletion":15630,"completion":15630,"start":15631,"enrollment":15632,"conditions":15633,"interventions":15635},"NCT03797651","Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial",[94],"2025-04-04","2019-04-24",2850,[15634],"Coronary Artery Disease, Acute Coronary Syndrome",[15612,15636],"Very-short DAPT less than 1 month after PCI",{"intervention":15636,"totalTrials":213,"cells":15638},{"EARLY_PHASE1":15639,"PHASE1":15641,"PHASE2":15643,"PHASE3":15645,"PHASE4":15647,"NA":15649},{"trials":15640,"activeCount":102},[],{"trials":15642,"activeCount":102},[],{"trials":15644,"activeCount":102},[],{"trials":15646,"activeCount":102},[],{"trials":15648,"activeCount":102},[],{"trials":15650,"activeCount":102},[15651],{"nctId":15627,"briefTitle":15628,"status":308,"phases":15652,"primaryCompletion":15630,"completion":15630,"start":15631,"enrollment":15632,"conditions":15653,"interventions":15654},[94],[15634],[15612,15636],{"intervention":15656,"totalTrials":213,"cells":15657},"carotid sonography and inferior vena cava sonography",{"EARLY_PHASE1":15658,"PHASE1":15660,"PHASE2":15662,"PHASE3":15664,"PHASE4":15666,"NA":15668},{"trials":15659,"activeCount":102},[],{"trials":15661,"activeCount":102},[],{"trials":15663,"activeCount":102},[],{"trials":15665,"activeCount":102},[],{"trials":15667,"activeCount":102},[],{"trials":15669,"activeCount":102},[15670],{"nctId":15671,"briefTitle":15672,"status":308,"phases":15673,"primaryCompletion":8051,"completion":8051,"start":10005,"enrollment":1886,"conditions":15674,"interventions":15675},"NCT03986112","Ability of Carotid Sonography and Inferior Vena Cava Sonography for the Prediction of Post-induction Hypotension in Hypertensive Patients",[],[24],[15656],{"intervention":15677,"totalTrials":213,"cells":15678},"Botulinum toxin",{"EARLY_PHASE1":15679,"PHASE1":15681,"PHASE2":15683,"PHASE3":15685,"PHASE4":15687,"NA":15689},{"trials":15680,"activeCount":102},[],{"trials":15682,"activeCount":102},[],{"trials":15684,"activeCount":102},[],{"trials":15686,"activeCount":102},[],{"trials":15688,"activeCount":102},[],{"trials":15690,"activeCount":102},[15691],{"nctId":15692,"briefTitle":15693,"status":204,"phases":15694,"primaryCompletion":15695,"completion":15695,"start":15696,"enrollment":19,"conditions":15697,"interventions":15698},"NCT02917967","A Pilot Study of the Effect of Botulinum Toxin Type a (Dysport®, Abobotulinum Toxin A) Injection on Changes in Musculotendinous Length and Dynamics of Hamstring Muscles During Gait in Children With Spastic Cerebral Palsy Walking With Excessive Knee Flexion",[94],"2018-09-03","2016-11-15",[8080],[15677],{"intervention":15700,"totalTrials":213,"cells":15701},"Caudal ropivacaine + normal saline",{"EARLY_PHASE1":15702,"PHASE1":15704,"PHASE2":15706,"PHASE3":15708,"PHASE4":15710,"NA":15712},{"trials":15703,"activeCount":102},[],{"trials":15705,"activeCount":102},[],{"trials":15707,"activeCount":102},[],{"trials":15709,"activeCount":102},[],{"trials":15711,"activeCount":102},[],{"trials":15713,"activeCount":102},[15714],{"nctId":15715,"briefTitle":15716,"status":204,"phases":15717,"primaryCompletion":4900,"completion":9276,"start":4900,"enrollment":233,"conditions":15718,"interventions":15720},"NCT02163980","Effect of Dexmedetomidine on the Characteristics of High Volume\u002FLow Concentration Ropivacaine in a Caudal Block in Pediatrics",[94],[15719],"Ambulatory Orchipexy",[15700,15721],"Caudal ropivacaine + dexmedetomidine",{"intervention":15721,"totalTrials":213,"cells":15723},{"EARLY_PHASE1":15724,"PHASE1":15726,"PHASE2":15728,"PHASE3":15730,"PHASE4":15732,"NA":15734},{"trials":15725,"activeCount":102},[],{"trials":15727,"activeCount":102},[],{"trials":15729,"activeCount":102},[],{"trials":15731,"activeCount":102},[],{"trials":15733,"activeCount":102},[],{"trials":15735,"activeCount":102},[15736],{"nctId":15715,"briefTitle":15716,"status":204,"phases":15737,"primaryCompletion":4900,"completion":9276,"start":4900,"enrollment":233,"conditions":15738,"interventions":15739},[94],[15719],[15700,15721],{"intervention":13002,"totalTrials":213,"cells":15741},{"EARLY_PHASE1":15742,"PHASE1":15744,"PHASE2":15746,"PHASE3":15748,"PHASE4":15750,"NA":15752},{"trials":15743,"activeCount":102},[],{"trials":15745,"activeCount":102},[],{"trials":15747,"activeCount":102},[],{"trials":15749,"activeCount":102},[],{"trials":15751,"activeCount":102},[],{"trials":15753,"activeCount":102},[15754],{"nctId":12995,"briefTitle":12996,"status":204,"phases":15755,"primaryCompletion":5398,"completion":5398,"start":11083,"enrollment":12998,"conditions":15756,"interventions":15757},[94],[13000],[12980,13002,13003],{"intervention":13003,"totalTrials":213,"cells":15759},{"EARLY_PHASE1":15760,"PHASE1":15762,"PHASE2":15764,"PHASE3":15766,"PHASE4":15768,"NA":15770},{"trials":15761,"activeCount":102},[],{"trials":15763,"activeCount":102},[],{"trials":15765,"activeCount":102},[],{"trials":15767,"activeCount":102},[],{"trials":15769,"activeCount":102},[],{"trials":15771,"activeCount":102},[15772],{"nctId":12995,"briefTitle":12996,"status":204,"phases":15773,"primaryCompletion":5398,"completion":5398,"start":11083,"enrollment":12998,"conditions":15774,"interventions":15775},[94],[13000],[12980,13002,13003],{"intervention":15777,"totalTrials":213,"cells":15778},"Calcitriol",{"EARLY_PHASE1":15779,"PHASE1":15781,"PHASE2":15783,"PHASE3":15785,"PHASE4":15787,"NA":15789},{"trials":15780,"activeCount":102},[],{"trials":15782,"activeCount":102},[],{"trials":15784,"activeCount":102},[],{"trials":15786,"activeCount":102},[],{"trials":15788,"activeCount":102},[],{"trials":15790,"activeCount":102},[15791],{"nctId":15792,"briefTitle":15793,"status":204,"phases":15794,"primaryCompletion":10160,"completion":10160,"start":5399,"enrollment":5124,"conditions":15795,"interventions":15796},"NCT01237028","Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers",[94],[7025],[15777],{"intervention":15798,"totalTrials":213,"cells":15799},"Icodextrin PD solution",{"EARLY_PHASE1":15800,"PHASE1":15802,"PHASE2":15804,"PHASE3":15806,"PHASE4":15808,"NA":15810},{"trials":15801,"activeCount":102},[],{"trials":15803,"activeCount":102},[],{"trials":15805,"activeCount":102},[],{"trials":15807,"activeCount":102},[],{"trials":15809,"activeCount":102},[],{"trials":15811,"activeCount":102},[15812],{"nctId":15813,"briefTitle":15814,"status":204,"phases":15815,"primaryCompletion":3888,"completion":3888,"start":4249,"enrollment":222,"conditions":15816,"interventions":15817},"NCT01170858","Effect of Icodextrin Solution on Preservation of Residual Renal Function in Patients on Peritoneal Dialysis",[94],[3522],[15798,15818],"glucose solutions",{"intervention":15818,"totalTrials":213,"cells":15820},{"EARLY_PHASE1":15821,"PHASE1":15823,"PHASE2":15825,"PHASE3":15827,"PHASE4":15829,"NA":15831},{"trials":15822,"activeCount":102},[],{"trials":15824,"activeCount":102},[],{"trials":15826,"activeCount":102},[],{"trials":15828,"activeCount":102},[],{"trials":15830,"activeCount":102},[],{"trials":15832,"activeCount":102},[15833],{"nctId":15813,"briefTitle":15814,"status":204,"phases":15834,"primaryCompletion":3888,"completion":3888,"start":4249,"enrollment":222,"conditions":15835,"interventions":15836},[94],[3522],[15798,15818],{"intervention":15838,"totalTrials":213,"cells":15839},"High dose dexamethasone",{"EARLY_PHASE1":15840,"PHASE1":15842,"PHASE2":15844,"PHASE3":15846,"PHASE4":15848,"NA":15850},{"trials":15841,"activeCount":102},[],{"trials":15843,"activeCount":102},[],{"trials":15845,"activeCount":102},[],{"trials":15847,"activeCount":102},[],{"trials":15849,"activeCount":102},[],{"trials":15851,"activeCount":102},[15852],{"nctId":15853,"briefTitle":15854,"status":204,"phases":15855,"primaryCompletion":15856,"completion":15857,"start":15858,"enrollment":15859,"conditions":15860,"interventions":15862},"NCT04841018","Does Low Dose of Dexamethasone Enhance Analgesic Quality of Caudal Analgesia in Children Undergoing Orchiopexy?",[94],"2023-08-29","2023-09-01","2021-03-24",273,[15861],"Patients With Cryptorchism Who Are Planning to Undergo Orchiopexy",[15838,15863],"Low dose dexamethasone",{"intervention":15863,"totalTrials":213,"cells":15865},{"EARLY_PHASE1":15866,"PHASE1":15868,"PHASE2":15870,"PHASE3":15872,"PHASE4":15874,"NA":15876},{"trials":15867,"activeCount":102},[],{"trials":15869,"activeCount":102},[],{"trials":15871,"activeCount":102},[],{"trials":15873,"activeCount":102},[],{"trials":15875,"activeCount":102},[],{"trials":15877,"activeCount":102},[15878],{"nctId":15853,"briefTitle":15854,"status":204,"phases":15879,"primaryCompletion":15856,"completion":15857,"start":15858,"enrollment":15859,"conditions":15880,"interventions":15881},[94],[15861],[15838,15863],{"intervention":15883,"totalTrials":213,"cells":15884},"up-and-down method to find out effective concentration of remifentanil for preventing cough",{"EARLY_PHASE1":15885,"PHASE1":15887,"PHASE2":15889,"PHASE3":15891,"PHASE4":15893,"NA":15895},{"trials":15886,"activeCount":102},[],{"trials":15888,"activeCount":102},[],{"trials":15890,"activeCount":102},[],{"trials":15892,"activeCount":102},[],{"trials":15894,"activeCount":102},[],{"trials":15896,"activeCount":102},[15897],{"nctId":15898,"briefTitle":15899,"status":204,"phases":15900,"primaryCompletion":6131,"completion":6131,"start":3575,"enrollment":1909,"conditions":15901,"interventions":15903},"NCT01351285","Comparison of Effect-site Concentration of Remifentanil for Preventing Cough Against Endotracheal Tube During Anesthetic Emergence According to Anesthetics (Sevoflurane, Desflurane, and Propofol)",[94],[15902],"Female Patients Undergoing Thyroidectomy",[15883],{"intervention":15905,"totalTrials":213,"cells":15906},"0.5 mcg\u002Fkg IV infusion for 10 min, 1.0 mcg\u002Fkg IV infusion for 10 min",{"EARLY_PHASE1":15907,"PHASE1":15909,"PHASE2":15911,"PHASE3":15913,"PHASE4":15915,"NA":15917},{"trials":15908,"activeCount":102},[],{"trials":15910,"activeCount":102},[],{"trials":15912,"activeCount":102},[],{"trials":15914,"activeCount":102},[],{"trials":15916,"activeCount":102},[],{"trials":15918,"activeCount":102},[15919],{"nctId":15920,"briefTitle":15921,"status":204,"phases":15922,"primaryCompletion":15923,"completion":15923,"start":15924,"enrollment":233,"conditions":15925,"interventions":15927},"NCT01584570","The Effects of Dexmedetomidine and Tracheal Intubation on Heart Rate Variability and QTc Interval",[94],"2013-12-23","2012-01-01",[15926],"Anesthesia, General",[15905],{"intervention":12215,"totalTrials":213,"cells":15929},{"EARLY_PHASE1":15930,"PHASE1":15932,"PHASE2":15934,"PHASE3":15936,"PHASE4":15938,"NA":15940},{"trials":15931,"activeCount":102},[],{"trials":15933,"activeCount":102},[],{"trials":15935,"activeCount":102},[],{"trials":15937,"activeCount":102},[],{"trials":15939,"activeCount":102},[],{"trials":15941,"activeCount":102},[15942],{"nctId":12207,"briefTitle":12208,"status":204,"phases":15943,"primaryCompletion":12210,"completion":12210,"start":3520,"enrollment":5124,"conditions":15944,"interventions":15945},[94],[12212],[12214,12215],{"intervention":15947,"totalTrials":213,"cells":15948},"Continuing aspirin",{"EARLY_PHASE1":15949,"PHASE1":15951,"PHASE2":15953,"PHASE3":15955,"PHASE4":15957,"NA":15959},{"trials":15950,"activeCount":102},[],{"trials":15952,"activeCount":102},[],{"trials":15954,"activeCount":102},[],{"trials":15956,"activeCount":102},[],{"trials":15958,"activeCount":102},[],{"trials":15960,"activeCount":102},[15961],{"nctId":15962,"briefTitle":15963,"status":243,"phases":15964,"primaryCompletion":15965,"completion":15965,"start":5447,"enrollment":7384,"conditions":15966,"interventions":15967},"NCT03184805","STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation",[94],"2018-04-09",[15],[15947,15968],"Stopping aspirin",{"intervention":15968,"totalTrials":213,"cells":15970},{"EARLY_PHASE1":15971,"PHASE1":15973,"PHASE2":15975,"PHASE3":15977,"PHASE4":15979,"NA":15981},{"trials":15972,"activeCount":102},[],{"trials":15974,"activeCount":102},[],{"trials":15976,"activeCount":102},[],{"trials":15978,"activeCount":102},[],{"trials":15980,"activeCount":102},[],{"trials":15982,"activeCount":102},[15983],{"nctId":15962,"briefTitle":15963,"status":243,"phases":15984,"primaryCompletion":15965,"completion":15965,"start":5447,"enrollment":7384,"conditions":15985,"interventions":15986},[94],[15],[15947,15968],{"intervention":15988,"totalTrials":213,"cells":15989},"Medical therapy group",{"EARLY_PHASE1":15990,"PHASE1":15992,"PHASE2":15994,"PHASE3":15996,"PHASE4":15998,"NA":16000},{"trials":15991,"activeCount":102},[],{"trials":15993,"activeCount":102},[],{"trials":15995,"activeCount":102},[],{"trials":15997,"activeCount":102},[],{"trials":15999,"activeCount":102},[],{"trials":16001,"activeCount":102},[16002],{"nctId":16003,"briefTitle":16004,"status":308,"phases":16005,"primaryCompletion":16006,"completion":16006,"start":6109,"enrollment":16007,"conditions":16008,"interventions":16009},"NCT04942171","EMOTIon and COgNitive Function After Atrial Fibrillation Catheter Ablation vs. Medical Therapy(EMOTICON Trial)",[94],"2026-02-23",320,[18],[15988],{"intervention":13048,"totalTrials":213,"cells":16011},{"EARLY_PHASE1":16012,"PHASE1":16014,"PHASE2":16016,"PHASE3":16018,"PHASE4":16020,"NA":16022},{"trials":16013,"activeCount":102},[],{"trials":16015,"activeCount":102},[],{"trials":16017,"activeCount":102},[],{"trials":16019,"activeCount":102},[],{"trials":16021,"activeCount":102},[],{"trials":16023,"activeCount":102},[16024],{"nctId":13041,"briefTitle":13042,"status":308,"phases":16025,"primaryCompletion":4476,"completion":13044,"start":13045,"enrollment":4300,"conditions":16026,"interventions":16027},[],[3914,664],[13015,13048],{"intervention":16029,"totalTrials":213,"cells":16030},"Atorvastatin 20 mg",{"EARLY_PHASE1":16031,"PHASE1":16033,"PHASE2":16035,"PHASE3":16037,"PHASE4":16039,"NA":16041},{"trials":16032,"activeCount":102},[],{"trials":16034,"activeCount":102},[],{"trials":16036,"activeCount":102},[],{"trials":16038,"activeCount":102},[],{"trials":16040,"activeCount":102},[],{"trials":16042,"activeCount":102},[16043],{"nctId":16044,"briefTitle":16045,"status":204,"phases":16046,"primaryCompletion":16047,"completion":16047,"start":16048,"enrollment":1886,"conditions":16049,"interventions":16050},"NCT02942602","Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia",[94],"2016-05-23","2014-04-03",[3578],[16029,16051,16052,16053],"Cholestyramine 8 g","Omega-3 2g","Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg",{"intervention":16051,"totalTrials":213,"cells":16055},{"EARLY_PHASE1":16056,"PHASE1":16058,"PHASE2":16060,"PHASE3":16062,"PHASE4":16064,"NA":16066},{"trials":16057,"activeCount":102},[],{"trials":16059,"activeCount":102},[],{"trials":16061,"activeCount":102},[],{"trials":16063,"activeCount":102},[],{"trials":16065,"activeCount":102},[],{"trials":16067,"activeCount":102},[16068],{"nctId":16044,"briefTitle":16045,"status":204,"phases":16069,"primaryCompletion":16047,"completion":16047,"start":16048,"enrollment":1886,"conditions":16070,"interventions":16071},[94],[3578],[16029,16051,16052,16053],{"intervention":16052,"totalTrials":213,"cells":16073},{"EARLY_PHASE1":16074,"PHASE1":16076,"PHASE2":16078,"PHASE3":16080,"PHASE4":16082,"NA":16084},{"trials":16075,"activeCount":102},[],{"trials":16077,"activeCount":102},[],{"trials":16079,"activeCount":102},[],{"trials":16081,"activeCount":102},[],{"trials":16083,"activeCount":102},[],{"trials":16085,"activeCount":102},[16086],{"nctId":16044,"briefTitle":16045,"status":204,"phases":16087,"primaryCompletion":16047,"completion":16047,"start":16048,"enrollment":1886,"conditions":16088,"interventions":16089},[94],[3578],[16029,16051,16052,16053],{"intervention":16053,"totalTrials":213,"cells":16091},{"EARLY_PHASE1":16092,"PHASE1":16094,"PHASE2":16096,"PHASE3":16098,"PHASE4":16100,"NA":16102},{"trials":16093,"activeCount":102},[],{"trials":16095,"activeCount":102},[],{"trials":16097,"activeCount":102},[],{"trials":16099,"activeCount":102},[],{"trials":16101,"activeCount":102},[],{"trials":16103,"activeCount":102},[16104],{"nctId":16044,"briefTitle":16045,"status":204,"phases":16105,"primaryCompletion":16047,"completion":16047,"start":16048,"enrollment":1886,"conditions":16106,"interventions":16107},[94],[3578],[16029,16051,16052,16053],{"intervention":16109,"totalTrials":213,"cells":16110},"tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration",{"EARLY_PHASE1":16111,"PHASE1":16113,"PHASE2":16115,"PHASE3":16117,"PHASE4":16119,"NA":16121},{"trials":16112,"activeCount":102},[],{"trials":16114,"activeCount":102},[],{"trials":16116,"activeCount":102},[],{"trials":16118,"activeCount":102},[],{"trials":16120,"activeCount":102},[],{"trials":16122,"activeCount":102},[16123],{"nctId":16124,"briefTitle":16125,"status":308,"phases":16126,"primaryCompletion":5984,"completion":5984,"start":16127,"enrollment":522,"conditions":16128,"interventions":16130},"NCT04583267","HIV Pre-exposure Prophylaxis Implementation Study in South Korea",[94],"2018-08-28",[16129],"HIV Infections",[16109],{"intervention":16132,"totalTrials":213,"cells":16133},"Remimazolam bolus does administration",{"EARLY_PHASE1":16134,"PHASE1":16136,"PHASE2":16138,"PHASE3":16140,"PHASE4":16142,"NA":16144},{"trials":16135,"activeCount":102},[],{"trials":16137,"activeCount":102},[],{"trials":16139,"activeCount":102},[],{"trials":16141,"activeCount":102},[],{"trials":16143,"activeCount":102},[],{"trials":16145,"activeCount":102},[16146],{"nctId":16147,"briefTitle":16148,"status":308,"phases":16149,"primaryCompletion":16150,"completion":16151,"start":16152,"enrollment":1394,"conditions":16153,"interventions":16154},"NCT05298228","Dose Finding Study of Remimazolam for Laryngeal Mask Airway Insertion",[94],"2023-07-26","2023-07-27","2022-03",[11884],[16132],{"intervention":12066,"totalTrials":213,"cells":16156},{"EARLY_PHASE1":16157,"PHASE1":16159,"PHASE2":16161,"PHASE3":16163,"PHASE4":16165,"NA":16167},{"trials":16158,"activeCount":102},[],{"trials":16160,"activeCount":102},[],{"trials":16162,"activeCount":102},[],{"trials":16164,"activeCount":102},[],{"trials":16166,"activeCount":102},[],{"trials":16168,"activeCount":102},[16169],{"nctId":12058,"briefTitle":12059,"status":204,"phases":16170,"primaryCompletion":12061,"completion":12061,"start":12062,"enrollment":12063,"conditions":16171,"interventions":16172},[94],[5831],[12066,4431],{"intervention":16174,"totalTrials":213,"cells":16175},"pepsinogen and gastrin",{"EARLY_PHASE1":16176,"PHASE1":16178,"PHASE2":16180,"PHASE3":16182,"PHASE4":16184,"NA":16186},{"trials":16177,"activeCount":102},[],{"trials":16179,"activeCount":102},[],{"trials":16181,"activeCount":102},[],{"trials":16183,"activeCount":102},[],{"trials":16185,"activeCount":102},[],{"trials":16187,"activeCount":102},[16188],{"nctId":16189,"briefTitle":16190,"status":308,"phases":16191,"primaryCompletion":310,"completion":310,"start":3520,"enrollment":5660,"conditions":16192,"interventions":16194},"NCT02184910","Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea",[],[16193],"Atrophic Gastritis",[16174],{"intervention":16196,"totalTrials":213,"cells":16197},"botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle",{"EARLY_PHASE1":16198,"PHASE1":16200,"PHASE2":16202,"PHASE3":16204,"PHASE4":16206,"NA":16208},{"trials":16199,"activeCount":102},[],{"trials":16201,"activeCount":102},[],{"trials":16203,"activeCount":102},[],{"trials":16205,"activeCount":102},[],{"trials":16207,"activeCount":102},[],{"trials":16209,"activeCount":102},[16210],{"nctId":16211,"briefTitle":16212,"status":204,"phases":16213,"primaryCompletion":16214,"completion":16214,"start":16215,"enrollment":1243,"conditions":16216,"interventions":16218},"NCT02444351","Botulinum Toxin Type A Injection Into the Gastrocnemius Muscle for Treatment of Nocturnal Calf Cramps in Patients With Lumbar Spinal Stenosis",[94],"2016-06-30","2015-06-26",[16217],"Spinal Stenosis With Nocturnal Calf Cramps",[16196],{"intervention":12005,"totalTrials":213,"cells":16220},{"EARLY_PHASE1":16221,"PHASE1":16223,"PHASE2":16225,"PHASE3":16227,"PHASE4":16229,"NA":16231},{"trials":16222,"activeCount":102},[],{"trials":16224,"activeCount":102},[],{"trials":16226,"activeCount":102},[],{"trials":16228,"activeCount":102},[],{"trials":16230,"activeCount":102},[],{"trials":16232,"activeCount":102},[16233],{"nctId":11996,"briefTitle":11997,"status":204,"phases":16234,"primaryCompletion":11999,"completion":12000,"start":12001,"enrollment":12002,"conditions":16235,"interventions":16236},[94],[10854],[12005,12006,12007],{"intervention":12007,"totalTrials":213,"cells":16238},{"EARLY_PHASE1":16239,"PHASE1":16241,"PHASE2":16243,"PHASE3":16245,"PHASE4":16247,"NA":16249},{"trials":16240,"activeCount":102},[],{"trials":16242,"activeCount":102},[],{"trials":16244,"activeCount":102},[],{"trials":16246,"activeCount":102},[],{"trials":16248,"activeCount":102},[],{"trials":16250,"activeCount":102},[16251],{"nctId":11996,"briefTitle":11997,"status":204,"phases":16252,"primaryCompletion":11999,"completion":12000,"start":12001,"enrollment":12002,"conditions":16253,"interventions":16254},[94],[10854],[12005,12006,12007],{"intervention":16256,"totalTrials":213,"cells":16257},"6% hydroxyethyl starch 130\u002F0.4 and 5% albumin",{"EARLY_PHASE1":16258,"PHASE1":16260,"PHASE2":16262,"PHASE3":16264,"PHASE4":16266,"NA":16268},{"trials":16259,"activeCount":102},[],{"trials":16261,"activeCount":102},[],{"trials":16263,"activeCount":102},[],{"trials":16265,"activeCount":102},[],{"trials":16267,"activeCount":102},[],{"trials":16269,"activeCount":102},[16270],{"nctId":16271,"briefTitle":16272,"status":204,"phases":16273,"primaryCompletion":1477,"completion":7909,"start":3453,"enrollment":1557,"conditions":16274,"interventions":16276},"NCT00978588","Comparison of 6% Hydroxyethyl Starch 130\u002F0.4 With 5% Albumin as Priming Solution for Cardiopulmonary Bypass",[94],[16275],"Mitral Valvular Heart Disease",[16256],{"intervention":16278,"totalTrials":213,"cells":16279},"Pressure Ulcer Nursing AI Application Training",{"EARLY_PHASE1":16280,"PHASE1":16282,"PHASE2":16284,"PHASE3":16286,"PHASE4":16288,"NA":16290},{"trials":16281,"activeCount":102},[],{"trials":16283,"activeCount":102},[],{"trials":16285,"activeCount":102},[],{"trials":16287,"activeCount":102},[],{"trials":16289,"activeCount":102},[],{"trials":16291,"activeCount":102},[16292],{"nctId":16293,"briefTitle":16294,"status":204,"phases":16295,"primaryCompletion":16296,"completion":16296,"start":16297,"enrollment":8897,"conditions":16298,"interventions":16301},"NCT07132320","Development and Effectiveness Verification of an AI Application for Pressure Injury Nursing Based on Clinical Judgment Model",[94],"2024-12-10","2024-11-15",[16299,16300],"Pressure Ulcer","Nursing Education",[16278,16302],"Traditional Pressure Ulcer Nursing Education",{"intervention":16302,"totalTrials":213,"cells":16304},{"EARLY_PHASE1":16305,"PHASE1":16307,"PHASE2":16309,"PHASE3":16311,"PHASE4":16313,"NA":16315},{"trials":16306,"activeCount":102},[],{"trials":16308,"activeCount":102},[],{"trials":16310,"activeCount":102},[],{"trials":16312,"activeCount":102},[],{"trials":16314,"activeCount":102},[],{"trials":16316,"activeCount":102},[16317],{"nctId":16293,"briefTitle":16294,"status":204,"phases":16318,"primaryCompletion":16296,"completion":16296,"start":16297,"enrollment":8897,"conditions":16319,"interventions":16320},[94],[16299,16300],[16278,16302],{"intervention":16322,"totalTrials":213,"cells":16323},"chloral hydrate",{"EARLY_PHASE1":16324,"PHASE1":16326,"PHASE2":16328,"PHASE3":16330,"PHASE4":16332,"NA":16334},{"trials":16325,"activeCount":102},[],{"trials":16327,"activeCount":102},[],{"trials":16329,"activeCount":102},[],{"trials":16331,"activeCount":102},[],{"trials":16333,"activeCount":102},[],{"trials":16335,"activeCount":102},[16336],{"nctId":16337,"briefTitle":16338,"status":204,"phases":16339,"primaryCompletion":4703,"completion":4703,"start":899,"enrollment":222,"conditions":16340,"interventions":16342},"NCT01149226","Effects of Chloral Hydrate on Induction, Maintenance, and Recovery From Sevoflurane Anesthesia in Day-case Pediatric Surgery",[94],[16341],"Pediatric",[16322],{"intervention":16344,"totalTrials":213,"cells":16345},"topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage",{"EARLY_PHASE1":16346,"PHASE1":16348,"PHASE2":16350,"PHASE3":16352,"PHASE4":16354,"NA":16356},{"trials":16347,"activeCount":102},[],{"trials":16349,"activeCount":102},[],{"trials":16351,"activeCount":102},[],{"trials":16353,"activeCount":102},[],{"trials":16355,"activeCount":102},[],{"trials":16357,"activeCount":102},[16358],{"nctId":16359,"briefTitle":16360,"status":204,"phases":16361,"primaryCompletion":12037,"completion":12037,"start":3866,"enrollment":9277,"conditions":16362,"interventions":16364},"NCT01692652","Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate",[94],[16363],"Moderate and Severe Meibomiang Gland Dysfunction (Stage 3 or Stage 4 Meibomiang Gland Dysfunction)",[16344],{"intervention":16366,"totalTrials":213,"cells":16367},"Deep neuromuscular block with 'rocunium®'",{"EARLY_PHASE1":16368,"PHASE1":16370,"PHASE2":16372,"PHASE3":16374,"PHASE4":16376,"NA":16378},{"trials":16369,"activeCount":102},[],{"trials":16371,"activeCount":102},[],{"trials":16373,"activeCount":102},[],{"trials":16375,"activeCount":102},[],{"trials":16377,"activeCount":102},[],{"trials":16379,"activeCount":102},[16380],{"nctId":16381,"briefTitle":16382,"status":204,"phases":16383,"primaryCompletion":16384,"completion":16384,"start":9230,"enrollment":7792,"conditions":16385,"interventions":16387},"NCT03937440","The Effect of Deep Neuromuscular Block on the Perioperative Stress Response Reduction and Postoperative Recovery Enhancement in Robot-assisted Stomach Cancer Surgery",[94],"2019-12-15",[16386],"Stomach Cancer",[16366,16388],"Moderate neuromuscular block with 'rocunium®'",{"intervention":16388,"totalTrials":213,"cells":16390},{"EARLY_PHASE1":16391,"PHASE1":16393,"PHASE2":16395,"PHASE3":16397,"PHASE4":16399,"NA":16401},{"trials":16392,"activeCount":102},[],{"trials":16394,"activeCount":102},[],{"trials":16396,"activeCount":102},[],{"trials":16398,"activeCount":102},[],{"trials":16400,"activeCount":102},[],{"trials":16402,"activeCount":102},[16403],{"nctId":16381,"briefTitle":16382,"status":204,"phases":16404,"primaryCompletion":16384,"completion":16384,"start":9230,"enrollment":7792,"conditions":16405,"interventions":16406},[94],[16386],[16366,16388],{"intervention":16408,"totalTrials":213,"cells":16409},"liothyronine sodium",{"EARLY_PHASE1":16410,"PHASE1":16412,"PHASE2":16414,"PHASE3":16416,"PHASE4":16418,"NA":16420},{"trials":16411,"activeCount":102},[],{"trials":16413,"activeCount":102},[],{"trials":16415,"activeCount":102},[],{"trials":16417,"activeCount":102},[],{"trials":16419,"activeCount":102},[],{"trials":16421,"activeCount":102},[16422],{"nctId":16423,"briefTitle":16424,"status":204,"phases":16425,"primaryCompletion":964,"completion":3798,"start":206,"enrollment":222,"conditions":16426,"interventions":16428},"NCT01153360","Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery",[94],[16427],"Non-thyroidal Illness Syndrome",[16408],{"intervention":16430,"totalTrials":213,"cells":16431},"Polaprezinc",{"EARLY_PHASE1":16432,"PHASE1":16434,"PHASE2":16436,"PHASE3":16438,"PHASE4":16440,"NA":16442},{"trials":16433,"activeCount":102},[],{"trials":16435,"activeCount":102},[],{"trials":16437,"activeCount":102},[],{"trials":16439,"activeCount":102},[],{"trials":16441,"activeCount":102},[],{"trials":16443,"activeCount":102},[16444],{"nctId":16445,"briefTitle":16446,"status":204,"phases":16447,"primaryCompletion":16448,"completion":16448,"start":16449,"enrollment":6385,"conditions":16450,"interventions":16452},"NCT02243618","The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer",[94],"2016-04-14","2015-01-14",[11475,16451],"Early Gastric Cancer",[16430,16453],"Rebamipide",{"intervention":16453,"totalTrials":213,"cells":16455},{"EARLY_PHASE1":16456,"PHASE1":16458,"PHASE2":16460,"PHASE3":16462,"PHASE4":16464,"NA":16466},{"trials":16457,"activeCount":102},[],{"trials":16459,"activeCount":102},[],{"trials":16461,"activeCount":102},[],{"trials":16463,"activeCount":102},[],{"trials":16465,"activeCount":102},[],{"trials":16467,"activeCount":102},[16468],{"nctId":16445,"briefTitle":16446,"status":204,"phases":16469,"primaryCompletion":16448,"completion":16448,"start":16449,"enrollment":6385,"conditions":16470,"interventions":16471},[94],[11475,16451],[16430,16453],{"intervention":16473,"totalTrials":213,"cells":16474},"Dexmedetomidine, Transesophageal echocardiography",{"EARLY_PHASE1":16475,"PHASE1":16477,"PHASE2":16479,"PHASE3":16481,"PHASE4":16483,"NA":16485},{"trials":16476,"activeCount":102},[],{"trials":16478,"activeCount":102},[],{"trials":16480,"activeCount":102},[],{"trials":16482,"activeCount":102},[],{"trials":16484,"activeCount":102},[],{"trials":16486,"activeCount":102},[16487],{"nctId":16488,"briefTitle":16489,"status":204,"phases":16490,"primaryCompletion":5575,"completion":5575,"start":8353,"enrollment":22,"conditions":16491,"interventions":16493},"NCT02300649","Transesophageal Echocardiographic Evaluation of the Effect of Dexmedetomidine Infusion as an Adjuvant to General Anesthesia on the Cardiac Function",[94],[16492],"Anesthesia",[16473,16494],"Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.",{"intervention":16494,"totalTrials":213,"cells":16496},{"EARLY_PHASE1":16497,"PHASE1":16499,"PHASE2":16501,"PHASE3":16503,"PHASE4":16505,"NA":16507},{"trials":16498,"activeCount":102},[],{"trials":16500,"activeCount":102},[],{"trials":16502,"activeCount":102},[],{"trials":16504,"activeCount":102},[],{"trials":16506,"activeCount":102},[],{"trials":16508,"activeCount":102},[16509],{"nctId":16488,"briefTitle":16489,"status":204,"phases":16510,"primaryCompletion":5575,"completion":5575,"start":8353,"enrollment":22,"conditions":16511,"interventions":16512},[94],[16492],[16473,16494],{"intervention":16514,"totalTrials":213,"cells":16515},"3% diquafosol eyedrops",{"EARLY_PHASE1":16516,"PHASE1":16518,"PHASE2":16520,"PHASE3":16522,"PHASE4":16524,"NA":16526},{"trials":16517,"activeCount":102},[],{"trials":16519,"activeCount":102},[],{"trials":16521,"activeCount":102},[],{"trials":16523,"activeCount":102},[],{"trials":16525,"activeCount":102},[],{"trials":16527,"activeCount":102},[16528],{"nctId":16529,"briefTitle":16530,"status":204,"phases":16531,"primaryCompletion":16532,"completion":10898,"start":12652,"enrollment":16533,"conditions":16534,"interventions":16537},"NCT05456061","Effect of ADDE on Tear Interferometry",[94],"2019-08-01",152,[16535,16536],"Tear","Dry Eye Syndromes",[16514],{"intervention":16539,"totalTrials":213,"cells":16540},"tiotropium\u002Folodaterol",{"EARLY_PHASE1":16541,"PHASE1":16543,"PHASE2":16545,"PHASE3":16547,"PHASE4":16549,"NA":16551},{"trials":16542,"activeCount":102},[],{"trials":16544,"activeCount":102},[],{"trials":16546,"activeCount":102},[],{"trials":16548,"activeCount":102},[],{"trials":16550,"activeCount":102},[],{"trials":16552,"activeCount":102},[16553],{"nctId":16554,"briefTitle":16555,"status":204,"phases":16556,"primaryCompletion":16557,"completion":16557,"start":16558,"enrollment":1678,"conditions":16559,"interventions":16560},"NCT04994574","Effects of Tiotropium\u002FOlodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE]",[94],"2024-07-25","2021-08-23",[2664],[16539],{"intervention":16562,"totalTrials":213,"cells":16563},"fentanyl at 10-15 min before end of surgery",{"EARLY_PHASE1":16564,"PHASE1":16566,"PHASE2":16568,"PHASE3":16570,"PHASE4":16572,"NA":16574},{"trials":16565,"activeCount":102},[],{"trials":16567,"activeCount":102},[],{"trials":16569,"activeCount":102},[],{"trials":16571,"activeCount":102},[],{"trials":16573,"activeCount":102},[],{"trials":16575,"activeCount":102},[16576],{"nctId":16577,"briefTitle":16578,"status":204,"phases":16579,"primaryCompletion":16580,"completion":16580,"start":16581,"enrollment":7384,"conditions":16582,"interventions":16584},"NCT03343002","Effect of Intravenous Fentanyl on the Occurrence of Postoperative Nausea and Vomiting According to Time of Administration Around the End of Tonsillectomy With or Without Adenoidectomy",[94],"2018-08-27","2017-11-26",[16583],"Follicular Tonsillitis (Chronic)",[16562,16585],"fentanyl at end of surgery",{"intervention":16585,"totalTrials":213,"cells":16587},{"EARLY_PHASE1":16588,"PHASE1":16590,"PHASE2":16592,"PHASE3":16594,"PHASE4":16596,"NA":16598},{"trials":16589,"activeCount":102},[],{"trials":16591,"activeCount":102},[],{"trials":16593,"activeCount":102},[],{"trials":16595,"activeCount":102},[],{"trials":16597,"activeCount":102},[],{"trials":16599,"activeCount":102},[16600],{"nctId":16577,"briefTitle":16578,"status":204,"phases":16601,"primaryCompletion":16580,"completion":16580,"start":16581,"enrollment":7384,"conditions":16602,"interventions":16603},[94],[16583],[16562,16585],{"intervention":16605,"totalTrials":213,"cells":16606},"Peritoneal dialysis",{"EARLY_PHASE1":16607,"PHASE1":16609,"PHASE2":16611,"PHASE3":16613,"PHASE4":16615,"NA":16617},{"trials":16608,"activeCount":102},[],{"trials":16610,"activeCount":102},[],{"trials":16612,"activeCount":102},[],{"trials":16614,"activeCount":102},[],{"trials":16616,"activeCount":102},[],{"trials":16618,"activeCount":102},[16619],{"nctId":16620,"briefTitle":16621,"status":204,"phases":16622,"primaryCompletion":10974,"completion":10974,"start":3520,"enrollment":11484,"conditions":16623,"interventions":16626},"NCT01758627","The Role of Peritoneal Dialysis in Patients With Refractory Heart Failure and Chronic Kidney Disease",[94],[16624,16625],"Refractory Heart Failure","Chronic Kidney Disease",[16605],{"intervention":16628,"totalTrials":213,"cells":16629},"Serum NGAL level",{"EARLY_PHASE1":16630,"PHASE1":16632,"PHASE2":16634,"PHASE3":16636,"PHASE4":16638,"NA":16640},{"trials":16631,"activeCount":102},[],{"trials":16633,"activeCount":102},[],{"trials":16635,"activeCount":102},[],{"trials":16637,"activeCount":102},[],{"trials":16639,"activeCount":102},[],{"trials":16641,"activeCount":102},[16642],{"nctId":16643,"briefTitle":16644,"status":308,"phases":16645,"primaryCompletion":4275,"completion":4275,"start":5852,"enrollment":16646,"conditions":16647,"interventions":16649},"NCT01987466","Plasma Neutrophil Gelatinase-associated Lipocalin (NGAL) as Early Biomarker for Renal Dysfunction and Good Neurologic Outcome in Out of Hospital Cardiac Arrest Patients",[],73,[16648],"Post Cardiac Arrest Patient Who Was Treated by Hypothermia Protocol",[16628],{"intervention":16651,"totalTrials":213,"cells":16652},"Oxygen",{"EARLY_PHASE1":16653,"PHASE1":16655,"PHASE2":16657,"PHASE3":16659,"PHASE4":16661,"NA":16663},{"trials":16654,"activeCount":102},[],{"trials":16656,"activeCount":102},[],{"trials":16658,"activeCount":102},[],{"trials":16660,"activeCount":102},[],{"trials":16662,"activeCount":102},[],{"trials":16664,"activeCount":102},[16665],{"nctId":16666,"briefTitle":16667,"status":204,"phases":16668,"primaryCompletion":16669,"completion":16669,"start":15495,"enrollment":1557,"conditions":16670,"interventions":16672},"NCT02625194","The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation",[94],"2017-09-04",[16671],"Lumbar Spinal Stenosis",[16651],{"intervention":13100,"totalTrials":213,"cells":16674},{"EARLY_PHASE1":16675,"PHASE1":16677,"PHASE2":16679,"PHASE3":16681,"PHASE4":16683,"NA":16685},{"trials":16676,"activeCount":102},[],{"trials":16678,"activeCount":102},[],{"trials":16680,"activeCount":102},[],{"trials":16682,"activeCount":102},[],{"trials":16684,"activeCount":102},[],{"trials":16686,"activeCount":102},[16687],{"nctId":13093,"briefTitle":13094,"status":204,"phases":16688,"primaryCompletion":13096,"completion":13096,"start":10160,"enrollment":6452,"conditions":16689,"interventions":16690},[94],[13098],[13078,13100],{"intervention":16692,"totalTrials":213,"cells":16693},"oral minocycline hydrochloride treatment",{"EARLY_PHASE1":16694,"PHASE1":16696,"PHASE2":16698,"PHASE3":16700,"PHASE4":16702,"NA":16704},{"trials":16695,"activeCount":102},[],{"trials":16697,"activeCount":102},[],{"trials":16699,"activeCount":102},[],{"trials":16701,"activeCount":102},[],{"trials":16703,"activeCount":102},[],{"trials":16705,"activeCount":102},[16706],{"nctId":16707,"briefTitle":16708,"status":204,"phases":16709,"primaryCompletion":9501,"completion":12037,"start":6852,"enrollment":7792,"conditions":16710,"interventions":16712},"NCT01600625","Effects of Minocycline on Cytokine Levels in Severe Meibomian Gland Dysfunction",[94],[16711],"Meibomian Gland Dysfunction",[16692],{"intervention":16714,"totalTrials":213,"cells":16715},"caudal block",{"EARLY_PHASE1":16716,"PHASE1":16718,"PHASE2":16720,"PHASE3":16722,"PHASE4":16724,"NA":16726},{"trials":16717,"activeCount":102},[],{"trials":16719,"activeCount":102},[],{"trials":16721,"activeCount":102},[],{"trials":16723,"activeCount":102},[],{"trials":16725,"activeCount":102},[],{"trials":16727,"activeCount":102},[16728],{"nctId":16729,"briefTitle":16730,"status":204,"phases":16731,"primaryCompletion":320,"completion":3657,"start":3730,"enrollment":233,"conditions":16732,"interventions":16733},"NCT01679353","Comparison of Analgesic Effect of Magnesium Added to Ropivacaine and Ropivacaine Alone in Caudal Analgesia on Postoperative Pain Control in Pediatric Patients Undergoing Inguinal Hernia Repair",[94],[10854],[16714,16734],"normal saline 0.5ml",{"intervention":16734,"totalTrials":213,"cells":16736},{"EARLY_PHASE1":16737,"PHASE1":16739,"PHASE2":16741,"PHASE3":16743,"PHASE4":16745,"NA":16747},{"trials":16738,"activeCount":102},[],{"trials":16740,"activeCount":102},[],{"trials":16742,"activeCount":102},[],{"trials":16744,"activeCount":102},[],{"trials":16746,"activeCount":102},[],{"trials":16748,"activeCount":102},[16749],{"nctId":16729,"briefTitle":16730,"status":204,"phases":16750,"primaryCompletion":320,"completion":3657,"start":3730,"enrollment":233,"conditions":16751,"interventions":16752},[94],[10854],[16714,16734],{"intervention":16754,"totalTrials":213,"cells":16755},"epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil",{"EARLY_PHASE1":16756,"PHASE1":16758,"PHASE2":16760,"PHASE3":16762,"PHASE4":16764,"NA":16766},{"trials":16757,"activeCount":102},[],{"trials":16759,"activeCount":102},[],{"trials":16761,"activeCount":102},[],{"trials":16763,"activeCount":102},[],{"trials":16765,"activeCount":102},[],{"trials":16767,"activeCount":102},[16768],{"nctId":16769,"briefTitle":16770,"status":204,"phases":16771,"primaryCompletion":4538,"completion":4538,"start":8523,"enrollment":344,"conditions":16772,"interventions":16774},"NCT01086956","Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General\u002FEpidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy",[94],[16773],"Prostatic Cancer",[16754],{"intervention":13012,"totalTrials":213,"cells":16776},{"EARLY_PHASE1":16777,"PHASE1":16779,"PHASE2":16781,"PHASE3":16783,"PHASE4":16785,"NA":16787},{"trials":16778,"activeCount":102},[],{"trials":16780,"activeCount":102},[],{"trials":16782,"activeCount":102},[],{"trials":16784,"activeCount":102},[],{"trials":16786,"activeCount":102},[],{"trials":16788,"activeCount":102},[16789],{"nctId":13005,"briefTitle":13006,"status":204,"phases":16790,"primaryCompletion":284,"completion":284,"start":3773,"enrollment":5081,"conditions":16791,"interventions":16792},[94],[13009],[13011,13012,13013],{"intervention":13013,"totalTrials":213,"cells":16794},{"EARLY_PHASE1":16795,"PHASE1":16797,"PHASE2":16799,"PHASE3":16801,"PHASE4":16803,"NA":16805},{"trials":16796,"activeCount":102},[],{"trials":16798,"activeCount":102},[],{"trials":16800,"activeCount":102},[],{"trials":16802,"activeCount":102},[],{"trials":16804,"activeCount":102},[],{"trials":16806,"activeCount":102},[16807],{"nctId":13005,"briefTitle":13006,"status":204,"phases":16808,"primaryCompletion":284,"completion":284,"start":3773,"enrollment":5081,"conditions":16809,"interventions":16810},[94],[13009],[13011,13012,13013],{"intervention":16812,"totalTrials":213,"cells":16813},"Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.",{"EARLY_PHASE1":16814,"PHASE1":16816,"PHASE2":16818,"PHASE3":16820,"PHASE4":16822,"NA":16824},{"trials":16815,"activeCount":102},[],{"trials":16817,"activeCount":102},[],{"trials":16819,"activeCount":102},[],{"trials":16821,"activeCount":102},[],{"trials":16823,"activeCount":102},[],{"trials":16825,"activeCount":102},[16826],{"nctId":16827,"briefTitle":16828,"status":204,"phases":16829,"primaryCompletion":8851,"completion":8851,"start":3798,"enrollment":1954,"conditions":16830,"interventions":16832},"NCT01637909","Korean Life-Style Modification Effects on Blood Pressure",[94],[16831,3375],"Prehypertension",[16812],{"intervention":16834,"totalTrials":213,"cells":16835},"Propofol TIVA",{"EARLY_PHASE1":16836,"PHASE1":16838,"PHASE2":16840,"PHASE3":16842,"PHASE4":16844,"NA":16846},{"trials":16837,"activeCount":102},[],{"trials":16839,"activeCount":102},[],{"trials":16841,"activeCount":102},[],{"trials":16843,"activeCount":102},[],{"trials":16845,"activeCount":102},[],{"trials":16847,"activeCount":102},[16848],{"nctId":16849,"briefTitle":16850,"status":204,"phases":16851,"primaryCompletion":16852,"completion":16852,"start":16853,"enrollment":233,"conditions":16854,"interventions":16856},"NCT05280236","Comparison of Quality of Recovery Between Remimazolam and Propofol Anesthesia in Patients Undergoing Arthroscopic Meniscectomy",[94],"2024-04-30","2022-03-14",[16855],"Adult Patients 19 or Older Scheduled for Elective Arthroscopic Meniscectomy",[16834,16857],"Remimazolam TIVA",{"intervention":16857,"totalTrials":213,"cells":16859},{"EARLY_PHASE1":16860,"PHASE1":16862,"PHASE2":16864,"PHASE3":16866,"PHASE4":16868,"NA":16870},{"trials":16861,"activeCount":102},[],{"trials":16863,"activeCount":102},[],{"trials":16865,"activeCount":102},[],{"trials":16867,"activeCount":102},[],{"trials":16869,"activeCount":102},[],{"trials":16871,"activeCount":102},[16872],{"nctId":16849,"briefTitle":16850,"status":204,"phases":16873,"primaryCompletion":16852,"completion":16852,"start":16853,"enrollment":233,"conditions":16874,"interventions":16875},[94],[16855],[16834,16857],{"intervention":16877,"totalTrials":213,"cells":16878},"ketorolac, fentanyl",{"EARLY_PHASE1":16879,"PHASE1":16881,"PHASE2":16883,"PHASE3":16885,"PHASE4":16887,"NA":16889},{"trials":16880,"activeCount":102},[],{"trials":16882,"activeCount":102},[],{"trials":16884,"activeCount":102},[],{"trials":16886,"activeCount":102},[],{"trials":16888,"activeCount":102},[],{"trials":16890,"activeCount":102},[16891],{"nctId":16892,"briefTitle":16893,"status":204,"phases":16894,"primaryCompletion":3937,"completion":3937,"start":4611,"enrollment":1243,"conditions":16895,"interventions":16897},"NCT01081535","The Effect of Intravenous (IV) Patient Controlled Analgesic (PCA) With Ketorolac or Fentanyl Combined With Caudal Block for Postoperative Analgesia in Small Children Undergoing Intravesical Ureteroneocystostomy",[94],[16896],"Ureteroneocystostomy",[16877],{"intervention":16899,"totalTrials":213,"cells":16900},"Beraprost sodium",{"EARLY_PHASE1":16901,"PHASE1":16903,"PHASE2":16905,"PHASE3":16907,"PHASE4":16909,"NA":16911},{"trials":16902,"activeCount":102},[],{"trials":16904,"activeCount":102},[],{"trials":16906,"activeCount":102},[],{"trials":16908,"activeCount":102},[],{"trials":16910,"activeCount":102},[],{"trials":16912,"activeCount":102},[16913],{"nctId":16914,"briefTitle":16915,"status":308,"phases":16916,"primaryCompletion":16917,"completion":16917,"start":16918,"enrollment":344,"conditions":16919,"interventions":16921},"NCT03142360","Effect of Beraprost Sodium (Berasil) on Hemodialysis",[94],"2019-04-04","2017-04-05",[16920],"Arteriovenous Fistula Patency",[16899],{"intervention":16923,"totalTrials":213,"cells":16924},"Flumazenil",{"EARLY_PHASE1":16925,"PHASE1":16927,"PHASE2":16929,"PHASE3":16931,"PHASE4":16933,"NA":16935},{"trials":16926,"activeCount":102},[],{"trials":16928,"activeCount":102},[],{"trials":16930,"activeCount":102},[],{"trials":16932,"activeCount":102},[],{"trials":16934,"activeCount":102},[],{"trials":16936,"activeCount":102},[16937],{"nctId":16938,"briefTitle":16939,"status":204,"phases":16940,"primaryCompletion":16941,"completion":16941,"start":16942,"enrollment":344,"conditions":16943,"interventions":16945},"NCT06563063","Finding ED90 of Flumazenil for Selective Improvement of Respiratory Distress by Remimazolam",[94],"2023-12-01","2023-08-23",[16944],"Stomach Neoplasm",[16923],{"intervention":10942,"totalTrials":213,"cells":16947},{"EARLY_PHASE1":16948,"PHASE1":16950,"PHASE2":16952,"PHASE3":16954,"PHASE4":16956,"NA":16958},{"trials":16949,"activeCount":102},[],{"trials":16951,"activeCount":102},[],{"trials":16953,"activeCount":102},[],{"trials":16955,"activeCount":102},[],{"trials":16957,"activeCount":102},[],{"trials":16959,"activeCount":102},[16960],{"nctId":10936,"briefTitle":10937,"status":204,"phases":16961,"primaryCompletion":979,"completion":979,"start":3469,"enrollment":1678,"conditions":16962,"interventions":16963},[94],[10940,2664],[10942,4996],{"intervention":16965,"totalTrials":213,"cells":16966},"Routine steroid administration group",{"EARLY_PHASE1":16967,"PHASE1":16969,"PHASE2":16971,"PHASE3":16973,"PHASE4":16975,"NA":16977},{"trials":16968,"activeCount":102},[],{"trials":16970,"activeCount":102},[],{"trials":16972,"activeCount":102},[],{"trials":16974,"activeCount":102},[],{"trials":16976,"activeCount":102},[],{"trials":16978,"activeCount":102},[16979],{"nctId":16980,"briefTitle":16981,"status":204,"phases":16982,"primaryCompletion":16983,"completion":16983,"start":16984,"enrollment":222,"conditions":16985,"interventions":16987},"NCT04996303","Efficacy of Steroid Pulse Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF) Admitted in ER",[94],"2024-07-18","2021-07-27",[16986],"Idiopathic Pulmonary Fibrosis With Acute Exacerbation",[16965],{"intervention":16989,"totalTrials":213,"cells":16990},"Combining electromyography with uroflowmetry",{"EARLY_PHASE1":16991,"PHASE1":16993,"PHASE2":16995,"PHASE3":16997,"PHASE4":16999,"NA":17001},{"trials":16992,"activeCount":102},[],{"trials":16994,"activeCount":102},[],{"trials":16996,"activeCount":102},[],{"trials":16998,"activeCount":102},[],{"trials":17000,"activeCount":102},[],{"trials":17002,"activeCount":102},[17003],{"nctId":17004,"briefTitle":17005,"status":308,"phases":17006,"primaryCompletion":3249,"completion":3249,"start":17007,"enrollment":2363,"conditions":17008,"interventions":17010},"NCT03399877","A Study on Accuracy Improvement of Repeated Measure Uroflowmetry- Electromyography",[94],"2017-12-04",[17009],"Enuresis",[16989,17011,17012],"Uroflowmetry","Uroflowmetry-Combining electromyography with uroflowmetry",{"intervention":17011,"totalTrials":213,"cells":17014},{"EARLY_PHASE1":17015,"PHASE1":17017,"PHASE2":17019,"PHASE3":17021,"PHASE4":17023,"NA":17025},{"trials":17016,"activeCount":102},[],{"trials":17018,"activeCount":102},[],{"trials":17020,"activeCount":102},[],{"trials":17022,"activeCount":102},[],{"trials":17024,"activeCount":102},[],{"trials":17026,"activeCount":102},[17027],{"nctId":17004,"briefTitle":17005,"status":308,"phases":17028,"primaryCompletion":3249,"completion":3249,"start":17007,"enrollment":2363,"conditions":17029,"interventions":17030},[94],[17009],[16989,17011,17012],{"intervention":17012,"totalTrials":213,"cells":17032},{"EARLY_PHASE1":17033,"PHASE1":17035,"PHASE2":17037,"PHASE3":17039,"PHASE4":17041,"NA":17043},{"trials":17034,"activeCount":102},[],{"trials":17036,"activeCount":102},[],{"trials":17038,"activeCount":102},[],{"trials":17040,"activeCount":102},[],{"trials":17042,"activeCount":102},[],{"trials":17044,"activeCount":102},[17045],{"nctId":17004,"briefTitle":17005,"status":308,"phases":17046,"primaryCompletion":3249,"completion":3249,"start":17007,"enrollment":2363,"conditions":17047,"interventions":17048},[94],[17009],[16989,17011,17012],{"intervention":251,"totalTrials":213,"cells":17050},{"EARLY_PHASE1":17051,"PHASE1":17053,"PHASE2":17055,"PHASE3":17057,"PHASE4":17059,"NA":17061},{"trials":17052,"activeCount":102},[],{"trials":17054,"activeCount":102},[],{"trials":17056,"activeCount":102},[],{"trials":17058,"activeCount":102},[],{"trials":17060,"activeCount":102},[],{"trials":17062,"activeCount":102},[17063],{"nctId":241,"briefTitle":242,"status":243,"phases":17064,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":17065,"interventions":17066},[94],[249],[251,172],{"intervention":17068,"totalTrials":213,"cells":17069},"Osimertinib",{"EARLY_PHASE1":17070,"PHASE1":17072,"PHASE2":17074,"PHASE3":17076,"PHASE4":17078,"NA":17080},{"trials":17071,"activeCount":102},[],{"trials":17073,"activeCount":102},[],{"trials":17075,"activeCount":102},[],{"trials":17077,"activeCount":102},[],{"trials":17079,"activeCount":102},[],{"trials":17081,"activeCount":102},[17082],{"nctId":17083,"briefTitle":17084,"status":308,"phases":17085,"primaryCompletion":71,"completion":6383,"start":17086,"enrollment":1394,"conditions":17087,"interventions":17088},"NCT04816838","A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations",[94],"2021-05-10",[1396],[17068],{"intervention":17090,"totalTrials":213,"cells":17091},"novel oral anticoagulant for 30 days",{"EARLY_PHASE1":17092,"PHASE1":17094,"PHASE2":17096,"PHASE3":17098,"PHASE4":17100,"NA":17102},{"trials":17093,"activeCount":102},[],{"trials":17095,"activeCount":102},[],{"trials":17097,"activeCount":102},[],{"trials":17099,"activeCount":102},[],{"trials":17101,"activeCount":102},[],{"trials":17103,"activeCount":102},[17104],{"nctId":17105,"briefTitle":17106,"status":308,"phases":17107,"primaryCompletion":9072,"completion":9072,"start":4225,"enrollment":17108,"conditions":17109,"interventions":17110},"NCT02504177","Clinical Trial for Optimal Novel Oral Anticoagulant (NOAC) Schedule Immediate Before Catheter Ablation for Atrial Fibrillation",[94],433,[18],[17090,17111],"novel oral anticoagulant for 24 hour",{"intervention":17111,"totalTrials":213,"cells":17113},{"EARLY_PHASE1":17114,"PHASE1":17116,"PHASE2":17118,"PHASE3":17120,"PHASE4":17122,"NA":17124},{"trials":17115,"activeCount":102},[],{"trials":17117,"activeCount":102},[],{"trials":17119,"activeCount":102},[],{"trials":17121,"activeCount":102},[],{"trials":17123,"activeCount":102},[],{"trials":17125,"activeCount":102},[17126],{"nctId":17105,"briefTitle":17106,"status":308,"phases":17127,"primaryCompletion":9072,"completion":9072,"start":4225,"enrollment":17108,"conditions":17128,"interventions":17129},[94],[18],[17090,17111],{"intervention":17131,"totalTrials":213,"cells":17132},"pediatric sedation",{"EARLY_PHASE1":17133,"PHASE1":17135,"PHASE2":17137,"PHASE3":17139,"PHASE4":17141,"NA":17143},{"trials":17134,"activeCount":102},[],{"trials":17136,"activeCount":102},[],{"trials":17138,"activeCount":102},[],{"trials":17140,"activeCount":102},[],{"trials":17142,"activeCount":102},[],{"trials":17144,"activeCount":102},[17145],{"nctId":17146,"briefTitle":17147,"status":308,"phases":17148,"primaryCompletion":7383,"completion":5852,"start":7502,"enrollment":17149,"conditions":17150,"interventions":17151},"NCT01855581","The Incidence and Nature of Adverse Events During Pediatric Sedation for MRI\u002FCT in One Korean University Hospital: Retrospective Study",[],3739,[13594],[17131],{"intervention":17153,"totalTrials":213,"cells":17154},"Sufentanil group",{"EARLY_PHASE1":17155,"PHASE1":17157,"PHASE2":17159,"PHASE3":17161,"PHASE4":17163,"NA":17165},{"trials":17156,"activeCount":102},[],{"trials":17158,"activeCount":102},[],{"trials":17160,"activeCount":102},[],{"trials":17162,"activeCount":102},[],{"trials":17164,"activeCount":102},[],{"trials":17166,"activeCount":102},[17167],{"nctId":17168,"briefTitle":17169,"status":204,"phases":17170,"primaryCompletion":17171,"completion":17171,"start":17172,"enrollment":11108,"conditions":17173,"interventions":17175},"NCT03171610","Study on Efficacy of iv PCA With Fentanyl or Sufentanil in Patients Undergoing Laparoscopic Nephrectomy",[94],"2018-01-03","2017-06-13",[17174],"Patients Undergoing Laparoscopic Nephrectomy",[17153,17176],"Fentanyl group",{"intervention":17176,"totalTrials":213,"cells":17178},{"EARLY_PHASE1":17179,"PHASE1":17181,"PHASE2":17183,"PHASE3":17185,"PHASE4":17187,"NA":17189},{"trials":17180,"activeCount":102},[],{"trials":17182,"activeCount":102},[],{"trials":17184,"activeCount":102},[],{"trials":17186,"activeCount":102},[],{"trials":17188,"activeCount":102},[],{"trials":17190,"activeCount":102},[17191],{"nctId":17168,"briefTitle":17169,"status":204,"phases":17192,"primaryCompletion":17171,"completion":17171,"start":17172,"enrollment":11108,"conditions":17193,"interventions":17194},[94],[17174],[17153,17176],{"intervention":12561,"totalTrials":213,"cells":17196},{"EARLY_PHASE1":17197,"PHASE1":17199,"PHASE2":17201,"PHASE3":17203,"PHASE4":17205,"NA":17207},{"trials":17198,"activeCount":102},[],{"trials":17200,"activeCount":102},[],{"trials":17202,"activeCount":102},[],{"trials":17204,"activeCount":102},[],{"trials":17206,"activeCount":102},[],{"trials":17208,"activeCount":102},[17209],{"nctId":12555,"briefTitle":12556,"status":204,"phases":17210,"primaryCompletion":5398,"completion":5398,"start":3575,"enrollment":2661,"conditions":17211,"interventions":17212},[94],[12559],[12536,12561],{"intervention":13201,"totalTrials":213,"cells":17214},{"EARLY_PHASE1":17215,"PHASE1":17217,"PHASE2":17219,"PHASE3":17221,"PHASE4":17223,"NA":17225},{"trials":17216,"activeCount":102},[],{"trials":17218,"activeCount":102},[],{"trials":17220,"activeCount":102},[],{"trials":17222,"activeCount":102},[],{"trials":17224,"activeCount":102},[],{"trials":17226,"activeCount":102},[17227],{"nctId":13195,"briefTitle":13196,"status":204,"phases":17228,"primaryCompletion":962,"completion":962,"start":3866,"enrollment":1259,"conditions":17229,"interventions":17230},[94],[13199],[13201,7027],{"intervention":17232,"totalTrials":213,"cells":17233},"Treatment of Meibomian gland dysfunction",{"EARLY_PHASE1":17234,"PHASE1":17236,"PHASE2":17238,"PHASE3":17240,"PHASE4":17242,"NA":17244},{"trials":17235,"activeCount":102},[],{"trials":17237,"activeCount":102},[],{"trials":17239,"activeCount":102},[],{"trials":17241,"activeCount":102},[],{"trials":17243,"activeCount":102},[],{"trials":17245,"activeCount":102},[17246],{"nctId":17247,"briefTitle":17248,"status":204,"phases":17249,"primaryCompletion":17250,"completion":17250,"start":17251,"enrollment":7247,"conditions":17252,"interventions":17253},"NCT02618304","Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland Dysfunction",[94],"2016-02-19","2015-04-20",[16711],[17232],{"intervention":17255,"totalTrials":213,"cells":17256},"TPI",{"EARLY_PHASE1":17257,"PHASE1":17259,"PHASE2":17261,"PHASE3":17263,"PHASE4":17265,"NA":17267},{"trials":17258,"activeCount":102},[],{"trials":17260,"activeCount":102},[],{"trials":17262,"activeCount":102},[],{"trials":17264,"activeCount":102},[],{"trials":17266,"activeCount":102},[],{"trials":17268,"activeCount":102},[17269],{"nctId":17270,"briefTitle":17271,"status":204,"phases":17272,"primaryCompletion":3631,"completion":284,"start":6340,"enrollment":1259,"conditions":17273,"interventions":17275},"NCT01845532","Analgesic Effect of Trigger Point Injection and EMLA for Shoulder Pain in Laparoscopic Hysterectomy",[94],[17274],"Myoma of Uterus",[17255,17276],"EMLA cream",{"intervention":17276,"totalTrials":213,"cells":17278},{"EARLY_PHASE1":17279,"PHASE1":17281,"PHASE2":17283,"PHASE3":17285,"PHASE4":17287,"NA":17289},{"trials":17280,"activeCount":102},[],{"trials":17282,"activeCount":102},[],{"trials":17284,"activeCount":102},[],{"trials":17286,"activeCount":102},[],{"trials":17288,"activeCount":102},[],{"trials":17290,"activeCount":102},[17291],{"nctId":17270,"briefTitle":17271,"status":204,"phases":17292,"primaryCompletion":3631,"completion":284,"start":6340,"enrollment":1259,"conditions":17293,"interventions":17294},[94],[17274],[17255,17276],{"intervention":17296,"totalTrials":213,"cells":17297},"Fluid loading",{"EARLY_PHASE1":17298,"PHASE1":17300,"PHASE2":17302,"PHASE3":17304,"PHASE4":17306,"NA":17308},{"trials":17299,"activeCount":102},[],{"trials":17301,"activeCount":102},[],{"trials":17303,"activeCount":102},[],{"trials":17305,"activeCount":102},[],{"trials":17307,"activeCount":102},[],{"trials":17309,"activeCount":102},[17310],{"nctId":17311,"briefTitle":17312,"status":204,"phases":17313,"primaryCompletion":5852,"completion":5852,"start":7503,"enrollment":3775,"conditions":17314,"interventions":17316},"NCT01819571","Pulse Pressure Variation for Prediction of Fluid Responsiveness in Coronary Artery Disease Patients With Diastolic Dysfunction",[94],[17315],"Fluid Responsiveness Predictability",[17296],{"intervention":12502,"totalTrials":213,"cells":17318},{"EARLY_PHASE1":17319,"PHASE1":17321,"PHASE2":17323,"PHASE3":17325,"PHASE4":17327,"NA":17329},{"trials":17320,"activeCount":102},[],{"trials":17322,"activeCount":102},[],{"trials":17324,"activeCount":102},[],{"trials":17326,"activeCount":102},[],{"trials":17328,"activeCount":102},[],{"trials":17330,"activeCount":102},[17331],{"nctId":12496,"briefTitle":12497,"status":204,"phases":17332,"primaryCompletion":7503,"completion":7503,"start":964,"enrollment":1980,"conditions":17333,"interventions":17334},[94],[12500],[12477,12502],{"intervention":17336,"totalTrials":213,"cells":17337},"up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence",{"EARLY_PHASE1":17338,"PHASE1":17340,"PHASE2":17342,"PHASE3":17344,"PHASE4":17346,"NA":17348},{"trials":17339,"activeCount":102},[],{"trials":17341,"activeCount":102},[],{"trials":17343,"activeCount":102},[],{"trials":17345,"activeCount":102},[],{"trials":17347,"activeCount":102},[],{"trials":17349,"activeCount":102},[17350],{"nctId":17351,"briefTitle":17352,"status":204,"phases":17353,"primaryCompletion":4751,"completion":4751,"start":964,"enrollment":7792,"conditions":17354,"interventions":17356},"NCT01614535","Comparison of the Effect Site Concentration of Remifentanil for Preventing Cough During Emergence Between Male and Female Patients With Thyroidectomy",[94],[17355],"Patients Undergoing Thyroidectomy",[17336],{"intervention":11554,"totalTrials":213,"cells":17358},{"EARLY_PHASE1":17359,"PHASE1":17361,"PHASE2":17363,"PHASE3":17365,"PHASE4":17367,"NA":17369},{"trials":17360,"activeCount":102},[],{"trials":17362,"activeCount":102},[],{"trials":17364,"activeCount":102},[],{"trials":17366,"activeCount":102},[],{"trials":17368,"activeCount":102},[],{"trials":17370,"activeCount":102},[17371],{"nctId":11546,"briefTitle":11547,"status":308,"phases":17372,"primaryCompletion":1079,"completion":46,"start":11549,"enrollment":11550,"conditions":17373,"interventions":17374},[94],[664,11552],[11554,11555,5747],{"intervention":11555,"totalTrials":213,"cells":17376},{"EARLY_PHASE1":17377,"PHASE1":17379,"PHASE2":17381,"PHASE3":17383,"PHASE4":17385,"NA":17387},{"trials":17378,"activeCount":102},[],{"trials":17380,"activeCount":102},[],{"trials":17382,"activeCount":102},[],{"trials":17384,"activeCount":102},[],{"trials":17386,"activeCount":102},[],{"trials":17388,"activeCount":102},[17389],{"nctId":11546,"briefTitle":11547,"status":308,"phases":17390,"primaryCompletion":1079,"completion":46,"start":11549,"enrollment":11550,"conditions":17391,"interventions":17392},[94],[664,11552],[11554,11555,5747],{"intervention":13254,"totalTrials":213,"cells":17394},{"EARLY_PHASE1":17395,"PHASE1":17397,"PHASE2":17399,"PHASE3":17401,"PHASE4":17403,"NA":17405},{"trials":17396,"activeCount":102},[],{"trials":17398,"activeCount":102},[],{"trials":17400,"activeCount":102},[],{"trials":17402,"activeCount":102},[],{"trials":17404,"activeCount":102},[],{"trials":17406,"activeCount":102},[17407],{"nctId":13248,"briefTitle":13249,"status":243,"phases":17408,"primaryCompletion":13251,"completion":13251,"start":3797,"enrollment":1369,"conditions":17409,"interventions":17410},[94],[30],[11276,13254],{"intervention":17412,"totalTrials":213,"cells":17413},"General anesthesia",{"EARLY_PHASE1":17414,"PHASE1":17416,"PHASE2":17418,"PHASE3":17420,"PHASE4":17422,"NA":17424},{"trials":17415,"activeCount":102},[],{"trials":17417,"activeCount":102},[],{"trials":17419,"activeCount":102},[],{"trials":17421,"activeCount":102},[],{"trials":17423,"activeCount":102},[],{"trials":17425,"activeCount":102},[17426],{"nctId":17427,"briefTitle":17428,"status":308,"phases":17429,"primaryCompletion":10092,"completion":14442,"start":17430,"enrollment":3731,"conditions":17431,"interventions":17433},"NCT04063046","Effect of Anesthesia Technique on Early Outcome in Diabetic Patients Undergoing Lower Extremity Amputation",[94],"2019-11-12",[17432],"Diabetic Foot",[17412,17434],"Peripheral nerve block",{"intervention":17434,"totalTrials":213,"cells":17436},{"EARLY_PHASE1":17437,"PHASE1":17439,"PHASE2":17441,"PHASE3":17443,"PHASE4":17445,"NA":17447},{"trials":17438,"activeCount":102},[],{"trials":17440,"activeCount":102},[],{"trials":17442,"activeCount":102},[],{"trials":17444,"activeCount":102},[],{"trials":17446,"activeCount":102},[],{"trials":17448,"activeCount":102},[17449],{"nctId":17427,"briefTitle":17428,"status":308,"phases":17450,"primaryCompletion":10092,"completion":14442,"start":17430,"enrollment":3731,"conditions":17451,"interventions":17452},[94],[17432],[17412,17434],{"intervention":17454,"totalTrials":213,"cells":17455},"atrovastatin",{"EARLY_PHASE1":17456,"PHASE1":17458,"PHASE2":17460,"PHASE3":17462,"PHASE4":17464,"NA":17466},{"trials":17457,"activeCount":102},[],{"trials":17459,"activeCount":102},[],{"trials":17461,"activeCount":102},[],{"trials":17463,"activeCount":102},[],{"trials":17465,"activeCount":102},[],{"trials":17467,"activeCount":102},[17468],{"nctId":17469,"briefTitle":17470,"status":204,"phases":17471,"primaryCompletion":17472,"completion":17472,"start":7383,"enrollment":522,"conditions":17473,"interventions":17474},"NCT01909739","The Effects of Statin on Postoperative Renal Function in Valvular Heart Surgery: a Randomized, Placebo-controlled Study",[94],"2015-08-21",[4252],[17454],{"intervention":12293,"totalTrials":213,"cells":17476},{"EARLY_PHASE1":17477,"PHASE1":17479,"PHASE2":17481,"PHASE3":17483,"PHASE4":17485,"NA":17487},{"trials":17478,"activeCount":102},[],{"trials":17480,"activeCount":102},[],{"trials":17482,"activeCount":102},[],{"trials":17484,"activeCount":102},[],{"trials":17486,"activeCount":102},[],{"trials":17488,"activeCount":102},[17489],{"nctId":12283,"briefTitle":12284,"status":204,"phases":17490,"primaryCompletion":12286,"completion":12286,"start":12287,"enrollment":12288,"conditions":17491,"interventions":17492},[94],[12290],[12292,12293],{"intervention":17494,"totalTrials":213,"cells":17495},"Heparin",{"EARLY_PHASE1":17496,"PHASE1":17498,"PHASE2":17500,"PHASE3":17502,"PHASE4":17504,"NA":17506},{"trials":17497,"activeCount":102},[],{"trials":17499,"activeCount":102},[],{"trials":17501,"activeCount":102},[],{"trials":17503,"activeCount":102},[],{"trials":17505,"activeCount":102},[],{"trials":17507,"activeCount":102},[17508],{"nctId":17509,"briefTitle":17510,"status":204,"phases":17511,"primaryCompletion":6741,"completion":8523,"start":17512,"enrollment":17513,"conditions":17514,"interventions":17516},"NCT01044888","Heparin Resistance: Predictors and Outcomes",[94],"2007-04",199,[17515],"Off Pump Coronary Artery Bypass Surgery",[17494],{"intervention":12345,"totalTrials":213,"cells":17518},{"EARLY_PHASE1":17519,"PHASE1":17521,"PHASE2":17523,"PHASE3":17525,"PHASE4":17527,"NA":17529},{"trials":17520,"activeCount":102},[],{"trials":17522,"activeCount":102},[],{"trials":17524,"activeCount":102},[],{"trials":17526,"activeCount":102},[],{"trials":17528,"activeCount":102},[],{"trials":17530,"activeCount":102},[17531],{"nctId":12339,"briefTitle":12340,"status":204,"phases":17532,"primaryCompletion":3730,"completion":3730,"start":3889,"enrollment":1394,"conditions":17533,"interventions":17534},[94],[12343],[11987,12345,12346],{"intervention":12346,"totalTrials":213,"cells":17536},{"EARLY_PHASE1":17537,"PHASE1":17539,"PHASE2":17541,"PHASE3":17543,"PHASE4":17545,"NA":17547},{"trials":17538,"activeCount":102},[],{"trials":17540,"activeCount":102},[],{"trials":17542,"activeCount":102},[],{"trials":17544,"activeCount":102},[],{"trials":17546,"activeCount":102},[],{"trials":17548,"activeCount":102},[17549],{"nctId":12339,"briefTitle":12340,"status":204,"phases":17550,"primaryCompletion":3730,"completion":3730,"start":3889,"enrollment":1394,"conditions":17551,"interventions":17552},[94],[12343],[11987,12345,12346],{"intervention":17554,"totalTrials":213,"cells":17555},"Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long",{"EARLY_PHASE1":17556,"PHASE1":17558,"PHASE2":17560,"PHASE3":17562,"PHASE4":17564,"NA":17566},{"trials":17557,"activeCount":102},[],{"trials":17559,"activeCount":102},[],{"trials":17561,"activeCount":102},[],{"trials":17563,"activeCount":102},[],{"trials":17565,"activeCount":102},[],{"trials":17567,"activeCount":102},[17568],{"nctId":17569,"briefTitle":17570,"status":204,"phases":17571,"primaryCompletion":17572,"completion":17572,"start":17573,"enrollment":17574,"conditions":17575,"interventions":17577},"NCT01359423","Comparison of Primary Long Full Coverage Stenting vs Primary Short Spot Stenting for Long Femoropopliteal Artery Disease.",[94],"2017-08-10","2011-09-26",89,[17576],"Claudication",[17554,17578],"short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.",{"intervention":17578,"totalTrials":213,"cells":17580},{"EARLY_PHASE1":17581,"PHASE1":17583,"PHASE2":17585,"PHASE3":17587,"PHASE4":17589,"NA":17591},{"trials":17582,"activeCount":102},[],{"trials":17584,"activeCount":102},[],{"trials":17586,"activeCount":102},[],{"trials":17588,"activeCount":102},[],{"trials":17590,"activeCount":102},[],{"trials":17592,"activeCount":102},[17593],{"nctId":17569,"briefTitle":17570,"status":204,"phases":17594,"primaryCompletion":17572,"completion":17572,"start":17573,"enrollment":17574,"conditions":17595,"interventions":17596},[94],[17576],[17554,17578],{"intervention":11365,"totalTrials":213,"cells":17598},{"EARLY_PHASE1":17599,"PHASE1":17601,"PHASE2":17603,"PHASE3":17605,"PHASE4":17607,"NA":17609},{"trials":17600,"activeCount":102},[],{"trials":17602,"activeCount":102},[],{"trials":17604,"activeCount":102},[],{"trials":17606,"activeCount":102},[],{"trials":17608,"activeCount":102},[],{"trials":17610,"activeCount":102},[17611],{"nctId":11356,"briefTitle":11357,"status":204,"phases":17612,"primaryCompletion":11359,"completion":11359,"start":11360,"enrollment":11361,"conditions":17613,"interventions":17614},[94],[11363],[11365,1023],{"intervention":11761,"totalTrials":213,"cells":17616},{"EARLY_PHASE1":17617,"PHASE1":17619,"PHASE2":17621,"PHASE3":17623,"PHASE4":17625,"NA":17627},{"trials":17618,"activeCount":102},[],{"trials":17620,"activeCount":102},[],{"trials":17622,"activeCount":102},[],{"trials":17624,"activeCount":102},[],{"trials":17626,"activeCount":102},[],{"trials":17628,"activeCount":102},[17629],{"nctId":11754,"briefTitle":11755,"status":204,"phases":17630,"primaryCompletion":4201,"completion":4201,"start":4249,"enrollment":11757,"conditions":17631,"interventions":17632},[94],[11759],[11683,10987,11741,11761],{"intervention":17634,"totalTrials":213,"cells":17635},"spinal anesthesia",{"EARLY_PHASE1":17636,"PHASE1":17638,"PHASE2":17640,"PHASE3":17642,"PHASE4":17644,"NA":17646},{"trials":17637,"activeCount":102},[],{"trials":17639,"activeCount":102},[],{"trials":17641,"activeCount":102},[],{"trials":17643,"activeCount":102},[],{"trials":17645,"activeCount":102},[],{"trials":17647,"activeCount":102},[17648],{"nctId":17649,"briefTitle":17650,"status":204,"phases":17651,"primaryCompletion":6131,"completion":6131,"start":3452,"enrollment":10984,"conditions":17652,"interventions":17654},"NCT01342562","The Effects of Intrathecal Dexmedetomidine on Spinal Anesthesia Using Diluted Low-Dose Bupivacaine for Transurethral Resection of Prostate in Elderly",[94],[17653],"Benign Prostatic Hypertrophy",[17634,17634],{"intervention":11886,"totalTrials":213,"cells":17656},{"EARLY_PHASE1":17657,"PHASE1":17659,"PHASE2":17661,"PHASE3":17663,"PHASE4":17665,"NA":17667},{"trials":17658,"activeCount":102},[],{"trials":17660,"activeCount":102},[],{"trials":17662,"activeCount":102},[],{"trials":17664,"activeCount":102},[],{"trials":17666,"activeCount":102},[],{"trials":17668,"activeCount":102},[17669],{"nctId":11877,"briefTitle":11878,"status":204,"phases":17670,"primaryCompletion":11880,"completion":11880,"start":11881,"enrollment":11882,"conditions":17671,"interventions":17672},[94],[11884],[11752,11886],{"intervention":17674,"totalTrials":213,"cells":17675},"nProfiler I Stomach Cancer Assay Kit",{"EARLY_PHASE1":17676,"PHASE1":17678,"PHASE2":17680,"PHASE3":17682,"PHASE4":17684,"NA":17686},{"trials":17677,"activeCount":102},[],{"trials":17679,"activeCount":102},[],{"trials":17681,"activeCount":102},[],{"trials":17683,"activeCount":102},[],{"trials":17685,"activeCount":102},[],{"trials":17687,"activeCount":102},[17688],{"nctId":17689,"briefTitle":17690,"status":204,"phases":17691,"primaryCompletion":17692,"completion":17692,"start":17693,"enrollment":17694,"conditions":17695,"interventions":17697},"NCT03403296","A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery (CLASSIC)",[],"2017-07-12","2016-07-13",640,[17696],"Stage II-III Gastric Cancer",[17674],{"intervention":11477,"totalTrials":213,"cells":17699},{"EARLY_PHASE1":17700,"PHASE1":17702,"PHASE2":17704,"PHASE3":17706,"PHASE4":17708,"NA":17710},{"trials":17701,"activeCount":102},[],{"trials":17703,"activeCount":102},[],{"trials":17705,"activeCount":102},[],{"trials":17707,"activeCount":102},[],{"trials":17709,"activeCount":102},[],{"trials":17711,"activeCount":102},[17712],{"nctId":11471,"briefTitle":11472,"status":204,"phases":17713,"primaryCompletion":6340,"completion":6340,"start":9501,"enrollment":11009,"conditions":17714,"interventions":17715},[94],[21,11475],[6572,11477,11478],{"intervention":11478,"totalTrials":213,"cells":17717},{"EARLY_PHASE1":17718,"PHASE1":17720,"PHASE2":17722,"PHASE3":17724,"PHASE4":17726,"NA":17728},{"trials":17719,"activeCount":102},[],{"trials":17721,"activeCount":102},[],{"trials":17723,"activeCount":102},[],{"trials":17725,"activeCount":102},[],{"trials":17727,"activeCount":102},[],{"trials":17729,"activeCount":102},[17730],{"nctId":11471,"briefTitle":11472,"status":204,"phases":17731,"primaryCompletion":6340,"completion":6340,"start":9501,"enrollment":11009,"conditions":17732,"interventions":17733},[94],[21,11475],[6572,11477,11478],{"intervention":17735,"totalTrials":213,"cells":17736},"HIPEC cytoreductive surgery",{"EARLY_PHASE1":17737,"PHASE1":17739,"PHASE2":17741,"PHASE3":17743,"PHASE4":17745,"NA":17747},{"trials":17738,"activeCount":102},[],{"trials":17740,"activeCount":102},[],{"trials":17742,"activeCount":102},[],{"trials":17744,"activeCount":102},[],{"trials":17746,"activeCount":102},[],{"trials":17748,"activeCount":102},[17749],{"nctId":17750,"briefTitle":17751,"status":204,"phases":17752,"primaryCompletion":7235,"completion":7235,"start":7677,"enrollment":11361,"conditions":17753,"interventions":17755},"NCT02325648","The Intraoperative Physiologic Changes of Patients Under Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Prospective Observational Study",[],[17754],"Peritoneal Surface Malignancies",[17735],{"intervention":11003,"totalTrials":213,"cells":17757},{"EARLY_PHASE1":17758,"PHASE1":17760,"PHASE2":17762,"PHASE3":17764,"PHASE4":17766,"NA":17768},{"trials":17759,"activeCount":102},[],{"trials":17761,"activeCount":102},[],{"trials":17763,"activeCount":102},[],{"trials":17765,"activeCount":102},[],{"trials":17767,"activeCount":102},[],{"trials":17769,"activeCount":102},[17770],{"nctId":10997,"briefTitle":10998,"status":308,"phases":17771,"primaryCompletion":5123,"completion":3729,"start":7085,"enrollment":2661,"conditions":17772,"interventions":17773},[94],[11001],[11003,11004,4996],{"intervention":11004,"totalTrials":213,"cells":17775},{"EARLY_PHASE1":17776,"PHASE1":17778,"PHASE2":17780,"PHASE3":17782,"PHASE4":17784,"NA":17786},{"trials":17777,"activeCount":102},[],{"trials":17779,"activeCount":102},[],{"trials":17781,"activeCount":102},[],{"trials":17783,"activeCount":102},[],{"trials":17785,"activeCount":102},[],{"trials":17787,"activeCount":102},[17788],{"nctId":10997,"briefTitle":10998,"status":308,"phases":17789,"primaryCompletion":5123,"completion":3729,"start":7085,"enrollment":2661,"conditions":17790,"interventions":17791},[94],[11001],[11003,11004,4996],{"intervention":17793,"totalTrials":213,"cells":17794},"gabapentin (neurontin® capsule 300mg) treatment",{"EARLY_PHASE1":17795,"PHASE1":17797,"PHASE2":17799,"PHASE3":17801,"PHASE4":17803,"NA":17805},{"trials":17796,"activeCount":102},[],{"trials":17798,"activeCount":102},[],{"trials":17800,"activeCount":102},[],{"trials":17802,"activeCount":102},[],{"trials":17804,"activeCount":102},[],{"trials":17806,"activeCount":102},[17807],{"nctId":17808,"briefTitle":17809,"status":204,"phases":17810,"primaryCompletion":17811,"completion":17811,"start":17812,"enrollment":458,"conditions":17813,"interventions":17815},"NCT05392361","Effect of Baclofen Treatment on Nocturnal Muscle Cramps in Patients With Lumbar Spinal Stenosis: a Randomized Clinical Trial",[94],"2023-03-24","2022-06-09",[17814],"Lumbar Spinal Stenosis With Nocturnal Calf Cramps",[17793,17816],"baclofen (baclofen Tab. 10mg) treatment",{"intervention":17816,"totalTrials":213,"cells":17818},{"EARLY_PHASE1":17819,"PHASE1":17821,"PHASE2":17823,"PHASE3":17825,"PHASE4":17827,"NA":17829},{"trials":17820,"activeCount":102},[],{"trials":17822,"activeCount":102},[],{"trials":17824,"activeCount":102},[],{"trials":17826,"activeCount":102},[],{"trials":17828,"activeCount":102},[],{"trials":17830,"activeCount":102},[17831],{"nctId":17808,"briefTitle":17809,"status":204,"phases":17832,"primaryCompletion":17811,"completion":17811,"start":17812,"enrollment":458,"conditions":17833,"interventions":17834},[94],[17814],[17793,17816],{"intervention":17836,"totalTrials":213,"cells":17837},"midazolam 0.02mg\u002Fkg",{"EARLY_PHASE1":17838,"PHASE1":17840,"PHASE2":17842,"PHASE3":17844,"PHASE4":17846,"NA":17848},{"trials":17839,"activeCount":102},[],{"trials":17841,"activeCount":102},[],{"trials":17843,"activeCount":102},[],{"trials":17845,"activeCount":102},[],{"trials":17847,"activeCount":102},[],{"trials":17849,"activeCount":102},[17850],{"nctId":17851,"briefTitle":17852,"status":204,"phases":17853,"primaryCompletion":5123,"completion":5123,"start":8353,"enrollment":1501,"conditions":17854,"interventions":17855},"NCT02504164","Effect of Midazolam Premedication on the Satisfaction Levels of Patients After Endoscopic Submucosal Dissection",[94],[16451,11475],[17836,17856],"No premedication",{"intervention":17856,"totalTrials":213,"cells":17858},{"EARLY_PHASE1":17859,"PHASE1":17861,"PHASE2":17863,"PHASE3":17865,"PHASE4":17867,"NA":17869},{"trials":17860,"activeCount":102},[],{"trials":17862,"activeCount":102},[],{"trials":17864,"activeCount":102},[],{"trials":17866,"activeCount":102},[],{"trials":17868,"activeCount":102},[],{"trials":17870,"activeCount":102},[17871],{"nctId":17851,"briefTitle":17852,"status":204,"phases":17872,"primaryCompletion":5123,"completion":5123,"start":8353,"enrollment":1501,"conditions":17873,"interventions":17874},[94],[16451,11475],[17836,17856],{"intervention":12976,"totalTrials":213,"cells":17876},{"EARLY_PHASE1":17877,"PHASE1":17879,"PHASE2":17881,"PHASE3":17883,"PHASE4":17885,"NA":17887},{"trials":17878,"activeCount":102},[],{"trials":17880,"activeCount":102},[],{"trials":17882,"activeCount":102},[],{"trials":17884,"activeCount":102},[],{"trials":17886,"activeCount":102},[],{"trials":17888,"activeCount":102},[17889],{"nctId":12970,"briefTitle":12971,"status":204,"phases":17890,"primaryCompletion":4703,"completion":4703,"start":206,"enrollment":4427,"conditions":17891,"interventions":17892},[94],[12974],[12976,12977,12978],{"intervention":12978,"totalTrials":213,"cells":17894},{"EARLY_PHASE1":17895,"PHASE1":17897,"PHASE2":17899,"PHASE3":17901,"PHASE4":17903,"NA":17905},{"trials":17896,"activeCount":102},[],{"trials":17898,"activeCount":102},[],{"trials":17900,"activeCount":102},[],{"trials":17902,"activeCount":102},[],{"trials":17904,"activeCount":102},[],{"trials":17906,"activeCount":102},[17907],{"nctId":12970,"briefTitle":12971,"status":204,"phases":17908,"primaryCompletion":4703,"completion":4703,"start":206,"enrollment":4427,"conditions":17909,"interventions":17910},[94],[12974],[12976,12977,12978],{"intervention":12099,"totalTrials":213,"cells":17912},{"EARLY_PHASE1":17913,"PHASE1":17915,"PHASE2":17917,"PHASE3":17919,"PHASE4":17921,"NA":17923},{"trials":17914,"activeCount":102},[],{"trials":17916,"activeCount":102},[],{"trials":17918,"activeCount":102},[],{"trials":17920,"activeCount":102},[],{"trials":17922,"activeCount":102},[],{"trials":17924,"activeCount":102},[17925],{"nctId":12094,"briefTitle":12095,"status":204,"phases":17926,"primaryCompletion":963,"completion":963,"start":3520,"enrollment":3250,"conditions":17927,"interventions":17928},[94],[9480],[11021,12099],{"intervention":17930,"totalTrials":213,"cells":17931},"(Glucose-Insulin-Potassium)GIK group",{"EARLY_PHASE1":17932,"PHASE1":17934,"PHASE2":17936,"PHASE3":17938,"PHASE4":17940,"NA":17942},{"trials":17933,"activeCount":102},[],{"trials":17935,"activeCount":102},[],{"trials":17937,"activeCount":102},[],{"trials":17939,"activeCount":102},[],{"trials":17941,"activeCount":102},[],{"trials":17943,"activeCount":102},[17944],{"nctId":17945,"briefTitle":17946,"status":204,"phases":17947,"primaryCompletion":11070,"completion":11070,"start":12037,"enrollment":5220,"conditions":17948,"interventions":17950},"NCT01825720","Effect of Glucose-Insulin-Potassium on Hyperlactatemia in Patients Undergoing Valvular Heart Surgery",[94],[17949],"Valvular Heart Disease",[17930,17951],"normal saline group",{"intervention":17951,"totalTrials":213,"cells":17953},{"EARLY_PHASE1":17954,"PHASE1":17956,"PHASE2":17958,"PHASE3":17960,"PHASE4":17962,"NA":17964},{"trials":17955,"activeCount":102},[],{"trials":17957,"activeCount":102},[],{"trials":17959,"activeCount":102},[],{"trials":17961,"activeCount":102},[],{"trials":17963,"activeCount":102},[],{"trials":17965,"activeCount":102},[17966],{"nctId":17945,"briefTitle":17946,"status":204,"phases":17967,"primaryCompletion":11070,"completion":11070,"start":12037,"enrollment":5220,"conditions":17968,"interventions":17969},[94],[17949],[17930,17951],{"intervention":17971,"totalTrials":213,"cells":17972},"no- BIS sensor attachment",{"EARLY_PHASE1":17973,"PHASE1":17975,"PHASE2":17977,"PHASE3":17979,"PHASE4":17981,"NA":17983},{"trials":17974,"activeCount":102},[],{"trials":17976,"activeCount":102},[],{"trials":17978,"activeCount":102},[],{"trials":17980,"activeCount":102},[],{"trials":17982,"activeCount":102},[],{"trials":17984,"activeCount":102},[17985],{"nctId":17986,"briefTitle":17987,"status":204,"phases":17988,"primaryCompletion":3773,"completion":3773,"start":3798,"enrollment":369,"conditions":17989,"interventions":17990},"NCT01921283","Monitored Anesthesia Care With Propofol Plus Remifentanil During Endoscopic Submucosal Dissection: Evaluation of Bispectral Index Monitoring",[94],[16451],[17971],{"intervention":11229,"totalTrials":213,"cells":17992},{"EARLY_PHASE1":17993,"PHASE1":17995,"PHASE2":17997,"PHASE3":17999,"PHASE4":18001,"NA":18003},{"trials":17994,"activeCount":102},[],{"trials":17996,"activeCount":102},[],{"trials":17998,"activeCount":102},[],{"trials":18000,"activeCount":102},[],{"trials":18002,"activeCount":102},[],{"trials":18004,"activeCount":102},[18005],{"nctId":11223,"briefTitle":11224,"status":204,"phases":18006,"primaryCompletion":7211,"completion":7211,"start":4453,"enrollment":11226,"conditions":18007,"interventions":18008},[94],[2918],[5197,11229,11230],{"intervention":11230,"totalTrials":213,"cells":18010},{"EARLY_PHASE1":18011,"PHASE1":18013,"PHASE2":18015,"PHASE3":18017,"PHASE4":18019,"NA":18021},{"trials":18012,"activeCount":102},[],{"trials":18014,"activeCount":102},[],{"trials":18016,"activeCount":102},[],{"trials":18018,"activeCount":102},[],{"trials":18020,"activeCount":102},[],{"trials":18022,"activeCount":102},[18023],{"nctId":11223,"briefTitle":11224,"status":204,"phases":18024,"primaryCompletion":7211,"completion":7211,"start":4453,"enrollment":11226,"conditions":18025,"interventions":18026},[94],[2918],[5197,11229,11230],{"intervention":11029,"totalTrials":213,"cells":18028},{"EARLY_PHASE1":18029,"PHASE1":18031,"PHASE2":18033,"PHASE3":18035,"PHASE4":18037,"NA":18039},{"trials":18030,"activeCount":102},[],{"trials":18032,"activeCount":102},[],{"trials":18034,"activeCount":102},[],{"trials":18036,"activeCount":102},[],{"trials":18038,"activeCount":102},[],{"trials":18040,"activeCount":102},[18041],{"nctId":11023,"briefTitle":11024,"status":308,"phases":18042,"primaryCompletion":10005,"completion":10005,"start":4727,"enrollment":222,"conditions":18043,"interventions":18044},[94],[11027],[11029,6456],{"intervention":18046,"totalTrials":213,"cells":18047},"rhEPO",{"EARLY_PHASE1":18048,"PHASE1":18050,"PHASE2":18052,"PHASE3":18054,"PHASE4":18056,"NA":18058},{"trials":18049,"activeCount":102},[],{"trials":18051,"activeCount":102},[],{"trials":18053,"activeCount":102},[],{"trials":18055,"activeCount":102},[],{"trials":18057,"activeCount":102},[],{"trials":18059,"activeCount":102},[18060],{"nctId":18061,"briefTitle":18062,"status":204,"phases":18063,"primaryCompletion":206,"completion":3936,"start":4384,"enrollment":4966,"conditions":18064,"interventions":18065},"NCT00939978","Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery",[94],[374],[18046],{"intervention":18067,"totalTrials":213,"cells":18068},"Ultrasound guided rectus sheath block with dexmedetomidine",{"EARLY_PHASE1":18069,"PHASE1":18071,"PHASE2":18073,"PHASE3":18075,"PHASE4":18077,"NA":18079},{"trials":18070,"activeCount":102},[],{"trials":18072,"activeCount":102},[],{"trials":18074,"activeCount":102},[],{"trials":18076,"activeCount":102},[],{"trials":18078,"activeCount":102},[],{"trials":18080,"activeCount":102},[18081],{"nctId":18082,"briefTitle":18083,"status":308,"phases":18084,"primaryCompletion":6408,"completion":6408,"start":18085,"enrollment":1980,"conditions":18086,"interventions":18088},"NCT05984212","Effect of Preoperative Rectus Sheath Block on Quality of Recovery in Single Port Laparoscopic Adnexal Surgery",[94],"2023-08",[18087],"Single Port Laparoscopic Adnexal Surgery",[18067,18089],"Ultrasound guided rectus sheath block with normal saline",{"intervention":18089,"totalTrials":213,"cells":18091},{"EARLY_PHASE1":18092,"PHASE1":18094,"PHASE2":18096,"PHASE3":18098,"PHASE4":18100,"NA":18102},{"trials":18093,"activeCount":102},[],{"trials":18095,"activeCount":102},[],{"trials":18097,"activeCount":102},[],{"trials":18099,"activeCount":102},[],{"trials":18101,"activeCount":102},[],{"trials":18103,"activeCount":102},[18104],{"nctId":18082,"briefTitle":18083,"status":308,"phases":18105,"primaryCompletion":6408,"completion":6408,"start":18085,"enrollment":1980,"conditions":18106,"interventions":18107},[94],[18087],[18067,18089],{"intervention":18109,"totalTrials":213,"cells":18110},"Arm1: Statin",{"EARLY_PHASE1":18111,"PHASE1":18113,"PHASE2":18115,"PHASE3":18117,"PHASE4":18119,"NA":18121},{"trials":18112,"activeCount":102},[],{"trials":18114,"activeCount":102},[],{"trials":18116,"activeCount":102},[],{"trials":18118,"activeCount":102},[],{"trials":18120,"activeCount":102},[],{"trials":18122,"activeCount":102},[18123],{"nctId":18124,"briefTitle":18125,"status":204,"phases":18126,"primaryCompletion":18127,"completion":18127,"start":3519,"enrollment":4226,"conditions":18128,"interventions":18129},"NCT01813994","Role of Statin on the Gastric Inflammation in Patients at High Risk of Gastric Cancer",[94],"2018-06-19",[14965],[18109,18130],"Arm2: Placebo",{"intervention":18130,"totalTrials":213,"cells":18132},{"EARLY_PHASE1":18133,"PHASE1":18135,"PHASE2":18137,"PHASE3":18139,"PHASE4":18141,"NA":18143},{"trials":18134,"activeCount":102},[],{"trials":18136,"activeCount":102},[],{"trials":18138,"activeCount":102},[],{"trials":18140,"activeCount":102},[],{"trials":18142,"activeCount":102},[],{"trials":18144,"activeCount":102},[18145],{"nctId":18124,"briefTitle":18125,"status":204,"phases":18146,"primaryCompletion":18127,"completion":18127,"start":3519,"enrollment":4226,"conditions":18147,"interventions":18148},[94],[14965],[18109,18130],{"intervention":18150,"totalTrials":213,"cells":18151},"10% reduction of combination of Esmeron® and Nimbex®",{"EARLY_PHASE1":18152,"PHASE1":18154,"PHASE2":18156,"PHASE3":18158,"PHASE4":18160,"NA":18162},{"trials":18153,"activeCount":102},[],{"trials":18155,"activeCount":102},[],{"trials":18157,"activeCount":102},[],{"trials":18159,"activeCount":102},[],{"trials":18161,"activeCount":102},[],{"trials":18163,"activeCount":102},[18164],{"nctId":18165,"briefTitle":18166,"status":204,"phases":18167,"primaryCompletion":8851,"completion":8851,"start":962,"enrollment":18168,"conditions":18169,"interventions":18171},"NCT02495038","Optimal Dose of Combination of Rocuronium and Cisatracurium",[94],81,[18170,16492],"Chronic Otitis Media",[18150,18172],"20% reduction of combination of Esmeron® and Nimbex®",{"intervention":18172,"totalTrials":213,"cells":18174},{"EARLY_PHASE1":18175,"PHASE1":18177,"PHASE2":18179,"PHASE3":18181,"PHASE4":18183,"NA":18185},{"trials":18176,"activeCount":102},[],{"trials":18178,"activeCount":102},[],{"trials":18180,"activeCount":102},[],{"trials":18182,"activeCount":102},[],{"trials":18184,"activeCount":102},[],{"trials":18186,"activeCount":102},[18187],{"nctId":18165,"briefTitle":18166,"status":204,"phases":18188,"primaryCompletion":8851,"completion":8851,"start":962,"enrollment":18168,"conditions":18189,"interventions":18190},[94],[18170,16492],[18150,18172],{"intervention":12903,"totalTrials":213,"cells":18192},{"EARLY_PHASE1":18193,"PHASE1":18195,"PHASE2":18197,"PHASE3":18199,"PHASE4":18201,"NA":18203},{"trials":18194,"activeCount":102},[],{"trials":18196,"activeCount":102},[],{"trials":18198,"activeCount":102},[],{"trials":18200,"activeCount":102},[],{"trials":18202,"activeCount":102},[],{"trials":18204,"activeCount":102},[18205],{"nctId":12898,"briefTitle":12899,"status":1475,"phases":18206,"primaryCompletion":1512,"completion":1512,"start":284,"enrollment":102,"conditions":18207,"interventions":18208},[94],[12892],[12903,12904,12873,12896],{"intervention":12904,"totalTrials":213,"cells":18210},{"EARLY_PHASE1":18211,"PHASE1":18213,"PHASE2":18215,"PHASE3":18217,"PHASE4":18219,"NA":18221},{"trials":18212,"activeCount":102},[],{"trials":18214,"activeCount":102},[],{"trials":18216,"activeCount":102},[],{"trials":18218,"activeCount":102},[],{"trials":18220,"activeCount":102},[],{"trials":18222,"activeCount":102},[18223],{"nctId":12898,"briefTitle":12899,"status":1475,"phases":18224,"primaryCompletion":1512,"completion":1512,"start":284,"enrollment":102,"conditions":18225,"interventions":18226},[94],[12892],[12903,12904,12873,12896],{"intervention":18228,"totalTrials":213,"cells":18229},"Sedate using sevoflurane via anesthetic conserving device(ACD, Anaconda®) after surgery",{"EARLY_PHASE1":18230,"PHASE1":18232,"PHASE2":18234,"PHASE3":18236,"PHASE4":18238,"NA":18240},{"trials":18231,"activeCount":102},[],{"trials":18233,"activeCount":102},[],{"trials":18235,"activeCount":102},[],{"trials":18237,"activeCount":102},[],{"trials":18239,"activeCount":102},[],{"trials":18241,"activeCount":102},[18242],{"nctId":18243,"briefTitle":18244,"status":204,"phases":18245,"primaryCompletion":18246,"completion":18246,"start":18247,"enrollment":7845,"conditions":18248,"interventions":18250},"NCT03559920","The Optimal Dose of Sevoflurane Via Anaconda® in Post-operative Patient Underwent Head & Neck Surgery",[94],"2019-03-31","2018-04-03",[18249],"Patients Who Needs Sedation After Head & Neck Surgery",[18228,18251],"Sedate using propofol.",{"intervention":18251,"totalTrials":213,"cells":18253},{"EARLY_PHASE1":18254,"PHASE1":18256,"PHASE2":18258,"PHASE3":18260,"PHASE4":18262,"NA":18264},{"trials":18255,"activeCount":102},[],{"trials":18257,"activeCount":102},[],{"trials":18259,"activeCount":102},[],{"trials":18261,"activeCount":102},[],{"trials":18263,"activeCount":102},[],{"trials":18265,"activeCount":102},[18266],{"nctId":18243,"briefTitle":18244,"status":204,"phases":18267,"primaryCompletion":18246,"completion":18246,"start":18247,"enrollment":7845,"conditions":18268,"interventions":18269},[94],[18249],[18228,18251],{"intervention":18271,"totalTrials":213,"cells":18272},"Keep DAPT",{"EARLY_PHASE1":18273,"PHASE1":18275,"PHASE2":18277,"PHASE3":18279,"PHASE4":18281,"NA":18283},{"trials":18274,"activeCount":102},[],{"trials":18276,"activeCount":102},[],{"trials":18278,"activeCount":102},[],{"trials":18280,"activeCount":102},[],{"trials":18282,"activeCount":102},[],{"trials":18284,"activeCount":102},[18285],{"nctId":18286,"briefTitle":18287,"status":204,"phases":18288,"primaryCompletion":18289,"completion":18289,"start":18290,"enrollment":18291,"conditions":18292,"interventions":18293},"NCT01752894","DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents(EES) Versus Biolimus A9-eluting Stents(BES)",[94],"2017-04-11","2013-01-02",776,[2557],[18271,18294],"Discontinue DAPT",{"intervention":18294,"totalTrials":213,"cells":18296},{"EARLY_PHASE1":18297,"PHASE1":18299,"PHASE2":18301,"PHASE3":18303,"PHASE4":18305,"NA":18307},{"trials":18298,"activeCount":102},[],{"trials":18300,"activeCount":102},[],{"trials":18302,"activeCount":102},[],{"trials":18304,"activeCount":102},[],{"trials":18306,"activeCount":102},[],{"trials":18308,"activeCount":102},[18309],{"nctId":18286,"briefTitle":18287,"status":204,"phases":18310,"primaryCompletion":18289,"completion":18289,"start":18290,"enrollment":18291,"conditions":18311,"interventions":18312},[94],[2557],[18271,18294],{"intervention":12571,"totalTrials":213,"cells":18314},{"EARLY_PHASE1":18315,"PHASE1":18317,"PHASE2":18319,"PHASE3":18321,"PHASE4":18323,"NA":18325},{"trials":18316,"activeCount":102},[],{"trials":18318,"activeCount":102},[],{"trials":18320,"activeCount":102},[],{"trials":18322,"activeCount":102},[],{"trials":18324,"activeCount":102},[],{"trials":18326,"activeCount":102},[18327],{"nctId":12563,"briefTitle":12564,"status":308,"phases":18328,"primaryCompletion":12566,"completion":12566,"start":12567,"enrollment":4612,"conditions":18329,"interventions":18330},[94],[12569],[12571,12536],{"intervention":18332,"totalTrials":213,"cells":18333},"PPI",{"EARLY_PHASE1":18334,"PHASE1":18336,"PHASE2":18338,"PHASE3":18340,"PHASE4":18342,"NA":18344},{"trials":18335,"activeCount":102},[],{"trials":18337,"activeCount":102},[],{"trials":18339,"activeCount":102},[],{"trials":18341,"activeCount":102},[],{"trials":18343,"activeCount":102},[],{"trials":18345,"activeCount":102},[18346],{"nctId":18347,"briefTitle":18348,"status":204,"phases":18349,"primaryCompletion":18350,"completion":18350,"start":13942,"enrollment":18351,"conditions":18352,"interventions":18354},"NCT03436914","Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux Disease",[94],"2019-10-18",62,[18353],"Non-erosive Gatroesophageal Reflux Disease",[18332],{"intervention":18356,"totalTrials":213,"cells":18357},"nefopam-propacetamol combination",{"EARLY_PHASE1":18358,"PHASE1":18360,"PHASE2":18362,"PHASE3":18364,"PHASE4":18366,"NA":18368},{"trials":18359,"activeCount":102},[],{"trials":18361,"activeCount":102},[],{"trials":18363,"activeCount":102},[],{"trials":18365,"activeCount":102},[],{"trials":18367,"activeCount":102},[],{"trials":18369,"activeCount":102},[18370],{"nctId":18371,"briefTitle":18372,"status":204,"phases":18373,"primaryCompletion":284,"completion":284,"start":6340,"enrollment":3842,"conditions":18374,"interventions":18376},"NCT01833728","A Comparison of Nefopam-propacetamol Combination and Propacetamol for Postoperative Quality of Recovery After Laparoscopic Nephrectomy",[94],[18375],"Renal Tumor",[18356,18377],"propacetamol alone",{"intervention":18377,"totalTrials":213,"cells":18379},{"EARLY_PHASE1":18380,"PHASE1":18382,"PHASE2":18384,"PHASE3":18386,"PHASE4":18388,"NA":18390},{"trials":18381,"activeCount":102},[],{"trials":18383,"activeCount":102},[],{"trials":18385,"activeCount":102},[],{"trials":18387,"activeCount":102},[],{"trials":18389,"activeCount":102},[],{"trials":18391,"activeCount":102},[18392],{"nctId":18371,"briefTitle":18372,"status":204,"phases":18393,"primaryCompletion":284,"completion":284,"start":6340,"enrollment":3842,"conditions":18394,"interventions":18395},[94],[18375],[18356,18377]]